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ABSTRACT
The human body contains approximately the same number of bacterial cells as human
cells1. These communities of bacteria are termed the human microbiome2. One human
microbial niche that has been previously overlooked is the bladder, because it has been
considered a sterile. Recent discoveries, however, have shown that the female urinary bladder
contains a unique microbiome3-6 and microbiota7 with distinct differences in healthy and
disease states3,6,8,9. Because of the sterile bladder dogma, the bladder was overlooked in the
initial characterization of the human microbiome10,11 and bacteria have not been considered to
be a factor in most urogynecological conditions. By understanding the microbiome/microbiota
of the female urinary bladder, we could develop better diagnostics, identify more effective
treatments, and improve the quality of life for millions of women.
The female urinary bladder contains a microbial community (the FUM) that can be
distinguished from vulvo-vaginal contamination4. However, the female bladder is separated
from the vagina, one of the highest biomass niches of the body, by the urethra, which is only a
few centimeters in length. Furthermore, recent studies have shown that the most common
organisms in the bladder are Lactobacillus, Gardnerella, Streptococcus, Corynebacterium, and a
diverse group of anaerobes3,6-8,12-14. These genera are also found commonly in the vagina15-18.
Thus, the bladder and vagina contain the same genera and often the same species. These

xxvi

observations beg the question, are these two adjacent anatomical sites microbiologically
interconnected?
Indeed, there is growing evidence for an interconnected urinary and vaginal
microbiome. Most reproductive age women have a vaginal microbiome dominated by
Lactobacillus15; however, this community often shifts to a more diverse community following
menopause18-20. No one has directly compared the FUM of pre- to post-menopausal women,
but our group has seen that younger, healthier, women have a FUM more dominated by
Lactobacillus compared to older women suffering from urgency urinary incontinence (UUI),
which is overactive bladder (OAB) accompanied by incontinence3,6. Menopause is a risk factor
for urinary disorders, such as UUI/OAB and urinary tract infection (UTI). Treatment with vaginal
estrogen improves symptoms of OAB21-23 and decreases the incidence of recurrent UTIs in this
population24-26. It is thought that estrogen’s effect on the vagina is mediated by a shift toward a
Lactobacillus-dominant microbiome, thereby protecting the bladder against a future ascending
infection by uropathogens, such as E. coli24-26. Because urine was considered sterile, however,
no one has ever looked to see if estrogen treatment results in corresponding changes to the
FUM.
Here, we observed that, within an individual, the vaginal and bladder microbiomes can
contain similar organisms in similar community structures and that the two sites are more
similar following estrogen treatment. Additionally, isolates from unrelated individuals are highly
similar, indicating that certain species can survive in both niches. Finally, isolates taken from
xxvii

each site within an individual can have highly similar core genomes indicating a recent common
ancestor. Many isolates taken from both sites at a given time point have identical CRISPR
arrays, indicating that the strains have been exposed to identical recent phage infections. The
implication is that these isolates are members of the same lineage and/or that they have been
exposed to the same environment. Taken together, these data suggest that microbial sharing
between these two anatomical sites is possible.

xxviii

CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
Historical Perspectives
A single human being has the same number of bacterial cells as human cells 1, making
the human body as complex an ecosystem as the rainforests or coral reefs. Some of these
bacteria are implicated in a wide range of acute and chronic diseases, while others are
associated with health. Microbial communities are being studied in the gut 27, mouth 28, skin 29,
reproductive organs 15, lung 30, and even the eye 31. It is becoming more apparent that the
future of individualized medicine will be based not only on the human genome, but also the
human microbiome. However, in the rush to characterize every microbiological niche, one
niche was overlooked, the bladder. This is because, traditionally, the bladder was considered
sterile.
The origin of the “urine is sterile” dogma dates to the mid-1800s and the attempt to
understand germ theory by the earliest bacteriologists, including Louis Pasteur, Joseph Lister,
and William Roberts 32-34, who showed that a vial of urine in a sealed container did not turn
cloudy, in contrast to a vial of urine exposed to air or with added tap water. The conclusion was
that “…fresh and healthy urine is perfectly free from bacteria or other minute organisms” 33,34.
In other words, the dogma originated in an era when microbiology was in its infancy and all
bacteria were considered pathogens. Yet, the dogma persists.
1

2

In the 1950s, Edward Kass, an infectious disease physician at Harvard Medical School,
established a threshold for infection to detect patients with pyelonephritis 35. After analyzing
the urine of symptomatic versus asymptomatic women in pregnancy or with diabetes or a
cystocele, Kass determined that 105 colony forming units per milliliter (CFU/ml) was the dividing
line between contamination and infection in most populations 36. This protocol was highly
effective at identifying the at-risk population, which allowed for pre-treatment and resulted in
greatly improved outcomes. Due to its efficacy in this situation, the test was adopted as the
standard method for all urine culture tests, despite several studies that have since provided
evidence that the ≥105 CFU/mL threshold is insufficient to detect significant bladder infections
37-41.

Our group has provided evidence that this protocol is highly effective at growing E. coli,

but not much else 42,43. Therefore, a clinical urine culture report that reads “no growth”
generally means, “no E. coli.” Over time, as patients with symptoms had positive urine cultures
and asymptomatic patients were deemed “no growth,” the collective medical dogma decided
that the urine of asymptomatic individuals must be sterile. This dogma persists today, but there
were those that argued against it.
Some in the medical establishment decided that, in some cases, going against this
dogma would improve patient outcomes. In the mid-1800s, Lister developed “aseptic
catheterization,” which requires the use of a sterile catheter, gloves, and disinfection of the
insertion site. All these precautions were put into place to theoretically prevent contamination
of a sterile body site. Aseptic catheterization soon became standard of practice for urethral
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catheterization 33. In the 1960s, however, the urologist Jack Lapides suggested that intermittent
catheterization did not have to be a sterile procedure performed exclusively by medical
professionals. He hypothesized that patients with spinal cord injuries, who could not void
normally, would retain urine and predispose them to recurrent urinary tract infections (UTIs).
However, if they could intermittently catheterize themselves, they would decrease their rate of
UTIs, even if the catheterization procedure was not sterile. He taught a “clean catheterization”
technique in which a patient, after washing his or her hands, would insert a catheter for
voiding, and immediately remove the catheter. Clean intermittent catheterization not only
improved continence, but decreased rates of UTI and pyelonephritis in these patients 33,44.
Thus, Lapides’ research in neurogenic bladder patients challenged the idea that UTIs were
caused by instrumentation, and demonstrated that UTIs could be prevented by, rather than be
the result of, catheterization.
Another individual who questioned the “sterile bladder” dogma was Rosalind Maskell, a
director of a clinical microbiology laboratory in England. In the late 1970s, Maskell noticed that
patients with UTI-like symptoms, but negative standard urine cultures, contained slow-growing
organisms that required growth conditions than differed from those of the standard method
45,46.

She concluded that standard urine culture was insufficient to diagnose many urinary

disorders, and she urged general practitioners to collaborate with microbiologists to
understand urinary disorders 45,46. Her advice was repudiated or ignored 47,48. It was not until
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culture-independent DNA-based methods were developed that we began to understand that
the slow-growing organisms revealed by Maskell’s experiments were just the tip of the iceberg.
The Human Microbiome Project
Only recently has it become accepted that most human body sites are colonized with
bacteria, and that the vast majority of those bacteria are non-pathogenic. The first large-scale
mapping of the human microbiome, using culture-independent methods, was the Human
Microbiome Project (HMP) in the early 2000s. Even though the number of bacterial cells is
equal to the number of human cells in the body 1, medical studies have traditionally focused on
disease-causing bacteria. Therefore, very little was known about the natural residents, or
commensals, of the human body. Initially, the HMP characterized the gut microbiome because
samples from this heavily colonized (high biomass) environment were easy to collect, contained
significant diversity between individuals 49, and had previously been observed to have
differences in health and disease states 50. Following the initial phase, the project was expanded
to sample the microbiome of 300 “normal” individuals at a total of five body sites: GI tract,
mouth, vagina, skin and nasal cavity, using culture-independent methods, such as metagenomic
and amplicon sequencing 2. Because the bladder was considered sterile, it was not included in
either of these two early stages of the HMP study.
Sequencing Technologies
Most current high throughput DNA sequencing technologies can only produce relatively
short sequence reads (~250-400 base pairs). These technologies (often called Next Generation
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Sequencing or NGS) use massively parallel sequencing approaches and thus generate large
numbers of sequences, thereby allowing for extensive coverage of a single genome or great
depth of a single genomic site. Sequencing strategies fall into two categories: whole genome
and metagenome. Whole genome sequencing (WGS) starts with an isolated pure culture; in
contrast, metagenomics is performed on patient samples with mixed populations, such as a
swab, fecal material, or urine. Each sequencing strategy uses a different technique to turn the
large amounts of short sequences generated by NGS into useful information (Figure 1).
Each sequencing method finds a way to use short read lengths to provide the desired
information. In WGS, the bacterial genome of a pure isolate is fragmented, sequenced in short
reads, and bioinformatically put back together again. There are two methods for re-assembling
a genome: align to a reference strain or assemble de novo (like assembling the puzzle with or
without the original picture as a guide).
The most common technique to classify bacteria within a population is 16S rRNA gene
amplicon sequencing (Figure 1B). The 16S rRNA gene is used because it is highly conserved
among bacteria 51-53, a direct result of its critical cellular role, but is lacking in other domains of
life. This gene is used as a molecular chronometer, with some highly conserved stretches and
some hypervariable regions that change slowly over evolutionary time. These hypervariable
regions contain specific polymorphisms that can be used for measuring evolutionary distance
and thus phylogenetic relatedness 3,53. When all 9 known hypervariable regions (V1-V9) of the
16S rRNA gene are sequenced (about 1,500 bases), there are sufficient polymorphisms for
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species level classification. However, due to the short sequence length of NGS, only one to
three hypervariable region(s) are covered. Typically, this is only sufficient to achieve taxonomic
classification to the family or genus level.
Lastly, metagenomic sequencing tries to reassemble larger regions of bacterial genomes
(called contigs) from a mixed community. Overlapping regions of genomes are pieced together
much in the same way as de novo WGS. These larger contigs can then be used to classify the
organism, thereby providing population data as well as a snapshot of the overall genetic
content of a sample.

Figure 1. Comparison of Sequencing Technologies.
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Figure 1. Continued
Much of the HMP research has relied on 16S rRNA amplicon sequencing to obtain a first
glimpse of bacteria present in different niches, at different times, and between different
disease states. Amplicon sequencing relies on polymerase chain reaction (PCR) amplification.
This method is not quantitative; different sequences amplify at different rates; thus, the
number of sequence reads obtained from different samples cannot be directly compared.
Instead, researchers compare these data qualitatively, looking at the relative amounts of
classified bacteria, rather than the numbers of raw sequences.
A relative abundance graph (Figure 2) depicts the bacterial community structure in
terms of percentage of total classified reads (y-axis) per sample collected (x-axis). Each color
represents a different taxonomic classification. These graphs can be shown at any taxonomic
level (Phylum, Class, Order, Family, or Genus) or combination of levels. For example, the
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previously published data in Figure 2 represents catheterized urines sequenced from women
with urgency urinary incontinence (UUI) or from continent controls 3. Some urine samples were
dominated by the genera Lactobacillus (blue) or Gardnerella (red) or by the family
Enterobacteriaceae (green). The V4 region does not contain enough variability to distinguish
genera of the Enterobacteriaceae family, which includes Escherichia, Klebsiella, and Proteus. In
other samples, no bacterium dominated; these were termed “diverse.” In this way, one graph
can display large amounts of taxonomic information concerning the qualitative differences
between samples.

Figure 2. Urinary Microbiome Profile by Cohort Based on 16S rRNA Gene V4 Sequencing.
Stacked bar plots depict the sequence abundances of the 15 most abundant genus- or family-level taxa in the
UUI and non-UUI cohorts. Taxa were ranked according to mean abundance across all samples. The y axis
represents the percentage of sequences for a particular bacterial taxa; the x axis represents the study
participants separated by cohort. The family Enterobacteriaceae could not be classified to the genus level. The
remainder of sequences was combined in the category labeled “Other.”

Visualizing the Results of HMP
Due to complex community structures, and variation between individuals, the data
obtained through HMP was more complex than initially expected and ecological analysis tools
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had to be adopted, including community typing, principle component analysis, and
measurements for diversity. One qualitative approach was the identification of community
types; they are called enterotypes in the gut 54, community state types (CSTs) in the vagina 15,
and urotypes in urine 3. To form community types, bacterial profiles are clustered together
based on taxonomic similarity (as measured by Bray Curtis dissimilarity). Each specific clade in
the tree contains similar community structures that can be grouped into types (for example see
Figure 8-9). Those clusters can then be tested for their statistical association between
individuals and diseases. Using this method, different enterotypes were found to be correlated
to one’s diet, obesity, or Crohn’s disease 54-56.
The HMP resulted in a significant increase in our understanding of the vaginal
microbiome. It is well documented that the vagina of reproductive age women is highly
colonized with bacteria (high biomass) and that the vaginal microbiome tends to fall into one of
five CSTs: CST 1, 2, 3, and 5 are dominated by different species of Lactobacillus (L. crispatus, L.
gasseri, L. iners, and L. jensenii, respectively)15. In contrast, CST 4 is dominated by a diverse
group of anaerobes, including Anaerococcus, Peptoniphilus, Prevotella, Streptococcus,
Atopobium, and Gardnerella 15.
While community typing provides qualitative information on the types of bacteria
present, principal component analysis (PCA) or discriminant analysis of principal components
(DAPC) provides information on which samples resemble each other and which are distinct.
Both methods rely on simplifying complex data to emphasize variation and highlight
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associations in the data. Once the principal components have been calculated, each sample is
represented as a single dot on either a two or three-dimensional plot. Similar samples will
cluster together, while samples with greater variation will be farther apart. PCA includes the
total variation, within and between groups 57, while DAPC highlights the variations between
groups while minimizing the within-group variation 58.
Finally, another method to compare complex community data is by calculating diversity.
There are two main types of diversity, richness (the total number of organisms in a niche) and
evenness (the distribution of those organisms). Certain diversity measurements calculate
richness only (species accumulation curves, species/OTU counts, Chao1), or evenness only
(Peilou), but many diversity measurements take both into account (inverse Simpson, Shannon,
Fisher’s alpha). The benefit to these types of measurements is that they provide a numerical
value that can be compared to patient demographics or symptom scores for statistical analysis.
The Bladder is not Sterile
Because the bladder was not originally tested in the original HMP, the study of the
bladder microbiome is years behind the study of other human niches. As Maskell
demonstrated, bacteria had not been detected in the bladder primarily because culture
techniques were developed for fast growing aerobic uropathogens, such as uropathogenic E.
coli. However, the paradigm is changing 59.
Two major hurdles prevented the bladder microbiome field from moving forward: first,
bacteria from the bladder had to be distinguished from vulvo-vaginal contamination; second,
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the detected DNA had to be shown to originate from live bacteria (as opposed to free floating
DNA or dead bacteria). To overcome the first hurdle, researchers from the Loyola Urinary
Education and Research Collaborative (LUEREC) used suprapubic aspiration (SPA) to sample
bladder urine directly 4. SPA collection uses a needle to collect urine directly through the lower
abdomen, thereby bypassing the vagina. The SPA urine in these patients was compared to
voided urine, a vaginal swab, a skin swab of the insertion site, and urine collected by
transurethral catheter (TUC). Using 16S amplicon sequencing, they found that SPA and TUC
urine had similar profiles, and were distinct from voided urine, vaginal swabs or skin swabs.
Since SPA sampling bypasses the vagina, they concluded that the bladder contained bacterial
DNA and additionally that TUC samples the bladder environment with minimal vulvo-vaginal
contamination 4. Since TUC is a more feasible urine collection method, currently it is the
sampling method of choice 3,6,14,60.
To overcome the second hurdle, LUEREC researchers cultivated organisms from
catheterized samples. The previous study had provided taxonomic identification of the 16S
sequences detected in the bladder 4, and most of the detected bacteria were cultivatable, but
not under standard urine culture conditions. Therefore, an enhanced quantitative urine culture
(EQUC) protocol was developed. Unlike the standard urine culture (SUC) protocol, which plates
1 l urine on blood and MacConkey agars with incubation in air for 24 hours, EQUC plates a
greater amount of urine (100 l) on a greater variety of media with incubation under diverse
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atmospheric conditions for 48 hours (Table 1) 7. The result is that many organisms detected by
sequencing can be cultured.
Table 1. Comparison between standard urine culture (SUC) and the expanded quantitative
urine culture (EQUC) methods.
Protocol

Volume

Media

Atmospheric
Conditions

Time

Standard Urine
Culture (SUC)a

1 µL

Blood Agar
MacConkey Agar

Aerobic

24 hrs
35°

Enhanced
Quantitative Urine
Culture (EQUC)b

100 µL

Blood Agar
CNA Agar
Anaerobic Blood Agar

Aerobic
CO2
Anaerobic

48 hrs
35°

aFor

standard urine culture, we struck 0.001 ml of urine onto 5% sheep blood (BAP) and MacConkey agars (BD BBL prepared
plated media), which were incubated aerobically at 35°C for 24 hours. Each separate morphological colony type was counted
and identified in any amount. The detection level was 1,000 colony-forming units per milliliter (CFU/ml), represented by 1
colony of growth on either plate. If no growth was observed, the culture was reported as “no growth,” indicating no growth of
bacteria at the lowest dilution, i.e., 1:1,000.
bFor EQUC, we struck 0.1 ml of urine onto BAP, chocolate and colistin, naladixic acid (CNA) agars (BD BBL prepared plated
media), which were incubated in 5% CO2 at 35°C for 48 hours. A second BAP plate and CDC anaerobe 5% sheep blood agar
plate (BD BBL prepared plated media) were also inoculated with 0.1 ml of urine and incubated under anaerobic conditions at
35°C for 48 hours. The detection level was 10 CFU/ml, represented by 1 colony of growth on any of the plates. Each
morphologically distinct colony type was isolated on a different plate of the same medium to prepare a pure culture for
identification.

These first two studies showed that there was bacterial DNA present in the bladder (a
microbiome) and that the DNA represented live, cultivatable bacteria (the microbiota) 14,61. Our
research also shows that standard culture misses the vast majority of known and emerging
uropathogens (Appendix H) 43,62. Throughout our studies, we have compared the results
obtained by sequencing and EQUC and found that they are comparable but not identical, and
are thus complementary (Figures C.7, D.7, and I.S1, for a full description, see the write up in the
addendum for Appendix D.
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The Female Urinary Microbiota in Relation to Health and Disease
Now that we know the female urinary microbiota (FUM) exist, the next obvious issue is
whether the resident bacteria contribute to health and disease. A few key things are known.
First, we know a bit about the microbiota and acute infectious diseases, such as urinary tract
infections (UTIs). For example, patients undergoing pelvic organ prolapse and urinary
incontinence (POP-UI) surgery were assessed by standard urine culture (SUC) on the day of
surgery. We found that 8% had urinary microbes detectable by standard culture, but a further
46% had a microbiome undetected by SUC, but identified via sequencing. On the day of
surgery, the SUC-positive population tended to be dominated by Enterobacteriaceae (E. coli
and relatives); 32% of these patients went on to develop a post-operative UTI. By contrast, the
SUC-negative group had only a 3.7% post-operative UTI rate; those with sequencing-detectable
microbiomes tended to be dominated by Lactobacillus instead of Enterobacteriaceae
(Appendix I)63,64. This not only illustrates the poor detection of SUC methods, but also suggests
that some microbiome profiles may pre-dispose the bladder to infection.
Second, in a study of women undergoing instrumentation, it was found that detection of
urinary bacteria correlated with greater symptom resolution and a decreased incidence of postinstrumentation UTIs (Appendix B)65, suggesting that certain FUM profiles can be beneficial or
protective. Third, our group and others have detected the presence of bacteria in kidney
stones, often pathogenic bacteria, suggesting that some kidney stones may have a bacterial
component (Appendix F)66.
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Fourth, we detect trends that correlate the microbiome with certain age-related
disorders, specifically incontinence, which are traditionally not thought to have a bacterial
etiology. We have seen that the FUM are distinct between overactive bladder (OAB) patients
and continent controls (Appendices B-D)3,6. Overall, OAB cohorts tend to be more diverse by
culture and sequencing, and have fewer Lactobacillus-dominant profiles. This is reminiscent of
the vaginal microbiome story. However, it is unclear how much of the difference in diversity is
due to the age, and therefore hormone status, of the individual versus the disease; part of this
thesis was designed to address this concern. Furthermore, the FUM profile (urotype), or
phenotype, of a patient’s bladder microbiome could be predictive of anticholinergic
(solifenacin) treatment response (Appendix D)6. A less diverse FUM (with a mean of 3 unique
organisms by EQUC) correlates with robust treatment response, whereas a FUM with more
diverse cultivatable organisms (a mean of 5 or more per individual) tend to require either an
increased dose of, or does not respond to, the medication. Finally, the evenness, or distribution
of the microbiota within an environment, is correlated with symptoms of urgency incontinence
but not stress incontinence (Appendix E)67.
Finally, notice that most of the organisms discussed so far are not commonly described
as uropathogens. In fact, the most common genus, Lactobacillus, is considered beneficial in
many other areas of the body, including the gut and vagina. But, not all Lactobacilli are created
equal; L. gasseri has been correlated with symptoms of OAB, while L. crispatus is associated
with continent controls (Appendix C, Figure C.6)3. Additionally, our lab has found urinary
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isolates of L. crispatus that can kill uropathogenic E. coli (UPEC) more efficiently than lactic acid
and H2O2 alone42,68,69.
All of these data provide evidence for correlation between the FUM and important
factors associated with health, incontinence, and infection; however, it is still unclear if these
correlations are simple biomarkers or play a pivotal role in the etiology, progression, or
resolution of each disease state.
Similarities Between the FUM and Vaginal Microbiome, and Relationship to Estrogen
As we have previously described, the “normal” bladder microbiome is usually
dominated by Lactobacillus, with another group dominated by one or more strict or facultative
anaerobes, such as Gardnerella, Streptococcus, or Staphylococcus (Figure 1) 3. A list of the
typical organisms residing in the vagina would be nearly identical to this list 15. However, from
our first study using supra-pubic aspirates, we know that the bladder microbiome is distinct
from vulvo-vaginal contamination 4. This led me to ask, is there any microbial link between the
bladder and vaginal communities?
There is preliminary evidence that the bladder and vaginal microbiomes are
interconnected, at least in part. We know that certain uropathogens, such as UPEC, can live in
both sites 70-72. What we do not know is if commensal organisms move between niches or are
specific to a given niche. We do know from preliminary data that the female bladder and
vaginal microbiomes are very similar in composition. In fact, early results in characterizing the
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FUM showed that Gardnerella vaginalis, previously only known to live in the vagina, was also
common in the bladder.
Following menopause, the vaginal environment becomes more diverse and shifts away
from Lactobacillus-dominant community state types 18. Following a few years of hormone
replacement therapy (HRT), the vaginal microbiome has been shown to shift back toward low
diversity and Lactobacillus dominance 73,74. As stated previously, we know that women with
OAB tend to have increased microbial diversity 3,6. However, OAB is a disease associated with
age and, in each of our previous studies, the OAB cohort was significantly older than the
continent controls 3,6. Therefore, it is possible that the differences in diversity are associated
with age and hormone status, rather than disease severity.
Due to the close proximity of the urethra and the vaginal introitus, the clinical dogma
connects urinary health to the health of the vagina. In the vagina, estrogen increases glycogen
storage in vaginal epithelial tissues. Lactobacillus species use the glycogen as a carbon source.
The result of glycogen metabolism by Lactobacillus is lactic acid, which decreases vaginal pH
75,76.

The resulting decrease in pH protects against colonization from acid-susceptible

organisms, such as UPEC 77,78. This estrogen-to-pH relationship, and the production of H2O2 by
Lactobacillus, is thought to be crucial for protection against UTIs. The reasoning is that the
invading uropathogen first infects the vaginal tract and then ascends to the urinary tract 26,79.
However, because the bladder was considered sterile, no one has determined if bladder
bacteria also play a protective role.
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This estrogen-to-urogenital-microbiome dogma is backed up by clinical observations.
For example, treatment with topically applied HRT can improve symptoms of OAB 21-23, and
decrease the incidence of recurrent UTIs 24-26. There is compelling evidence to suggest that
vaginal estrogen therapy relieves symptoms of OAB, including urgency and frequency, in
postmenopausal women 21,22,80-82. Estrogen therapy is currently used as a first line treatment
for OAB in Europe. However, the data are inconclusive for treatment of UUI, a subset of OAB
that includes all the symptoms of OAB with the addition of incontinence. For the treatment of
UTIs, one study found that topical estrogen is as effective in decreasing recurrent UTI rates as
the oral antibiotic nitrofurantoin macrocrystal (nitro), decreasing the rate of UTIs from 5.9
episodes per year without estrogen to 0.5 episodes per year with vaginal estrogen cream
compared to 0.8 episodes per year with nitro 24. The current dogma is that a healthy vagina will
result in a healthy bladder, primarily due to the protective effects of Lactobacillus species in the
vagina.
It is known that estrogen affects the bladder epithelium. In studies of estrogen-deficient
mouse models (ovariectomized vs sham-treated mice), decreases in uroepithelial cell-cell
adhesion and in antimicrobial peptide (AMP) production were observed 83. When
ovariectomized mice were infected with UPEC, bacterial levels increased, but both bacterial cell
invasion and uroepithelium proliferation decreased compared to the sham-treated mice 72,83.
All of these changes were reversed with HRT 72. This suggests that estrogen has a strong effect
on the physiology of the bladder epithelium.
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The bladder can be simply divided into two main parts, the trigone and the dome. The
dome is the main body of the bladder and consists of all cells that lie above the ureter
openings. It is the main portion of the bladder that expand and contracts during filling and
voiding and therefore is very closely associated with the detrusor muscle. In contrast, the
trigone is the triangular portion of tissue at the base of the bladder; two points of the triangle
are the entry points of the ureters while the third is the urethra. Unlike the dome, the trigone
does not stretch during filling84. The trigone and dome have been shown to have distinct gene
expression profiles84, and originate from different embryonic lineages 85. In fact, the trigone is
derived from the same embryonic progenitors as the vagina 85, and the anterior vaginal wall
and the trigone lie parallel to each other and are separated by the vesicovaginal space. Because
of this shared lineage, about 50% of women contain “squamouse epithelium of the vaginal
type” in the trigone area 86. Additionally, estradiol has been shown to bind to estrogen
receptors in the trigone area but not in tissues collected from the dome of the bladder 85.
Considering these numerous connections between the bladder and vaginal epithelium, it is
reasonable to expect that estrogen treatment will have an effect on the bladder epithelium and
this could result in alterations to the resident microbiota.
Difficulties in Studying Niche Interconnectivity
Are the bladder and vaginal microbiomes connected? On the surface, this is a simple
question, but it encompasses some complex ideas and presents some unique challenges. Asking
if the two niches are microbiologically linked suggests that the organisms have the ability to
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migrate from one niche to another. However, other than known uropathogens (such as UPEC,
Pseudomonas, Proteus, and some Klebsiella strains), none of the commensal organisms contain
known motility genes. A rotation student under my supervision, Cesar Montelongo-Hernandez,
tested at least one isolate of each species we isolated from bladders and, except for those listed
above, none demonstrated motility in vitro (Appendix L). Some may be motile, but they would
have to be novel methods of motility encoded by novel motility genes. Another way of
detecting migration is to inoculate women or animal models and measure the progression from
one niche to another over time. However, doing this in human subjects is infeasible and, due to
differences in reproductive anatomy, it is not possible to do this in rats or mice 87,88. Therefore,
we are left with finding specific examples where this does or does not happen in a community
or within an individual.
More than simple technical hurdles, the question of niche linkage is muddied by the
intricacies of environmental and evolutionary factors. Each niche contains distinct
environmental factors. For example, the vaginal environment contains a high biomass of
bacteria living in complex vaginal communities 89. The environment can be highly acidic and
there is an abundance of carbon sources both in the biofilm and on the epithelium. In
comparison, the bladder environment seems much harsher. Unfortunately, due to the sterile
bladder hypothesis, very few studies have been done regarding the bladder environment a
bacterium may experience. We have measured the biomass and found that is is substantially
lower than the vaginal tract. Furthermore, the bacteria either would have to attach to the cell
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wall, or live inside epithelial vesicles 90,91 to resist the shear forces of voiding. A few recent
studies have shown that immune cells are present and the bladder epithelium creates
antimicrobial peptides, but very little else is known about the bladder immune system 92-94.
From preliminary data in our lab looking at E. coli and Lactobacillus grown in artificial urine, we
know that urine is a poor culture medium and contains high amounts of urea, amines, and salt
and no amount of sugar 95. Instead, we hypothesize that the bacteria are adhering to the
uroepithelium.
The bladder epithelium is coated in a quasi-crystalline array of uroplakin proteins that
act as a permeability boundary 96. Three of the four uroplakin subtypes are highly glycosylated
96.

In addition to the uroplakins, there is a negatively charged glycosaminoglycan (GAG) layer

that prevents bacterial attachment by E. coli 97-99. E. coli bypasses this charge deterrent by
specifically binding to mannose on uroplakin subunit (UPIa) using type 1 pilus with a FimH tip92.
We have been unsuccessful in finding FimH homologues in our bladder isolate genomes. This
suggests that the attachment and adherence methods for UPEC are distinct from the
commensal bacteria. If bladder bacteria have a novel method for attachment to the urothelium,
then it would suggest that they are feeding off of the GAG layer and/or glycosylated uroplakins,
but more research is needed to test this hypothesis.
All of this illustrates that each niche represents a dramatically different environment
with unique evolutionary pressures. But it is not unheard of for bacteria to survive, or even
thrive, in different environments. Many bacteria can survive in our gut and in the soil and there
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are many examples of opportunistic pathogens where the human is not the traditional host.
However, in these cases there is usually something (nutrient sources, moisture, or an
intracellular environment) that is similar between the two niches. If the same strains of bacteria
can live in both the bladder and vaginal niches, we do not yet fully know which environmental
factors are in common or even may be required for transmission between sites.
Additionally, we have the issue of how we measure similarity between strains. Bacterial
genomes contain two general sets of genes: the core and accessory genomes. The core genome
contains all the genes required for life, such as genes involved in transcription, translation,
replication, metabolism and DNA repair. A comparison of these genes will provide an accurate
representation of the phylogenetic relatedness between organisms (see description of the 40core gene and average nucleotide identity approaches in Methods). In theory, the accessory
genome contains genes that can be horizontally transferred, such as pathogenicity islands, and
genes for attachment and adherence factors, and antibiotic resistance. We think of this set of
genes as those required for adaptation to a given environment. If two bacteria have the same
core genome, we can conclude that they had a recent common ancestor, but without looking at
the accessory genome, we cannot conclude anything about how identical they really are, or
how adapted they are to a given niche.
If we find two bacteria with the same core genomes, we have to accept the possibility of
parallel evolution. If, at some point in the history of the host, say around birth, both niches
were simultaneously inoculated with an ancestor strain, then that strain may have adapted to a
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given niche but never left. We would have two strains of the same species, one that has
evolved to inhabit the bladder and another that has evolved to inhabit the vagina. But, they are
entirely different bacterial strains that have not migrated from one niche to another.
Therefore, if we find evidence of the same species with the same core genome, we can
only conclude that the strains share a recent common ancestor. To conclude that actual
microbial sharing is happening, we would either need to observe the migration in real time,
which is currently infeasible, or we would need to make an assessment of the accessory
genome, which is a far more subtle and complex question. Even selecting target genes for
analysis is not straightforward. As stated previously, with a few exceptions, we do not know
enough about the bacterial physiology required in the bladder to make an educated guess
about which genes would be adaptive in that niche. Additionally, due to the stochastic nature
of horizontal gene transfer (HGT), we would have no way of knowing if a gene was recently
added or removed from a genome. That, in combination with issues of overall genome
coverage in first-pass whole genome sequencing (WGS), we do not know if the absence of a
gene in a genome is indicative of the absence of the gene in that strain or our inability to
sequence it. Therefore, is seems unlikely that we can currently use a single gene as a marker for
the relatedness of any two accessory genomes. However, due to recent discoveries, we can ask
about the recent environmental history of a given strain using CRISPR arrays.

23

Using CRISPR Arrays to Assess Recent Phage Exposure History
The CRISPR/Cas system is a bacterial adaptive immune system. If a bacterium
successfully evades infection by a bacteriophage (phage), it will store a short segment of the
phage’s DNA in its own genome to better defend itself against future infections by that
particular phage. The clustered regularly interspaced short palindromic repeats (CRISPR) array
holds these short segments of phage DNA separated (spaced) by known repeated sequences
100.

If that bacterium encounters the same phage again, the Cas proteins will use these short

segments to identify the foreign phage DNA and destroy it. The discovery of these systems has
led to many exciting breakthroughs in genetic engineering, but here we will use the system as a
chronologic log, because these arrays represent the recent infection history of a clonal
population. In these arrays, the most recent viral infection is represented by the first insert
followed by consecutively older inserts from older infections 101,102; thus, the array represents
the clone’s recent exposure history.
Phages are an integral part of any bacterial ecosystem and can represent one of the
main evolutionary pressures within a bacterial community 103,104. Phages have been previously
detected in bladder samples 105-107. Bladder phages have been detected as prophages in
bacterial genomes (Appendix G) 105,107, and phages themselves also have been isolated from
bladder cultures 106. Therefore, we can conclude that phages do exist in the bladder
environment, and if CRISPRs are present in our isolates they would reflect the recent history of
phage infection for that bacterial population 108,109. If the arrays were identical between strains
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isolated from each site, it would suggest that the bacteria were infected with the same phage.
Achieving this result would occur for one of two reasons: either the isolates were completely
identical strains, or the isolates were exposed to the same history of phages, which suggests
exposure to identical environments. Either way, if the arrays were similar then it would be
further evidence of a shared environmental history, which suggests movement between sites.
Summary
Because urine has long been considered sterile, the microbial content of the bladder
(the FUM) has been ignored, and its role in female health has been overlooked. Previous work
has shown us that the bladder and vagina contain similar organisms, and there seems to be an
increase in diversity in both sites following menopause. We know that estrogen improves
urinary symptoms and alters the community structure, by decreasing diversity, of the
microbiome in the vagina. But, we do not know if there is a corresponding change in the
bladder. In this thesis, I will show evidence that both niches respond similarly to estrogen and
there are at least some organisms that are identical in both niches at any given time point.
Many studies assume that the measured UTI, or OAB, symptom improvement is due
entirely to a change in the vaginal community. However, none of these studies have directly
captured the shift in vaginal community throughout treatment. Instead, these studies have
compared hypoestrogenic women to pre-menopausal or women who have been on HRT for 510 years. To my knowledge, this is the first study designed to capture the shift in community
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structure in real time. Seeing the community response to an environmental shift will provide
insight into the stability of the urogenital microbiome and could influence future treatments.
In the next few chapters, I will present data that suggests that the bladder and vaginal
microbiomes are connected, at least in part. Following the methods (Chapter II), we will look at
global differences and similarities between the niches (Chapter III). The subsequent chapters
will provide evidence that the community structures of the two sites are similar and respond
similarly to change (Chapter IV), and that the species within a given individual at a given point in
time are highly similar (Chapter V), suggesting that some bacteria may be able to reside in both
niches.
Due to the constraints discussed previously, we are unable to conclusively determine if
the two microbiomes are interconnected, but this thesis is an important first step in
understanding how these two microbiomes interact with each other. Additionally, the data
presented here should be the foundation for new lines of research into niche boundaries, hostbacterial interactions in the bladder, and bacterial adaptation. It is my hope that this work will
lead to new discoveries and new therapies to treat lower urinary symptoms, such as therapies
that treat the whole urogynecological microbiome, modulation of the bladder and vaginal
communities prior to pharmacologic intervention, or inform the use of urogenital probiotics.
We anticipate that this work will lead to better understanding and exciting new therapies for
post-menopausal women that incorporate, modulate, or maintain the bacteria already present
in an individual’s bladder.
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CHAPTER II
MATERIALS AND METHODS
Clinical Study Design (The Estrogen Study)
The data in this thesis were collected from a study designed by myself and Susanne
Taege, a urogynecology fellow in LUEREC. We designed this study with three goals in mind. (1)
To collect both vaginal and bladder samples at the same point in time from individual women.
(2) To measure the changes of both the bladder and vaginal microbiomes in response to
estrogen treatment. (3) Finally, Susanne wanted to assess microbiome changes as they
correlate to estrogen’s treatment response for women with OAB.
This protocol describes the samples collected for analysis in this study. In addition, I will
describe additional samples that were collected for future work, but were not analyzed in this
current study; these include perineal swabs, voided urine, and enriched culture samples. Dr.
Taege and other members of the Loyola Urogynecology department were responsible for all
recruitment and initial sample collection. This work would not have been possible without their
help. The following is a description of the study design (and may include some language written
by Dr. Taege).
Study Design Overview.
We recruited 40 post-menopausal women with OAB symptoms. Their menopausal
status was determined clinically. From these recruits, we collected vaginal swabs, perineal
27
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swabs, voided urine and urine obtained by transurethral catheter (TUC). The FUM was
characterized using the EQUC protocol prior to, and following 12-weeks of, topical estrogen
treatment. In this way, each patient acted as her own control, setting the baseline prior to
estrogen treatment. This thesis will present data from the patients currently recruited (40
baseline patients, 21 who have returned for their 12-week assessment). But, the study will
continue until at least 40 patients have returned for their 12-week assessment. We will wait to
run the symptoms and demographic assessments until at least 40 patients have returned for
their 12-week visit. Therefore, this thesis will not include any symptom-to-microbiome
assessment. This study was funded by the Urogynecology department research fund, an
Investigator Initiated grant from the Kimberly Clark Corporation, two NIH awards to Drs. Wolfe
and Brubaker (R01 DK104718 and R56DK104718) and the Arthur J Schmitt Dissertation
Fellowship.
Patient Recruitment and Clinical Assessment.
Recruitment. Women were recruited from the ambulatory urogynecology clinic at
Loyola University Medical Center. Informed research consent was obtained prior to enrollment.
Visit 1 (Baseline). Following approved research consent, catheterized urine was
collected for culturing by the EQUC and SUC protocols (see below). Voided urine, a perineal
swab, and a vaginal swab also were collected for characterization by a modified EQUC protocol
(see below). Perineal swabs and voided urine will not be the focus of work, but were collected
and cultured so that the data is available for future analyses. Patients were asked to complete
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the validated questionnaire, OAB-q, to measure OAB-related symptoms and quality of life 110.
Demographic information and clinical characteristics were collected, including age, parity,
medical illness, previous hysterectomy, previous incontinence surgery, and BMI.
Physical examination was completed, including evaluation for pelvic organ prolapse with
the POP-q examination. Patients were counseled on the evidence-based first-line options for
the treatment of OAB, including behavioral modifications, physical therapy, and vaginal
estrogen per standard practice in the Female Pelvic Medicine and Reproductive Surgery
(FPMRS) clinic. All consented patients were prescribed vaginal estrogen, estradiol cream,
provided by the study, based on the clinical practice guidelines for vaginal estrogen use in
postmenopausal women with urogynecological complaints developed by the Society of
Gynecological Surgeons Systematic Review Group 111. Patients received compensation with a
parking voucher.
Visit 2 (12-weeks). Patients were scheduled to return at twelve weeks from the initial
visit for follow up. At this time, we collected catheterized and voided urine, a perineal swab,
and a vaginal swab, and patients repeated the OAB-q to reassess symptoms and quality of life
measures. Again, all samples were characterized using culture protocols. After collection of
these samples, the patient’s participation in the study was concluded and the patient was
compensated with a second parking voucher.
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At this point, based on the patients’ response to treatment, continued clinical treatment
may have included, but was not limited to, vaginal estrogen. The symptoms of OAB were
reassessed and the next step in treatment was based on the clinician’s usual practice.
Inclusion Criteria. Inclusion criteria were as follows: (1) Women who present with
symptoms of OAB, defined as a condition characterized by urgency, with or without urgency
incontinence, usually with frequency and nocturia in the absence of obvious pathology or
infection, and who do not answer often to any of questions 10 – 15 on the Medical,
Epidemiological and Social Aspects of Aging (MESA) urinary incontinence questionnaire 112,113,
which the FPMRS clinicians give to all new patients as standard practice. (2) Postmenopausal by
history, defined as twelve months or greater since last menstrual period or over the age of 55 if
they have had a previous hysterectomy. (3) English language skills sufficient to complete
questionnaires. (4) Clinical indication for vaginal estrogen use. (5) Patients not currently
receiving vaginal estrogen therapy.
Exclusion Criteria. The following were the exclusion criteria: (1) Patients currently on
systemic hormone replacement therapy (HRT) or who have been on HRT within the past three
months. (2) Patients with current diagnosis or history of estrogen dependent malignancies
(breast, endometrial). (3) Contraindication or allergy to local estrogen therapy. (4) Insufficient
language skills to complete study questionnaires. (5) Women with active, SUC-positive urinary
tract infection at baseline assessment. (6) Patients who have received antibiotics within the
past two weeks. (7) Advanced pelvic organ prolapse greater than stage II based on the pelvic
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organ prolapse quantitation system (POP-q). (8) Patient not willing to use vaginal estrogen
preparation. (9) Patients currently on anticholinergic medication or who have received
anticholinergic medication within the past three months. (10) Patients wishing to start
anticholinergic medication at the initial encounter.
Clinical Sample Collection.
The human subjects-certified research team personnel immediately de-identified each
sample, removing all protected health information prior to submission to any non-clinical
investigators. Only the study ID was available to individuals who were not involved in human
subject recruitment, retention and oversight. All urine was collected in sterile blue capcollection cups (BD #364956), from which a dipstick test was preformed and a grey-top culture
tube was filled, as is standard practice for clinical microbiology samples. The grey-top culture
tubes contain a preservative that inhibits bacterial growth, but does not kill the cells. The greytop tubes were left at room temperature, and the blue-top collection cups were refrigerated,
until processed by the Wolfe lab, in order to prevent bacterial growth. The swabs were
collected using the BD ESwab (BD#220245), which contains a swab resting in 1 ml of bacterial
preservative. Following collection, swabs were kept at room temperature. All samples were
sent to the Wolfe lab for EQUC assessment within 4 hours of collection.
Power Calculation and Sample Size.
In a previous study, we observed that UUI women had a more diverse FUM than non-UI
controls 3,6. The species accumulation analysis (Figure 3 also in Figure D.2) illustrates the
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number of unique species cultured and identified (using EQUC) with each new patient sampled.
When the curve plateaus, it indicates that the community is fully sampled and few, if any, new
species will be identified. Therefore, it also measures the overall diversity of the population by
total number of unique species isolated. The UUI group isolated 80 unique species at baseline
and the control cohort isolated 36 unique species. Therefore, the species isolated from UUI was
far more diverse than the species isolated from controls. There was statistical difference in the
median number of isolates collected from each individual in each cohort [M=3 (IQR: 1-7) versus
M=1 (IQR: 1-2), p<0.001].
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Figure 3. UUI Communities are More Diverse than Non-UI Controls. A rarefaction analysis
showing the number of unique species of bacteria isolated (using EQUC) with each new
patient sampled. More unique species of bacteria are seen in the UUI population than the
non-UI controls. The median number of unique species isolated from each individual in the
group is shown in the inset table.
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Based on the difference in diversity between UUI and non-UI controls (Figure 3), we
determined that a sample size of 40 will give us sufficient power (0.816), using the WilcoxonMann-Whitney test, to detect the difference between patients whose urinary microbiomes
retain high diversity compared to those that change to a low diversity state.
Laboratory Assessments
Sample Processing and Storage.
All samples were processed for culturing and stored for sequencing within 24 hours of
arriving at the Wolfe Lab.
Standard Urine Culture (SUC) and Enhanced Urinary Quantitative Culture (EQUC) Procedures.
All cultures were set up in a biosafety cabinet in a room designated biosafety level 2
(BSL2) to prevent cross contamination from any other bacterial experiments happening in the
department.
Grey-topped catheter samples were processed with SUC and EQUC methods. For SUC, 1
µl of urine was inoculated onto 5% sheep blood agar plate (BAP) and MacConkey agar plate,
incubated aerobically at 35°C for 24 h. EQUC uses 100 µl of urine grown under 5 conditions: (1)
blood agar plates (BAP) in CO2 for 48 h, (2) chocolate agar (CHOC) in CO2 for 48 h, (3) colistin
and nalidixic acid (CNA) agar in CO2 for 48 h, (4) CDC anaerobe BAP in an anaerobic jar for 48 h,
and (5) BAP in aerobic conditions for 48 h (Table 2). If the SUC contained high growth at 24 h,
we read all the other plates, for all samples, for that patient and did not incubate the extra 24
h.
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We initially used the exact same protocol for all samples (urine obtained by TUC or void
and vaginal and perineal swabs), but after the 10th patient, it was evident that the extra work
involved for the high biomass samples (voided and both swabs) was not resulting in more data,
and the overgrowth could be masking lower biomass organisms. We thus decided to pare down
both the number of plates and the overall volume plated for the high biomass samples. From
patient 11-30 we used 10 µl of urine onto BAP, CNA, and Anaerobic BAP (ABPA) for voided
urine and both swabs. Between the 30th and 34th individual, we stopped culturing the perineal
swab and voided urine all together. Then, we decided to continue culturing, but to bring the
volume down even further to 1 µl for the perineal swab and voided urine (Table 2).
Each morphologically distinct colony type in both SUC and EQUC procedures was
counted and isolated onto a fresh plate of the same media to be used for identification with
Matrix-Assisted Laser Desorption/Ionization Time-of Flight (MALDI-TOF) mass spectroscopy.
This is the protocol used for our recent publications 3,6,7. Following identification, we stored
down isolates in our collection in CryoSavr tubes pre-filled with Brucella medium and glycerol
(Hardy Diagnostics CS100BNB) at -80°C. Because we use multiple media and conditions, we
often isolate the same species on each plate. Initially, we isolated 2 clonal species from each
species represented from each niche. However, this was a large burden on our storage facility,
and following the 10th patient, we stepped down to 1 representative of each species from each
niche. A full list of isolates collected can be found in the culture master list for this project
(Share drive: WolfeLab\LUREC\EST_Effect of Estrogen_KTW_ST).
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Table 2. Culture conditions for all Estrogen study samples

Catheterized Urine
Standard
EQUC
Vaginal Swab*
Perineal Swab**
Voided Urine**

BAP in
O2 for
24 hr

MAC in
O2 for
24 hr

1 µl

1 µl

BAP in
CO2 for
48 hr

CHOC in
CO2 for
48 hr

CNA in
CO2 for
48 hr

Anaerobic BAP in
BAP for
O2 for
48hr
48 hr

100 µl
10 µl
1 µl
1 µl

100 µl

100 µl
10 µl
1 µl
1 µl

100 µl
10 µl
1 µl
1 µl

100 µl

* Initially, all samples were process the same way as the catheterized samples. But, it was discovered that the high
biomass made the plates difficult to read. Therefore, the volume plated and the overall conditions were decreased
to what is shown in the chart. This decrease happened at the 11th baseline patient. See the first tab of the culture
worksheet in the share drive for complete time point information: N:\WolfeLab\LUREC\EST_Effect of
Estrogen_KTW_ST
** The perineal swabs and voided urine underwent the same decrease in volume as the vaginal swabs, but it was
still too much to cultivate. We decided to decrease the volume even further to 1 µl at patient EST35.

Enriched Culture Samples.
In addition to storing down pure isolates, we also stored down “enriched culture”
samples. There is the possibility of multiple strains of the same species residing in a given niche,
and, by selecting only a single isolate, we could be missing species diversity in each location.
Since storing down multiple isolates was cost-prohibitive, we decided to store down the entire
plate instead. Following selection of individual morphologies for MALDI ID, the plates were
swabbed and stored down in PBS with 10% AssayAssure. This storage media should be
sufficient for preservation of the nucleic acids for future metagenomic sequencing, but not for
future culturing. These samples represent the total biomass cultured on a given plate and are
therefore not indicative of the overall biomass of the original sample. These samples were
collected through the 16th baseline sample and the first 6 12-week samples.
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16S rRNA Gene Sequencing.
All samples were also stored down for future 16S rRNA gene sequencing. Each sample
was processed under a PCR hood to prevent environmental contamination. Each sample was
given a unique Wolfe-lab identifier, and overall volume was recorded. The general color,
turbidity, and pH were recorded for all urine samples. 10% of the nucleic acid preservative
AssayAssure (Sierra Molecular) was added to each sample prior to storage at -80°C.
The bladder is a low biomass niche and low biomass samples. High throughput
sequencing technologies are susceptible to sequencing contamination 114. Therefore, we use a
wide variety of methods (such as soaking materials in bleach, wiping down in DNA away,
working in a PCR hood, and using extraction controls); however, there is still a low level of
contamination. We estimate that the detection threshold for sequencing is about 1000 CFU/ml,
and in our previous studies, only 50% of our populations could be characterized by sequencing
3,6.

On the other hand, EQUC can characterize 80-90% of our populations. For this reason, we

chose to focus our analyses on EQUC data and not report our 16S analysis. See the methods
sections for Appendices B-E and I-J for more information on the methods used for 16S
sequencing.
Statistical Analysis
Statistical analyses of the EQUC data were performed using SAS software version 9.3.
Wilcoxon rank sum tests were used to compare the median abundance for the most abundant
sequenced taxa, and all cultured genera between groups. The frequency of detected genera
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was compared between groups, using either Pearson chi-square or Fisher’s exact tests,
depending on assumption validity. Each individual functioned as her own control, with the
initial visit establishing the baseline profiles prior to estrogen treatment. Because we were not
finished recruiting and collecting samples for this study, no analyses were be done comparing
patient demographics and microbiome profiles. Appendix M lists scripts for creating relative
abundance graphs, calculating diversity and generating dendrograms in RStudio 115.
Microbial Whole Genome Sequencing and Analysis
As described in the study design, we obtained paired urine samples and vaginal swabs
from the same individual, isolated microbes from these paired samples, and used MALDI-TOF
mass spec to obtain a putative classification to the species level. Additionally, a subset of
organisms underwent whole genome sequencing to allow for more in-depth genome analysis.
Here, I asked whether the same species were observed in both niches. The analysis was
performed at multiple levels, species presence/absence, phylogeny, and genetic markers. I also
performed genomic comparisons on samples collected from other studies, as well as publicly
available genomes. I will go over each of these protocols in turn.
Whole Genome Sequencing Library Prep.
The isolates were grown in their preferred medium and pelleted. Genomic DNA was
extracted from pelleted cells using a phenol-chloroform method 116. Genome sequencing was
either completed at the Loyola core genomics facility, or with our collaborators in the Lawley
lab at the Wellcome Trust Genome Campus in Hintxon, UK. Samples processed at either facility
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underwent similar processing. The Illumina Nextera kit was used for whole genome library
preparation, as described previously 117. Briefly, the bacterial genome was fragmented and
tagged using a transposon system, and then Illumina sequencing adapters and dual-index
barcodes were added to allow for multiplexing of samples. The resulting fragments were
purified and size-selected using AMPure XP beads, quantified via the Qubit 2.0 Fluorometer and
Agilent Bioanalyzer, normalized to equimolar concentrations, and sequenced using the Illumina
MiSeq System. The concentrations of DNA loaded onto the sequencer were calculated based on
the expected genome size and average fragment size to achieve 10X coverage of the entire
genome. Quality control and de-multiplexing of sequence data was done with onboard MiSeq
Control software and MiSeq Reporter (current version: 2.1.43).
Whole Genome Assembly and Annotation.
Annotated assemblies were produced using a pipeline, as previously described118. For
each sample, sequence reads were used to create multiple assemblies using VelvetOptimiser
v2.2.5119 and Velvet v1.2120. An assembly improvement step was applied to the assembly with
the best N50 and contigs were scaffolded using SSPACE121 with sequence gaps filled using
GapFiller122. Automated annotation was performed using PROKKA v1.11123 and genus-specific
databases from RefSeq124. Genomes of good quality and with at least 10X coverage were used
for further processing.
If the genomes required modification, reprocessing was completed in Catherine
Putonti’s lab. Briefly, the reads were run through Sickle for QC 125, using the standard
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parameters from the Wellcome Trust and a minimum length of 100bp. The sequences were
assembled with SPAdes 126, using the paired-end reads that passed QC and the non-paired end
(singletons) reads. Five assemblies were generated (k=33,55,77,99, and 127) in the ‘onlyassembler’ option, and the best was chosen, as defined by Spades. The genomes were then
filtered based on < 10x coverage and < 1kb per contigs. The genomes were filtered again, this
time for low level contamination; if contamination was detected, the genomes were run
through peasant (written by the Putonti lab) to exclude the lower abundance samples. These
genomes were then annotated using the above specifications.
To confirm accurate speciation, the 16S rRNA gene was extracted from the annotation
using Artemis 127, and BLASTed for classficiation 128. For phylogenetic analysis of the 16S gene,
alignments were generated using MAFFT 129 in Galaxy 62, RAxML 130 for bootstrapping and tree
generation, and Figtree and ITOL 131 for tree visualization.
Phylogenetic Analysis
In bacteriology, phylogeny is typically determined using the 16S gene rRNA gene, which
can be used to classify a bacterium to the species level. If the gene contains 100% to 97%
similarity to a known species, then it is considered a member of that species. If the gene
contains more variability, then it is a different species in the same genus. However, this method
is not without flaws. It relies on measurement of just one gene, and does not account for
potential horizontal gene transfer of the 16S gene. There are well-documented cases where the
16S gene shares similarity between two divergent species (see Appendix K) 132,133. Therefore,
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for our purposes, the 16S gene is insufficient to differentiate between related organisms. To
overcome this, phylogenetic relatedness was measured in three separate ways: using the 16S
gene, using 40 marker genes 134,135, and using average nucleotide identify (ANI) 136-138.
Compared to the 16S-based phylogeny, fetchMG extracts 40 universal phylogenetic
marker genes 135,139. Like the 16S gene, all 40 genes are essential for life; the genes include
ribosomal subunits, tRNA synthetases, and RNA polymerases. All of the genes have been
experimentally shown to have low horizontal transfer rates 134, and even if one gene was
transferred, transfer of all 40 would be highly unlikely. In this way, we increase the
informational input and, therefore, the accuracy of each tree.
In contrast to choosing specific marker genes, with fetchMG, we can compare the
average nucleotide identity (ANI) between the core, or conserved, genomes of any two given
strains. The more closely related the two strains are, the greater amount of the genome is
compared in this method. ANI is the bioinformatics equivalent of DNA-DNA hybridization
(DDH), albeit more accurate, and as such is the new gold standard for speciation 136. Previously,
the definition of a new species included at least one diagnostic phenotypic trait and a DDH
score of at least 70% or less 140. This 70% DDH cutoff is equivalent to about 95% sequence
identity 138. Although there is debate about the exact cutoff threshold, 96% seems to be the
consensus. For our purposes, we will use ANI to detect overall phylogenetic differences
between isolates from the vagina or bladder, and to determine whether or not these shifts
correspond to distinct strains.
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Synteny.
The percent identity obtained from ANI can give a relatively clear picture of the
similarity between strains, but it is not complete. It is possible that the same genes are present,
but in a completely different genomic orientation. To assess genomic orientation one must
measure synteny, or the conservation of the order of genes within a genome. Using the Artemis
Comparison Tool (ACT), we can visualize blocks of synteny between two genomes 141.
Additionally, we can visualize the regions that might be present in one genome but missing
from another.
To measure synteny, the contigs must be ordered; otherwise, very little information can
be gained about the arrangement and position of the contigs. Ordering is normally done by
aligning to a reference genome; but, as you can see in Chapter V, the reference genomes do not
usually share a high percent identity with the bladder and vaginal isolates. Instead, I chose to
use one of the isolate genomes as the reference and ordered the contigs from the other isolate
genomes to it, using ABACAS 142. ABACAS uses MUMmer143 to align contigs and automatically
generates a comparison file for use in ACT.
Identifying Genomic Signatures (CDS, Domain, and CRISPR analysis).
The previous methods all rely on phylogenetic differences between strains; however, it
is very likely that a distinct niche-associated signature would not reside in the core genome but
rather in the accessory genome. Therefore, we used other bioinformatics tools to analyze
differences between the genomes. To explore differences in the genomes across a wide range
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of individuals, my collaborators, Nitin Kumar and Sam Forster, post-doctoral fellows in the
Lawley lab at the Sanger Institute, performed both the CDS and domain analyses. To explore
differences in the genomes from isolates within a given individual, my collaborators in the
Putonti lab at the Loyola Lake Shore Campus performed CRISPR array analysis.
CDS analysis. The genome annotation process relies on comparisons to known genes. In
a newly assembled genome, an open reading frame, otherwise known as a coding sequence
(CDS), is identified based on the regions lacking stop codons. The CDSs are then compared to
known genes. If the database contains a homologous gene, the CDS is given that label; if it does
not, the CDS is labeled a “hypothetical protein” or “genes of unknown function”. CDS
characterization can be a flawed process; ideally, each gene’s identification should be
experimentally verified, but this is not practical. Using this method, however, many of the
common genes involved in metabolism and basic cell functions can be easily and accurately
identified.
Domain analysis. Alternatively, many genes have no known function or are misidentified by either the annotation or COG method, but we can fairly accurately predict
domains of proteins through homology. NCBI’s conserved domain database (CDD) is a
repository of multiple sequence alignments representing conserved protein domains 144. The
whole genome of each isolate was compared to the CDD database, resulting in a list of protein
domains for each isolate. Using principle component analysis (PCA) and Discriminant Analysis of
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Principal Components (DAPC), we determined how closely related each isolate’s list of domains
is to any other list, and color-coded based on isolation location.
CRISPR array analysis. CRISPR arrays were identified using CRISPRFinder 145. The
upstream and downstream regions were identified using an in-house python script to read in
the CRISPRFinder results (specifically the locations of the arrays in the contigs) and then parse
out the upstream and downstream regions from the contigs.

CHAPTER III
A GLOBAL COMPARISON OF BLADDER GENOMES TO GUT AND VAGINAL GENOMES
Overview of the Study Design
This study was conducted in collaboration with Sam Forster and Nitin Kumar in Trevor
Lawley’s lab at the Wellcome Trust Genome Campus in Hinxton, UK. To represent the total
phylogenetic diversity of bacteria cultivated from the bladder, we chose to sequence 130
isolates from species that spanned that diversity. Most of the sequenced isolates were
collected as part of the Astellas study (Appendix C-D)3,6 or the maternal urinary microbiome
study (Appendix I); two E. coli genomes from a UTI study were also included (one from a
symptomatic woman and one from an asymptomatic woman, Appendix H)43. These genomes
were compared to a collection of 209 previously published gut isolates collected by the Lawley
lab 146, and a set of 135 publicly available vaginal isolates (the majority of which were collected
by the HMP) 11. Vaginal genomes were only included if the metadata specifically stated that the
isolate had been collected from the vagina (i.e., “urogenital” isolates were excluded). A full list
of the isolates used are listed in Appendix N. As described below, these data show that bladder
isolates closely resembles the vaginal isolates, but not the gut.
Phylogenetic Diversity of Cultivated Bladder Isolates
Figure 4 shows the complete phylogenetic diversity of the cultivatable organisms from
bladder. Uropathogenic species, such as E. coli, Klebsiella, and Proteus (members of the
44

45

Enterobacteriaceae family) represent only a small portion of the phylogenetic diversity in the
bladder. In fact, other than these uropathogens, very few Proteobacteria or even Gramnegative organisms were found. Instead, the largest amount of phylogenetic diversity was
found from the Gram-positive phyla Firmicutes and Actinomycetes, particularly the families
Streptococcaceae, Lactobacilliaceae, and Bifidobacteriaceae.
Comparison Functional Markers from the Bladder, Vaginal, and Gut Isolates
The bladder isolate genomes were then compared to a dataset of vaginal and gut
isolates cultivated from unrelated individuals. Using the genome annotations, we compared the
CDSs that fall within given functional categories. Specifically, we used the categories
standardized by the clusters of orthologous groups (COGs), which are organized into specific
functional groups. We compared the number of genes in each COG functional group between
niches (Figure 5A). Unsurprisingly, being the most diverse niche, the gut dataset contained the
most CDS in every category measured. In contrast, the vaginal microbiome consistently had the
fewest number of CDS in each category. The bladder dataset was consistently intermediate,
having the same number of CDS with the gut in categories such as secondary metabolites
biosynthesis, transport and catabolism, and lipid transport and metabolism. But, it had
numbers of CDS similar to the vaginal dataset for categories such as cell cycle control, cell
division, and chromosome partitioning. In all other categories, the bladder dataset fell directly
between the vaginal and gut datasets (Figure 5A). We are currently unclear as to the underlying
reason for this pattern.
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Figure 4. Phylogenetic Diversity of Bladder Bacteria. A representation of the full diversity
that can be isolated using the EQUC method from catheterized urine samples. A maximum
likelihood tree generated from the 40 marker genes extracted from each genome. Each
branch is labelled with the species ID from PROKKA. The inner grey ring labels the three
phyla (Firmicutes, Actinobacteria and Proteobacteria) and the colored outer ring indicates
the Families represented in the tree.
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A.

B.

Figure 5. Comparing Functional Differences Between the Bladder, Vagina, and Gut Bacterial
Genomes. Bladder data is represented in red, vaginal in yellow and gut in blue. (A) COG
analysis of isolates and (B) DAPC of conserved proteins domains from the genomes collected
from the three sites.
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Table 3. A List of Isolates that are 100% identical Between the Bladder and Vagina by DAPC.
Species
Bladder Isolate ID Vaginal Isolate ID
ANI (%)
16933_8#44
MJR8396A
98.4712
Actinomyces neuii
16933_8#7
MJR8396A
98.5629
Alloscardovia omnicolens
17957_1#65
CMW7705A
96.9694
Lactobacillus crispatus
16933_8#46
Vmc8
98.4497
Lactobacillus gasseri
16933_8#18
202-4
99.543
16933_8#49
SJ-7A-US
99.8639
Lactobacillus jensenii
17957_1#81
SJ-7A-US
98.6966
Lactobacillus rhamnosus
17957_1#9
51B
96.8512
Streptococcus mitis
16933_8#21
CMW7705B
97.4119
Two vaginal species (A. neuii and L. jensenii) pair with two separate bladder isolates

Many genes have no known function or are misidentified by either the annotation or
COG method, but homologous protein domains can be accurately predicted. The predicted
protein domains were extracted from each genome and the list of these domains were
compared between all isolates using DAPC, which highlights the variations between groups,
minimizing the within-group variation (See Domain Analysis in the Methods chapter) 58.
Isolates with similar domain profiles clustered together. When the DAPC plot was colorcoded based on niche, we observed strong clustering based on isolate collection location
(Figure 5B). The cluster of gut isolates was distinct from the bladder and vaginal isolates,
indicating that the bladder and gut isolates do not contain similar protein domains. This lack of
overlap suggests that these niches share few of the same strains, and little to no functionality.
About half of the bladder and vaginal isolates overlapped (Figure 5B), indicating that many
isolates in each group contain the same functionality and suggesting that at least half of the
organisms could be shared between sites. This result also indicates that a few isolates may be
unique to each niche and do not share functionality.
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Upon further analysis, we identified a few isolates whose protein domains are 100%
identical between the bladder and vagina (Table 3). This is remarkable, considering that these
isolates were collected at different times from completely unrelated individuals. This identity
indicates that a bacterium isolated from the bladder of one individual has the same protein
domain profile as a bacterium isolated from the vagina of another. In the case of two species
(A. neuii and L. jensenii), one vaginal isolate matched two different bladder isolates (Table 3).
From these observations, we infer that certain organisms with certain functionality profiles are
highly conserved across humans. We further compared the isolates that had 100% identical
protein domains using ANI (Table 3). Even though the protein domains profiles were 100%
identical, ANI showed a decent amount of variability, from 96.8% to 99.5% identical. This
difference suggests that even if the strains have the same function there might still be distinct
differences between bladder and vaginal isolates.
Summary
These data highlight the possibility of an interconnected urogenital microbiome, one
that has specific and highly conserved functions between humans. If we could understand the
function of these shared genes, we would be closer to understanding how a single bacterium
could live in both anatomical sites. These data also suggest that a bladder-specific genetic
signature may be identifiable. About half of the isolates in both the bladder and vagina were
distinct from each other and did not share a corresponding functional profile in the other site.
Even if some bacteria can live in both sites, this observation suggests that some do not.
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Additionally, even the bacteria whose protein domain profiles were 100% similar still showed
some variation in their overall genomes. These data may be the first snapshot of niche-specific
functionality and species.

CHAPTER IV
THE BLADDER AND VAGINAL COMMUNITY STRUCTURE SHIFTS FOLLOWING
ESTROGEN TREAMENT
Overview
It is documented that estrogen therapy changes the vaginal community 26. Although
some studies have assessed the vaginal microbiome of post-menopausal women 18,147, no one
has tried to capture that change in real time, and no one has explored the effect of estrogen on
the FUM. Here, we measured the bladder and vaginal communities at baseline and following 12
weeks of estrogen treatment.
This document describes 40 patients, 21 of whom have returned for their 12-week
sample. Due to sample collection errors, we lack CFU/ml data for patients EST01 at the 12-week
time point, and EST08 at the baseline time point. However, we do have the isolate identifiers
for these samples; therefore, they are included in the species accumulation analysis, but must
be excluded from the relative abundance and diversity measurements. Thus, there is a slight
discrepancy between sample counts for each specific analysis.
As stated in the study design, we collected perineal swabs and voided urine at each time
point for each individual. Data for these samples will be presented for overall biomass and
diversity, but will be excluded from figures and discussions of community structure data.
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In this chapter, I will present data describing the changes in the bladder and vaginal
microbiomes prior to and following treatment. Based on previous literature, we expect the
vaginal microbiome to decrease in diversity and transition to a more Lactobacillus-dominant
community, without changing the overall biomass of the niche. If the two sites are
microbiologically linked, and the FUM responds to estrogen, we would expect to see a
corresponding decrease in diversity and shift towards Lactobacillus-dominance in the bladder.
The data do follow these patterns, suggesting that estrogen modifies both pelvic floor niches.
Diversity Decreases in the Bladder and Vagina Following Treatment
Species accumulation curves were used to assess the diversity of the bladder and
vaginal environments (Figure 6A), as well as the perineal and voided urine samples (Figure 6B).
The curves represent the increase in the detection of additional unique species identified from
each newly sampled participant in each group. Once the curve reaches a plateau, it represents
the near total number of unique species found in that population. In Figure 6A, the vaginal
samples are in red and the bladder samples are in blue; both darker lines represent baseline
samples, while lighter lines represent 12-weeks samples. The baseline vaginal community was
much more diverse than the baseline bladder community (80 versus 53 isolates, respectively).
At 12-weeks, this relationship was retained. From baseline to 12 weeks, the vaginal microbiome
showed a decrease in overall diversity, with a difference of 63 versus 55 isolates, at the same
recruitment level (21 patients). A corresponding decrease was observed in the bladder
community, with a difference of 40 versus 32 at the same recruitment level (21 patients)
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(Figure 6A). In contrast, neither the perineum (yellow lines) nor the voided urine (green lines)
had measurable decreases in diversity using this method (Figure 6B).
In addition to species accumulation curves, different alpha diversity measurements
were calculated, including measurements of richness (total number of species found) and
evenness (the distribution of those species (Figure 6C and D). The vaginal community showed
significant differences in 2 of the 5 diversity measurements, Fisher’s alpha (p=0.01) and overall
richness (0.01). In contrast, the Peilou measurement of evenness alone is not significant
(p=0.98) (Figure 6C). Since Fisher’s alpha takes into account both richness and evenness, but
Peilou measures evenness, we can infer that the change in diversity is primarily driven by
richness. This conclusion is supported by the species accumulation curve, which inherently
measures species richness. Thus, both methods of measuring diversity demonstrate that the
overall number of unique species is decreasing in the vagina following estrogen treatment. For
the bladder environment, we saw no decrease in any diversity measurement (Figure 6C), a
result that does not match those from the species accumulation curves.
Voided urine showed an intermediate phenotype. By species accumulation curves, there
was no decrease in diversity at 12 weeks (compare light to dark green lines in Figure 6B). This
indicates that voided urine is not a measurement of the bladder environment, nor is it a
combination of bladder and vaginal flora. Potentially, it also contains perineal, or skin, flora.
However, empirical measurements of richness and evenness, specifically Fisher’s alpha (p=
0.03), do show a significant decrease (Figure 6C). Additionally, the voided urine boxplots show a
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trend toward a decrease in richness, but it was not significant (p=0.13) (Figure 6C). Overall, this
suggests that voided urine is a poor measure of total diversity in the bladder.

A.

B.

Figure 6. Diversity of the Microbiota in the Bladder, Vagina, Perineum and Voided Urine.
Species accumulation curves are shown for (A) the bladder (blue) and vaginal swabs (red) and
(B) perineal swabs (brown )and voided urine (green). (C) Five diversity measurements were
calculated for each niche at each time point and compared with boxplots: Shannon diversity,
inverse Simpson, overall richness, Peilou, and Fisher’s alpha diversity.
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Figure 6. Continued…

C.
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Figure 7. The Biomass of Each Site Sampled at Baseline and 12-weeks.
The biomass does not change in response to estrogen.
To check that the change in diversity was not associated with an overall decrease in
biomass, we measured the total biomass of each sample at baseline and 12 weeks by total
CFU/ml (Figure 7). The bladder had a consistently lower biomass than the vagina, the perineum,
and voided urines, which all had similar biomasses. When the biomass at baseline was
compared to the biomass at 12 weeks, the bladder and vagina did not show significant
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differences (p=0.21 and 0.82, respectively). This illustrates that any decrease in diversity we
measured in the bladder and vagina could not be due to overall decrease in biomass. However,
the voided urine sample showed a significant elevation in total CFU/ml by 12 weeks (p=0.029),
and the perineum seemed to show a trend towards increased biomass, suggesting that voided
urine may be more closely related to the perineum because both sites did not stay stable, but
increased following treatment.
The Frequency of Lactobacillus-Dominant Profiles Increases by 12-weeks
Measurements of diversity show that a change had occurred, but do not provide any
information as to the identity of the organisms involved. We hypothesized that there would be
an increase in the frequency of Lactobacillus dominance. To measure this, we compared the
relative abundance of all baseline and 12-week samples from the vagina and bladder (Figure 89). Each bar represents the percent of total CFU/ml with each color representing a different
genus. For example, Lactobacillus is in blue. For each baseline and 12-week dataset, Bray-Curtis
dissimilarity was used to group similar environments together. Relative abundance graphs were
aligned with the corresponding Bray-Curtis derived dendrogram, and the Lactobacillusdominant clades were identified (Figure 8A-B, Figure 9A-B). Using this method, we measured
the frequency of Lactobacillus-dominant profiles at baseline and 12 weeks for both the vagina
(Figure 8) and bladder (Figure 9). To determine how many of the 12-week samples started as
Lactobacillus, the 12-week samples were aligned with their corresponding baseline samples
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(Figure 8C, Figure 9C). The frequency of Lactobacillus profiles for the vagina and bladder are
listed in Figure 8D and 9D, respectively.
In the vagina, 21% (8/38) of the patients were dominated by Lactobacillus at baseline,
and that shifted to 40% (8/20) by 12 weeks (Figure 8A-B). This is a modest increase, but an
increase nonetheless. Of the 8 12-week Lactobacillus-dominant profiles, 4 of them (50%)
started out as Lactobacillus-dominant and 4 shifted towards Lactobacillus-dominance (Figure
8C).
In the bladder, 10% (4/38) of the patients were dominated by Lactobacillus at baseline.
By 12 weeks, that number had increased to 35% (7/20). Of the 7 12-week Lactobacillus
dominant samples, 2 of them started out as Lactobacillus-dominant, and 5 (71%) shifted
towards Lactobacillus-dominant from a different background (Figure 9).
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Figure 8. Vaginal Microbiome Community Structures at Baseline and 12 weeks. The vaginal
microbiota from each individual are organized by the Bray-Curtis dendrogram groupings at
(A) baseline and (B) 12-weeks. From the relative abundance graphs, it is clear that each
group has a population of people dominated by Lactobacillus (blue). To determine which
individuals shifted from a non-Lacto to a Lacto profile, (C) the 12-week samples were aligned
with their corresponding baseline samples. Due to mix-ups in sample collection EST08 did
not have CFU/ml for the baseline sample but did in the 12-week. Therefore, the last bar in
figure C does not have a corresponding baseline sample. (D) The overall frequency of
Lactobacillus-dominant individuals is listed.
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Figure 9. Bladder Microbiome Community Structures at Baseline and 12 weeks. As in
Figure 6, each baseline and 12-week sample is not only organized by dendrogram (A-B),
but the 12-weeks are also aligned with their corresponding baseline sample (C). Due to
mix-ups in sample collection EST08 did not have CFU/ml for the baseline sample but did
in the 12-week. Therefore, the last bar in figure C does not have a corresponding
baseline sample. The overall frequency of Lacto-dominant individuals is listed (D).
The Bladder and Vaginal Microbiota Profiles are More Similar by 12-weeks
Thus far, we have looked at the patient data as a population, but not at an individual
level. Here, we analyzed how an individual’s microbiota profile shifts following 12 weeks of
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treatment. Of the 20 that have returned for their 12-week visit, two patient’s samples lacked
CFU/ml count data, EST01_12w, and EST08_B; therefore, these two samples have been
excluded from this analysis. Overall, eighteen patients have EQUC data from both the baseline
and 12-week time points. In Figure 10, each patient was represented by two sets of bars, the
first being the urine and vaginal swab collected at baseline (top graph), and the second being
the same two samples collected at 12 weeks (bottom graph). We assessed each paired set for
similarity between niches by grouping them into one of 4 classes: sets where both niches
contain the same organisms in similar proportions are called Class 1; sets where each niche had
the same dominant organism, but in different proportions are Class 2; sets where one sample
was below the level of detection (culture negative, black bars) are Class 3; and sets where both
niches were distinctly different are Class 4 (Table 4). I considered sample sets to be similar if
they fell into Class 1 and Class 2, and different if they fell into Class 3 or 4.
At baseline, 28% (5/18) of patients were Class 1 and another 28% (5/18) were Class 2.
Also, at baseline, 11% (2/18) were Class 3, and 33% (6/18) were Class 4. Overall, at baseline,
56% (10/18) were considered mostly similar, and 44% were considered mostly different (Figure
10, Table 4). In contrast, at 12 weeks, 44% (8/18) were Class 1 and 33% are Class 2, while 17%
were Class 3 and 6% are Class 4. Therefore, by 12 weeks, 77% of the samples were considered
mostly similar (Figure 10, Table 4).

62

Figure 10. Comparison of the Bladder and Vaginal EQUC Data of Each Individual Prior to
and Following 12-weeks of Estrogen Treatment. (A) The relative abundance graphs for
each patient’s paired bladder and vaginal sample at baseline (top graph) and 12 weeks
(bottom graph). Each bar represents the percent of total classified CFUs/ml with the color
representing a unique species.
Table 4: Calculating the Number of Similar Bladder and Vaginal Pairs at Each Time Point. Sets
where both niches contain the same organisms in similar proportions are called Class 1. Sets
where each niche has the same dominant organism, but in different proportions are Class 2.
Sets where one sample is below the level of detection (culture negative, black bars) are Class 3.
And sets where both niches are distinctly different are Class 4.
Considered mostly similar
Timepoint
Class 1 – Very similar Class 2 – Somewhat
similar
Baseline
EST05, EST25, EST28, EST06, EST10,
EST29, EST30
EST16, EST19, EST20
Proportion
28% (5/18)
28% (5/18)
56% (10/18)
12 weeks
EST05, EST06, EST09, EST04, EST10,
EST14, EST15, EST16, EST11, EST12,
EST28, EST30
EST19, EST20,
Proportion
44% (8/18)
33% (6/18)
77% (14/18)

Considered mostly different
Class 3 –culture Class 4 – Not similar
negative
EST04, EST23
EST03, EST09, EST11,
EST12, EST14, EST15,
11% (2/18)
33% (6/18)
44% (8/18)
EST23, EST25,
EST03
EST29
17% (3/18)

6% (1/18)
22% (4/18)
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Summary
We observed a decrease in overall diversity from baseline to 12 weeks; specifically, a
decrease in species richness. Additionally, there was a modest increase in the frequency of
Lactobacillus-dominant profiles by 12 weeks, but neither shift was as dramatic as anticipated.
We think this can be attributed to the short treatment interval. All other studies measuring the
effects of estrogen on the vaginal microbiome relied on cross-sectional analysis of cohorts of
women. Some compared cohorts of premenopausal and post-menopausal women 18. Other
studies compared groups of estrogen-negative postmenopausal women to those that have
been on HRT for months or even years 73; the average for one was 13 years 74. Therefore, no
other previous study has tracked the vaginal microbiome of individual women throughout
estrogen therapy. This leads us to hypothesize that the changes we observe during this 12-week
window are intermediate community states, and in some women the bacterial communities
have not yet fully adapted to the estrogen-rich environment. We would anticipate that if we
were to follow up with these patients at 6 months to 1 year, we might see the majority of them
have become Lactobacillus-dominant.
We also demonstrated that a given individual’s bladder and vaginal microbiome are
more similar to each other following estrogen treatment. At baseline, about half of the women
(56%) had similarities between the bladder and vaginal communities, but by 12 weeks that
number increased to three-quarters of the population (77%) (Table 4). It is even more striking
when you consider that the bladder and vagina have dramatically different biomasses (Figure
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7), but by 12 weeks, 44% of the populations contained similar organisms in similar proportions
(Table 4). This indicates that even with the discrepancies in environment, similar community
structures can exist in each niche. This could be explained in one of two ways, either (1) the
communities are responding similarly yet independently to treatment, or (2) that the two sites
are microbially linked and therefore a change to one niche results in a corresponding change to
the other. In the first scenario, we would expect the estrogen to affect the vaginal and bladder
epithlium, increasing glycogen storage in both locations, which would in turn enrich for the
same species of bacteria in each site. Alternatively, estrogen could be having an effect on
glycogen storage only in the vagina or the bladder but because the microbiomes are shared,
there is a community shift in both niches. Realistically, the truth may be somewhere in between
and estrogen results in changes in both epithelial layers, but because the bacteria are shared,
the community profiles change similarly in both niches.

CHAPTER V
NICHE SPECIFICITY BETWEEN THE VAGINAL AND BLADDER MICROBIOMES
WITHIN AN INDIVIDUAL
Overview
Our next goal was to determine if the bladder and vaginal communities within a given
individual at a given point in time were similar or distinct. We already know from Chapter III
that at least some organisms in the bladder and vagina are similar, even when they are isolated
from different individuals. Additionally, from Chapter IV we know that the bladder and vaginal
community structures look more similar to each other following estrogen treatment. However,
it is possible that, even in individuals with similar dominant organisms in both sites, there can
be less abundant bacteria that are distinct to a given niche. Hence, we wanted to know if there
were any common species that were commonly isolated and specific to a given niche. We
recognize that even if the same species are detected in each site, there could be distinct strains
with distinct functionality. Therefore, we also went on to sequence specific species sets and
compare each genome for strain similarity.
Bladder and Vaginal Species Accounting within Individuals
First, we asked if there is a species or set of species that is commonly and exclusively
found in one site. I analyzed all the culture data from each individual in the estrogen study.
Table 5 displays the number of species found in the bladder and vagina of 40 baseline samples
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and 21 12-week samples. Columns 2 and 3 list the total number of isolates found in the bladder
and vagina, respectively. It is important to note that the vagina consistently has a greater
number of unique species when compared to the bladder, which correlates with the greater
richness measured in Figure 4. The 4th column lists the number of species that are the same
between both niches for a given individual. This number is consistently greater than half, or
equal to, the number of isolates found in the bladder. Therefore, the species found in the
bladder are usually also found in the vagina of the same individual.
Next, I asked if there were any species that were unique to a given site. If a species was
found in a single site of that individual, I checked to see if that species had ever been found in
the other site in any other individual in this study, or in any previous study. Only 3 species were
unique to the bladder of a given individual, i.e. never isolated in that patient’s vagina (Table 4,
column 5). Of the 3, one of those species was isolated in the perineum of that individual at that
time point, one had been isolated from vaginal swabs in a separate study (dark highlight), and
the final one has only been isolated once. Therefore, using this method, we have not identified
a subset of species that are frequently and uniquely isolated from the bladder.
Of the species isolated from the vagina and not from the bladder, the majority has been
isolated from a catheterized sample in previous studies (dark highlight). That leaves 5
organisms that seem to be unique to the vaginal tract of these patients (Table 4, column 6).
Again, these “unique” species are not frequently isolated, and would not constitute commonly
detected isolates. These data suggest that most urogenital species can be detected in both
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sites. However, this analysis was performed only at the species level and did not consider
differences between strains of the same species.
Table 5. Comparison of the Total Isolates Found in the Bladder Compared to the Vagina of
Each Patient and Lists of Organisms Unique to Each Site.
Total organisms
found*
Study ID
EST01_B
EST02_B
EST03_B
EST04_B
EST05_B
EST06_B
EST07_B
EST08_B
EST09_B
EST10_B
EST11_B
EST12_B
EST13_B
EST14_B
EST15_B
EST16_B
EST17_B
EST18_B
EST19_B
EST20_B
EST21_B
EST22_B
EST23_B
EST24_B
EST25_B
EST26_B
EST27_B
EST28_B
EST29_B
EST30_B
EST32_B
EST33_B

# in
Organisms Not found in
Bladder Vagina common
the Vagina**◊
7
8
5
Lacto amylovorus Ϯ
1
10
1
Bifido longum
1
6
1
Coryne jeikeium
0
7
0
4
8
4
1
7
1
10
13
6
4
3
3
5
7
3
5
13
5
9
11
6
1
10
1
3
9
1
1
13
1
4
11
2
5
11
3
0
15
0
11
9
6
6
6
5
1
5
1
1
8
1
4
12
2
0
1
0
0
19
0
1
1
1
7
11
6
2
16
1
2
9
2
7
8
5
2
7
1
7
13
3
5
13
3

Organisms Not found in
the Bladder◊
Actinomyces radingae
Actinomyces urogenitalis
Candida albicans
Comamonas kerstersii Ϯ Ϯ
Dermabacter hominis
Gemella morbillorium
Globicatella sulfidiciens
Lacto johnsonii
Lacto parabuchneri
Lacto vaginalis
Micrococcus luteus
Proteus mirabilis
Staph cohnii
Strep vestibularis
Staph pasteuri
Staph simulans
Staph warneri
Strept constellatus
Strept lutetiensis
Rosamonas mucosa Ϯ Ϯ
Bacillus subtillus
Lacto acidophilus
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Table 5. Continued
Total organisms
found*
Study ID
EST34_B
EST35_B
EST36_B
EST37_B
EST38_B
EST39_B
EST40_B
EST01_12week
EST03_12week
EST04_12week
EST05_12week
EST06_12week
EST08_12week
EST09_12week
EST10_12week
EST11_12week
EST12_12week
EST14_12week
EST15_12week
EST16_12week
EST19_12week
EST20_12week
EST23_12week
EST25_12week
EST28_12week
EST29_12week
EST30_12week
EST32_12week

Bladder
3
2
0
5
3
4
1
5
3
1
1
1
3
3
1
3
7
6
3
3
6
8
0
0
2
0
3
5

Vagina
4
9
9
8
6
12
6
7
10
10
9
8
12
3
9
5
9
8
7
13
4
10
3
6
5
8
5
7

# in
common
2
1
0
3
1
2
1
2
3
1
1
1
3
2
1
3
4
4
3
2
4
7
0
0
2
0
2
3

*not including unknowns
**From our entire study, each listed organism in this column has only been isolated once.
Ϯ
Found in the perineum of the same individual
◊
This list contains all organisms found in only one site in this study. Darkened organisms means it has been found in
the opposite site in previous studies.
ϮϮ
Isolated only once from this, or any, study.
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Genetic Analysis of Species Sets
For this analysis, we selected patients in the estrogen study with the same isolate in
both sites at both time points (sets of 4 isolates each) to test two related but unique
hypotheses. First, we asked how stable a given niche was over time. If there were great stability
over time, we would expect the strains within a given niche to be identical at baseline and 12
weeks. If there was a great amount of transience, or the community contains a population of
two or more strains of a species, the strains would be different at baseline and 12 weeks. We
must understand this stability first, to draw any conclusions about the interconnectedness of
the two sites. If a niche were not stable, then we could not conclude anything about the
similarity or differences when comparing strains from another niche, because we would not
know if the observed differences were due to niche interconnectivity or transient loss of an
organisms from a volatile system. Therefore, in the sites with stable (and therefore
hypothetically clonal) populations, we can compare the two sites with each other.
The isolates chosen for WGS are listed in Table N.4A and Table 6, and the reference
genomes, used to place these clinical isolates into phylogenetic context, are listed in Table
N.4B. Isolates are organized into sets of four: a baseline bladder, a baseline vaginal, a 12-week
bladder and a 12-week vaginal isolate. The only exception is G. vaginalis, which only contains
two isolates. S. anginosus and C. coyleae have isolate sets from two individuals. Additionally,
some patients have multiple sets of isolates represented (patient EST08 has an isolate set for A.
urinae and E. coli and patient EST11 has an isolate set for C. amycolatum, G. vaginalis and C.
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coyleae Table N.4A). In total, we have sequenced 36 genomes, representing 8 different species
from 7 different individuals. To assess the quality of the genome sequence, the number of
overall contigs, the N50 (or the contig that when summed with the larger contigs contains half
of the total genome size), the median contig size, and the average sequencing coverage are
listed in Table 6. To assess the dominance of that isolate in the original sample, we have listed
the relative abundance of that isolate in Table 6.
Table 6. Assembly statistics for all strains used in Each Species Set

C. amycolatum
(EST11)
AW24_Cath_B
AW12_Cath_12w
AW06_Vag_B
AW10_Vag_12w
E. coli (EST08)
AW04_Cath_B
AW14_Cath_12w
AW01_Vag_B
AW16_Vag_12w
L. iners (EST16)
AW08_Cath_B
AW18_Cath_12w
AW09_Vag_B
AW19_Vag_12w
L. crispatus (EST10)
AW22_Cath_B
AW32_Cath_12w
AW23_Vag_B
AW33_Vag_12w
A. urinae (EST08)
AW03_Cath_B
AW15_Cath_12w
AW02_Vag_B
AW17_Vag_12w

Relative
Abundance
by EQUC

Number of
Contigs

N50

Median
Contig
Length

Average
coverage

12.5%
0.2%
0.3%
0.3%

70
45
646
707

111415
160628
143372
146370

11146
25270
355
359

84.3
182.4
165.5
7.7

No info
99.9%
No info
28%

169
201
117
132

115344
247182
107673
247226

1355
635
9444
978

66.8
72.5
75.7
72.3

88%
66%
43%
80%

10
380
7
42

99769
22918
839239
840074

11783
3021
99769
1155

412
134
214.0
435.6

100%
32%
36%
42%

238
298
286
1478

19090
19460
20244
15241

4827
2997
2877
325

395.5
64
291.8
56.2

No info
0.005%
No info
16%

99
35
1254
124

200719
153022
14660
135785

499
22273
760
3711

229.2
224.2
126.7
272.6
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Table 6. Continued

G. vaginalis (EST11)
AW30_Cath_12w
AW25_Vag_B
C. coyleae (EST11)
AW05_Cath_B
AW11_Cath_12w
AW07_Vag_B
AW13_Vag_12w
C. coyleae (EST05)
AW20_Cath_B
AW28_Cath_12w
AW21_Vag_B
AW29_Vag_12w
S. anginosus (EST14)
AW26_Cath_B
AW34_Cath_12w
AW27_Vag_B
AW35_Vag_12w
S. anginosus (EST15)
AW36_Cath_B

Relative
Abundance
by EQUC

Number of
Contigs

N50

Median
Contig
Length

Average
coverage

99%
28%

21
25

284146
234052

23932
23933

88.2
64.0

29%
0.2%
5.6%
7.4%

6387
86
9499
121

1185
97011
1692
127535

585
6107
413
896

42
163
74.8
171.3

38%
20%
16%
3.9%

97
3940
115
182

131576
707
131577
33638

1827
435
1047
6091

95.2
8.2
125.8
31.6

100%
4.9%
100%
0.8%

53
82
695
44

116687
55854
106465
116729

4011
11798
265
16118

47.5
60.8
34.9
680.6

44%
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107821

3192

788

The sets of isolates were analyzed in multiple different ways: measuring phylogenetic
relatedness using 40 core genes and ANI, overall synteny, and CRISPR array comparison. To
prevent repetition, I will describe each test in detail once, then for each additional set, I will
explain only the conclusions gained from that analysis. In the phylogenetic analysis, each clinical
isolate will be color-coded in the trees based on its anatomical isolation location (red for vaginal
isolates, and blue for bladder isolates). In the percent identity tables, if the percent identity
suggests that the isolates are the same strains, it is colored green; if not, it is colored red, and
all reference strains are in grey. Finally, the results of some species sets are more clear-cut than
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others. The three most straightforward sets (C. amycolatum, E. coli, and L. iners) will be
described first.
Corynebacterium amycolatum.
The four isolates of C. amycolatum collected from patient EST11 were compared using
the 40-marker genes and ANI approaches. A maximum likelihood trees for 40 marker genes
show 100% identity between all 4 clinical isolates, which are also distinct from the reference
strains (Figure 11A). This indicates that the strains at least had a very recent common ancestor.
ANI calculated that the genomes of all four isolates were greater than 99% similar to each other
and only 94% similar to the reference strains (Figure 11B-C). The data show that the baseline
and 12-week bladder samples are similar (blue boxes) and the baseline and 12-week vaginal
samples are similar (red boxes), indicating that this organism was highly stable over time within
each niche. Since each niche was highly stable, we can then compare the bacteria between
niches and we see that they are highly similar (>99.4%) between sites.
To assess the recent history of these bacterial lineages, we looked at the CRISPR arrays.
Figure 12 shows a schematic of the CRISPR array analysis. Two strains contain the same array
when they have the spacers in the same order (indicated in green, a unique spacer is indicated
in blue). The 4 C. amycolatum strains contained identical arrays of 20 spacers each (Figure 13).
Taken together, these data indicate that all 4 strains are identical. However, I cannot conclude
that this is indicative of microbial sharing between sites. When we take the relative abundance
into account (Table 6), we see that these 4 C. amycolatum strains were low abundance in each
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of the samples (0.2% to 12.5%). Thus, it is possible that this particular organism may be a low
abundance cross-contaminant, perhaps a urethral organism. An organism that lives on the
urethral surface would theoretically be picked up by both a vaginal swab and catheter sample.
Overall, we can conclude that these organisms are most likely the same strain, but it is not
concrete evidence that this isolate can effectively live in each niche.
A.

B.

C.

Figure 11. Comparison of 4 strains of Corynebacterium amycolatum show 100% similarity
The genomes of 4 isolates of C. amycolatum (baseline bladder, baseline vaginal, 12 week
bladder, and 12-week vaginal) were compared (bladder isolates = blue, vaginal isolates =
red). (A) Maximum likelihood tree of the 40 core genes, (B) average nucleotide identity (ANI),
and (C) the percent identity calculated from ANI. All show great similarity between strains
(99%) compared to the references strains (94%).

1. Find the CRISPR arrays using CRISPRFinder
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2. Isolate the spacers/inserts

3. Compare the spacers in each isolate to every other isolate
USEARCH clustering with 70% identity
Green = same spacer
Blue = unique spacer

Figure 12. Schematic of CRISPR Array Comparison.
Step 1: CRISPRFinder was used to identify the arrays in the bacterial genomes.
Step 2: the output from CRISPRFinder was parsed into the individual phage genomic inserts.
The metadata of each insert indicated the array number (if there were multiple in the
genome) and the order of the spacers within the array.
Step 3: Each spacer was compared to every other spacer from every other genome using
USEARCH with a 70% identity threshold.
Step 4: I went through these data and created diagrams for each spacer in each genome. If
the spacer matched another array, the spacer was green. If the spacer was unique and
didn’t match anything it was blue. To simplify the diagrams, I combined all spacers from one
array into a single block. Some genomes contained spacers that only partially matched the
full array from another genome. In this case, I listed the spacers in common by number.
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Figure 13. CRISPR arrays for four C. amycolatum strains.
Escherichia coli.
E. coli has well described motility genes and has been shown to ascend from the gut into
the vagina and bladder 70-72. Therefore, we expect these isolates to migrate between sites,
which would result in a highly transient community. Consistent with that theory, we see that
baseline bladder and vaginal samples are 100% identical, 12-week bladder and vaginal samples
are 100% identical, but the isolates from the two time points are only 97% identical by both the
40 core gene analysis and ANI (Figure 14A-B). The 97% similarity between time points is
comparable to the differences seen between reference genomes and clinical isolates.
Additionally, there is large amount of synteny between the two baseline strains and
between the two 12-week strains, but little to no synteny when the baseline and 12-week
samples are compared to each other (Figure 14C). Finally, CRISPR analysis shows that the
baseline samples share an array with 17 spacers and identical 100pb flanking regions, none of
which are seen in the 12-week samples. Additionally, the 12-week samples contain an array of
23 spacers with identical 1000bp flanking regions (Figure 14D).
These data demonstrate a lack of stability within a niche over time, but a high likelihood
of microbial sharing between sites at any given time point. Again, this is consistent with the
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theory that E. coli colonization is transient and two distinct populations of E. coli colonized this
patient, one at baseline and another by 12-weeks.
A.

B.

Figure 14. Genomic Analysis of E. coli Demonstrates Low Stability Within a Niche, but High
Similarity Between Sites at Any Given Time Point. The genomes of 4 isolates of E. coli
(baseline bladder, baseline vaginal, 12-week bladder, and 12-week vaginal) were compared
(bladder isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40 core
genes, (B) a tree and table of the average nucleotide identity (ANI), (C) comparative
genomic analysis using ACT, and (D) CRISPR array analysis
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Figure 14. Continued
C.
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Figure 14. Continued
D.

Lactobacillus iners.
Analysis by the 40 marker genes shows 100% identity between all four isolates,
indicating that they at least share a recent common ancestor (Figure 15A). Of all the genomes
sequenced, the L. iners baseline strains had some of the best assemblies: AW08_Cath_B had
only 10 contigs with an N50 of 99769bp, and AW09_Vag_B had only 7 contigs with an N50 of
839239bp (Table 6). Having fewer contigs with decently long lengths is ideal for comparing
strains (Figure 15B). This is also well illustrated with the synteny results, where AW18 contains
more dark lines (start and stop sites for the contigs) and more gaps than the other strains
(Figure 15C). If we ignore AW18, we do see similarity between the bladder and vagina at ANI
and synteny analysis. In comparison, the 12-week samples had more contigs with a much lower
N50: AW18_Cath_12w had 380 contigs and N50 of 22918bp, AW19_Vag_12w had 42 with an
N50 of 840074bp (Table 6). This means that the 12-week samples have more gaps, particularly
where each contigs starts and stops.
This discrepancy in assembly quality might account for the divergence seen with ANI
and synteny analysis; particularly, that AW18 does not share a high percent identity with the
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baseline (AW08 and AW09) and within the vaginal niche over time (AW09 to AW19) by both
ANI and Artemis Comparison Tool (ACT) (Figure 15 B-C).
However, the CRISPR analysis shows a slightly different story. There is still great
similarity between the two sites at baseline, where AW08 and AW09 share a six-spacer array
with identical 1,000bp flanking regions (Figure 15D), indicating that the same strain was
present in both sites at baseline. However, this strain does not appear to be maintained by 12
weeks, as AW19 does not contain the baseline six-spacer array, but does contain a distinct sixspacer array. Two of the spacers from the AW19 array are present in AW18, but due to the
short contig lengths, there it is only a partial match (Figure 15D). It is possible that AW18 and
AW19 do contain the baseline six-spacer array, but due to lack of genomic completeness, it is
not detectable. I suggest this possibility because the ANI and synteny results seem to show that
the rest of the AW19 genome is highly identical to both AW09 and AW08. To determine a
difference, further sequencing may be required. Overall, these data show that the same strain
is present in both sites at baseline, but we cannot make any conclusions about niche stability
due to sequence coverage.
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A.

B.

Figure 15. Genomic Analysis of L. iners Isolates Indicate that all Four Isolates Have a Close
Common Ancestor, but a Potentially Different Recent History. The genomes of 4 isolates
of L. iners (baseline bladder, baseline vaginal, 12-week bladder, and 12-week vaginal) were
compared (bladder isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of
the 40 core genes, (B) a tree and table of the average nucleotide identity (ANI), (C)
comparative genomic analysis using ACT, and (D) CRISPR array analysis.
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Figure 15. Continued
C.

D.
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Lactobacillus crispatus.
Phylogeny of the 40 marker genes shows 100% similarity between all 4 strains (Figure
16A), suggesting that all 4 strains share a recent common ancestor. Even though all 4 strains
have a relatively large number of contigs (Table 5, Figure 16D), ANI shows between 99.7-99.9%
similarity between all four strains (Figure 16B-D), and there is a great amount of synteny
between all 4 strains (Figure 16D). This suggests that this organism was highly stable in both
niches, and that the overall genomes are highly similar between sites.
The CRISPR analysis confuses that data somewhat, for not all isolates are identical. The
baseline samples (AW23 and AW22) do not contain any spacers in common, but those two
strains are the only ones that lack a connection. The two 12-week samples and the baseline
vaginal sample share an array of 4 spacers with identical 1,000bp flanking regions. Additionally,
the baseline vaginal sample and the 12-week catheter sample share a six-spacer array, and the
baseline catheter sample and 12-week vaginal sample share a separate 6-spacer array (Figure
16E).
There are potentially two explanations for these results: there is a problem with
coverage, or we are working with mixed communities. As I stated previously, having a lot of
small contigs can be problematic because, by definition, certain regions of the genome were
not sequenced. Three of these genomes had about 200 contigs while one, AW33 had 1478
contigs (Table 5). It is possible there were more than one clonal population of L. crispatus in
that environment, we would have inadvertently sampled both of them. Even if we think we are
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sequencing a pure colony of L. crispatus, we could be sequencing two populations. This might
also account for the large number of contigs, if the genomes are distinct enough, there would
be difficulty in piecing each genome together during de novo assembly. Due to these caveats,
all we can conclude is that all 4 isolates share a recent common ancestor and contain a great
amount of similarity, but may not be the same strains.
A.

B.

Figure 16. Genomic Analysis of L. crispatus Isolates Indicate that All Four Isolates Have a
Close Common Ancestor. The genomes of 4 isolates of L. crispatus (baseline bladder,
baseline vaginal, 12-week bladder, and 12-week vaginal) were compared (bladder isolates =
blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40 core genes, (B) a tree
and table of the average nucleotide identity (ANI), (C) Table of ANI results, (D) comparative
genomic analysis using ACT, and (E) CRISPR array analysis.
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Figure 16. Continued
C.

D.
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Figure 16. Continued
E.

Aerococcus urinae.
The 40-core gene phylogeny showed that three of the clinical isolates were similar to
each other, but AW15 (the 12-week bladder sample) is distinct (Figure 17A). ANI confirmed
that the baseline bladder sample and both vaginal samples are greater than 99% similar (Figure
17B). This suggests great stability within the vaginal tract, but not the bladder. The 12-week
bladder sample was about 92% similar to the other clinical isolates, which is comparable to the
percent similarity between the reference strains and clinical isolates. Additionally, a genome
comparison by ACT shows very low synteny between AW15 and the rest of the genomes
(Figure 17C). This suggests one of two things. Either the A. urinae community in the bladder
shifted over time, or there are multiple clones of A. urinae in the bladder community, which we
did not detect at baseline due to limits in sampling as described earlier.
The CRISPR array analysis shows that the baseline catheterized sample (AW03) and the
12-week vaginal sample (AW17) share two arrays. The baseline vaginal sample (AW02) only
shares a partial array with the 12-week vaginal samples. AW15 did not have any detectable
CRISPRs (Figure 17D). The differences in CRISPR arrays may also be explained by the mixture of
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two or more clonal A. urinae isolates. Overall, it is possible that the same strains are present in
both niches at both time points, but we cannot make any conclusions until we decipher the
number of distinct species in each population.
A.

B.

Figure 17. Genomic Analysis of A. urinae Suggests Two Genetic Populations in Each Site.
The genomes of 4 isolates of A. urinae (baseline bladder, baseline vaginal, 12-week bladder,
and 12-week vaginal) were compared (bladder isolates = blue, vaginal isolates = red). (A) A
maximum likelihood tree of the 40 core genes, (B) a tree and table of the average nucleotide
identity (ANI), (C) comparative genomic analysis using ACT, and (D) CRISPR array analysis.

87

Figure 17. Continued
C.

D.

*AW15 did not have any detectable spacers
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Gardnerella vaginalis.
The G. vaginalis isolates were the only set with fewer than four isolates. As you can see
in the relative abundance graphs (Figure 10), G. vaginalis (in red) was detected in the vagina of
patient EST11 at baseline, but not the bladder. Then, at 12-weeks, both sites contained G.
vaginalis, and it was highly dominant in the bladder. I wanted to know if the bladder isolate
from the baseline vaginal sample was the same as the 12-week bladder sample, which would
suggest migration of G. vaginalis to the bladder followed by the dominance of that organism.
Alternatively, G. vaginalis could have been present but undetectable at baseline. Unfortunately,
the 12-week vaginal sample was contaminated or incorrectly stored down, because the 16S
gene extracted from the annotation blasted as L. crispatus; therefore, this sample was
discarded. However, blast analysis of the 16S genes from the baseline vaginal sample and 12week bladder both identified as G. vaginalis.
Both sequences (AW25 and AW30) had few contigs with very high length and were,
therefore, well suited for genomic analysis (Table 6). The baseline vaginal sample was 100%
similar by 40 marker genes, and 99.88% similar by ANI to the 12-week bladder sample,
compared with 88-94% similarity to the reference strains (Figure 18A-B). ACT analysis shows a
high amount of synteny between the two genomes (Figure 18C). We did not detect any CRISPR
arrays in these isolates, so we cannot make any conclusions about the recent history of these
isolates. Although not definitive, these data do show that the two strains are highly similar,
indicating that the baseline vaginal sample could have migrated to the bladder by 12-weeks.
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A.

B.

C.

Figure 18. Genomic Analysis of G. vaginalis Indicated that the Baseline Bladder Sample
and 12-week Vaginal Sample Share a Recent Common Ancestor. The genomes of 2
isolates of G.vaginalis (baseline vaginal and 12-week bladder) were compared (bladder
isolates = blue, vaginal isolates = red). The 12-week vaginal sample was contaminated with
L. crispatus, and was therefore excluded from further analysis. (A) A maximum likelihood
tree of the 40 core genes, (B) a tree and table of the average nucleotide identity (ANI), and
(C) comparative genomic analysis using ACT. No CRISPR arrays were found.
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Streptococcus anginosus.
It was the original plan to sequence two sets of S. anginosus isolates, four from EST14
and four from EST15. However, due to sequencing flow-cell capacity, we could only load one of
the isolates from EST15. The other three are extracted and can be sequenced on a future
sequencing run. Phylogenetic analysis of the 40 marker genes showed that all four samples
from patient EST14 were 100% identical (Figure 19A) compared to 94% similarity to the
reference strains, indicating that these 4 strains have a recent common ancestor. Surprisingly,
the sample from patient EST15, AW36, was 99.8% similar to patient EST14’s strains. This
suggests that, for S. anginosus, some urogenital isolates are more similar to each other than
strains from other isolation sites.
ANI presented a similar story (Figure 19B). All four isolates from EST14 were greater
than 99.9% similar to each other, again suggesting high stability and similarity between sites.
The bladder isolate from EST15 (AW36) was as similar as the reference strains to EST14.
Therefore, even though the isolates from these two individuals have highly similar core genes,
there are sufficient differences to distinguish isolates collected from different individuals. The
reference strains all seem to be associated with virulence and were isolated from blood, oral,
airway, and one (SA1) from the catheter of a quadriplegic suffering from a UTI. It is possible
that the phylogenetic differences between the reference strains and study is due to virulence,
and the less virulent strains of our study are clading separately from the more virulent
reference strains.
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A.

B.

Figure 19. Genomic Analysis of Streptococcus anginosus from Two Individuals. The
genomes of 5 isolates of S. anginosus (4 from EST14 and 1 from EST15) were compared
(bladder isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40
core genes, (B) a tree and table of the average nucleotide identity (ANI), and (C)
comparative genomic analysis using ACT. No CRISPR arrays were found.
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Figure 19. Continued
C.
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All 4 isolates from EST14 show a great amount of synteny (Figure 19C). Strain AW36
from EST15 shows some synteny with the other clinical isolates, but also large and distinctive
gaps, again indicating that isolates collected from different individuals have distinguishing
features. No spacers were detected for any of these strains, which is apparently not uncommon.
Previous publications have detected CRISPR arrays and/or genes in less than half the isolates
sequenced (7/18). With the great amount of similarity between strains, I would conclude that
the S. anginosus strains are stably colonized within a given niche and are highly similar between
niches, which suggests that S. anginosus may be shared between sites.
Corynebacterium coyleae.
In this final dataset, we isolated four stains of C. coyleae each from patient EST11 and
patient EST05. As with S. anginosus, this dataset allows us to compare groups of isolates from
different individuals to a reference strain. We found that, when comparing the 40 marker
genes, isolates collected from within an individual were 100% similar (Figure 20A), but only
99.2-99.1% similar between individuals or to the reference strain. ANI shows that samples
within an individual were 99% similar to each other, but 96% similar between individuals or
compared to the reference strain (Figure 20B). Additionally, comparison of the genomes shows
a great amount of synteny between isolates collected from within a given individual, with the
exception of AW28, which seems to be divergent (Figure 20C & E). The two baseline samples
from patient EST11 (AW05 and AW07) contain a series of small contigs not present in the other
genomes (Figure 20E). It is possible that if these genomes were cleaned up, then they would
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show a greater similarity to the other genomes from that individual. Finally, if we compare a
single genome from each individual, we see some synteny, but also rather large gaps (AW21 to
AW11 in Figure 20D), suggesting that there is a great difference between strains collected from
different individuals.
A.

B

A.

Figure 20. Genomic Analysis of Corynebacterium coyleae From Two Individuals. The
genomes of 8 isolates of C. coyleae (4 from ES11 and 4 from EST05) were compared (bladder
isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40 core genes,
(B) a tree and table of the average nucleotide identity (ANI), and (C-E) comparative genomic
analysis using ACT, and (F) CRISPR array analysis.
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Figure 20. Continued
C. Table of ANI results

D. Comparative genomics of the 4 strains collected from patient EST05.
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Figure 20. Continued
E. Comparison of a strain from EST05 and EST11

F. Genome Comparison for strains from EST11
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Figure 20. Continued
G.

Even though the genomes are highly similar, the CRISPR analysis indicates a common
recent history for the baseline samples in EST05 that is distinct from the 12-week samples
(Figure 20G). The CRISPR analysis from EST11 is less clear-cut; the baseline of one niche is
similar to the 12-week of another. This could mean that the strains swapped locations over 12
weeks, or that each niche contained a mixed population of both strains, but by chance, we only
sampled one. Overall, these data indicate that for at least two people, the C. coyleae present in
each niche of a given individual is highly similar and stable over time.
A Comparison of Multiple Strains Within an Individual.
Multiple isolate sets were taken from a single patient. Both the A. urinae and E. coli
isolate sets were taken from patient EST08, and C. amycolatum, G. vaginalis, and one set of C.
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coyleae were taken from patient EST11. I wanted to check that the similarity we detected
between strains was not solely dependent on the patient’s niches. It is possible that, within one
individual, a bladder isolate will always have greater similarity to other bladder isolates rather
than vaginal isolates. Alternatively, it is possible that, within one individual, regaurdless of
niche, all baseline samples will show greater similarity to other baseline samples rather than a
12-week sample. To check for this, I compared all ANI trees from EST08 (Figure 21A) and EST11
(Figure 21B). Neither set of trees elucidated a specific pattern. There did not seem to be a
correlation of the patient’s isolation location and the relatedness of the samples. These data
suggest that any similarity or differences we detect with phylogeny are the result of divergence
within a specific species, not any one individual’s specific niche requirements.
Here, I have shown that no single species is commonly and exclusively found in either
the bladder or the vagina. Most species can be found in both sites. At the strain level of
identification, isolates taken from the same individual at any given point in time tend to be
closely related. Most have evidence of a recent common ancestor and some have evidence of
great genetic synteny and recent enviromental history (as shown by analysis of CRISPR arrays).
These data suggest that there is the potential for microbial sharing between sites within an
individual.
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A. A. urinae and E. coli from EST08

Figure 21. Comparison of Isolate Sets Collected from the Same Individual. Comparing the
ANI trees of (A) A. urinae and E. coli isolate sets from EST08 and (B) C. amycolatum, C.
coyleae, and G. vaginalis isolate sets from EST11. For each tree, bladder isolates = blue,
vaginal isolates = red.
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Figure 21. Continued
B. Isolate sets from EST11
C. amycolatum

C. coyleae

G. vaginalis
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Summary
We analyzed 10 species sets, each collected from a single individual at baseline and
following 12-weeks of treatment to determine if any of specific species has the potential for
surviving in both the bladder and vaginal environments. Phylogenetic and genome comparison
analysis show a high amount of similarity between most isolates. With the exception of E. coli
(which seems to be a transient population), most isolate sets are highly similar phylogenetically.
This tells us that the strains are stable over time within a niche and seem to be highly similar
between niches. This could indicate that each site contains the same organism, or that the
organisms share a very recent common ancestor.
When we look at the recent phage history of these organisms, we often see that the
baseline samples contain the same CRISPR arrays in both the bladder and vagina; this was true
for C. amycolatum, E. coli, L. iners, and C. coyleae. However, for each of these sets, the 12-week
arrays were distinct from the baseline arrays, indicating that there might have been a shift in
the dominant clonal population by 12 weeks. For the strains that did not have similar CRISPRs
at baseline (L. crispatus and A. urinae), their data suggests that two clonal populations were
present at baseline and 12 weeks, but only one was sampled at any given time point. Overall,
these data suggest that there is a high probably of microbial sharing of pathogenic (E. coli),
commensal (Corynebacterium species, and L. iners), and even beneficial bacteria (L. crispatus).

CHAPTER VI
DISCUSSION
Summary of Data
In this work, we attempted to acquire evidence to support or refute the idea that
bacteria are shared between the bladder and the vagina. We tested this in three separate ways,
comparing whole genomes of bacteria collected from unrelated individuals (Chapter III),
comparing the community structure of both sites at a given point in time (Chapter IV), and
comparing the genomes of bacteria collected from both sites of a woman at a given point in
time (Chapter V).
From previous work, we already knew that the same species of bacteria are often found
in both the bladder and vagina. The data in Chapter III confirmed that the same species are not
only collected from the bladder and vagina, but that these genomes have overlapping
functionality. The DAPC of protein domains shows that the bladder and vaginal datasets overlap
with each other, and are distinct from the gut dataset (Figure 5B). The DAPC also shows that
not all the species from the bladder have overlapping functions in the vagina. About half of
each dataset is distinct; therefore, it is possible that there are some organisms that share
functionality and some that may have functionality specific to a given niche. For the
overlapping section, some vaginal and bladder genomes have close to 100% identical protein
domains on the DAPC, indicating that these bacteria have highly similar protein functions.
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These data are intriguing because of the high similarity between strains isolated from unrelated
individuals. These datasets were collected almost a decade apart, from different patient
populations, in different areas of the world; thus, the similarity is striking. I would conclude that
some strains of some organisms are specific for one niche or the other, but others possess the
functionality to live in both sites. The fact that these highly similar bladder and vaginal isolates
were collected from different individuals indicates that urogenital functionality is highly
conserved in women.
Next, we looked at the microbiomes of the bladder and vagina within individual women.
We found that about 50% of hypoestrogenic post-menopausal women have similar bladder and
vaginal communities. That number increases to about 75% following estrogen treatment
(Figure 10, Table 4). Therefore, at any time point, there are women whose samples are not just
mostly similar, but are in similar proportions in each site. I find this remarkable, particularly
considering that the biomass of each site does not appreciably change over time and that each
site contains a vastly different biomass; as mentioned previously, the bladder contains many
orders of magnitude fewer organisms than does the vagina. Even with this stability and
discrepancy in biomass, we observed almost identical distributions of organisms in each site.
There are a few caveats to this study and the resultant data. First, we cannot conclude
that the observed changes are due to microbial sharing between sites. It is possible that each
site is responding similarly yet independently from one another. Also, we have minimal data
about the normal stability of the FUM of post-menopausal women. Our only other study
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collecting longitudinal data included only UUI women as they took an anti-cholinergic
medication 3,6. In that study, we observed some women remained stable throughout treatment,
but many changed. However, we do not have any information to indicate if these changes were
due to normal shifts over time or medication use. In this estrogen study, we do have the
strength that each woman is her own control, so we could determine when a shift occurred
regardless of the underlying reason and our data show that the bladder and vaginal
microbiomes of several women experienced corresponding shifts over the 12-week estrogen
treatment period.
Finally, we took specific isolates from women in the estrogen study and compared their
whole genomes (Chapter V). Here, we compared the same species cultured at baseline and 12
weeks in the bladder and vagina, resulting in sets of 4 isolates each. The genomic data from 10
species sets (8 different species across 7 different individuals) were analyzed. For the majority
of species sets, (C. amycolatum, L. iners, L. crispatus, G. vaginalis, S. anginosus, and C. coyleae
EST11 and EST05) marker gene analysis indicated that all strains within a species set were
highly similar, and therefore shared a recent common ancestor. Comparison of the full genome
by ANI and ACT concurred with the 40-marker gene analysis, indicating that these strains
shared more than a common ancestor, but had very similar genomes and were therefore
closely related.
The recent phage history, as measured by CRISPR array analysis, showed that for some
of the samples (L. iners, E. coli, C. coyleae EST05), baseline vaginal and bladder samples are

105

similar, and that the 12-week samples are similar, but each time point is distinct from each
other. Two conclusions can be made. First, at any given time point, the same clonal population
can be present in both sites, suggesting that that strain is shared between sites at a given point
in time. Second, that something about the estrogen treatment causes a shift in the dominant
population. Further data by Catherine Putonti showed that one isolate set (C. amycolatum)
contained a variety of prophages in the baseline genomes, most of which had excised from the
genome by 12 weeks (Putonti, unpublished data). Therefore, it is possible that estrogen hanges
the expression of phages, which in turn would change the environment and could select for a
population with a specific CRISPR profile.
One strength of this analysis is the diversity of the datasets. We tested pathogenic
species sets (E. coli, A. urinae), commensal species sets (L. iners, Corynebacterium species), and
beneficial species sets (L. crispatus). The E. coli species set provides an example of a motile and
transient population, with two distinct phylogenetic groups, one at baseline and one at 12
weeks. The commensal and beneficial species sets are examples of much more stable
phylogenetic populations over time, even considering the changes in estrogen levels. These
data seem to suggest that a population of species within a given niche can be clonal.
A limitation of this analysis is sampling bias. During initial culturing, if the colony is
pinpoint, multiple colonies are picked up in order to ensure enough growth for identification
and storage. This was the case for L. crispatus and A. urinae. Their genomes indicate a mixed
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population, with multiple clones. If we had sequenced multiple individual colonies, we might
have captured a mixed population at both time points.
Implications and Discussion
Throughout this analysis, we have tried to be very careful about what we can and
cannot conclude from these data. We are trying to answer a very basic, yet nuanced, question:
are the bladder and vaginal microbiomes interconnected or distinct? The current data provides
evidence that the two sites are potentially connected microbiologically - that microbes might
move between the two adjacent niches. This discovery should change the way we view the
bacteria of the female pelvic floor and should inform research into UTIs, women’s health, and
treatments moving forward.
Medical dogma has always connected the health of the vagina to the health of the
bladder, and the data shown here backs that up, with one important difference. Previously, it
was thought that a healthy vaginal microbiota prevents ascending infections from migrating
into a sterile bladder. Now, I would propose that the protection comes from the bacteria that
reside in both the bladder and vagina, particularly in the presence of estrogen.
To our knowledge, this is the first microbiome study to compare the strain similarity
between close anatomical sites. Although the HMP dataset compared multiple human niches to
each other, none of the datasets were as anatomically close as that vagina and bladder, and
none of the analysis was completed at the species level11. There have been separate studies
that compare regions of the mouth microbiome104, between sections of the gut microbiome of
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mice148, or on areas of the skin149, but no other that has searched for strain specific connections
from one human organ to another.
Exploring the Implications of Interconnectivity.
Considering that the bacteria are non-motile, how do the organisms move from one site
to the other? Two options present themselves. First, both sites could be colonized soon after
birth and two relatively stable environments are established, the low biomass of the bladder
and the high biomass of the vagina. This would imply that the two sites started from a common
ancestor but have had little connection over time. It would also imply that the two communities
would eventually diverge from each other. The ANI and CRISPR data seem to refute this
hypothesis. If it were true, we would not necessarily expect the genomes to be as similar as
they are or to see that the CRISPR arrays are 100% identical between the two sites. Even if
phages could migrate and bacteria could not, it still seems improbable that both niches would
be exposed to the same phages in the same order. It is much more likely that the bacteria are
moving between sites and bringing their phages and their CRISPR immunity with them.
From the data presented here, it seems more likely that a second scenario is true - one
site acts as a reservoir and periodically colonizes the other site. If this were the case, it is easy to
imagine how the bladder could act as a reservoir for vaginal flora because it would re-seed the
vagina following every void. In this case, we would expect to find low levels of the same
organisms in the bladder all through life. Unfortunately, until we can properly interpret voided
urine, this question cannot be answered.
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Alternatively, the high biomass of the vagina could provide bacteria for ascending
colonization. It is possible that even without motility, the mucosa between the vagina and
bladder could transmit bacteria past the urethra. The data shown here even suggests that
mechanical factors, such as the application of an estrogen cream, may be sufficient for
movement. One can also imagine how any sort of pad (such as an infant diaper, menstrual pad,
or continence diaper) could allow for a mechanical passage of vaginal organisms to the bladder.
Physicians often recommend changing such pads frequently to decrease the risk of developing
UTIs, but no significant research has been done on the subject in relation to commensal
bacteria. This mechanical human intervention could also partially explain the increase in
bladder diversity measured in incontinent patients and patients with increased BMI. If a patient
continuously uses absorbent pads, those pads would provide vaginal flora, as well as those of
the skin or gut, with a conduit for bladder colonization. Much in the same way, obesity could
result in more friction, and therefore more movement of bacteria around the pelvic floor.
If there is a stable bladder community, how does it survive? I would expect these
organisms to live on the uroepithelium not in the urine itself. Lactobacillus species are known
to feed off of glycogen produced by vaginal epithelium 75,76, so it would not be hard to imagine
that they feed on something expressed on the surface of bladder cells, such as the
glycosaminoglycan (GAG) layer. Even if that were true, it still would not explain why the bladder
maintains a low biomass. It could be possible that the host actively regulates bacterial cell
density through regulation of cell surface carbon sources. If there were limited nutritional
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resources, then it would limit the overall bacteria cell density. Alternatively, the host could
regulate the population through innate immunity, such as the use of antimicrobial peptides
(AMPs). Finally, the composition of the urine itself, such as the presence of urea, salts, or
amines, could be inhibitory to robust cell growth.
Even if all of this were true, how could the bladder microbiome survive so long in such
low density? The bladder epithelium is unique in that it can dramatically increase and decease
its surface area as the bladder is filled and then voids. The luminal facing layer of the
uroepithelium is comprised of umbrella cells 150. To increase their surface area, these cells keep
a reserve of intracellular vesicles that provide additional membrane when needed 86. As the
bladder is emptied, parts of the surface membrane bleb into the cell’s cytoplasm and are stored
for later, therefore these vesicles contents contain both uroplakin and lumina contents and
would not differ significantly from the surface of the bladder 86,150. If bacteria are attached to
the bladder epithelium, they too could be living in these intracellular vesicles and periodically
be re-introduced into the bladder lumen. If this hypothesis were true, fluorescent microscopy
could be used to detect bacterial cells in these vesicles. To my knowledge, no one has tried this
experiment.
Multiple mechanisms can be hypothesized that would explain how bacteria could
migrate from one site to another or how the bladder bacteria are maintained in a low biomass
state, but it is also important to explore an alternative hypothesis, i.e., we are simply collecting
vaginal flora or urethral flora when we catheterize the bladder. In theory, the subsampling of
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vaginal flora is possible, given the vastly different amounts of bacteria and the presence of
similar species in both niches. However, in our group’s initial study, Wolfe and co-workers 4
excluded the possibility of vulvo-vaginal contamination in the bladder. In surgical patients with
and without urinary symptoms, voided urine, vaginal swabs, and catheterized urine were
compared to suprapubic aspirates (SPA) 4. Aspirated urine was collected by a needle directly
through the lower abdomen and therefore the collection method bypassed vulvo-vaginal
contamination. In that study, the microbiome of aspirated urine was highly similar to
catheterized urine and vastly different from voided urine and vaginal swabs. However, the
samples size was very small (N=23), the samples did not undergo enhanced culturing (because
it did not yet exist), and we have since learned a lot about sequencing low-biomass samples.
The work from this thesis has shown that there can be connections between the bladder and
vagina. Yet, this first study suggested that the vagina was distinct from the bladder. In light of
the work from this thesis, I would recommend that the SPA-to-catheterized urine comparison
study be repeated.
Even given these concerns, the microbiome of catheterized samples has clearly provided
useful information. As stated previously, we have identified associations between bladder
microbiome characteristics and urgency symptoms3,6,65,151, response to UUI medication6, risk of
post-operative63,64 and post-instrumentation UTIs65, and kidney stones152. Additionally, the
data presented here shows that the profiles of the bladder and vagina are not always similar,
particularly in hypoestrogenic women. Thus, although it would be a good idea to repeat the
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original SPA-to-catheterized urine comparison study, sufficient evidence links the bladder
microbiome to bladder health and disease/disorder.
The design of this study takes for granted the idea that topically applied estrogen will be
delivered into the bladder, but how does this happen? Due to the proximity of the vagina and
urethra, some estrogen cream will be delivered to the urethra during application, and it is
possible that some hormone will be transmitted through the urethra at that time. However, we
also know that the anterior vaginal wall lies parallel to the bladder trigone, separated only by
the vesicovaginal space and connected by common blood supply. Additionally, we know that
the trigone contains estrogen receptors, and it is known that estrogen can be absorbed through
epithelial layers153, therefore, it is possible that estrogen could be absorbed and transmitted
through the tissue. Not much is known about the vesicovaginal space, other than it is avascular
and contains a layer of connective tissue154. It seems possible that estrogen could diffuse
through the vaginal epithelium, vaginal lamina propria, through the vesicovaginal space and
effect the bladder lamina propria beneath the trigone of the bladder. To distinguish between
the possibility of the urethral exposure versus tissue diffusion, we could modify how the
estrogen is delivered. Instead of a topical cream, an intravaginal delivery mechanisms (such as a
tablet or pessury) could be used. These alternative mechanisms would have been found to be
as effective at modulating symptoms, but would prevent urethral transmission of estrogen or
mechanical spreading of organisms (as with the cream application).
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Implications for Infection and Probiotics.
UTIs, particularly those caused by UPEC, are the common bacterial infection in the US
155.

They are more prevalent in women, with 50% experiencing a UTI in her lifetime 155.

Additionally, no specific genetic signature has been identified that is predictive of pathogenesis
156.

Yet, the dogma persists that there are two types of E.coli: pathogenic strains (like UPEC)

and asymptomatic bacteriuria (ABU) strains. ABU strains have even been used in women with
UTIs to prevent recurrence 157. But the idea of ABU is flawed; an infection is more likely to be
the result not just of the strain but also the environment in the host. The data presented here
shows that E. coli colonization might be more transient than we first expected. After just 12
weeks, the population of strains had completely changed (Figure 10). This suggests that the UTI
field not only has to reconsider their definition of ASB and UPEC, but also begin to think about
an E. coli infection as something highly dynamic. This raises a range of questions, where are
these new strains coming from? How long do they stay? And, does the strain of UPEC change
throughout the course of disease or treatment?
The findings are just as exciting from the probiotic standpoint. L. crispatus is the only
species that we consistently find strongly associated with continent control patients, whereas
other Lactobacillus species, especially L. gasseri, are associated with OAB patients (Figure C.6)
3,6.

Additionally, we have unpublished data that show that L. crispatus supernatants can kill E.

coli cultures better than lactic acid and hydrogen peroxide alone42,68,69. All these data suggest
that L. crispatus is a beneficial microbe in the bladder, and a potential probiotic for future
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therapeutic use. These niche analysis data provide compelling evidence that a successful L.
crispatus probiotic would not need to be administered directly into the bladder, which would
increase cost and decrease patient comfort. Instead, a future therapy could use a L. crispatus
inoculated in the vagina, much like the estrogen cream used in this study. A cream would be
cheaper and easier to apply and there would still be high confidence that the probiotic could be
transmitted into the bladder. Additionally, my data suggest that adding L. crispatus to the
estrogen cream may prime the vagina and bladder microbiota and epithelium for maintenance
of the probiotic.
In the age of antibiotic stewardship, I find it interesting that we were able to modify the
urogenital microbiome with a non-antibiotic compound. If estrogen can be used to modify the
microbiome, what else can be used? Are there small molecules, carbon sources, AMPs, host
factors, or even bacterial signaling molecules that could be used to locally maintain a healthy
urogenital environment? If another treatment could be found, particularly one that is effective
in reproductive age women, we could dramatically reduce the amount of antibiotics used in this
country.
Future Directions
The data presented here should be a starting point for a wide variety of future studies
exploring the bacterial and host components of the pelvic floor microbiome. I have already
briefly covered a few future directions in the implications section; for example, repeating the
SPA versus catheterized urine study, exploring the dynamics of E. coli infection, and trying to
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inoculate L. crispatus in tandem with the estrogen cream. Here, I will address more immediate
future directions, such as creating a reference genome database, continued longitudinal
studies, interpretation of voided urine, and metagenomic analysis with the enriched culture
samples.
Reference Genome Database.
The genomic comparison data in Chapter V highlights just how different our urogenital
strains are compared to GenBank reference strains. Future studies of urogenital isolates will
need a reference dataset, and that is exactly what I have created here. The genomes sequenced
with the Lawley Lab represent the breadth of phylogenetic diversity currently cultured from the
bladder (Figure 4), and the isolates sequenced in Chapter V provide a direct comparison of
bladder and vaginal isolates. These datasets will be turned into a publicly available reference
genome database. Not only will these bladder genomes be a reference for future phylogenetic
studies, but they can be used for functional studies as well. We need to mine these genomes to
understand the functional requirements for surviving in the bladder, attaching to the
urothelium, and promoting health and/or disease.
Enriched Culture Samples.
Many of these organisms cultured in Chapter V are very slow growers (e.g. Gardnerella
and Lactobacillus). Therefore, during initial isolation, it was unrealistic to sub-culture a single
colony. Instead, a group of colonies was collected, sub-cultured, and used for isolation and
identification. Following identification using MALDI-TOF, all growth on the plate used for sub-
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culture was used to generate stored cultures (freezer stocks). Therefore, many of these
genomes may in fact represent a consensus of multiple clonal populations within a given niche
at a given time point. Additionally, for those isolates that do grow large enough colonies for
clonal isolation (e.g. Aerococcus, Corynebacterium and Streptococcus), only a single colony was
chosen for identification and storage. Therefore, it likely, that some genetic variation was not
captured. This may account for the differences seen in A. urinae (Figure 17) and L. crispatus
(Figure 16). It is possible that the bladder contained multiple clones of A. urinae, one
represented by AW15 and the other by AW03, but both clones were not detected at both time
points. Therefore, the data suggest an unstable environment when the reality might be bias in
our sampling techniques.
I had thought about this eventuality when designing this study. However, I had no way
of knowing exactly how many colonies to store down, or whole genomes to sequence, to
capture the full genetic potential. Instead, I opted for a storage protocol that would allow
others to extend my work. After reading a plate and sub-culturing one of each unique colony, I
used a sterile cotton swab to pick up all the colonies on the plate and inoculate into a storage
media. These mixtures were frozen at -80C. I call these mixtures “enriched culture samples”
(see Methods), and I performed this extra storage on all the plates from the first 20 patients. It
would be possible to go back to these tubes, perform metagenomics, and measure species- or
strain-specific sequences. Building from the work in this thesis and using the enriched cultured
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samples, it might be possible to measure the total genomic diversity of a given species at a
given time point.
These samples could also be used for a variety of future studies. Unfortunately, the
enriched samples cannot be re-cultured because they were stored down with nucleic acid
preservative, not a culture preservative. However, I think metagenomic analysis would allow us
to explore the genomic content in a mixed community, not just one genome at a time. Based on
how our urinary isolates clade with reference genomes, it seems that the urogenital strains are
dramatically different. It would be interesting to see if there is similar functionality between
urogenital isolates that is absent in isolates from other collection sites. Metagenomic data from
these samples may also be useful in exploring for prophages. As I mentioned earlier, C.
amycolatum was found to lack the majority of its prophages by 12 weeks. Previous work in
vaginally isolated Lactobacilli have shown that when the cell is stressed, it will release its
prophages, and these phages can infect multiple Lactobacillus species 158. In addition, it is
known that phage predation can change the gut community structure 159,160, therefore, I think it
would be very important to start understanding how phages interact with the bladder
microbiome specifically in response to estrogen. Using these samples, we could test a wide
variety of species before and after treatment. We have only explored the tip of the iceberg for
bladder phages, and a metagenomic approach would allow us to see which phages have
species-specific targets and which are able to infect multiple types of bacteria.
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Interpreting Voided Urine.
One consistent problem we face in the urinary microbiome field is interpreting voided
urine. We want to be able to conduct long-term longitudinal studies, sample from biobanks, or
do large population studies, yet all of this is infeasible if the participants must be catheterized.
For example, we do not want to needlessly catheterize individuals, so we cannot study the
urinary microbiome in infants and children, or in healthy reproductive aged women. Therefore,
the next major step will be in interpreting voided urine. As I stated in Chapter III, we now have
evidence that voided urine is a mixture not only of bladder and vaginal flora, but also potential
skin flora (Figure 6). The estrogen study collected not only paired catheterized urine and vaginal
swabs, but also voided urine and perineal swabs. It is imperative that these data be compared
and explored to tease apart the composition of voided urine. Ideally, we would want to find a
bladder-specific signature, but based on the data from this thesis, I think it would be more likely
to find a urogenital-specific signature. If we can find that signature, we could at least be able to
distinguish bladder/vaginal (urogenital) organisms from any other contaminant (e.g., skin or
perineum).
Long-term Estrogen Effects.
It would be in interesting to follow the women of the estrogen study for longer time
frames, and capture longitudinal data as their symptoms improve. We would expect that, given
enough time on estrogen therapy, most of the women would shift to a Lactobacillus-dominant
community. However, we do not know if the observed changes are transient, stable, or stable
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only for as long as estrogen is applied. It would be interesting in future studies to track
hypoestrogenic women at baseline, 12 weeks, 6 months and 1 year of treatment.
It would also be interesting to follow women throughout their lifespans. A long-term or
multi-cohort study would allow us to ask some important questions, e.g. what is the
composition of the infant bladder microbiome? How does the bladder microbiome change after
an infant’s first antibiotic exposure? How does the bladder and vaginal microbiome change
throughout puberty? What is the change in the bladder microbiome following initiation of
sexual activity? Do any of these things predispose individuals to recurrent UTIs or UUI later in
life?
As you can see, we are just beginning to explore the possibilities of this research. My
hope is that this thesis is an important building block for future urogenital microbiome research
that will improve women’s health.
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This appendix provides the texts of all current publications that are not directly related
to the dissertation. The thesis itself combined with this appendix represent the entirety of my
graduate work. At the beginning of each appendix section, the manuscript citation will be listed,
followed by a short summary of the work. The full manuscript text, all figures and tables, and
complete methods are included. Please note that due to ongoing optimization and validation,
the methods listed in each appendix section may vary from the methods listed in the main
thesis. If there was any further work that did not make it into publication, such work will be
listed in the adendum following each appendix section.

APPENDIX B
THE FEMALE URINARY MICROBIOME IN URINARY URGENCY INCONTINENCE

Pearce, M. M., Zilliox, M. J., Thomas-White, K., Richter, H.E., Nager, CW., Visco, A.G., Nygaard,
I., Barber, M.D., Schaffer, J., Maolli, P., Sung, V.W., Smith, A.L., Rogers, R., Nolen, T.L., Wallace,
D., Meikle, S.F., Gai, X. Wolfe, A. J., and Brubaker, L.
The Female Urinary Microbiome in Urgency Urinary Incontinence. Am J Obstet Gynecol. 2015
Sep;213(3):347.e1-11. doi: 10.1016/j.ajog.2015.07.009. Epub 2015 Jul 23. PubMed PMID:
26210757
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Overview of Appendix B
In this study, catheter samples were collected from women with UUI who were
participants in the Anticholinergic versus Botulinum Comparison (ABC) trail, a randomized trial
investigating two alternative treatments for OAB161. All urines were negative by standard
culture, but 16S rRNA gene sequencing showed that many contained bacterial DNA.
Approximately half of the samples contained bacterial DNA above backgound levels. In these
“sequence-positive” urines, we identified 8 major bacterial community structures (urotypes)
where a single bacterial genus or family dominated most urotypes (i.e., >45% total sequence
reads). This paper was the first publication descibing the urotype analysis and the distribution
of those urotypes: nearly half were dominated by the genus Lactobacillus, followed by
Gardnerella, Gardnerella/Prevotella, Enterobacteriaceae, Staphylococcus, Aerococcus and
Bifidobacterium. The remaining urotype was called ‘Diverse’ to signify those without a
dominant genus.
All individuals in this study underwent instrumentation to inject either the botulinum
toxin or a placebo into the detrusor muscle. Therefore, this paper analyzed the microbiomes of
those individuals that developed a post-instrumentation UTI and those that did not. We found
that sequence negative indivudals were at a greater risk for a post-instrumentation UTI.
Therefore, this is the first piece of evidence that a protective microbiome might exist.
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Abstract
Objectives. To characterize the urinary microbiota in women planning treatment for
urgency urinary incontinence and to describe clinical associations with urinary symptoms,
urinary tract infection and treatment outcomes.
Study Design. Catheterized urine samples were collected from female multi-site
randomized trial participants without clinical evidence of urinary tract infection and 16S rRNA
gene sequencing was used to dichotomize participants as either DNA sequence-positive or
sequence negative. Associations with demographics, urinary symptoms, urinary tract infection
risk, and treatment outcomes were determined. In sequence-positive samples, microbiota were
characterized on the basis of their dominant microorganisms.
Results. Over half [51.1% (93/182)] of the participants’ urine samples were sequencepositive. Sequence-positive participants were younger (55.8 vs. 61.3, p=0.0007), had a higher
body mass index (33.7 vs. 30.1, p=0.0009), had a higher mean baseline daily urgency urinary
incontinence episodes (5.7 vs. 4.2, p<0.0001), responded better to treatment (decrease in
urgency urinary incontinence episodes −4.4 vs. −3.3, p=0.0013) and were less likely to develop
urinary tract infection (9% vs. 27%, p=0.0011). In sequence-positive samples, eight major
bacterial clusters were identified; seven clusters were dominated by a single genus, most
commonly Lactobacillus (45%) or Gardnerella (17%), but also other taxa (25%). The remaining
cluster had no dominant genus (13%).
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Conclusions. DNA sequencing confirmed urinary bacterial DNA in many women without
signs of infection and with urgency urinary incontinence. Sequence status was associated with
baseline urgency urinary incontinence episodes, treatment response and post-treatment
urinary tract infection risk.
Introduction
Urgency urinary incontinence (UUI) is a heterogeneous condition usually attributed to
abnormalities in detrusor neuro-muscular functioning and/or signaling. However, most
incontinence experts suspect that UUI etiology is likely more complex. Current first line
treatment for UUI is behavioral and/or pharmacologic, but many affected patients have
persistent symptoms. Thus, the group of women affected by the generic symptom of UUI may
have multiple, heterogeneous etiologies.
The Anticholinergic Versus Botulinum Toxin A Comparison (ABC) Trial was a 10-center,
double-blind, double-placebo-controlled randomized trial in which women received either one
intra-detrusor injection of 100 U of onabotulinumtoxin A and daily oral placebo or daily oral
anticholinergic medication and one intra-detrusor injection of saline161. The ABC study was
designed and conducted prior to knowledge that the female lower urinary tract (bladder and/or
urethra) contains bacterial communities (termed the female urinary microbiome).
Growing evidence suggests that the female urinary microbiota may play a role in certain
urinary disorders such as UUI162. Our research team previously described the female urinary
microbiota of women with UUI163 using catheterized urine samples obtained at baseline from
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patient-participants in a randomized clinical trial for the treatment of UUI who did not have
clinical urinary tract infection (UTI)161. Previously, we also compared various techniques to
verify that transurethral catheterization was an appropriate method to collect urine samples
with minimal vulvo-vaginal contamination4. This current analysis goes beyond the initial testing
of the prior samples to formally characterize the female urinary microbiota by 16S rRNA gene
sequence analysis. Relationships between sequence status, microbiota characteristics and
clinical variables of interest, including treatment response and post-treatment UTI risk, were
also assessed.
Materials and Methods
Subjects and Specimen Acquisition.
The full methods of the trial and the primary outcome of the ABC trial have been
published161,164. Briefly, the trial randomized women without neurologic disease with
moderate-to-severe UUI, defined as having ≥5 episodes of UUI per 3-day period. Participants
were anticholinergic drug naïve or had previously used ≤2 anticholinergic medications other
than the study drugs. Exclusion criteria included a post-void residual volume ≥150 mL or
previous therapy with oral study medications or onabotulinumtoxin A.
The primary outcome was reduction from baseline in mean episodes of urgency urinary
incontinence (UUIE) per day over the 6-month period, as recorded in 3-day diaries submitted
monthly. Secondary outcomes included resolution of UUI symptoms, quality of life, use of
catheters, and adverse events including UTI, which was defined as a positive standard urine
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culture with >105 colony-forming units of a known uropathogen or treatment with antibiotic for
UTI within 6 months of randomization. Following treatment, intermittent catheterization was
recommended if post-void residual was either >300mL or >150mL with “moderate” to “quite a
bit” of bother associated with incomplete voiding.
All subjects were free of clinical UTI prior to study injection, as determined by a negative
nitrite and leukocyte esterase result on a urine dipstick evaluation of a catheterized specimen.
Urine culture was not required. Following baseline assessment and prior to injection, subjects
provided a baseline catheterized urine sample, which was placed at -80°C within 1 hour; the
frozen samples were batch-shipped on dry ice to Loyola University Chicago for 16S rRNA gene
sequence analysis. Staff and investigators were blinded to clinical information during laboratory
research analyses.
16S rRNA Sequencing.
DNA was isolated in a laminar flow hood to avoid contamination. Genomic DNA was
extracted from 1 ml of urine using previously validated protocols7,165,166. Variable region 4 (V4)
of the bacterial 16S rRNA gene was amplified via a two-step nested polymerase chain reaction
(PCR) protocol, using modified universal primers 515F and 806R, as previously described7,165.
Two quality controls assessed the contribution of extraneous DNA from laboratory reagents: a
DNA extraction negative control with no urine added and a PCR negative control with no
template DNA added. The final PCR product was purified from unincorporated nucleotides and
primers using Qiaquick PCR purification kit (Qiagen, Valencia, CA) and Agencourt AMPure XP-
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PCR magnetic beads (Beckman coulter). Samples were normalized to equal DNA concentration,
as determined by Nanodrop spectroscopy (Thermo Scientific, Waltham, MA). The sample
library and the PhiX sequencing control library (Illumina) were denatured and added to the
2x250 bp sequencing reagent cartridge, according to manufacturer’s instructions (Illumina).
DNA Sequencing Analysis.
Illumina MiSeq post-sequencing software preprocessed sequences, removing primers
and sample indices. The open-source program mothur (v1.31.2) combined paired end reads and
removed contigs (overlapping sequence data) of incorrect length (<285 bp, >300 bp) and/or
contigs containing ambiguous bases167. The remaining modified sequences were aligned to the
SILVA reference database168. Chimeric sequences were removed using UCHIME. The remaining
sequences were taxonomically classified using a naïve Bayesian classifier and the RDP training
set v9, and clustered into operational taxonomic units (OTUs)169. METAGENassist was used to
link OTU nomenclature to taxonomic assignments170.
The ABC trial was conducted with full IRB approval at all participating sites. All samples
were processed in duplicate and characterized as sequence-positive, sequence-negative or
inconclusive. A sequence-negative sample was one in which DNA was not amplified in either
technical replica. To avoid accidentally sequencing rare contaminants, we conservatively
considered samples to be negative if DNA amplification was not visible on an agarose gel. A
sequence-positive sample was one in which DNA was amplified from both replicas, the replicas
had a Euclidian distance score less than 0.3, and the dominant genus (>45% sequences per
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sample), if present, was the same in both replicas. Samples not meeting these criteria were
deemed inconclusive and disregarded from further analysis (n= 12). For each sequence-positive
sample, percent reads were calculated and replicates were then averaged for downstream
analysis.
To display the average sequence abundances, a histogram was produced, color-coded
by bacterial taxa. Euclidean distance was calculated between samples and the complete
method was used for hierarchical clustering in the statistical package R v2.15.1. The resulting
dendrogram was divided into 8 urotypes165. The rare urotypes were grouped into an “other”
category, condensing the original 8 urotypes to a total of 5 urotypes for use in the analysis
(Lactobacillus, Gardnerella, Gardnerella/Prevotella, Diverse, and Other) plus the negative
category. These urotypes, along with the sequence-negative group, were then compared to
participant demographics, symptoms at baseline and clinical outcomes.
Statistical Analysis.
Differences were examined descriptively at baseline, as were changes in clinical
outcome measures for individuals defined as sequence-positive and sequence-negative, as well
as for individuals classified by urotype, further described below. The differences in binary
baseline and outcome measures across these two categorical measures of sequence were
examined via contingency tables, with p values generated from Chi-squared tests and
differences in mean values for continuous measures evaluated using general linear models.
Because all analyses were considered descriptive, no adjustments were made for multiple
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comparisons and p values should be interpreted accordingly. To compare the mean abundance
of the top 10 most abundant taxa, the Wilcoxon rank sum test was performed. Statistical
analyses were conducted using SAS version 9.3.
Results
Approximately half (51.1%, 93/182) the urine samples were sequence-positive. Table
B.1 displays demographics and baseline characteristics of participants relative to sequence
status; the mean age was 58.5 years and most participants were white (77%). Sequencepositive subjects were younger (55.8 +/- 12.2 vs. 61.3 +/-9.0 years, p=0.0007), had a higher
body mass index (33.7 +/- 7.3 vs. 30.1 +/- 6.6 kg/m2, p=0.0009) and had a higher mean number
of baseline UUIE (5.7 +/- 2.5 vs. 4.2 +/- 2.1 per day, p<0.0001). Race, ethnicity, prior
anticholinergic use, or study treatment assignment did not differ between sequence-positive
and sequence-negative cohorts.
Sequence-positive subjects responded better to treatment with a larger decrease in baseline
UUIE (-4.4 +/- 2.7 vs. -3.3 +/- 1.9, p=0.0013) with no evidence of interaction with treatment
group (p=0.92). In both groups, sequence-positive subjects were less likely to develop UTI after
initiation of study anti- incontinence treatment (9% vs. 27% post treatment UTI’s, p=0.0011)
(Table B.2). In sequence-positive urines, hierarchical clustering revealed eight major urotypes,
as shown by the horizontal line (Figure B.1, top). In seven of these urotypes, a single bacterial
genus or family dominated (i.e., represented >45% total sequences in a sample) (Figure B.1,
bottom).
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Table B.1. Baseline Characteristics and Sequence Status
Characteristic
Overall Sequence
Positive
Age, N
182
93
Mean (SD)
55.8 (12.2)
Median (Min-Max)
55.8 (31.1-85.4)
Ethnicity, N (%)
Hispanic
23 (25%)
Non-Hispanic
70 (75%)
Race, N (%)
White
68 (73%)
Non-White
25 (27%)
BMI, N
93
Mean (SD)
33.7 (7.3)
Median (Min-Max)
32.8(20.5-52.4)
Menopausal Status, N (%)
Pre-menopausal
17 (20%)
Post-menopausal
70 (80%)
Prior anticholinergic use, N
(%)
Yes
52 (56%)
No
41 (44%)
Baseline Urgency Urinary
Incontinence Episodes (UUIE)
Stratum, N (%)
5 to 8
11 (12%)
9+
82 (88%)
Baseline UUIE, N
93
Mean (SD)
5.66 (2.5)
Median (Min-Max)
5.00 (1.7-12.0)
OABq** Symptom Severity, N
93
Mean (SD)
45.6 (20.7)
Median (Min-Max)
47.7 (0-90.8)
Treatment, N (%)
Active onabotulinumtoxin A
42 (45%)
Active anticholinergic
51 (55%)
medication

Sequence
Negative
89
61.3 (9.0)
61.2 (43.1–83.1)

p-value
0.0007

0.054
12 (13%)
77 (87%)
0.15
73(82%)
16 (18%)
89
30.1 (6.6)
28.8 (18.7-48.5)

0.0009

0.059
8 (9%)
77 (91%)
0.97
50 (26%)
39 (44%)
0.0036

26 (29%)
63 (71%)
89
4.20 (2.1)
3.67 (1.7-9.7)
89
46.3 (24.0)
46.2 (6.2-98.5)

<0.0001

0.78

0.47
45 (51%)
44 (49%)

*p-value, testing sequence positive versus negative, ** OABq: Overactive Bladder quantitative
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Figure B.1. The Urinary Microbiota Profile of Sequence Positive Participants.
The urinary microbiota profiles of sequence positive participants cluster together, as
demonstrated in the dendrogram (top), and by the dominant bacterial taxa present, as
depicted in the histogram (bottom). The dendrogram was based on clustering of the
Euclidean distance between urine samples and each line represents a separate individual.
Urine samples that possessed the same dominant bacterial taxa grouped together in the
dendrogram and were classified into the following urotypes, as shown by the dashed
horizontal line: Lactobacillus, Gardnerella, Gardnerella/Prevotella, Enterobacteriaceae,
Staphylococcus, Aerococcus and Diverse. The placement of the urotype grouping line
provided clear distinction of urine samples by the dominant genera, while maintaining
clusters that contain at least 2 urine samples. The histogram displays the bacterial taxa
detected by sequencing as the percentage of sequences per urine by sequence positive
participants (N=93). Each bar on the x-axis represents the urinary microbiota sequence based
composition of a single participant. The y-axis represents the percentage of sequences per
participant with each color corresponding to a particular bacterial taxon. Bacteria were
classified to the genus level with the exception of Enterobacteriaceae and Lachnospiraceae,
which could only be classified to the family level. The 15 most sequence abundant bacterial
taxa were displayed and the remainder of the taxa, including unclassified sequences, were
grouped into the category “Other”.
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For example, in the first urotype, Enterobacteriaceae accounted for >90% of the total
sequences in all of the eight samples. Nearly half of the sequence positive urines were
dominated by the genus Lactobacillus (45%), followed by Gardnerella (17%),
Gardnerella/Prevotella (9%), Enterobacteriaceae (9%), Staphylococcus (3%), Aerococcus (2%)
and Bifidobacterium (2%). The remaining cluster was labeled “Diverse” to signify those (13%)
without a dominant genus. While these more diverse samples were often composed of
different genera, they grouped together (Figure B.1, bottom). Each urotype was observed in
samples from ≥2 performance sites and several urotypes were observed at multiple clinical
sites (Table B.3).
Most sequence-positive samples had a dominant genus (Figure B.1). To assess the
prevalence of these genera in samples where they did not dominate, we calculated the
proportion of sequences belonging to the dominant taxon of each urotype across all sequencepositive samples. Figure B.2 demonstrates that nearly all the sequence-positive samples
contained Lactobacillus (with a median 20% Lactobacillus sequences per urine sample). With
the exception of Gardnerella, the other urotype-defining taxa were less commonly detected in
samples outside those they dominated. Cluster analysis (Figure B.1) revealed eight major
urotypes: Lactobacillus, Gardnerella, Gardnerella/Prevotella, Enterobacteriaceae,
Staphylococcus, Aerococcus, Bifidobacterium, and Diverse. Although some major clusters
(especially Lactobacillus, Gardnerella and Diverse) branched into sub-clusters, for further
analyses, we treated these sub-clusters as one urotype.
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We also combined the less common urotypes (Gardnerella/Prevotella,
Enterobacteriaceae, Staphylococcus, Aerococcus and Bifidobacterium) together (Other). We
compared these five urotypes and the sequence-negative group to baseline demographic and
clinical variables.
Table B.2. Clinical Outcomes by Sequence Status
Characteristics
Sequence
Positive
Urinary tract infection, N (%)
Yes
8 (9%)
No
85 (91%)
Change in UUIE, N
90
Mean (SD)
-4.36 (2.7)
Median (Min-Max)
-4.03 (-11.7 – 0.7)
OABq Symptom Severity Change, N
90
Mean (SD)
-46.8 (23.8)
Median (Min-Max)
-48.1 (-86.7 –
11.1)
OABq HRLQ* Change, N
90
Mean (SD)
39.2 (21.9)
Median (Min-Max)
37.5 (-9.0-96.7)
*Health Related Quality of Life Measurement

Sequence Negative

p-value
0.001

24 (27%)
65 (73%)
89
-3.32 (1.9)
-3.17 (-9.3-2.5)
89
-43.7 (22.7)
-44.4 (-93.3 – 9.2)
89
37.2 (25.2)
36.9 (-28.8-93.8)

0.0013

0.37

0.60

Table B.3. Urotype Distribution Among Collection Locations.
For each urotype, we verified that the samples came from at least two study sites, to rule out
bias due to the collection location.
Urotype
N
Site ID
Aerococcus
2
08, 22
Bifidobacterium
2
02, 16
Diverse
12
02, 07, 15, 17, 18, 21
Enterobacteriaceae
8
02, 06, 07, 17, 18
Gardnerella
16
02, 06, 07, 15, 16, 17, 18, 22
Gardnerella/Prevotella 8
02, 07, 08, 18, 22
Lactobacillus
42
02, 06, 07, 14, 15, 16, 17, 18, 21, 22
Staphylococcus
3
02, 17
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Figure B.2. Distribution of Dominant Taxa in Urine of All Sequence Positive Participants
The sequence proportion of dominant taxa (taxa that accounted for greater than 45% of
the sequences in at least one sample) were graphed for the sequence positive samples
(N=93). The boxplots represent the 25th, 50th and 75th percentile of the sequence
proportion, while points represent outliers. Lactobacillus was detected in the majority of
urine samples and the sequence abundance ranged from 0 to 100% of the total
sequences per sample. The median amount of Lactobacillus sequences detected per
urine was 20%. Gardnerella was the second most frequently detected genus, with 43%
of samples containing >1% Gardnerella sequences Whereas Staphylocccus, Aerococcus,
Enterobacteriaceae and Bifidobacterium were detected in high abundance in a few
samples, they were present at very low levels or not at all in the remainder of samples.
For example, Staphylococcus and Aerococcus were detected at >45% of total sequences
in only 3 and 2 samples, respectively. Lacto, Lactobacillus; Gard, Gardnerella; Prev,
Prevotella; Staph, Staphylococcus; Aero, Aerococcus, Entero, Enterobacteriaceae, and
Bifido, Bifidobacterium.
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Figure B.3. Demographic Variable Distribution by Urotype, Including the SequenceNegative Group.
Boxplots are shown comparing each urotype and the sequence negative group to A)
age, B) weight, BMI and C) the number of UUI episodes at baseline for each
participant. Aero=Aerococcus, Bif=Bifidobacterium, Ent=Enterobacteriaceae,
Gard=Gardnerella, Lac=Lactobacillus, Div = diverse, G/P =Gardnerella/Prevotella,
Staph=Staphylococcus and Neg = sequence-negative group. N stands for the number
of samples within each group.
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Whereas race, ethnicity and menopausal status were similar across urotypes, age
(p=0.005) and body mass index (p=0.014) differed (Table B.4). Additional analysis detected an
upward trend for age with the Enterobacteriaceae-dominant and Staphylococcus-dominant
urotypes and a downward trend with the Gardnerella/Prevotella-dominant urotype (Figure
B.3A). Body mass index tended to be lower in the Enterobacteriaceae-dominant,
Staphylococcus-dominant and sequence negative groups (Figure B.3B), whereas symptom
severity was similar across urotypes.
While Staphylococcus-dominant and sequence-negative groups showed a trend towards
lower baseline UUIE (Figure B.3C), the number of urine samples representing these urotypes
was small and the analysis lacked statistical power. Treatment response (change in UUIE,
p=0.0017) and development of post-treatment UTI (p=0.0058) differed among the 5 urotypes
(Table B.5). Baseline UUIE differed by incontinence severity (p=0.046) and frequency
(p<0.0001) (Table B.4). We compared the mean sequence abundance of sequence-positive
participants by clinical variables. The two treatment cohorts (anticholinergic and
onabotulinumtoxin A) displayed very similar mean sequence profiles at baseline, as predicted
given randomized treatment assignment (Figure B.4). However, the mean sequence profile of
the sequence-positive women who developed a post-treatment UTI differed from those who
did not develop a UTI. On average, sequence-positive women who developed a post-treatment
UTI had fewer Lactobacillus sequences (14 vs. 46%, p=0.009) (Figures B.4 and B.5).
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Table B.4. Baseline Characteristics as a Function of Urotype.
Characteristic
Age, N
Mean (SD)
Median
Ethnicity, N (%)
Hispanic
Non-Hispanic
Race, N (%)
Caucasian
Non-Caucasian
BMI, N
Mean (SD)
Medain
Menopausal
Status,
N (%)
Pre-menopausal
Postmenopausal
Prior
anticholinergic
use, N (%)
Yes
No
Baseline UUIE
Stratum,
N (%)
5 to 8
9+
Baseline UUIE, N
Mean (SD)
Median
OABq Symptoms
Severity, N
Mean (SD)
Median
OABq HRQL, N
Mean (SD)
Median

Lactobacillus
42
53.2 (11.5)
53.5

Gardnerella
16
53.7 (10.0)
54.2

Diverse
12
61.0(11.2)
60.3

Other
23
59.5 (14.0)
58.4

Negative
89
61.3 (9.0)
61.2

10 (24%)
32 (76%)

5 (31%)
11 (69%)

4 (33%)
8 (67%)

4 (17%)
19 (83%)

12 (13%)
77 (87%)

28 (67%)
14 (33%)
42
33.8 (7.6)
32.5

11 (69%)
5 (31%)
16
32.6 (5.2)
32.4

11 (92%)
1 (8%)
12
35.2 (8.7)
36.0

18 (78%)
5 (22%)
23
33.3 (7.3)
32.8

73 (82%)
16 (18%)
89
30.1 (6.6)
28.8

p-value
0.0005

0.24

0.20

0.014

0.22

10 (26%)
29 (74%)

4 (22%)
14 (78%)

2 (17%)
10 (83%)

1 (6%)
17 (94%)

8 (9%)
77 (91%)
0.71

23 (55%)
19 (45%)

8 (50%)
8 (50%)

9 (75%)
3 (25%)

12 (52%)
11 (48%)

50 (56%)
39 (44%)
0.046

6 (14%)
36 (86%)
42
5.0 (2.1)
4.50
42

2 (12%)
14 (88%)
16
6.0 (2.8)
5.17
16

65.2 (17.4)

66.6 (19.1)

60.0
42
49.0 (17.7)

71.67
16
49.5 (21.2)

50.8

53.7

0 (0%)
12 (100%)
12
6.2 (1.9)
6.50
12
69.2
(17.5)
70.0
12
42.9
(24.1)
40.0

3 (13%)
20 (87%)
23
6.3 (2.9)
6.00
23

26 (29%)
63 (71%)
89
4.2 (2.1)
3.67
89

73.8 (21.4)

68.8
(18.5)
70.0
89
46.3
(24.0)
46.2

76.7
23
37.5 (22.5)
43.1

<0.0001

0.49

0.32
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Table B.5. Clinical Outcomes as a Function of Urotype
Characteristics
UTI, N (%)
Yes
No
Change in
UUIE, N
Mean (SD)
Median
OABq
Symptom
Severity
Change, N
Mean (SD)
Median
OABq HRQL
Change, N
Mean (SD)
Median

Lactobacillus

Gardnerella

Diverse

Other

Negative

p-value
0.0058

1 (2%)
41 (98%)
42

1 (6%)
15 (94%)
16

1 (9%)
11 (91%)
12

5 (22%)
18 (78%)
23

24 (27%)
65 (73%)
89

0.0017

-3.8 (2.3)
-3.61
42

-4.9 (3.0)
-4.08
16

-5.2 (1.9)
-5.53
12

-5.0 (3.1)
-4.90
23

-3.3 (1.9)
-3.17
89

0.38

-42.7 (24.7)

-48.0 (25.2)

-51.8 (18.5)

-51.1 (24.2)

-45.0
42

-46.7
16

-48.2
12

-54.4
23

-43.7
(22.7)
-44.4
89

0.38

35.2 (19.7)

36.4 (28.6)

48.5 (17.4)

43.8 (21.3)

33.5

35.3

48.5

46.4

37.3
(25.2)
36.9

Discussion
In adult women with UUI, the composition of the urinary microbiota is identifiable,
variable and related to certain clinical variables of potential importance. As the female urinary
microbiota has only recently been detected4,7,14,60,93,163,165, an expanded perspective is
warranted. The current study demonstrates that the status of the female urinary microbiota
(sequence-positive or sequence-negative) can be used to sub-classify women with UUI and that
sequence-positive women can be further sorted by composition into urotypes, based on the
dominant bacterial genus or family or the lack thereof. The clinical utility of such sorting is yet
to be established. However, the likelihood that UUI is a heterogeneous urinary disorder could
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make this new approach useful for patient phenotyping.

Figure B.4. Urinary Microbiota Profiles by UTI Outcome
The 15 most abundant bacteria detected by sequencing were displayed as the percentage of
sequences per sample on the y-axis. The vertical bars along the x-axis represent the microbiota
profile of individual participants separated by UTI outcome. The urinary microbiota profiles of
the eight UTI positive participants consist of the following urotypes: 1 Lactobacillus, 1
Gardnerella, 2 Enterobacteriaceae, 1 Staphylococcus, 1 Aerococcus, 1 Bifidobacterium and 1
diverse. The proportion of Lactobacillus-dominant urines and diverse urines is less in the UTI
positive group compared to the UTI negative group.
Although the ABC study was designed prior to knowledge of the female urinary
microbiota and our analysis was not based on an a priori hypothesis, the current findings add to
the growing evidence that document the existence and define the characteristics of the female
urinary microbiota4,7,14,60,93,163,165. Further study of the differences in biomass (sequence
positive vs. sequence negative) and the microbial diversity by specific and dominant organisms
is likely to advance our knowledge of UUI. The composition of the urinary microbiota and its
clinical relationships also requires further study in other clinically relevant groups, including
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women undergoing surgery for prolapse and/or stress urinary incontinence, and those without
lower urinary tract symptoms.
To understand potential clinical relationships with the female urinary microbiota,
studies of comparison populations are clearly needed, including asymptomatic women and
those affected by non-UUI urinary symptoms. In an unrelated, smaller study, we compared the
female urinary microbiota of adult women with and without UUI165. The results of this previous
study closely align with those of the current one. Approximately half the samples were
sequence-positive and most of those were dominated by one genus, with the Lactobacillus and
Gardnerella urotypes most common. However, several species were strongly associated with
UUI. These include emerging uropathogens (e.g., Aerococcus urinae, Gardnerella vaginalis, and
Lactobacillus gasseri). In contrast, Lactobacillus crispatus was associated with women without
lower urinary tract symptoms.
The bladder is an environment with low bacterial abundance, unlike the gut or the
vagina. Although bacterial DNA was not sequenced from approximately half of our participants’
urine samples, it is possible that these sequence-negative bladders are not sterile, but rather
contain bacteria at low difficult-to-sequence levels. The existence of this sequence-negative
status is clinically important, as this group was at significantly greater risk for post-treatment
UTI. This finding will require further study; it is possible that certain organisms, such as
Lactobacillus, play an important regulatory or protective role to challenge the growth of
common uropathogens, such as E. coli.
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Figure B.5. Comparison of Average Bacterial Sequence Abundance in Urine by
Treatment Group and UTI Outcome.
The average amount of bacterial sequences detected in the sequence positive urine of
each randomized treatment cohort (anticholinergic versus botox) and UTI outcome cohort
(positive versus negative) was calculated. The average bacterial sequence abundance
profiles were similar between treatment cohorts, whereas the profiles differed between
UTI outcome cohorts.
Combined with the extreme sensitivity of PCR, caution is needed in low abundance
environments to appropriately distinguish true members of the urinary microbiota from rare
contaminants. Thus, we conservatively considered samples that amplified weakly to be
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sequence-negative to avoid over-interpretation of microbiota components. Even so, it is
notable that the improved methods used in the current study reproducibly detected bacterial
DNA in the urine of 56% of women in this population, compared to 39% in our previous
analysis163.
DNA-based techniques are increasingly popular for microbiota study because they can
detect bacteria without culture. Indeed, several groups have used 16S rRNA gene sequence
analysis to detect a microbiota in the lower urinary tract of adult women and men 4,7,60,93,165,171173.

Clinical reliance on standard urine cultures has limited our consideration of bacteria as

etiological contributors to idiopathic lower urinary tract disorders, including UUI. This is
because standard urine culture techniques underestimate the composition and diversity of
bacteria, especially those that inhabit the lower urinary tract. Expanded urine culture
techniques have been recently developed and shown to significantly outperform the standard
techniques7,14, but these new methods were developed after the samples in this study were
obtained. Importantly, recent studies using our newly developed expanded quantitative urine
culture (EQUC) method have documented that bacteria detected by 16S rRNA sequencing are
alive and thus the sequencing is not simply detecting DNA of dead organisms 7,165.
Some investigators may consider our analysis limited because our operational definition
of “clinically free of UTI” used a negative dipstick, rather than require that they have a negative
standard urine culture at baseline. Given the significant limitations of standard urine
culture7,14,165, however, we do not consider this a major limitation for the ABC study or this
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analysis. Furthermore, few samples included uropathogens, typically detected by standard
urine culture (e.g., E. coli) that could be indicative of a UTI. Given the nature of the index study,
which was aimed at clinical treatment of affected patients, there is no age-matched control
population without UUI symptoms in this randomized trial. As one of the first studies of the
female urinary microbiota, it is underpowered to definitively assess differences in the
distribution of the urinary microbiota by race or certain other variables.
Women with UUI are a heterogeneous population on the basis of their baseline urine
bacterial sequence status and/or urotype. Nearly half of female trial participants with UUI,
without evidence of clinical infection, had a urotype that was typically dominated by a single
genus, most often Lactobacillus or Gardnerella. These bacterial communities appear to have
clinical relationships with baseline UUI symptoms, response to treatment and risk for posttreatment UTI. As research in this area expands and incorporates samples from other clinically
relevant populations, we fully anticipate further refinements in our understanding of the role of
the female urinary microbiota in health and disease. Our findings suggest that previously
undetected bacteria in the bladder of women may have a role in UUI, providing expanded
opportunities for prevention and improved treatment approaches for UUI, such as modification
of the microbiota to improve response to UUI treatments. Our findings also suggest that some
bacteria may play a protective role in the bladder as they do in other human biological niches.
The potential for such a protective role warrants further study.

APPENDIX C

THE FEMALE URINARY MICROBIOME: A COMPARISON OF WOMEN WITH AND WITHOUT
URINARY URGENCY INCONTINENCE

Pearce, M. M., Hilt, E. E., Rosenfeld, A. B., Zilliox, M. J., Thomas-White, K., Fok, C., Kliethermes,
S., Schreckenberger, P. C., Brubaker, L., Gai, X. and Wolfe, A. J.
The Female Urinary Microbiome: a Comparison of Women with and without Urgency Urinary
Incontinence. MBio. 2014 Jul 8;5(4):e01283-14. doi: 10.1128/mBio.01283-14. PMID: 25006228
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Overview of Appendix C
This paper was the first comparison between women with UUI and continent controls.
Women with urgency urinary incontinence and continent controls were recruited at the Loyola
urogynecgology department. At the initial visit, all UUI women underwent a clinical assesment,
provided a catheterized urine speciment, and were prescribed 5mg of an anticholinergic. This is
the description of the two cohorts at baseline. All sampels underwent 16S sequencing and
EQUC. Another publication, Thomas-White & Hilt et al. 2016 (Appendix D)6, describes the
conclusion of the study.
We found that the microbiomes of UUI women are more diverse than controls, by total
species isolated and number of OTUs. We also identified a single bacterial species, Lactobacillus
crispatus, that is associated with controls and 10 species associated with UUI, including
Actinobaculum schaalii, Actinomyces neuii, Aerococcus urinae, Arthrobacter cumminsii,
Corynebacterium coyleae, Corynebacterium riegelii, Gardnerella vaginalis, Lactobacillus gasseri,
Oligella urethralis, and Streptococcus anginosus. Finally, this paper included an analysis of the
comparison of 16S sequencing to EQUC and found that the two results are comparable, but
both have strengths and weaknesses.
Abstract
Bacterial DNA and live bacteria have been detected in human urine in the absence of
clinical infection, challenging the prevailing dogma that urine is normally sterile. Urgency
urinary incontinence (UUI) is a poorly understood urinary condition characterized by symptoms
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that overlap urinary infection, including urinary urgency and increased frequency with urinary
incontinence. The recent discovery of the urinary microbiome warrants investigation into
whether bacteria contribute to UUI. In this study, we used 16S rRNA gene sequencing to classify
bacterial DNA and expanded quantitative urine culture (EQUC) techniques to isolate live
bacteria in urine collected by using a transurethral catheter from women with UUI and, in
comparison, a cohort without UUI. For these cohorts, we demonstrated that the UUI and nonUUI urinary microbiomes differ by group based on both sequence and culture evidences.
Compared to the non-UUI microbiome, sequencing experiments revealed that the UUI
microbiome was composed of increased Gardnerella and decreased Lactobacillus. Nine genera
(Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, Corynebacterium, Gardnerella,
Oligella, Staphylococcus, and Streptococcus) were more frequently cultured from the UUI
cohort. Although Lactobacillus was isolated from both cohorts, distinctions existed at the
species level, with Lactobacillus gasseri detected more frequently in the UUI cohort and
Lactobacillus crispatus most frequently detected in controls. Combined, these data suggest that
potentially important differences exist in the urinary microbiomes of women with and without
UUI, which have strong implications in prevention, diagnosis, or treatment of UUI.
New evidence indicates that the human urinary tract contains microbial communities;
however, the role of these communities in urinary health remains to be elucidated. Urgency
urinary incontinence (UUI) is a highly prevalent yet poorly understood urinary condition
characterized by urgency, frequency, and urinary incontinence. Given the significant overlap of
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UUI symptoms with those of urinary tract infections, it is possible that UUI may have a
microbial component. We compared the urinary microbiomes of women affected by UUI to
those of a comparison group without UUI, using both high-throughput sequencing and
extended culture techniques. We identified statistically significant differences in the frequency
and abundance of bacteria present. These differences suggest a potential role for the urinary
microbiome in female urinary health.
Introduction
The female urinary tract is a previously overlooked microbial niche. Recent detection of
bacterial DNA4,60,174, and live bacteria7,14 in urine from women with and without lower urinary
tract symptoms has provided compelling evidence that the female urinary tract possesses its
own unique microbiota. Research into the roles of these bacterial communities in urinary
health and disease requires sensitive and specific detection and classification. Although the
comparatively low bacterial load in urine challenges such effort, expanded culture conditions
have allowed researchers to detect bacteria at lower levels than previously used techniques.
For example, we recently reported that bacteria overlooked by standard culture conditions are
cultivable by adjusting the growth conditions to include increased urine volume, diverse growth
media and atmospheric conditions, and lengthened incubation time7. Using expanded
quantitative urine culture (EQUC), we isolated bacteria from 80% of examined urine samples
collected by transurethral catheter, most (92%) of which had been reported as “no growth,”
using a standard clinical microbiology urine culture protocol and a 103-CFU/ml threshold7.
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Despite this significant advance, many urinary bacteria cannot be cultured under these
conditions. Thus, culture-independent methods for bacterial detection, such as highthroughput sequencing of the 16S rRNA gene, have emerged as the predominant research
technique, especially as they become increasingly accessible due to declining sequencing cost
and improved bioinformatics tools175.
There is a clinical need for these improved research techniques. For example, urgency
urinary incontinence (UUI) is poorly understood chronic urinary condition that is often
attributed to abnormal neuromuscular signaling and/or functioning. However, alternative or
complementary mechanisms beyond neuromuscular abnormalities must be considered, since
UUI pharmacological treatments aimed at the overactive bladder are ineffective in
approximately half of the pharmacologically treated UUI population176,177.
UUI is common, affecting 1.5 to 22% of the U.S. population, most frequently women and
the elderly177. Affected patients experience a sudden, intense need to urinate with involuntary
urine loss that detracts from the patient’s quality of life178. A proportion of UUI cases resolve
over time; however, it is a chronic condition for most women177. There is a large socioeconomic
burden, with the costs of UUI in the United States projected to reach $76.2 billion by 2015 110.
The clinical diagnosis of UUI requires exclusion of urinary tract infections (UTI); thus,
infectious etiology is not considered for UUI. Given the clinical similarly of UUI and UTI
symptoms, however, we and others have recently used expanded culture techniques 7,14 and
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quantitative PCR174 to show the presence of bacteria in standard culture-“negative” urine
samples collected from UUI patients.
In this analysis, we utilized both 16S rRNA gene sequencing and EQUC to characterize
the microbiome in urine obtained by transurethral catheter from women seeking treatment for
UUI and a comparison group of women without UUI. Utilizing both techniques, we identified
statistically significant differences in the frequency and abundance of bacteria present,
suggesting a potential role for the urinary microbiome in female urinary health.
Results
Cohort Description.
Table C.1 displays the UUI symptoms by cohort. Consistent with the intended
composition of the cohorts, the UUI cohort reported more distress on both the urinary and
prolapse subscales of the Pelvic Floor Distress Inventory (PFDI) (urinary distress inventory [UDI],
102 [±47] versus 11 [±11] [P < 0.05]; Pelvic Organ Prolapse Distress Inventory [POPDI], 70 [±52]
versus 28 [±32] [P < 0.05]). The UUI cohort also reported more-severe overactive bladder (OAB)
symptoms (66 [±23] versus 4 [±7]; P < 0.05) and decreased quality of life as measured by healthrelated quality of life (HRQL) (56 [±25] versus 99 [±3]; P < 0.05) compared to the non-UUI
cohort. Table C.1 also displays the participant demographics by cohort. Marital status, diabetes,
smoking, and prior pelvic surgeries did not differ by group. However, the UUI cohort was
heavier (body mass index [BMI], 32 [±8] versus 28 [±6]; P = 0.01), less likely to be using estrogen
(27% versus 61%; P < 0.05), and older (63 [±12] versus 49 [±14]; P < 0.05).
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Table C.1. Participant demographics and symptoms
Characteristic
Demographics
Age (yrs)
Race [no. (%)]
Caucasian
African American
Asian
Estrogen Status [no. (%)]
Estrogen Positive
Estrogen Negative
BMI (kg/m2)
Hypertension [no. (%)]
Coronary artery disease [no. (%)]
Symptoms
Symptom scored
Health related quality of life (HRQL)d
Urinary Distress Inventory (UDI)e
Pelvic Organ Prolapse Distress Inventory
(POPDI)e
Colorectal-Anal Distress Inventory
(CRADI)e

Value for group (na)b or statistic
UUI (60)
Non-UI
Controls p-value
(58)
63 (±12)

49 (±14)

50 (83)
10 (17)
0 (0)

41(77)
11 (21)
1 (2)

<0.05
0.42

<0.05
16 (27)
43 (73)
32 (±8)
21 (35)
9 (15)

31 (61)
20 (39)
28 (±6)
9 (17)
1 (2)

0.01
0.03
0.02

66 (±23)
56 (±35)
102 (±47)
70 (±52)

4 (±7)
99 (±3)
11 (±11)
28 (±32)

<0.05
<0.05
<0.05
<0.05

71 (±61)

43 (±62)

0.02

a

b
n, no. of subjects.
Mean ± SD or no. (%).
Pearson’s chi-square and Fisher’s exact tests were used with categorical variables. Student’s t test was used with
continuous variables.
d
Based on OAB questionnaire.
e
Based on Pelvic Floor Disease Inventory.
c

Sequence-Based Characterization of Female Urinary Microbiome.
Bacterial DNA was detected in similar proportions of urine samples (UUI, 63.9% [23/36];
non-UUI, 65.8% [25/38]). The lack of bacterial detection in the remaining samples may be due
to low bacterial load, insufficient bacterial lysis, and/or primer bias rather than being conclusive
evidence of no bacteria in these urine samples.
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Figure C.1. Urinary microbiome profile by cohort based on 16S rRNA gene V4 sequencing.
Stacked bar plots depict the sequence abundances of the 15 most abundant genus- or
family-level taxa in the UUI and non-UUI cohorts. Taxa were ranked according to mean
abundance across all samples. The y-axis represents the percentage of sequences for a
particular bacterial taxon; the x-axis represents the study participants separated by cohort.
The family Enterobacteriaceae could not be classified to the genus level. The remainder of
sequences was combined in the category labeled Other.
Further analyses were performed on the samples with detectable bacterial DNA (for
UUI, n = 23; for non-UUI, n = 25). The sequences from these samples were classified into 22
phyla, 34 classes, 69 orders, 150 families, and 386 genera. The most abundant phyla detected
were Firmicutes, with a median abundance of 60%, followed by Actinobacteria (16%),
Proteobacteria (1.5%), and Bacteroidetes (0.6%). From each sample, the majority of sequences
could be classified to the genus level. The two exceptions (C031 and C033) were
predominantly Enterobacteriaceae (Figure C.1). In the remainder of the samples, the
percentage of sequences per sample that could not be classified to the genus level ranged from
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0.02 to 24.1%. At the genus level, the majority of urine samples were dominated by one or two
bacterial families or genera, most frequently Lactobacillus and Gardnerella (Figure C.1).
Table C.2. Urotype frequency by cohort
No. (%) of participants for group (na) p-valuec
Urotype
UUI (23)b
Non-UI Controls
p-value
b
(25)
Gardnerella
6 (26)
3 (12)
0.23
Sneathia
2 (9)
0 (0)
0.22
Diverse
4 (17)
5 (20)
0.99
Staphylococcus
1 (4)
0 (0)
0.48
Enterobacteriaceae
0 (0)
2 (8)
0.49
Lactobacillus
10 (43)
15 (60)
0.39
a

n, no. of subjects. cFisher’s exact test.
DNA.

b

Analysis performed on the subset of samples with detectable bacterial

Urine samples with the same dominant taxa clustered together in a dendrogram
generated via hierarchical clustering of the Euclidean distance between urine samples (Figure
C.2). We observed six groups, now termed urotypes, which were named based on either the
dominant family or genus (Gardnerella, Sneathia, Staphylococcus, Enterobacteriaceae, and
Lactobacillus) or the lack of a dominant family or genus (“diverse”). The most frequent urotype
in both cohorts was Lactobacillus (43% UUI and 60% non-UUI controls), followed
by Gardnerella (26% UUI and 12% non-UUI controls) (Table C.2). Three urotypes were present
in both cohorts (Gardnerella, Lactobacillus, and diverse). The Staphylococcus and Sneathia
urotypes were present only in the UUI cohort, whereas the Enterobactericeae urotype was
present only in the Non-UI cohort; however, these differences were not statistically significant
at our current sample size.
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Figure C.2. Clustering of the urinary microbiome into urotypes. The dendrogram was based
on hierarchical clustering of the Euclidean distance between samples in the combined UUI
and non-UUI cohorts. The dashed line depicts where the clades were divided into 6
urotypes: Gardnerella, Sneathia, Diverse, Staphylococcus, Enterobacteriaceae, and
Lactobacillus. The Stacked bar plot below the dendrogram depicts the sequence
abundances of the overall most abundant taxa.
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We calculated the frequency that each genus was observed in each cohort (Figure C.3A).
While Lactobacillus was detected in every sample in both cohorts, some genera were observed
more frequently in one cohort than in the other. For example, Gardnerella (99% UUI, 60% nonUUI; P = 0.003) and Aerococcus (74% UUI, 28% non-UUI; P = 0.002) were detected more
frequently in the UUI cohort than in the non-UUI one. Conversely, Staphylococcus (61% UUI,
92% non-UUI; P = 0.01) was observed less frequently in the UUI cohort than among non-UUI
women. Actinobaculum (61% UUI, 44% non-UUI; P = 0.24) and Sneathia (22% UUI, 4% non-UUI;
P = 0.09) exhibited a trend toward increased detection in the UUI cohort; however, this
difference was not statistically significant at our current sample size.
By calculating frequency, all samples are weighted similarly regardless of sequence
abundance. For example, urine samples collected from control participants C013 and C036 both
contained Lactobacillus sequences; however, the sequence abundances differed. For
C013, Lactobacillus represented more than 99% of the sequences; for
C036, Lactobacillus represented less than 5% of the total sequences (Figure C.1). To further
investigate these differences, the median sequence abundance was calculated and compared
between the cohorts (Figure C.3). The UUI cohort exhibited decreased Lactobacillus (14% UUI,
67% non-UUI; P = 0.01) and increased Gardnerella (4% UUI, 0% non-UUI; P = 0.003) sequence
abundances compared to those for the control cohort. Figure C.S2 in the supplemental
material displays the distribution of the 15 most abundant taxa detected by sequencing.

- 155 -

Figure C.3. Comparison of sequence-based urinary microbiome by cohort. The frequency (A)
and median sequence abundance (B) of the overall most abundant taxa detected by
sequencing were calculated. The families Enterobacteriaceae, Lachnospiraceae, and
Ruminococcaceae could not be classified to the genus level. In panel A, a combination of
Pearson chi-square and Fisher’s exact tests was used to compare the frequency of genera
detected by sequencing between the cohorts. “*” represents a P value of <0.05. In panel B, a
Wilcoxon rank sum test was used to compare the median sequence abundances between the
cohorts. IQR, interquartile range. “*” represents P values of <0.05.
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To measure the richness of the UUI and non-UUI urinary microbiomes, the number of
observed operational taxonomic units (OTUs) and the Chao1 estimator were calculated. To
measure diversity, the Shannon index and inverse Simpson index were calculated. Overall, the
urinary microbiome exhibited an average of 97 OTUs per urine, a Chao1 index of 7,210, an
inverse Simpson’s index of 1.72, and a Shannon index of 3.93 (Table C.3) There were no
statistically significant differences between the UUI and non-UUI control cohorts based on
these estimators of richness and diversity.
Table C.3. Richness and diversity measures of the urinary microbiome
Metric
Total
UUI (n=23)a
Non-UUI controls
[mean
(n=25)a
(SD)]
Mean
Min-Max
Mean
Min-Max
(SD)
(SD)
No. of observed
97.02
86.35
25-155
106.84
39-201
OTUs (richness)
(40.6)
(36.89)
(42.17)
Chao1 estimator
7,210
5, 977
2,6888,344
1,697(richness)
(5331)
(4647)
20,021
(5,750)
22,997
Shannon index
1.72 (0.96)
1.70
0.17-3.68
1.74
0.30-3.83
(diversity)
(0.91)
(1.02)
Inverse Simpson
3.93 (4.28)
3.69
1.034.15
1.07(diversity)
(3.39)
16.08
(5.07)
20.40
a
b

p-valueb

0.08
0.12
0.88
0.71

Analysis performed on the subset of samples with detectable bacterial DNA. Min, minimum; Max, maximum.
Student’s t test.

Culture-Based Characterization of the Female Urinary Microbiota
Of the urine specimens assayed via EQUC, 71/90 (78.9%) grew bacterial species, while
64 of the 71 (90.1%) that grew bacterial species were deemed culture negative (no growth) by
standard culture. For the UUI and control cohorts, standard culture had false-negative rates of
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90.3% and 90.0%, respectively. This highlights the limitations of the standard clinical
microbiology protocol.
Rarefaction curves comparing the number of bacteria species to the number of urine
samples assayed reveal that the UUI cohort curve began to plateau at a higher number of
isolates than the non-UUI cohort curve (Figure C.4), indicating that these two cohorts possess
different urinary microbiota. In support of this supposition, there was a statistically significant
difference between the median numbers of bacterial isolates cultured from the UUI women
and those for the non-UUI women (4 [interquartile ratio (IQR) = 1 to 7] versus 1 [IQR = 1 to
7]; P < 0.001).

Figure C.4. Rarefaction curves of the cultured bacterial species by cohort. The plot depicts
the number of species cultured via EQUC by the number of urine samples assayed.
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Figure C.5. Genus-level comparison of cultured urinary microbiota by cohort. The Pearson
chi-square and Fisher’s exact tests were used to compare the frequencies of the genera
isolated from urine via EQUC. *, P <0.05; **, P < 0.001.

The frequencies at which we culture each genus were compared between cohorts. Nine
genera (Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, Corynebacterium, Gardnerella,
Oligella, Staphylococcus and Streptococcus) were more frequently isolated from the UUI cohort
than from controls (Figure C.5). Four of these genera were isolated solely from the UUI cohort
(Actinobaculum, Aerococcus, Arthrobacter, and Oligella); the concentrations ranged from
10 CFU/ml to 100,000 CFU/ml. Using matrix-assisted laser desorption ionization–time of flight
mass spectrometry (MALDI-TOF MS), the majority of the cultured isolates were classified to the
species level, one taxonomic level further than was achievable with V4 sequencing. This finer
level of resolution revealed additional differences between the cohorts. For example, the
genus Lactobacillus was frequently detected in both cohorts; however, when examination at
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the species level was done, distinct differences were detected between cohorts. Lactobacillus
gasseri was more frequently isolated from the UUI cohort (27% UUI, 9% non-UUI; P = 0.02),
whereas Lactobacillus crispatus was more frequently isolated from the control cohort (4% UUI,
18% non-UUI; P = 0.037) (Figure C.6). Also, Actinobaculum schaalii, Actinomyces neuii,
Aerococcus urinae, Arthrobacter cumminsii, Corynebacterium coyleae, Gardnerella vaginalis,
Oligella urethralis, and Streptococcus anginosus were more frequently isolated from UUI
women (see Table S2 in the supplemental material).

Figure C.6: Species-level comparison of cultured urinary microbiota by cohort. The Pearson
chi-square and Fisher’s exact tests were used to compare the frequencies of the species
isolated from urine via EQUC. *, P < 0.05; **, P < 0.01.
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A

B

Figure C.7. Comparison of taxa detected by 16S rRNA gene sequencing and EQUC. (A)
Comparison of sequence status and EQUC status for the 52 urine samples that were assayed by both
methods. (B) Comparison of the taxa detected by sequencing and culture of the sequence-positive,
EQUC-positive urine samples (n = 30). Each square was color coded based on whether the taxa were
detected by sequence only (green), EQUC only (red), sequence and EQUC (yellow), or neither
sequence nor EQUC (gray).
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Comparison of Culture Versus Sequencing for Defining the Urinary Microbiome.
More than half (58%; 30/52) of specimens examined by both EQUC and 16S rRNA gene
sequencing tested positive for bacteria by both techniques. Bacteria were cultured from 14
(27%) sequence-negative urine samples, while bacterial DNA was sequenced from 3 (6%) EQUCnegative urine samples. Altogether, bacteria were detected in 90% (47/52) of urine samples by
EQUC or sequencing or both. Only 10% (5/52) of the urine samples tested negative for bacteria
by both approaches (Figure C.7A).
Of the 30 urine samples that were positive by both sequencing and EQUC, there was
considerable overlap in terms of the bacterial taxa detected (Figure C.7B). A total of 18
different genera were cultured, the majority of which were detected by sequencing, thus
providing additional evidence of their presence in the urinary microbiome and indicating that
many of the sequenced genera represent live bacteria. In some urine samples, EQUC detected
genera that were not detected by sequencing; however, these nine genera were detected by
sequencing in other urine samples, demonstrating that these genera could be amplified by the
universal primers. Trueperella was the only cultured genus that was not detected at the
sequencing level in any of the urine samples. In contrast, some genera, such as Atopobium,
were detected via sequencing but not by culture, suggesting that even the expanded culture
technique was limited.
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Discussion
This analysis directly compared the urinary microbiome of women with UUI to that of
women without UUI symptoms. We used two independent yet complementary techniques, 16S
rRNA gene sequencing and extended culture, to characterize the female urinary microbiome.
Both techniques identified statistically significant differences in the frequency and abundance
of bacteria. These differences suggest a potential role for the urinary microbiome in female
urinary health and warrant further study.
Each technique detected similar but not identical microbiome profiles. High-throughput
sequencing provided the broader view of the bacteria present in the bladder, regardless of
ability to cultivate the organisms. On the other hand, the cultured isolates could be identified to
the species level, thus providing a finer level of resolution for the female urinary microbiome.
Furthermore, these cultured isolates can be utilized in future studies to further investigate their
potential for symbiosis or pathogenesis. Combined, these complementary techniques yielded
overlapping results and provided the most complete description of the female urinary
microbiome to date.
In both cohorts, one or two genera dominated the majority of the sequence profiles.
The two most frequently detected genera, by both sequencing and culture, were Lactobacillus
and Gardnerella. The former are lactic acid-producing, facultative anaerobic bacteria known to
play protective roles in the vaginal tract by decreasing pH and producing various
bacteriostatic/cidal compounds179,180. The latter are also facultative anaerobic bacteria
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frequently isolated in the vaginal tract, often in association with bacterial vaginosis. In this
study, Lactobacillus was detected at similar frequencies in both cohorts but displayed lower
median sequence abundance for women with UUI than for those without UUI. Furthermore, at
the species level, the Lactobacillus species differed between cohorts. Whereas L. gasseri was
more frequently cultured in samples from the UUI cohort, L. crispatus was more frequently
cultured in samples from controls. Why the distribution of these two Lactobacillus species
differs between women with and without UUI remains unknown, but it is possible that these
two members of the normal vagina flora perform distinct functions in the bladder. A similar
scenario seems to be developing for Gardnerella, which was detected more frequently and in
increased sequence abundance for the UUI cohort than for the non-UUI cohort.
Since Gardnerella was detected in the urine of women without UUI, it is unlikely that the simple
presence of Gardnerella indicates a dysbiotic environment. G. vaginalis can be cultured from
the vaginal tracts of women with and without bacterial vaginosis181,182. G. vaginalis strains
isolated from these two groups of women vary in their ability to adhere and induce cytotoxicity,
suggesting the possibility of pathogenic and symbiotic strains of G. vaginalis182. Whether the
isolates identified by MALDI-TOF MS as Gardnerella species fall into the latter category remains
to be determined.
Several bacterial genera were more frequently sequenced and cultured from the urine
of women with UUI, including Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, and
Oligella. Interestingly, many of these genera contain emerging uropathogens, including
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Actinobaculum schaalii, Aerococcus urinae, Oligella urealytica, and Arthrobacter cumminsii183187.

Whether these bacteria contribute to UUI is unknown at this time.
In addition to Lactobacillus and Gardnerella, many of the genera detected in the urinary

microbiome are often found in the vaginal tract, including Bifidobacterium, Enterococcus,
Actinomyces, Prevotella, and Atopobium15,181. Since the urine samples in this study were
collected via transurethral catheter, as opposed to a voided approach, these genera are likely
true inhabitants of the urinary tract and not vaginal contamination. This contention is
supported by our previous demonstration that the microbiome sequence profile of
catheterized urine is distinct from that of voided urine and instead closely resembles that of
urine collected via suprapubic aspiration, which bypasses the vagina and urethra 4. Genera
found in both the urinary and vaginal tracts could suggest a shared urogenital microbiome.
Alternatively, there could be differences at the species or strain levels, such that the vaginal and
urinary community members differ. It is easy to imagine that the specific conditions of these
quite different environmental niches could select for different traits.
Two genera, Corynebacterium and Streptococcus, were cultured more frequently from
UUI women yet were detected at similar frequencies by sequencing. A third
genus, Staphylococcus, was more frequently cultured from UUI women but more frequently
detected by sequencing in the control cohort. The simplest explanation for these discrepancies
would be that certain species of these genera do not grow under the current EQUC conditions.
Efforts to further extend this new protocol are planned.
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Although the urinary microbiome shares a number of genera in common with other
microbial sites within the human body, two key differences set the urinary microbiome apart.
Compared to the colon, which contains 1011 to 1012 CFU/g188, on average, the urinary tract
microbiome consists of <104 CFU/ml total bacteria. In our study, the median amount of bacteria
per urine was 85 CFU/ml. The urinary microbiome, with a median inverse Simpson index of 2.3
and Shannon index of 1.5, is also less diverse than other microbial sites in the human body,
such as the skin, mouth, and gastrointestinal tract2,189. Taken together, these findings suggest
that the bladder is a relatively unique microbial site within the human body and may be more
akin to other low-abundance sites, such as the eye171.
Changes in microbial diversity within a niche have been linked to disease. Examples
include decreased fecal microbiome diversity associated with Clostridium difficile infection190
and increased vaginal microbiome diversity associated with bacterial vaginosis191. In this study,
we did not detect large differences in sequence-based diversity between the two cohorts. It is
possible that we were unable to detect a difference due to the lack of power with our small
sample size. Alternatively, the amount of diversity within the urinary microbiome of UUI
women may not differ from that for non-UUI women. Instead, the key distinction might be the
bacterial types that are present. Although we did not detect differences in richness or diversity
by sequence, we detected differences in the species richness between the cohorts by culture. A
greater number of bacterial species were cultured from the UUI cohort than from the non-UUI
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control cohort. This finding further demonstrates the power of utilizing multiple approaches to
define a microbial community.
The urine of UUI women was more likely to contain Actinomyces, Aerococcus,
and Gardnerella and less likely to contain Lactobacillus than urine collected from women
without UUI. The mechanism behind this observation is unknown. One possibility is that the
UUI bladder selects for some bacteria over others, and as such, the presence of these
organisms in the bladder could serve as a marker for dysbiosis. Another possibility is that these
bacteria contribute to UUI symptoms, a supposition supported by the observation that each of
the genera associated with the UUI cohort contains at least one reported pathogenic species.
Taken together, this study, along with others, will eventually allow us to define a core or
common urinary microbiome that can be used to detect alterations to that community.
A limitation of this analysis is that our UUI and non-UUI cohorts differed in several
characteristics that may have clinical relevance for the female urinary microbiome. Thus, we
are unable to say whether age, BMI, or hormonal status affects our findings, and it is possible
that our findings are related to these differences rather than to urinary symptomatology.
Studies that describe the female urinary microbiome in large, well-characterized populations
have not been published. Future studies, with larger sample sizes, will be required to evaluate
these potentially important differences. Studies describing the longitudinal stability of the
female urinary microbiome (including populations undergoing treatment for urinary disorders)
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are also lacking. Such studies should be prioritized given the emerging evidence that the female
urinary microbiome may yield important clinical information.
Materials and Methods
Study Design and Population.
Following Loyola institutional review board (IRB) approval, participants gave verbal and
written consent for chart abstraction and urine collection with analysis for research purposes.
Participants were recruited from the clinical practice of the Female Pelvic Medicine and
Reconstructive Surgery Center of Loyola University Medical Center between August 2012 and
February 2014. These included women undergoing UUI treatment (UUI cohort) and a
comparison group of women not bothered by urinary symptoms (non-UUI control cohort). All
women were screened for potential study participation using the validated symptom
questionnaire, the Pelvic Floor Distress Inventory (PFDI)192,193. Exclusion criteria for both
cohorts included current UTI (based on urine dipstick) or history of recurrent UTI, antibiotic
exposure in the past 4 weeks for any reason, immunologic deficiency, neurological disease
known to affect the lower urinary tract, pelvic malignancy or radiation, untreated symptomatic
pelvic organ prolapse (POP) greater than POP-Q stage II (vaginal protrusion more than 1 cm
outside of the vaginal hymen), or pregnancy. Clinical and demographic information were
abstracted from the electronic medical record. Enrolled participants completed the long form
of the PFDI and the Overactive Bladder Questionnaire (OAB-q)110. Premenopausal woman and
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postmenopausal women taking any form of estrogen replacement were considered estrogen
positive.
Sample Collection.
Urine was collected aseptically via transurethral catheter. A portion of the urine sample
was placed in a BD Vacutainer Plus C&S preservative tube for culturing. A separate portion for
sequencing was placed at 4° C for <4 h following collection; 10% AssayAssure (Thermo
Scientific; Waltham, MA) was added before storage at −80° C.
The first urine samples collected (14 UUI samples and 8 non-UUI control samples) were
screened exclusively by 16S rRNA gene sequencing; this was before we implemented EQUC.
Subsequent urine samples (22 UUI and 30 non-UUI control samples) were screened by both 16S
rRNA gene sequencing and EQUC. The final urine samples (23 UUI and 15 non-UUI control
samples) were screened only by EQUC without high-throughput sequencing. Thus, we used
EQUC for 45 UUI and 45 non-UUI samples and 16S rRNA gene sequencing for 36 UUI and 38
non-UUI samples.
Urine Culture.
For standard urine culture, we struck 0.001 ml of urine onto 5% sheep blood (BAP) and
MacConkey agars (BD BBL prepared plated media), which were incubated aerobically at 35°C
for 24 h. Each separate morphological colony type was counted and identified in any amount.
The detection level was 1,000 CFU/ml, represented by 1 colony of growth on either plate. If no
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growth was observed, the culture was reported as “no growth,” indicating no growth of
bacteria at the lowest dilution, i.e., 1:1,000.
For EQUC, we struck 0.1 ml of urine onto BAP, chocolate and colistin, naladixic acid
(CNA) agars (BD BBL prepared plated media), which were incubated in 5% CO2 at 35°C for 48 h
(see Figure S1). A second set of BAPs was inoculated with 0.1 ml of urine and incubated in room
atmosphere at 35°C and 30°C for 48 h. We also inoculated 0.1 ml of urine onto each of two CDC
anaerobe 5% sheep blood agar plates (BD BBL prepared plated media) and incubated either in a
Campy gas mixture (5% O2, 10% CO2, and 85% N) or under anaerobic conditions at 35°C for
48 h. The detection level was 10 CFU/ml, represented by 1 colony of growth on any of the
plates. Finally, to detect any bacterial species that may be present at quantities lower than
10 CFU/ml, 1.0 ml of urine was placed in thioglycolate medium (BD BBL prepared tubed media)
and incubated aerobically at 35°C for 5 days. If growth was visually detected in the thioglycolate
medium, the medium was mixed, and a few drops were plated on BAP and CDC Anaerobe 5%
sheep blood agars for isolation and incubated aerobically and anaerobically at 35°C for 48 h.
Each morphologically distinct colony type was isolated on a different plate of the same medium
to prepare a pure culture that was used for identification. Matrix-assisted laser desorption
ionization–time of flight mass spectrophotometry (MALDI-TOF MS) with the MALDI Biotyper 3.0
software program (Bruker Daltonics, Billerica, MA) was used to identify the bacterial isolates, as
described elsewhere7. To determine the false-negative rate, the following equation was used:
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the number of false negatives (EQUC positive, standard negative) divided by the sum of the
number of true positives (EQUC positive) and false negatives (EQUC positive, routine negative).
DNA isolation from urine
We used a previously validated DNA extraction protocol developed for the Human
Microbiome Project. The protocol includes the addition of the peptidoglycan-degrading
enzymes mutanolysin and lysozyme, which ensure robust lysis of Gram-positive and Gramnegative species, to isolate genomic DNA from urine samples166. Briefly, 1 ml of urine was
centrifuged at 13,500 rpm for 10 min, and the resulting pellet was resuspended in 200 µl of
filter-sterilized buffer consisting of 20 mM Tris-Cl (pH 8), 2 mM EDTA, 1.2% Triton X-100, and
20 µg/ml lysozyme and supplemented with 30 µl of filter-sterilized mutanolysin (5,000 U/ml;
Sigma-Aldrich, St. Louis, MO). The mixture was incubated for 1 h at 37°C, and the lysates were
processed through the DNeasy blood and tissue kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. DNA was eluted into 50 µl of buffer AE, pH 8.0, and stored at −20°C.
16S rRNA Gene Library Generation and MiSeq Sequencing.
Sequencing was performed using a MiSeq desktop sequencer (Illumina, San Diego, CA).
First, a 16S rRNA gene amplicon library was generated via two consecutive PCR amplifications.
In the first reaction, the variable 4 region (V4) of the 16S rRNA gene was amplified using the
universal primers 515F and 806R, which were modified to encode the Illumina MiSeq
sequencing primer sequence at the 5′ end (see Table C.S1 in the supplemental material).
Reaction mixtures were incubated at 94°C for 2 min to denature the DNA template and
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amplified for 30 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 90 s. To ensure complete
amplification, samples were incubated at 72°C for an additional 10 min. Ten-microliter aliquots
of each reaction mixture were run on a 1% agarose gel. Samples containing a band of
approximately 360 bp were considered PCR positive and subjected to further library
preparation. Samples with no visible amplified product were considered PCR negative and not
processed further. The PCR-positive reaction mixtures were diluted 1:50 and amplified for an
additional 10 cycles, utilizing primers encoding the required adapter sequences for Illumina
MiSeq sequencing and an 8-nucleotide (nt) sample index (see Table S1), using the PCR
conditions described above. Unincorporated nucleotides and remaining primers were removed
via use of the QIAquick PCR purification kit (Qiagen, Valencia, CA), and the DNA concentration
of the eluted product was determined by Nanodrop spectroscopy (Thermo Scientific; Waltham,
MA). One hundred nanograms of each sample amplicon was pooled and run through a 1%
agarose gel. The final product, which includes the V4 region and the adapter sequences (390 to
450 bp in length depending upon the length of the V4 region), was gel extracted via the
QIAquick gel extraction kit and further purified via Agencourt AMPure XP-PCR magnetic beads
(Beckman Coulter, Pasadena, CA). The final concentration of the pooled DNA was determined
via Nanodrop spectroscopy and diluted in EBT (Elution Buffer with Tris; Illumina, San Diego, CA)
to 2 nM. An equal volume of 0.2 N NaOH was added, incubated at room temperature for 5 min,
and quenched with hybridization buffer (Illumina, San Diego, CA) to a final concentration of
8 pM. The Human Microbiome Project mock community HM-782D (BEI Resources, ATCC,

- 172 -

Manassas, VA), a standard used to optimize our approach, was mixed 1:1 with randomly
generated PhiX libraries, which are added to help focus the cameras on the sequencing clusters.
This mixture was added to the sample library at equal volumes and placed in the 2 × 250 bp
sequencing reagent cartridge according to the manufacturer’s instructions (Illumina, San Diego,
CA).
Care was taken to avoid bacterial DNA contamination by utilizing DNA-free reagents
when applicable, filter sterilizing all solutions through a 0.2 µM filter, and working in a PCRclean hood. To control for the introduction of contaminating DNA, negative controls for
extraction (no urine) and PCR (no template) were included in each experiment. The extraction
negative control for each experiment was sequenced to identify spurious genera likely
introduced from contaminated reagents and materials.
Sequence Analysis.
The Illumina MiSeq post-sequencing software preprocessed sequences by removing
primers and sequence adaptors. Using the open-source software program mothur (v 1.31.2),
the paired-end reads were assembled and contigs of incorrect length (<285 bp or >300 bp)
and/or contigs containing ambiguous bases were removed167,194. These modified sequences
were aligned to the SILVA reference database, and any potential chimeric sequences were
detected and removed using the program UCHIME169. The remaining sequences were
taxonomically classified, using a naive Bayesian classifier195 and the mothur-formatted RDP
training set v9, and clustered into operational taxonomic units (OTUs), an operational definition
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of a species-level cluster based on sequence similarity, using a 97% cutoff. The software
program METAGENassist was used to link OTU nomenclature to taxonomic assignments 170.
All samples were processed in duplicate, and the percent reads of the replicates were
averaged for downstream analysis. Stacked bar plots based on sequence abundance were
produced for each sample. Euclidean distance was calculated between samples, and the
complete method was used for hierarchical clustering via R software, version 2.15.1 196.
Richness and diversity metrics, including the number of observed OTUs, Chao1 estimator,
Shannon index, and inverse Simpson’s index, were calculated using mothur and were based on
subsampling to the number of sequences in the sample with the least coverage. Urine is a lowbiomass environment, and thus the sequencing results are more likely to be influenced by
extraneous DNA arising from reagents and resources; therefore, only reads representing
>0.01% of the sample total were included in the stacked bar plots, dendrogram, and frequency
and abundance analyses.
Statistical Analysis.
Statistical analyses, comparing participant demographics and symptoms, were
performed using the SPSS software program, version 19. For continuous variables,
Student’s t tests were applied. For categorical variables, Pearson chi-square and Fisher’s exact
tests were performed. Results were considered significant when the P value was less than 0.05.
Statistical analyses of the microbiome data were performed using the SAS software
program, version 9.3. The Wilcoxon rank sum tests were used to compare the median
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abundances for the 15 most abundant sequenced taxa and all cultured genera between groups.
The frequencies of detected genera were compared between groups, using either the Pearson
chi-square or Fisher’s exact test, depending on assumption validity. No adjustments for multiple
comparisons were made, since these analyses were considered descriptive.
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Supplemental Material

Figure C.S1. Outline of EQUC procedure.
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Figure C.S2. Distribution of taxa detected by sequencing. The distribution of the top 15 most
abundant taxa detected by sequencing is displayed as box plots.
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Table C.S1. 16S ribosomal DNA (rDNA) V4 Amplicon Library Primers
Primer

Primer sequence (5’ to 3’)

Primary PCR primers
Modified 515F

TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA

Modified 806R

GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT

Secondary PCR primers
501
AATGATACGGCGACCACCGAGATCTACACTAGATCGCTCGTCGGCAGCGTC
502
AATGATACGGCGACCACCGAGATCTACACCTCTCTATTCGTCGGCAGCGTC
503
AATGATACGGCGACCACCGAGATCTACACTATCCTCTTCGTCGGCAGCGTC
504

AATGATACGGCGACCACCGAGATCTACACAGAGTAGATCGTCGGCAGCGTC

505

AATGATACGGCGACCACCGAGATCTACACGTAAGGAGTCGTCGGCAGCGTC

506

AATGATACGGCGACCACCGAGATCTACACACTGCATATCGTCGGCAGCGTC

507

AATGATACGGCGACCACCGAGATCTACACAAGGAGTATCGTCGGCAGCGTC

508

AATGATACGGCGACCACCGAGATCTACACCTAAGCCTTCGTCGGCAGCGTC

701

CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGTGGGCTCGG

702

CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCTCGTGGGCTCGG

703

CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTCTCGTGGGCTCGG

704

CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG

705

CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG

706

CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG

707

CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCGG

708

CAAGCAGAAGACGGCATACGAGATCCTCTCTGGTCTCGTGGGCTCGG

709

CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG

710

CAAGCAGAAGACGGCATACGAGATCAGCCTCGGTCTCGTGGGCTCGG

711

CAAGCAGAAGACGGCATACGAGATTGCCTCTTGTCTCGTGGGCTCGG

712

CAAGCAGAAGACGGCATACGAGATTCCTCTACGTCTCGTGGGCTCGG

The adapter sequences are underlined in the 501 and 701 secondary primer sequences. The same
sequences are found in each of the 500 and 700 primer series. The 8-nucleotide sample indices are
bolded.

APPENDIX D
INCONTINENCE MEDICATION RESPONSE RELATES TO
THE FEMALE URINARY MICROBIOTA

Thomas-White, K., Hilt, E. E., Fok, C., Pearce, M. M., Mueller, E.R., Kliethermes, S., Jacobs,
K., Zilliox, M. J., Brincat, C., Price, T.K., Kuffel, Schreckenberger, P. C., G., Gai, X. Brubaker, L.
and Wolfe, A. J. Incontinence Medication Response Relates to the Female Urinary
Microbiota Int Urogynecol J. 2016 May;27(5):723-33. doi: 10.1007/s00192-015-2847-x.
Epub 2015 Sep 30. PMID: 26423260

- 178 -

- 179 -

Overview of Appendix D
These data represent our first evidence that the bladder microbiome correlates with a
health outcome, the response to medication. Because the symptoms of UUI and UTIs can
overlap, a diagnosis of UUI is contingent upon a negative standard urine culture. Therefore, a
bacterial etiology has not been considered for this disease. Instead, it is thought to be caused
by aberrant signaling to the detrusor muscle, causing contractions and resulting in the urge to
urinate. All medications aim to block this pathway in one way or another; however, all
medications on the market have about a 50% efficacy rate. Therefore, we asked if there could
be a bacterial component that would relate to response or lack of response to medication.
This paper is the conclusion of the study reported on previously (Pearce et al 2014,
Appendix C)3. In total, 74 UUI women and 60 controls were recruited. All patients had a clinical
assessment and provided a catheterized urine sample for 16S rRNA sequencing and EQUC. The
UUI patients were prescribed 5mg of the anticholinergic medication solifenacin. If they had not
reported improvement from the medication by 4 weeks, they were given the option to increase
to a 10mg dosage. By 12 weeks, we had 4 groups: controls, UUI patients that responded at
5mg, UUI patients that responded to 10mg, and UUI patients that did not respond, even with
an increased dose. We discovered that 5mg responders had a much less diverse (less rich)
microbiota than 10mg and non-responders. Four bacterial species were more frequently
isolated from 10mg and non-responders than from 5mg responders (Actinomyces neuii,
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Staphylococcus simulans, Streptococcus anginosus, and Streptococcus pneumoniae
/mitis/oralis).
These data suggest that a more diverse bladder microbiota either prevents response to
this medication or is the result of an environment that will not respond to medication. It also
suggests that it is possible to predict who will respond to medication by measuring the total
number of organisms in their bladder prior to treatment.
Abstract
Introduction. Many adult women have resident urinary bacteria (urinary
microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the
etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown.
Hypothesis. Microbiome/microbiota characteristics will relate to clinically relevant
treatment response to oral UUI medication.
Methods. Adult women initiating oral medication treatment for UUI and a comparator
group of unaffected women were recruited in a tertiary care health care system. All participants
provided baseline clinical data and urine. Women with UUI were given 5mg solifenacin with
potential dose escalation to 10mg for inadequate UUI symptoms control at 4 weeks. Additional
data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples
were assessed by 16S rRNA gene sequencing and enhanced quantitative urine culturing. The
primary outcome was treatment response as measured by the validated Patient Global
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Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as
a 4 or 5 score on the PGSC.
Results. The diversity and composition of the urinary microbiome/microbiota of women
with and without UUI differed at baseline. Women with UUI had more bacteria and a more
diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was
related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria
and a less diverse community at baseline. Non-responders had a more diverse community that
often included bacteria not typically found in responders.
Conclusions. Knowledge of an individual’s urinary microbiome/microbiota may help
refine UUI treatment. Complementary tools, DNA sequencing and expanded urine culture,
provide information about bacteria that appear related to UUI incontinence status and UUI
treatment response in this population of adult women.
Introduction
Many adult women undergo treatment for urinary urgency incontinence (UUI), often
with oral anticholinergic medication, such as solifenacin177. This medication class targets M3
muscarinic receptors to decrease smooth muscle contraction, relieving UUI symptoms of
urgency, frequency and urgency incontinence177. Although solifenacin decreases urgency
episodes in approximately 60% of treated patients, symptoms may persist197-199 with
approximately 40% of treated patients reporting bothersome symptoms 200. Clinicians recognize
this lack of response, although the cause remains unclear and studies into the biologic basis for
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persistent symptoms are lacking. Many UUI-affected patients are considered to have idiopathic
etiology; however, this view pre-dates emerging evidence of resident urinary bacterial
communities (urinary microbiota), recently reviewed 59,201,202. DNA sequencing and expanded
urine culture techniques have demonstrated that adult urine is not sterile 4,5,7,13,14,59,60,203,204 and
UUI-affected women have different resident bacterial compositions than non-UUI control
populations203.
In this prospective cohort of adult women with UUI, we compared baseline urinary
microbiota of women with UUI to those of non-affected controls. For UUI-affected women
subsequently undergoing clinically indicated UUI treatment with solifenacin, we also
determined urinary microbiota profiles throughout 12 weeks of treatment, using additional
longitudinal samples collected at 4 and 12 weeks. We hypothesized that the
microbiome/microbiota (e.g. diversity, overall community structure, and/or specific organisms)
would differ between women with and without UUI and between those that responded to
solifenacin and those that did not. Two complementary bacterial assessments, sequencing and
expanded quantitative urine cultures (EQUC)7, were used to overcome the insensitivity of
standard urine cultures. EQUC was not initially available; however, once this technique was
available, it was applied to all remaining samples.
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Methods
Study Design and Population.
This 12-week open label study began following Institutional Review Board approval.
Participants gave verbal and written research consent for chart abstraction and urine collection
with analysis for research purposes. Between August 2012 and July 2014, two cohorts of adult
women were recruited at a tertiary health care setting, Loyola University Medical Center.
Potential participants were screened for eligibility using the long version of the validated
symptom questionnaire, the Pelvic Floor Distress Inventory (PFDI)193,205. Women seeking UUI
treatment were recruited from a specialty Female Pelvic Medicine and Reconstructive Surgery
center. Comparison controls screened negative for UUI using the PFDI and were recruited from
women’s health practices within Loyola’s system. These controls were derived from a
population of gynecologic patients; those who underwent surgical procedures had a variety of
benign gynecologic conditions, most commonly abnormal uterine bleeding confirmed to be of a
benign nature. Enrolled participants also completed the overactive bladder questionnaire (OABQ)110. Exclusion criteria for both cohorts included current urinary tract infection (UTI) (based on
urine dipstick), history of recurrent UTI, antibiotic exposure in the past four weeks for any
reason, immunologic deficiency, neurological disease known to affect the lower urinary tract,
pelvic malignancy or radiation, untreated symptomatic pelvic organ prolapse (POP) greater than
POP-Q Stage II (vaginal protrusion more than one centimeter outside of the vaginal hymen) or
pregnancy.
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Figure D.1. Flow of study participants

Control participants, without overactive bladder symptoms, provided a single
catheterized urine sample for research purposes as well as clinical and questionnaire data. As
part of normal clinical care, UUI-affected participants provided a catheterized urine sample
prior to UUI treatment with solifenacin, which was provided at no cost for 12 weeks.
Participants with UUI also agreed to provide 2 additional catheterized urine samples at 4 and 12
weeks during UUI treatment for longitudinal analysis. The primary outcome was treatment
response at 12 weeks. Treatment response was assessed (at 4 and 12 weeks) using the
validated Patient Global Symptom Control (PGSC) questionnaire, which consists of a single
question that addresses improvement following treatment. Scores of 4 or 5 were defined as
“response”. PGSC scores <3 were considered “non-response”; these participants were offered a
dosage increase to 10mg at 4 weeks. Women whose PGSC score >4 continued the solifenacin
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5mg dose for 8 more weeks until primary outcome assessment at 12 weeks. Thus, definitions
for 3 response groups were determined a priori: non-responders, 5mg responders and 10mg
responders. Participants who were intolerant of the medication could withdraw at any point
during the study. The research team assessed adverse events at normally scheduled visits, and
at other intervals during participant-initiated contact. Figure D.1 shows the flow of UUIaffected study participants. The primary outcome was symptomatic response, based on PGSC
score, at 12 weeks.
Sample Collection and Analysis.
Urine was collected aseptically via transurethral catheter and a portion placed in a BD
Vacutainer Plus C&S preservative tube for culture. Urine culture was performed as described 7
(E-Methods 1). A separate aliquot for sequencing was placed at 4°C for <4 h following
collection; 10% AssayAssure (Sierra Molecular; Incline Village, NV) was added before storage at
-80°C. Our protocols for DNA extraction, library construction, 16S rRNA sequencing and
bioinformatics analysis have been described203. All genomic samples were processed in
duplicate and analysis was performed using mothur software167. Relative abundance was
calculated by generating the percent of total classified reads for each individual. All samples
were processed in duplicate and the percent reads of replicates were averaged for downstream
analysis, which included urotype identification and statistical analysis. Urotypes were
determined as described203. Briefly, a culture urotype is determined by the dominant (>50%)
identified organisms within a given sample. A sequencing urotype is determined by first
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clustering sequences using a dendrogram and grouping based on similarity; this usually
correlates with dominance (>50%) of one organism. Those communities without a dominant
organism were classified as “Diverse” urotype. Dendrograms were calculated using Bray Curtis
dissimilarity between samples, and the complete method was used for hierarchical clustering
via R software, version 2.15.1196. To measure the diversity (richness and evenness of species
within a sample), the alpha diversity (inverse Simpson’s index) was calculated using mothur
software167.
Protocol for the Eexpanded Quantitative Urine Culture (EQUC).
Full protocol in supplement (Methods D.S1). For standard urine culture, 0.001 mL of
urine was spread quantitatively onto 5% sheep blood (BAP) and MacConkey agars (BD BBL™
Prepared Plated Media), then incubated aerobically (35°C for 24 hours). Any amount of each
separate morphologic colony type was identified and counted using a detection level of 1,000
colony forming units (CFU)/mL (represented by 1 colony of growth on either plate). “No
growth” was reported when no growth was observed, indicating no growth of bacteria at
lowest dilution, i.e., 1:1000.
The expanded quantitative urine culture (EQUC) technique uses 0.1 mL of urine spread
quantitatively onto BAP, Chocolate and Colistin, Naladixic Acid (CNA) agars (BD BBL™ Prepared
Plated Media), then incubated in 5% CO2 (35°C for 48 hours). A second set of BAPs were
inoculated with 0.1 mL of urine and incubated in room atmosphere at 35°C and 30°C for 48
hours, respectively. In addition, 0.1 mL of urine was inoculated onto each of two CDC Anaerobe
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5% sheep blood agar (ABAP) plates (BD BBL™ Prepared Plated Media), and incubated in either a
Campy gas mixture (5% O2, 10% CO2, 85% N) or in anaerobic conditions at 35°C for 48 hours.
The detection level was 10 CFU/mL, represented by 1 colony of growth on any of the plates.
Finally, to detect any bacterial species that may be present at quantities lower than 10 CFU/mL,
1.0 mL of urine was placed in Thioglycollate Medium (BD BBL™ Prepared Tubed Media) and
incubated aerobically at 35°C for 5 days. If growth was visually detected, the Thioglycollate
Medium was mixed and a few drops were plated on BAP and ABAP agars for isolation, and
incubated aerobically and anaerobically (35°C for 48 hours). Each morphologically distinct
colony type was isolated on a different plate of the same media to prepare a pure culture that
was used for organism identification. Matrix-Assisted Laser Desorption Ionization Time of Flight
Mass Spectrometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 software (Bruker Daltonics,
Billerica, MA) was used to identify the bacterial isolates7. To determine the false-negative rate,
the following equation was used: the number of EQUC positive but standard negative samples
divided by the total number of EQUC positive samples. To determine the culture diversity
within a population, a species accumulation curve was generated. Species accumulation curves
illustrate the number of unique species cultured and identified (using EQUC) with each new
patient sampled. When the curve plateaus, it indicates that the community is fully sampled and
few, if any, new species will be identified. Therefore, it also measures the overall diversity of
the population by total number of unique species isolated.
Statistical Analysis.
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Standard statistical methods were used to compare participant demographics and
symptom data between UUI patients and controls. Continuous variables are reported as means
and standard deviations (SD) or medians and interquartile ranges (IQR) and categorical
variables are reported as frequencies and percentages. Collection of the primary outcomes at
12 weeks was necessary for assignment to UUI response groups; therefore, participants who
did not provide data through 12 weeks were not included in analyses involving response to
solifenacin. Fisher’s exact and Kruskal-Wallis tests were used to compare demographic and
culture (e.g., abundance and diversity) information among UUI response groups. For cultured
organisms, abundance was measured using total CFU/ml; for sequencing, abundance was
measured using percent classified reads or classified organisms. Post-hoc pairwise comparisons
were made using Wilcoxon Rank sum tests for continuous variables with significant overall pvalues. A kappa statistic was estimated to determine agreement between urotype classification
from samples with both EQUC and sequencing. All statistical analyses were conducted using
SPSS software version 19 or SAS software v9.4 (SAS Institute, Cary, NC). Significance was
assessed at an alpha level of 0.05. Results were not adjusted for multiple-comparisons since the
analyses are considered descriptive.
Results
Population Description Over the Course of the Study.
Figure D.1 displays the flow of UUI subjects through the 12-week follow-up period. The
study investigators withdrew participants who had received antibiotics for unrelated clinical

- 189 -

indications (2) and subjects who underwent a cystoscopy for clinical indications (2). An
additional 17 participants withdrew by the 4-week visit: 7 due to side effects and 6 lost to
follow up. Of the participants who provided UUI symptom response data at 4 weeks, 56%
(32/57) reported adequate symptom control; all of the remaining 25 accepted dose escalation
(10mg daily).
Comparison of Baseline UUI to Controls.
At baseline, participants included 74 UUI-affected women and 60 controls. The cohorts
were similar with respect to race/ethnicity, diabetes, and smoking (Table D.1). Participants with
UUI were more likely to suffer from hypertension [35% versus 18%, p=0.02] and coronary artery
disease [12% versus 2%, p=0.02]. The UUI population also was older [61.5 years (SD:11.5)
versus 49 (SD:14.7), p<0.001], heavier [BMI 32.7 (SD:8.4) versus 28 (SD:5.5), p<0.001], and more
likely to be estrogen-negative (post-menopausal and not on hormone replacement therapy)
[88% versus 43%, p-value<0.001]. As expected, UUI symptoms were significantly worse in UUIthan non-UUI participants.
We detected the presence of bacterial DNA in a similar proportion of urine samples for
each cohort (Controls: 43%, N=26/60, UUI: 50%, N=37/74, p=0.44 Table D.2A). Table D.2A and
Table D.S2 display the assigned sequence urotypes. In both groups, the majority of samples
were dominated by Lactobacillus [controls (61.5%, N=16/26), UUI (40.5%, N=15/37), p=0.13].
Alpha diversity (measured by the inverse Simpson index) of classified sequences between UUI
and control was similar (p=0.76).
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Table D.1. Participant demographics and symptoms scores
Comparison of baseline demographics between cohorts and response groups. Independent t-tests and
Chi-square tests used unless otherwise indicated. Fisher's Exact Test due to small, expected cell counts
unless otherwise indicated.

Demographics
Age (years) [Mean
(SD)]
Body Mass Index
(kg/m2) [Mean (SD)]
Race/Ethnicity*
Non Hispanic
Caucasian
Hispanic
Caucasian
African-American
Asian
Marital Status
Married
Separated
Divorced
Widowed
Single
Estrogen Status**
Estrogen Positive
Estrogen Negative
Unsure
Smoking
Diabetes
Hypertension
Coronary Artery
Disease
Prior Treatment for
OAB
Vaginal Parity
[Median, (IQR)]

UUI
(N=74)

Baseline
Non-UUI
Control (N=60)

61.5
(SD:11.5)
32.7
(SD:8.4)

49
(SD:14.7)
28
(SD:5.5)

56
(77%)
5
(7%)
13
(18%)
0 (0%)

Baseline: 3 Response Groups
10mg
Non
p-value
(N=15)
(N=10)

p-value

5mg
(N=25)

<0.001a

60
(SD:12.4)
31
(SD:7.6)

63
(SD:13.5)
30
(SD:7)

67
(SD:9)
34
(SD:9)

43
(72%)
4 (7%)

17
(68%)
3 (12%)

12
(80%)
2 (13%)

9 (90%)

12
(20%)
1 (2%)

5
(20%)
0 (0%)

1
(7%)
0 (0%)

1 (10%)

15
(60%)
1 (4%)
1
(4%)
4
(16%)
4
(16%)

8
(53%)
0 (0%)
3
(20%)
2
(13%)
2
(13%)

5 (50%)

4 (16%)
20
(80%)
1
(4%)
1 (4%)
2
(8%)
9
(36%)
2
(8%)
13
(52%)
2
(2-3)

2 (13%)
13
(87%)
0
(0%)
1 (7%)
1
(7%)
5
(33%)
2
(13%)
11
(73%)
2
(0-3)

0 (0%)
10
(100%)
0 (0%)

<0.001a
0.70

37
(62%)
1 (2%)
6
(10%)
1
(2%)
15
(25%)

7 (9%)
65
(88%)
2
(3%)
6 (8%)
7
(9%)
26
(35%)
9
(12%)
37
(50%)
2
(0-2.5)

32 (53%)
26
(43%)
2
(2%)
4 (7%)
2
(3%)
11
(18%)
1
(2%)
0
(0%)
2
(1-3)

0 (0%)

0 (0%)
0.71

0 (0%)
3 (30%)
1 (10%)
1 (10%)

<0.001

0.51
0.14
0.02
0.02
<0.001
0.02c

0.41b
0.70

0.01
38
(51%)
3 (4%)
9
(12%)
14
(19%)
10
(14%)

0.36b

0.68

0 (0%)
1 (10%)

0.99
0.99

7 (70%)

0.13

1 (10%)

0.84

6 (60%)

0.45

2
(0-5)

0.88c
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Table D.1. Continued
Symptom comparison at baseline and 12 weeks

Baseline Symptoms
[Median (IQR)]
Symptom Score d
HRQL d
UDI e
POPDI e
CRADI e

12 Week Symptoms
[Median (IQR)]
Symptom S,core d
HRQL d
UDI e
POPDI e
CRADI e

UUI
(N=74)

Baseline
Non-UUI
Control
(N=60)

70
(55-85)
52
(33-75)
110
(61-143)
70
(30-105)
66
(34-112)

0
(0-5)
100
(98-100)
8
(3-17)
14
(0-42)
17
(2-56)

p-value

<0.001c
<0.001c
<0.001c
<0.001c
<0.001c

Baseline: 3 Response Groups
5mg
10mg
Non
(N=25)
(N=15)
(N=10)

p-value

62
(42-88)
68
(50-76)
93
(55-131)
68
(42-129)
68
(44-120)

75
(65-85)
59
(36-87)
95
(52-120)
40
(8-70)
43
(11-81)

69
(55-78)
50
(31-70)
98
(80-149)
70
(8-101)
75
(20-89)

0.61c

18
(8-33)
93
(86-99)
22
(14-59)
32
(17-68)
24
(7-89)

18
(5-28)
94
(88-99)
46
(8-64)
13
(4-19)
18
(8-39)

54
(18-63)
70
(61-86)
95
(58-113)
54
(32-93)
53
(32-68)

0.01c

0.43c
0.63c
0.11c
0.43c

0.008c
0.01c
0.002c
0.08c

a

Student’s T-Test
One-Way ANOVA
c
Wilcoxon rank sum test
d
Symptom Score and Health Related Quality of Life Score (HRQL), Based on OAB questionnaire
e
Urinary Distress Inventory (UDI), Pelvic Organ Prolapse Distress Inventory (POPDI), Colorectal-Anal Distress
Inventory (CRADI), based on Pelvic Floor Disease Inventory
* Self reported by participant
** Estrogen status is defined as negative if the patient is post-menopausal and not on hormone replacement
therapy. Estrogen positive is anyone pre-menopausal and/or on hormone replacement therapy.
b

A large subset of baseline samples was processed by EQUC (UUI N=59/74, control
N=52/60). A greater proportion of UUI-affected women had cultivatable bacteria in their urine
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compared to control women (84.7% versus 63.5%, p=0.01). The groups differed in proportion of
cultured samples characterized by dominant organisms (culture urotypes) (Table D.2A):
Lactobacillus [controls (45.5%, N=15/33) versus UUI (22%, N=11/50) p=0.03], and diverse
[controls (6%, N=2/33) versus UUI (32%, 16/50) p=0.006 Table D.2A]. Relative to controls, UUIaffected women had significantly more diversity in unique cultivatable organisms, as assessed
by the number of unique cultivatable organisms per cohort (UUI= 80, Controls= 36, Figure D.2),
significantly more cultured bacterial isolates per participant, as measured by the median [UUI
(3) versus Controls (1), p<0.001, Figure D.2 inset] and significantly more cultivatable bacteria, as
measured by median number of CFU per mL per urine specimen [UUI: 340 CFU (IQR: 50-1710)
versus Controls: 20 CFU (IQR: 0-305), p=0.002].
Characteristics in the Baseline Samples Correlated with Primary Outcome.
Primary outcome data were available for 50 participants at 12 weeks, with 25 “5mg
responders”, 15 “10mg responders” and 10 “non-responders”, for an overall response rate of
80%. At baseline, compared to the withdrawn population, participants with primary outcome
data weighed less [BMI 31.2 (SD:7.7) versus 35.8 (SD:9.2), p=0.03] and were more likely to have
had previous pharmacologic treatment for OAB (60% versus 29%, p=0.01). They also had
greater HRQL scores [61 versus 37, p=0.001] larger urinary distress inventory scores [95 versus
131, p=0.02] (Table D.S1). We did not detect other significant group differences in baseline
variables for participants who competed the study. (Table D.S1).
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*Undetermined urotype means the bacterial load in the
sample was below the detectable threshold by either
sampling method.
**50 patients returned for the 12-week visit, however,
only 48 were sequenced due to unclear specimen
labeling. These two samples were processed by EQUC.

Table D.2. Urotype proportions
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Figure D.2. Diversity of cultivatable bacteria is distinct between cohorts and response
groups at baseline. Species accumulation analysis illustrates the number of unique species
cultured and identified using expanded quantitative urine cultures (EQUC) with each new patient
sampled. When the curve plateaus, it indicates that the community is fully sampled and few, if any,
new species will be identified. Therefore, it also measures the overall diversity of the population by
total number of unique species isolated. The urgency urinary incontinence (UUI) curve represents
samples at baseline from individuals who may or may not respond. When we divide this curve into
each group stratified by response, we see that baseline diversity of each groups is distinct,
suggesting that baseline diversity could be predictive of treatment response. The 5-mg responders
(grey triangles) had low diversity, with a total of 32 unique species isolated. The 10-mg responders
(dark x) had high diversity, with a total of 54 unique isolates. Nonresponders (light x) had high
diversity, with a total of 42 unique isolates. The median number of unique species was not
significantly different between 10-mg responders and nonresponders: 5 [interquartile range (IQR)
3–6] versus 8 (IQR 3–15), p value = 0.25 but was significantly different between 5-mg and 10-mg
responders and between 5-mg and nonresponders: 1 (IQR 0–5) versus 5 (IQR 3–6), p value = 0.03;
and 1 (IQR 0–5) versus 8 (IQR 3–15); p value = 0.02
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At baseline, the 3 response groups had similar demographics and symptom severity
(Table S.1). At 12 weeks, the HRQL scores differed among all response groups (p=0.008). The
median score for non-responders (70, IQR: 61-86) differed significantly from both responder
groups: 5mg group (93, IQR: 86-99) and 10mg group (94, IQR: 88-99) (p=0.004 and p=0.008,
respectively) (Table D.1).
The urine samples from all 50 participants with primary outcome data were tested for
detectable bacteria. At baseline, a similar proportion of each response group had detectable
bacterial DNA [5mg: 56% N=14/25, 10mg: 46.7% N=7/15, non-responders: 40% N=4/10, p=0.66,
(Table D.2B], suggesting that there is no difference in the frequency of samples with detectable
bacteria present in each response group. In contrast, when we compared bacterial community
composition by distribution of urotypes (i.e., the number of individuals with microbiomes
dominated by one organism), the baseline samples from each response group tended to be
different; however, no statistical testing was conducted due to limited sample sizes. Compared
to 10mg responders (12.5%, N=1/8), 5mg responders had a larger proportion of individuals with
Lactobacillus-dominant urine (50%, N=7/14) (Table D.2B). The response groups had similar
alpha diversities [5mg: 1.6 (IQR: 1.2-3.7), 10mg: 1.9 (IQR: 1.1-6.3), non-responders: 2.8 (IQR:
1.7-4.1), p=0.55].
The subset (N=39/50) of baseline urine samples from participants with primary outcome
data that were cultured with EQUC included 19 “5mg responders”, 13 “10mg responders”, and
7 “non-responders”. Cultivatable organisms (EQUC) were detected in most participants: 5mg
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responders: 73.7% (N=14/19), 10mg responders: 100% (N=13/13) and non-responders: 85.7%
(N=6/7) (p=0.13, Table D.2B). The dominant urotype by response group was: 5mg response Lactobacillus-dominant urotype 35.7% (N=5/14); 10mg - diverse urotype 38.5% (N=5/13) and
30.8% (N=4/13) Streptococcus-dominant urotype; and non-responders – diverse urotype 50%
(N=3/6). Each response group had a distinct species accumulation curve, with different total
number of unique cultured bacterial isolates: 5mg (32), 10mg (54) and non-responders (42)
(Figure D.2). Overall, there was a difference in the number of unique species isolated by
response group (p=0.02). The median number of unique species isolated from each individual
within each cohort was similar in the 10mg and non-responder groups [5 versus 8, p= 0.25
Figure D.2 inset]. However, there was a statistically significant difference between the 5mg and
the other responder groups: [5mg: 1 versus 10mg responders: 5 p= 0.03, or non-responders: 8,
p= 0.02 Figure D.2 inset].
Each response group contained several genera that differed from other response groups
(Figure D.3A), with Actinomyces cultivated more commonly from 10mg responders and nonresponders than from 5mg responders (p=0.01 and 0.04, respectively). Streptococcus was
cultivated more commonly from non-responders (p=0.002). In addition, several bacterial
species differed between response groups (Figure D.3B).
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Figure D.3. Detection frequency of genera and significant species between response
groups. Comparison of frequency of culture-based detection at genus (a) and species (b)
levels for baseline urine by response group. Fisher’s exact test was used to
calculate p values. * p = 0.05; ** p = 0.00
Primary Outcome Comparison – 12 weeks.
At 12 weeks, 48 of the 50 participants with primary outcome data were sequenced. Two
samples were not sequenced due to inconclusive labeling. Of the remaining 48, 23 samples
were positive for bacterial DNA (Table D.2B). Similar to baseline, the response groups had
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similar proportions of 12-week samples with detectable bacterial DNA [5mg: 43.5% N=10/23,
10mg: 46.7% N=7/15, and non-responders: 60% N=6/10, p=0.70]. Statistical testing was not
performed because of limited sample size; however, the 3 response groups trended toward
different sequence urotype distributions, with larger proportions of Lactobacillus urotypes in
5mg responders (70%, N=7/10), compared to 10mg responders (28.6%, N=2/7) and nonresponders (33.3%, N=2/6) (Table D.2B). The response groups had similar alpha diversity
(p=0.18).
At 12 weeks, most (86%, N=38/44) EQUC-characterized urines demonstrated
cultivatable organisms (Table D.2B). At 12 weeks, each response group tended toward different
culture urotypes distributions: 5mg response - Lactobacillus-dominant urotype 38.9% N=7/18;
10mg - diverse urotype 23.1% N=3/13 and 23.1% N=3/13 Streptococcus-dominant urotype; and
non-responders – Lactobacillus 42.8% N=3/7 (Table D.2B). The species accumulation analysis of
the baseline and 12-week samples show that the 10mg and non-responders decreased in
diversity by 12 weeks, from 55 unique isolates to 23 for the 10mg group and from 40 to 29 for
the non-responders. In contrast, the 5mg group increased in diversity, from 32 unique isolates
to 41 (Figure D.S1). We did not detect a specific single genus that significantly declined in
responders (5mg or 10mg) (Figure D.S2). At the conclusion of the specimen collection, we
compared the two methods of bacterial assessment. Approximately half (49.8%, N=119/239) of
all urine specimens sequenced had detectable bacterial DNA, whereas most specimens (80%,

- 199 -

N=140/177) cultured with EQUC grew organisms. Among the sequence-positive, culturepositive individuals, the urotype classifications were moderately comparable (Kappa = 0.45) 206.
When comparing EQUC to standard culture, we found EQUC detected more organisms
overall. Of all the urine samples in the study, 81.3% (N=165/203) grew bacteria by EQUC. Of
those, 149 had been deemed culture negative (“No Growth”) by the standard culture, resulting
in 90.3% false negative rate for standard culture.
Discussion
The female urinary microbiota in women affected by UUI appears to differ from a
comparison group of unaffected women. Using two complementary techniques, we report
differences in composition (urotype), diversity (number of unique bacterial species) and
identity of certain bacteria at the genus and species levels. These differences, which were
detectable prior to UUI treatment, appear related to treatment response. Moreover, following
UUI treatment, certain microbiota characteristics appear associated with a clinically significant
response to treatment. Overall, less diversity appears associated with fewer UUI symptoms and
with treatment response at 5mg. We also found that bacterial diversity in women who required
a higher dose to achieve adequate symptom control is more similar to the diversity found in
non-responders, indicating that the diversity of cultivatable organisms might be used to predict
treatment response.
The mechanistic relationship between bacterial diversity and UUI symptoms is
unknown. However, given our findings, important clinical questions regarding UUI etiology or
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consequences will need careful study. In this research work, we selected 2 complementary
study techniques to assess the bacterial milieu, one of which was developed after we started
enrollment. Sequencing, which was available at the onset of our study, provided a broad
picture of bladder bacteria, allowing a more complete analysis of bacterial diversity. In addition,
sequencing could detect bacteria that even EQUC could not cultivate. However, urine samples
contain low biomass relative to other anatomical sites (e.g., gut or vagina). Thus, a proportion
of the study population did not contribute sequencing data. This lack of information was often
resolved by the use of EQUC. This expanded culture technique for urine became available after
our study started. EQUC not only confirms that bladder organisms are alive, but it also allows
phenotyping of low biomass individuals not measurable by sequencing.
The very low CFUs associated with UUI may prompt consideration of a lower CFU cut-off
(perhaps >102) for a standard urine culture. Others have suggested lowering the culture
threshold for UTI 14,46,207-209 and even for UUI 210; however, these studies focused on growing
known uropathogens. Here, we showed that the bladder can contain a variety of organisms.
Some are likely non-pathogenic normal flora. Others might have an impact on UUI and other
lower urinary tract symptoms. Some of these might be protective, whereas others may
contribute to symptoms. Indeed, we recently reported that detection of urinary microbiota by
quantitative PCR is associated with a reduced risk of post-instrumentation UTI 5 and an
association between Lactobacillus crispatus and the lack of lower urinary tract symptoms 203.
Furthermore, several bacterial species appear to be associated with UUI 203. Thus, we
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recommend the use of expanded culture conditions until our understanding of unrecognized
uropathogens improves. EQUC is more likely than sequencing to be readily available in the
clinical setting, and may prove useful for rapid phenotyping of individual patients, prior to
treatment selection. This is especially important as no single clinical demographic variable
adequately predicted treatment outcome.
We have considered the implications of the minority of samples that were “negative”
for both techniques. We currently consider this group to be “sub-threshold” rather than
“sterile” and fully anticipate that the very low biomass individuals will be more fully described
as technologies evolve.
The dominance of certain genera, such as Lactobacillus and Gardnerella, may prompt
thoughts of vaginal contamination. Our use of aseptically collected specimens via transurethral
catheter by experienced individuals, and our prior publications demonstrating the presence of
Lactobacillus and Gardnerella in female bladder urine collected through suprapubic aspirates 4,
supports the evidence that both genera are capable of residing in the bladder. The role of these
organisms as members of the urinary microbiome and their relationships to vaginal microbiota
requires further study. Because the bladder and vagina can contain the same species, the use of
catheterized samples is recommended whenever possible and careful interpretation is required
when using samples obtained by void.
It is possible that baseline group differences contributed to our findings. However, since
UUI incidence increases with age and is therefore linked to menopause status, our sample size
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is not sufficient to further describe the separate effects of estrogen status, age, and UUI
symptoms in relation with microbiota diversity. We acknowledge this possibility; yet, we wish
to highlight the importance of the findings between treatment response groups (Figure C.2).
Women with 1-4 bacterial isolates on EQUC were most likely to respond to the initial 5mg dose
of solifenacin, whereas women with more diversity (≥5 bacterial isolates) were less likely to
respond or needed an increased dose. These simple cut-offs, detectable prior to treatment, will
require validation in larger patient populations. Therefore, in future studies, the use of both
EQUC and sequencing for all collected urine specimens is recommended. The results are highly
complementary, with sequencing measuring a broad picture of the population and the EQUC
protocol measuring the cultivatable organisms within that population.
Clinicians can benefit from expanded knowledge about the bacterial communities that
are present in patients with UUI. Although specific changes in clinical management cannot yet
be recommended, this promising area of research is generating many new hypotheses. In
addition, our findings should inform the design of larger clinical studies that have potential to
personalize UUI treatment, provide insight into UUI etiology, and offer promise for novel UUI
prevention strategies. We believe that related urinary tract disorders may also benefit from this
new knowledge.
Conclusions.
The response to oral UUI medication (solifenacin) may relate to individual urinary
microbiota characteristics that are detectable prior to treatment. Our findings, especially the
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importance of organism diversity, offer promising possibilities for new ideas for prevention and
treatment of UUI in women.
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Supplemental Material
Methods D.S1. Protocol for the Expanded Quantitative Urine Culture (EQUC): For standard
urine culture, 0.001 mL of urine was spread quantitatively onto 5% sheep blood (BAP) and
MacConkey agars (BD BBL™ Prepared Plated Media), then incubated aerobically (35°C for 24
hours). Any amount of each separate morphologic colony type was identified and counted
using a detection level of 1,000 colony forming units (CFU)/mL (represented by 1 colony of
growth on either plate). “No growth” was reported when no growth was observed, indicating
no growth of bacteria at lowest dilution, i.e., 1:1000.
The expanded quantitative urine culture (EQUC) technique uses 0.1 mL of urine spread
quantitatively onto BAP, Chocolate and Colistin, Naladixic Acid (CNA) agars (BD BBL™ Prepared
Plated Media), then incubated in 5% CO2 (35°C for 48 hours). A second set of BAPs were
inoculated with 0.1 mL of urine and incubated in room atmosphere at 35°C and 30°C for 48
hours, respectively. In addition, 0.1 mL of urine was inoculated onto each of two CDC Anaerobe
5% sheep blood agar (ABAP) plates (BD BBL™ Prepared Plated Media), and incubated in either a
Campy gas mixture (5% O2, 10% CO2, 85% N) or in anaerobic conditions at 35°C for 48 hours.
The detection level was 10 CFU/mL, represented by 1 colony of growth on any of the plates.
Finally, to detect any bacterial species that may be present at quantities lower than 10 CFU/mL,
1.0 mL of urine was placed in Thioglycollate Medium (BD BBL™ Prepared Tubed Media) and
incubated aerobically at 35°C for 5 days. If growth was visually detected, the Thioglycollate
Medium was mixed and a few drops were plated on BAP and ABAP agars for isolation, and
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incubated aerobically and anaerobically (35°C for 48 hours). Each morphologically distinct
colony type was isolated on a different plate of the same media to prepare a pure culture that
was used for organism identification. Matrix-Assisted Laser Desorption Ionization Time of Flight
Mass Spectrometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 software (Bruker Daltonics,
Billerica, MA) was used to identify the bacterial isolates7. To determine the false-negative rate,
the following equation was used: the number of EQUC positive but standard negative samples
divided by the sum of the EQUC positive and standard positive samples and the EQUC positive
but standard negative samples.
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Table D.S1. Comparison of demographics and symptoms of completed and withdrawal
populations at baseline

Demographics
Age (years)
[Mean (Standard Deviation)]
Body Mass Index (kg/m2)
[Mean (Standard Deviation)]
Race/Ethnicity*
Non Hispanic Caucasian
Hispanic Caucasian
African-American
Asian
Marital Status
Married
Separated
Divorced
Widowed
Single
Estrogen Status**
Estrogen Positive
Estrogen Negative
Unsure
Smoking
Diabetes
Hypertension
Coronary Artery Disease
Prior Treatment for OAB
Vaginal Parity [Median (IQR)]
Symptoms [Median (IQR)]
Symptom Score c
Health Related Quality of Life (HRQL) c
Urinary Distress Inventory (UDI) d
Pelvic Organ Prolapse Distress Inventory (POPDI)

Completed Study
(N=50)

Withdrawal
(N=24)

p-value

62.5 (SD:12.2)

59.5 (SD:10)

0.30a

31.2
(SD:7.7)

35.8
(SD:9.2)

0.03a

38 (76%)
5 (10%)
7 (14%)
0 (%)

17 (71%)
1 (4%)
6 (25%)
0 (%)

28 (56%)
1 (2%)
7 (14%)
7 (14%)
7 (14%)

10 (42%)
2 (8%)
2 (8%)
7 (29%)
3 (13%)

6 (12%)
43 (86%)
1 (2%)
2 (4%)
4 (8%)
21 (42%)
5 (10%)
30 (60%)
2 (1-3)

1 (4%)
22 (92%)
1 (4%)
4 (17%)
3 (13%)
11 (46%)
4 (17%)
7 (29%)
2 (0.5-3)

0.08
0.68
0.75
0.46
0.01
0.56b

70 (53-85)
61 (42-82)
95 (56-131)
59 (15-95)

80 (56-86)
37 (15-52)
131 (108-161)
83 (42-132)

0.31b
0.001b
0.02b
0.13b

60 (20-112)

71 (43-127)

0.38b

0.40

0.31

0.47

d

Colorectal-Anal Distress Inventory (CRADI) d

Fisher's Exact Test due to small, expected cell counts unless otherwise indicated. a Student’s T-Test,
b
Wilcoxon rank sum test c Based on OAB questionnaire d Based on Pelvic Floor Disease Inventory * Self-reported
by participant. ** Estrogen status is defined as negative if the patient is post-menopausal and not on hormone
replacement therapy. Estrogen positive is anyone pre-menopausal and/or on hormone replacement therapy.

- 207 -

Table D.S2. A list of each patient’s urotype. It was included to fulfill the primary aim of the
clinical trial: to phenotype each individual’s microbiome. Due to its size, it was excluded from
this document. See PMID: 26423260 Supplementary Table 2.

5mg Responders

Non-Responders

10mg Responders

Number of Unique Bacterial Species

60

50

40

30

20

10

0

0

5

10

15

0

5

10

15

0

5

10

15

Recruitment of Pa ents
Baseline

12-week

Figure D.S1. Species accumulation curves comparing baseline and 12-week diversity by
response group
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Figure D.S2. Frequency of detection of bacterial genera at baseline and 12 weeks of all
responders (5mg and 10mg). Comparison of the frequency of detection for baseline and 12
week urines in responders (including both 5mg and 10mg responders). There is no one genus
that decreases significantly over that timeframe in individuals that respond to solifenicin.
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Addendum
For the Astellas projects (Appendix B-C), we completed many comparisons that were
not published. Specifically, we were interested in any specific differences between the 5mg
responders and either the non-responders or 10mg responders, analysis on the longitudinal
data, and further comparison between sequencing and culture. Overall, the following data was
inconclusive and therefore most was excluded from the publication.
We did find a few organisms at baseline that were statistically different between the
5mg responds and 10mg responders, as well as the 5mg responders and non-responders
(Figure D.4). But in a 3-way comparison between all groups, only 4 species were found to be
significant, and those were published (Figure D.3). We are not sure if the correlations we find in
Figure D.4 are biologically significant.
The longitudinal data requires further investigation. We did not detect a change in the
overall biomass of each niche over time (Figure D.5), suggesting that neither the treatment, nor
the response to treatment, influenced bacterial load. We also did not detect a change in the
overall frequency of species detection (Figure D.6). Therefore, there was no single organism
that “disappeared” by 12 weeks and would account for symptom improvement. But, we did see
that diversity in the 10mg and non-responders began to decrease by 12 weeks (Figure D.S1),
suggesting that diversity is still the main contributing factor.
The longitudinal data was tricky. Since we did not have any comparable longitudinal
data from controls, we could not know if any changes we saw were due to medication,
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symptom improvement, or basic every-day fluctuations. These data, and longitudinal data from
the Mirabegron study, should be re-analyzed once we have a better understanding of
longitudinal fluctuations from controls.
Finally, I performed a comparison of 16S sequencing and EQUC (Figure D.7), which can
be compared to the published heatmap in Figure D.7. While Figure D.7 compared species
detection between EQUC and 16S sequencing, Figure D.7 compares the overall niche profiles in
each group. First, I will focus on the left-most part of the graph, which describes samples that
were characterized by both methods (no black bars). If you focus on the abundant genera, it
becomes clear that certain organisms (e.g., Lactobacillus, Enterobacteriaceae, Gardnerella, and
Bifidobacterium) appear in similar abundances in sequencing and EQUC. However, other genera
(e.g. Micrococcus, Staphylococcus, Enterococcus, Alloscardovia, and Streptococcus) dominate
the culture profiles, but are only a small percentage of the sequencing profiles. It could be that
these organisms are more readily cultivatable or that they have difficulty being detected by
sequencing. Throughout all our studies, we have had difficulty sequencing Streptococcus,
particularly when it is dominant by EQUC. Additionally, the sequencing profiles of these
samples indicate a predominance of low-abundance organisms (the “other” grouping). It could
be that much of the sequencing is representing populations of as yet uncultivated bacteria
(such as strict anaerobes), or simply an abundance of contamination.
Next, we will focus on the right side of the graph that contains all the samples that were
either culture- or sequence-negative, or both (with black bars). We know that EQUC has a lower
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level of detection (>10 CFU/ml compared to >1000 CFU/ml); therefore, it makes sense that
many samples would be EQUC-positive and sequence-negative. It is possible that those samples
simply have a biomass in the range of 10-1000 CFU/ml. It is more confusing to consider the
samples that are culture-negative but sequencing-positive, as this would not be a biomass
issue. It is possible that these sequencing profiles might represent dead bacteria, or (since we
know that bacteria can grow in improperly refrigerated samples) an overgrowth of bacteria
following sample collection. Alternatively, it could be that these sequence results are from a
contaminated sample-cup or some other contamination that was introduced early in the
sample collection.
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A.

B.

Figure D.4. Major genera (A) and species (B) isolated from controls and 3 response groups.
These figures expand on Figure C.3. It includes controls as well as the response groups. (A) The
frequency of isolation of common genera followed by the species within that genera. (B)
Genera and species present at significantly different frequencies in the 5-mg solifenacin
responder cohort (red) relative to either the 10-mg responder cohort (green) or the nonresponder cohort (purple). p < 0.05. Many of these organisms were significantly different from
5mg responders in a two-way comparison (shown here) but only 4 organisms were
significantly different in a 3-way comparison (Figure C.3B).
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Figure D.5. Solifenacin does not exert a consistent effect upon urinary bacterial abundance.
Total CFU/ml of baseline, 4-week and 12-week urine samples was plotted for each member of
the 5-mg responder (top) and non-responder (bottom) groups. A similar lack of consistent
effect was observed for 10-mg responders (data not shown). Notice that some data are missing,
either because the sample was not subjected to EQUC or because the EQUC assay was negative.
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Figure D.6. Solifenacin does not exert a major effect on the frequency of the most common
FUM genera. For UUI patients, we plotted the frequency of each common genus detected in
baseline, 4-week & 12-week urine samples. For comparison, we plotted the frequency of the
same genera in the baseline urine samples of non-UUI controls.
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Figure D.7. 16S rRNA sequence and EQUC analyses are complementary. Analyses of the
baseline urines from the 10-mg responder group are compared. Each bar represents a patientparticipant; each color or family of colors represents an organism or a group of related
organisms. For example, blues, reds and greens represent the genera Lactobacillus,
Gardnerella, and Streptococcus, respectively. Light gray bars represent samples that were not
assayed by EQUC; black bars represent samples that were PCR-negative and thus were not
sequenced.

APPENDIX E
EVALUATION OF THE URINARY MICROBIOME OF WOMEN WITH
UNCOMPLICATED STRESS URINARY INCONTINENCE

Thomas-White K., Kliethermes, S., Rickey, L., Lukacz, E., Richter, H.E., Moalli, P., Zimmern,
P., Norton, P., Kusek, J.W., Wolfe, A.J., and Brubaker, L. Evaluation of the Urinary Microbiota
of Women with Uncomplicated Stress Urinary Incontinence. AJOG, Aug 4 2016. DOI:
10.1016/j.ajog.2016.07.049. PMID: 27498309
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Overview of Appendix E
This study is our first published work on voided urine. The data confirms that increased
diversity is associated with symptoms of UUI and demonstrated that voided urine can be used
under some circumstances to detect a bladder microbiome urine signal.
This study was in collaboration with the Urinary Incontinence Treatment Network
(UITN). This network was put together to determine if doctors required patients to undergo
urodynamic testing for a diagnosis of stress urinary incontinence. The value of urodynamic
evaluation (ValUE) study211 had been previously published, but the network had biobanked
urines from this study population. The majority of these urines were voided samples. All
samples were sequenced in duplicate and diversity measurements were compared to
demographics and symptom scores.
All the patients for this study were diagnosed with stress urinary incontinence (SUI),
which is a sphynteric disorder that results in the loss of urine following coughing, sneezing, or
lifting. SUI can be treated effectively with surgery, and often following surgery these patients
will discover underlying UUI symptoms. Therefore, all patients took the Medical, Epidemiologic,
and Social Aspects of Aging (MESA) questionnaire112,113 to measure symptoms of both SUI and
UUI. Using a generalized estimating equation (GEE) model, we found correlations between
diversity and BMI, hormone status, and symptoms of UUI. Specifically, decreased evenness is
associated with symptoms of UUI but not SUI. This paper was reviewed in Nature Reviews
Urology 2016212.
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Abstract
Background. Female urinary microbiota (FUM) are associated with urgency urinary
incontinence (UUI) and treatment response to UUI medication. FUM of women with stress
urinary incontinence (SUI) has not been described.
Objective. Study the cross-sectional relationships between FUM features and
demographic and clinical characteristics of women undergoing SUI surgery.
Design, Setting, and Participants. Pre-operative urine specimens were available from
197 women (174 voided, 23 catheterized) enrolled in a multi-center prospective randomized
trial, the Value of Urodynamic Evaluation (ValUE) study. VaLUE excluded samples from women
with urine dipstick suggestive of urinary tract infection. Collected demographic and clinical
variables included SUI and UUI symptom measures, menopausal status, and hormone use.
Outcome Measurements and Statistical Analysis. The bacterial composition of the
urine was measured by sequencing the bacterial 16S rRNA gene. Phylogenetic relatedness and
microbial diversity were compared to demographics and symptoms using generalized
estimating equation (GEE) models.
Results. The majority of 197 urine samples (86%) had detectable bacterial DNA.
Bacterial diversity was significantly associated with higher BMI (p=0.02), increased Medical,
Epidemiologic, and Social Aspects of Aging (MESA) urge index score (p=0.04), and hormonal
status (p<0.001). No associations were detected with SUI symptoms. This increased diversity
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was also associated with a concomitant lower frequency of Lactobacillus in hormone-negative
women.
Conclusions. Women undergoing SUI surgery have detectable urinary microbiota. The
diversity of the microbiota was associated cross-sectionally with hormonal status, UUI
symptoms and BMI. Further studies should elucidate the FUM effect on SUI treatment
outcomes, especially with respect to persistent or de novo UUI symptoms.
Introduction
The influence of the human microbiota on health and disease is increasingly appreciated
in a variety of medical fields. The female urinary microbiota (FUM), composed of resident
bladder bacteria, was recently recognized when bacterial DNA and low levels of live bacteria
were detected in catheterized urine specimens considered “sterile” by standard urine
culture4,5,7.
The FUM may have clinical relevance for a variety of urinary disorders. Microbial
communities, such as the FUM, are often described by the predominant organism, the diversity
of organisms and the amount of those organisms. We recently showed FUM diversity and/or
composition to be associated with the presence and response to treatment of urgency urinary
incontinence (UUI) in adult women3,6. We also showed an association between the FUM and
risk of urinary tract infection (UTI) following urinary tract surgery63 or instrumentation5,65.
However, the FUM of adult women with stress urinary incontinence (SUI) has not been
investigated.
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A biorepository of urine samples collected from a large, multi-center, National Institutes
of Health sponsored clinical trial of women with uncomplicated SUI planning surgery had been
previously established 211. This study describes the analysis of these samples by 16S rRNA gene
sequencing to characterize the cross-sectional relationships between FUM parameters and
demographic and clinical characteristics of adult women with SUI.
Materials and Methods
Subject Recruitment and Urine Collection.
The Value of Urodynamic Evaluation (ValUE) study was an Institutional Review Board
(IRB) approved, multi-center prospective randomized trial comparing surgical outcomes using 2
strategies for pre-surgical testing: multichannel urodynamic testing versus standardized basic
office evaluation113,211. Participants in the main study also provided written research consent to
contribute a single baseline urine specimen to the biorepository. The Loyola University Chicago
IRB approved this analysis.
Eligibility for the ValUE trial included adult women who reported symptoms of SUI >3
months, had a post-void residual <150 mL, a negative urinalysis/standard urine culture, clinical
assessment of urethral mobility, desire for SUI surgery, a positive provocative stress urinary test
and a qualifying Medical, Epidemiologic, and Social Aspects of Aging (MESA) questionnaire112,113
subscale score (stress > urge). Demographic and clinical characteristics were obtained by selfreport including hormonal status, which was categorized by the study team into the hormone
group that most appropriately described the patient’s hormone use: pre-menopausal, post-
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menopausal (with or without self-reported, current exogenous hormone use) or uncertain
about status.
Urine specimens were collected prior to surgery by a standard protocol and tested by
dipstick to exclude UTI at study entry. Specimens were centrifuged at 500-1500g for 10
minutes and the supernatant dispensed into ten 2cc Eppendorf tubes, which were frozen at 80°C until shipped on dry ice to the National Institute of Diabetes and Digestive and Kidney
diseases (NIDDK) biorepository. For this analysis, we retrieved available baseline urine
specimens, which were shipped to Loyola University Chicago on dry ice, and stored at -80°C
until processed for sequence analysis. The available samples came from 197 of the 630 (31%)
ValUE participants; 174 samples were obtained by clean catch and 23 by catheterization.
16S rRNA Gene Sequencing.
Microbial composition was determined by sequencing the variable 4 (V4) region of the
bacterial 16S rRNA gene, as described3,6,7,65. The V4 region is ~250 bp, ideal for MiSeq sequence
technology (Illumina), and sufficient to classify most bacteria to the family or genus level 194,213215.

DNA isolation was performed in a laminar flow hood to avoid contamination. Genomic DNA

was extracted from 1 ml of urine, using validated protocols3,7,166. The V4 region was amplified
by a two-step polymerase chain reaction (PCR), using modified universal primers 515F and
806R, as described3,7. Extraction negative controls (no urine) and PCR negative controls (no
template) were included to assess contribution of extraneous DNA from reagents. Final PCR
products were purified from unincorporated nucleotides and primers using Qiaquick PCR
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purification kit (Qiagen, Valencia, CA) and Agencourt AMPure XP-PCR magnetic beads (Beckman
coulter). Purified samples were normalized to equal DNA concentration, as determined by
Nanodrop spectroscopy (Thermo Scientific, Waltham, MA). The sample library and PhiX
sequencing control library (Illumina) were denatured and added to the 2x250 bp sequencing
reagent cartridge, according to manufacturer’s instructions (Illumina).
Sequence Processing.
Each specimen was sequenced in duplicate and classified by phylogenetic diversity as
measured by Bray-Curtis dissimilarity. A phylogenetic tree was generated and compared to
percent total classified reads (relative abundance) at each taxonomic level (phyla, class, order,
family, genus). For a genus level example, see Figure E.1.
Each major branch or clade (termed urotype) in the phylogenetic tree was named for
the predominant classified taxon (e.g., Lactobacillus). When there was no predominant taxon,
we used the term “non-predominant” to describe the urotype3,6,201. MiSeq sequence reads
were processed following mothur’s MiSeq SOP at http://www.mothur.org/wiki/MiSeq_SOP194,
with minor modifications. Mothur software (version 1.34.4) 167 was used to process raw reads
and, using default mothur parameters, to remove low quality and chimeric sequences.
Taxonomic classification from phylum to genus level of sequence reads was performed by the
RDP Classifier (version 2.5)195 using the default 0.8 confidence threshold. The sampling depth
for this analytic set was set at 2000; the Kolmogorov–Smirnov test confirmed that when
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subsampling depth exceeded 2000, the distribution of subsampled and original reads
distribution had >95.9% similarity amongst all samples.
Most (171/197) samples had detectable DNA with 338,000 and 340,000 reads
subsampled for replicates 1 and 2, respectively. The 26 samples without detectable DNA were
classified as “below the detection threshold.” Due to read depths less than 2000, two samples
from replica 1 and one sample from replica 2 were also classified as “below the detection
threshold”, for a total of 28 in replica 1 and 27 in replica 2. Using mothur’s built-in averagelinkage clustering algorithm, the cleaned high-quality sequences were clustered into species
level operational taxonomic units (OTUs) based on the commonly used 97% similarity cutoff,
resulted in 2579 and 3082 OTUs for replicas 1 and 2, respectively. We used the resultant OTU
count table and the R package vegan196,216 to determine the Chao1 richness estimate, Pielou
evenness index, and Shannon diversity index, which accounts for both richness and evenness,
two measures of microbial diversity. Richness is a measure of the total number of unique taxa
within a given individual, but does not take into account the distribution of those taxa. In
contrast, evenness is a measure of distribution, or equality of representation, of taxa within an
environment. Samples “below the detection threshold” lack diversity measurements; these
were excluded from subsequent diversity comparisons.
Statistical Analysis.
Generalized Estimating Equations (GEE), extensions of Generalized Linear Models that
account for correlation between replicas, were used to describe associations between
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demographic and clinical factors with diversity measurements after adjusting for genus
urotype. A gamma distribution with a log link was assumed for Shannon, Chao, and Peilou
diversity measurements, due to their skewed nature. To be inclusive, we did not make
adjustments for Type I error in the GEE analyses when determining potential clinical and
demographic associations with microbiota characteristics. Only results from the lowest
detected resolution level (i.e., genus) are reported. There was insufficient sample size and
power to compare urotypes between catheterized and voided samples. All statistical analyses
were conducted using SAS v9.4 (SAS Software Cary, NC) and statistical significance was assessed
at α=0.05 level.
Results
The demographic and clinical characteristics of the 197 participants we studied (Table
E.1) were similar to those of the overall trial population211. Most of these participants were
non-Hispanic Caucasian (79%) and currently married (74%). The mean age of the subset was 51
(SD:9.7) years. Forty-two percent of women were pre-menopausal, 31% post-menopausal
without current exogenous hormone use, and 18% were using exogenous hormones; the
remaining 10% were “unsure” of their status. Consistent with the entrance requirements for
the trial211, women reported stress predominant UI with a median MESA stress index score of
78 (IQR:59-89) and 76% reporting urinary leakage every day and/or night. Concomitant urinary
symptoms were common at time of trial enrollment; the median MESA UUI score was 33
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Table E.1. Baseline clinical demographic characteristics of ValUE participants assessed for
urinary microbiota
Demographics
Age [Mean (SD)]
Body Mass Index (kg/m2) [Mean (SD)]
Race/Ethnicity*
Hispanic
Non-Hispanic Caucasian
African-American
Other
Education
Less High School
High School/GED
Some College
Completed 4 Years of College
Graduate/Professional Degrees
Self Reported Hormonal Status*
Pre-Menopausal
Post-Menopausal lacking exogenous hormones
Post-Menopausal or Uncertain about status on
Exogenous hormones
Uncertain about status lacking exogenous
hormones
Ever Pregnant
Number of Pregnancies, Mdn(Range)
Vaginal Parity, Mdn (Range)
History of Smoking
Currently Smoking
Currently Married
Prior Pelvic Surgeries
Prior Non-surgical Treatment
Symptom Severity
MESA score a
Stress Index, Mdn(IQR)
Urge Index, Mdn(IQR)
Frequency of Urine Leakage
Less than once a month
A few times a month
A few times a week
Every day and/or night
Voiding Phase Dysfunction
Suspected Intrinsic Sphincter Deficiency

N=197
51 (9.7)
29 (5)
23 (12%)
156 (79%)
9(5%)
9(5%)
6 (3%)
39 (20%)
58 (29%)
53 (27%)
41(21%)
82 (42%)
61 (31%)
35 (18%)
19 (10%)
190 (96%)
3 (0-10)
2 (0-7)
66 (33%)
20 (10%)
145 (74%)
151 (77%)
122 (62%)

78 (59-89)
33 (17-50)
0
11 (6%)
36 (18%)
150 (76%)
7 (4%)
39 (20%)
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Table E.1. Continued
Urine Measures
Specific Gravity, Mdn(IQR)
Urine pH, Mdn(IQR)
Blood
Negative
Trace (Non-hemolyzed)
Moderate (Non-hemolyzed)
Trace
Small (+)
Moderate (++)
Large (+++)
Protein
DIVERSITY OUTCOME MEASURES [Mean (SD)]b
Shannon
Chao
Pielou
Glucose positive n (%)

N=167
1 (1:01-1.02)
6 (5-7)
110 (70%)
11 (7%)
5 (3%)
11 (7%)
6 (4%)
6 (4%)
9 (6%)
25 (16%)
1.86 (0.97)
124.08 (59.35)
0.43 (0.19)
6 (4%)

Total number of SUI participants is 197. Mean (SD) or N(%) reported unless otherwise specified.
Mdn=Median; SD=Standard deviation; IQR = Interquartile Range;
a
Stress Index and Urge Indices were calculated using the MESA questionnaire.
*Race/Ethnicity and Hormonal status per subject report
b
Least Squares Means- adjusted for correlation between both replicas

(IQR:17-50). As only 21 participants had an urgency index score of zero, dichotomous group
comparisons by urgency index were not performed.
Fourteen percent of the tested urine samples had bacterial DNA below the level of
detection, were classified “below the detection threshold” [replica 1: 14% (27/197), replica 2:
14% (28/197)] and not further analyzed. Figure E.1 displays a representative phylogenetic tree
and histogram for replica 1 of the remaining samples classified at the genus level. Together, the
phylogenetic tree and histogram show how samples cluster into urotypes. Supplementary
Figure E.S1 displays similar representations for each replica at other taxonomic levels.
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Figure E.1. Using phylogenetic similarity to determine similar profiles (aka urotypes)
For each taxonomic level (Phylum, Class, Order, Family, Genus), all samples were compared
to each other using Bray-Curtis similarity, which produces a phylogenetic tree, or
dendrogram, in which shorter branches link similar samples, and longer branches link more
dissimilar samples. Therefore, each tree can be divided into groups or clades. When aligned
to relative sequencing abundance, the clades of each tree separate by the identity of the
predominant organism. Below is one example, the genus classification from the first replica.
The urotype indicates the clades that fall into the same urotype. Each urotype is named for
the predominant genus. If no one genus is predominant, then the urotype is considered
non-predominant. All corresponding graphs for each replica and each taxonomic level can
be found in supplementary Figure S1. Genus Identification from the first sequencing replica
set.
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Table E.2. Urotype frequency across all taxonomic levels and between replicas
Using Bray-Curtis dissimilarity, each dataset was divided into clades (row). A urotype is defined as a clade that is
predominated by a single organism, or labeled as “non-predominant” when no single organism predominates.
Here, the frequency of urotype identification is shown for each taxonomic classification for both replicas.
Urine is a low biomass niche and some samples had so little DNA that the signal could not be distinguished from
background, these samples are labeled as “below detection level”.

Replica 1: Frequency of Sequencing Urotype

Replica 2: Frequency of Sequencing Urotype

- 229 -

Replicas 1 and 2 yielded similar results (Table E.2). The only major difference involved
samples of the Lactobacillus urotype, the most common urotype in both replicas (replica 1:
46%, 90/197; replica 2: 37%, 72/197). The difference in Lactobacillus urotype frequency
between replicas was mirrored by an inverse difference in the frequency of the “nonpredominant” urotype (replica 1: 5%, 10/197; replica 2: 12%, 23/197). This inverse classification
of the most diverse samples in the Lactobacillus urotype as members of the “non-predominant”
urotype (replica 1: 5%, 10/197; replica 2: 12% 23/197). This inverse relationship was primarily
caused by phylogenetic reorganization and therefore reclassification of the most diverse
samples in the Lactobacillus urotype as members of the non-predominant urotype.
The results of the GEE analyses before and after adjustment for urotype were similar,
thus only adjusted results are presented (Table E.3). We used two types of microbial diversity
measurements: richness (total number of unique taxa) and evenness (equality of
representation of taxa within an environment). Richness, as estimated by Chao1, was
significantly associated only with urine pH (p=0.03). In contrast, richness and evenness, as
measured together by the Shannon index, were significantly associated with BMI (p=0.02),
MESA urge index score (p=0.04), and hormonal status (p<0.001) (Table E.3). Specifically, on
average, a 10-unit increase in BMI was associated with a 0.1-unit increase in Shannon diversity
(p=0.02). For a 10% increase in MESA urge index score, the Shannon index increased by 0.03
units (p=0.04). Post-menopausal women not on exogenous hormones had a Shannon index
0.23 units higher than did pre-menopausal women (p=0.004).

- 230 -

Table E.3. Association between microbiota characteristics and demographic factors or
symptom severity adjusted for genus urotype

Demographics
BMI
Race/Ethnicity*
Hispanic
Non-Hispanic
Caucasian
African-American
Other
Education
Less High School
High School/GED
Some College
Completed 4 Years of
College
Graduate/Professiona
l Degrees
Hormonal Status*
Pre-Menopausal
Post-Menopausal
lacking exogenous
hormones
Post-menopausal or
Uncertain about
exogenous
hormonal status
Uncertain about
exogenous hormonal
status
Ever Pregnant
Smoking History
Currently Married
Prior Pelvic Surgeries
Prior Non-surgical
Treatment

Community Diversity
Gamma GEE Models Adjusted for Genus Urotype
Shannon
Chao1
Peilou
Beta
SE
p-value Beta
SE
p-value Beta
SE
p-value
0.01 0.006
0.02
0.006 0.005
0.18
0.01 0.005
0.02
0.53
0.25
0.52
0.07 0.11
0.55
0.05 0.08
0.58
0.04
0.09
0.66
Ref
-0.15
-0.30

0.22
0.30

0.08
-0.28

0.09
0.15

0.19
0.11

0.51
0.27
0.51
0.84
0.77

0.039
-0.03
Ref

-0.17
-0.25

0.20
0.23

0.08
0.09

0.36
0.05
0.31
0.02
0.23

-0.01
-0.03

0.16
0.09

0.40
0.28
0.59
0.96
0.70

0.18
0.11

-0.12

0.09

0.18

0.003

0.07

0.97

-0.10

0.08

0.21

-0.16

0.11

0.15

0.07

0.08

0.34

-0.14

0.10

0.17

<0.001

0.32

<0.001

Ref
0.23

0.08

0.004

0.08

0.07

0.25

0.21

0.07

0.02

-0.28

0.14

0.05

-0.07

0.08

0.39

-0.26

0.12

0.04

0.21

0.09

0.02

-0.03

0.10

0.73

0.22

0.07

0.003

-0.21
-0.16
0.10
-0.14

0.15
0.07
0.08
0.07

0.16
0.04
0.21
0.08

-0.04
-0.07
-0.04
-0.02

0.10
0.06
0.06
0.06

0.73
0.21
0.54
0.72

-0.18
-0.13
0.11
-0.13

0.12
0.06
0.07
0.07

0.22
0.06
0.11
0.07

0.03

0.08

0.66

-0.02

0.06

0.73

0.04

0.07

0.54

Generalized Estimating Equations (GEE), assuming a gamma distribution and log link, were used to assess the
association between each demographic or symptom measurement for three separate microbial diversity
measurements after adjusting for urotype at the genus level. P-values are not adjusted for type I error. Diversity
measurements include Shannon diversity (richness and evenness), Chao diversity (richness only) and Peilou
(evenness only).
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Table E.3 continued

Symptom Severity
MESA scorea
Stress Index
Urge Index
Frequency of Leakage
A few times a month
A few times a week
Every day and/or
night
Urine Characteristics
Protein
Specific Gravity
Urine pH
Glucose
Blood
Negative
Trace (Nonhemolyzed)
Moderate
(Non-hemolyzed)
Trace
Small (+)
Moderate (++)

Beta

Community Diversity
Gamma GEE Models Adjusted for Genus Urotype
Shannon
Chao1
Peilou
PPPSE
Beta
SE
Beta
SE
value
value
value

0.002
0.003

0.002
0.002

0.28
0.04
0.08
0.11
0.12

0.0003
0.002

0.002
0.001

-0.38
-0.15

0.24
0.10

0.87
0.18
0.61
0.53
0.30

0.002
0.003

0.002
0.001

-0.05
0.05

0.09
0.07

0.10
0.01
0.04
0.19

0.09
0.32
0.11
0.70
0.40

0.08
-0.10
-0.07
-0.13

-0.08

0.16

0.60

-0.001

0.25

0.18
0.21
0.39

0.11
0.13
0.18

0.31
0.04
0.04
0.07
0.06

-0.37
-0.15

0.21
0.08

0.08
0.01
0.03
0.11

0.38
0.31
0.03
0.25
0.69

0.14
-0.14
-0.05
-0.03

0.08
0.008
0.04
0.15

0.09
0.32
0.13
0.82
0.29

-0.06

0.14

0.66

-0.06

0.14

0.69

0.10

0.0853

0.13

0.50

0.008

0.24

0.97

0.09
0.11
0.03

0.16
-0.10
0.13

0.10
0.12
0.15

0.10
0.43
0.39

0.18
0.23
0.32

0.10
0.09
0.14

0.08
0.01
0.03

Ref
0.18
-0.18
-0.06
-0.07
Ref

a

MESA Questionnaire - SUI and UUI index scores each ranging from 0-100 with higher scores indicating greater
symptom severity)
*Race/Ethnicity and Hormonal status per subject report

Because these parameters did not associate with richness (Chao1), we tested evenness
alone, as measured by Peilou diversity (Table E.3). Evenness was significantly associated with
BMI (p=0.02), MESA urge index score (p=0.04), and estrogen status (p<0.001). On average, a 10unit increase in BMI was associated with a 0.1-unit increase in Peilou diversity. For a 10%
increase in the MESA urge index score, the Pielou diversity. Finally, post-menopausal women
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had a 0.21-unit higher diversity measurement compared to pre-menopausal women (p=0.02).
Since these results were similar to those observed with the Shannon index, we conclude that
increased community evenness associates with BMI, UUI symptoms and especially hormonal
status.

Figure E.2. Phylogenetic diversity and urotype distribution between estrogen status
Relative abundance of the microbial community at the genus level for each of the 4 estrogen
groups. Each bar is a separate individual with the percent of total classified reads to the genus
level represented on the y-axis. Phylogenetic relatedness as measured by Bray-Curtis
dissimilarity is depicted in the dendrograms above each group.
The full cohort is separated by hormone status: pre-menopausal, post-menopausal (with or
without self-reported, current exogenous hormones) or uncertain about hormonal status.
Estrogen positive groups (pre-menopausal and those currently on exogenous estrogen) have a
greater prevalence of Lactobacillus-predominant individuals (blue) than the estrogen negative
group. The estrogen negative group has a greater number of non-predominant (multicolored) profiles compared to the estrogen positive populations.
Because community evenness associates strongly with hormonal status, we constructed
a visual comparison of microbial diversity subdivided by hormonal use (Figure E.2). Compared
to other groups, the hormone-positive women (pre-menopausal and post-menopausal on
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exogenous hormones) had a higher frequency of Lactobacillus or Gardnerella urotypes (66%)
and a lower frequency of ‘non-predominant’ urotypes, while the hormone-negative women
(post-menopausal not on exogenous hormones) had a lower frequency of Lactobacillus or
Gardnerella urotypes (38%) and greater frequency of ‘non-predominant’ urotypes (p<0.001).
Discussion
In this study of women undergoing surgery for uncomplicated SUI, the presence of UUI
symptoms appears related to increased microbial evenness, indicating that the FUM of women
with UUI symptoms was less likely to be predominated by a single microbe. A similar
relationship was observed between microbial evenness and hormone status and BMI. The
clinical impact of these findings is significant, given the common coexistence of UUI in women
who undergo surgical SUI treatment. While considerable uncertainty persists about the effects
of SUI surgery on preexisting UUI symptoms and each individual patient’s risk of developing de
novo UUI symptoms following SUI surgery, the microbiota may provide useful information for
clinical phenotyping of patients prior to surgery. Without comparison to an age- and hormone
status -matched continent control group, we cannot conclude that women with “pure” SUI are
like continent women. However, it does appear that the presence and characteristics (i.e.
evenness) of the FUM relate to UUI in this clinically relevant cohort of women undergoing SUI
surgery. Our findings will require further research to validate and clarify the physiological
mechanisms.
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We observed this associated between microbial evenness and UUI symptoms despite
the possibility of vulvovaginal contamination in these voided urine samples. Interestingly, the
FUM detected in the pre-surgical voided urine samples of this cohort was similar to those
assessed in catheterized samples obtained from other cohorts of women; specifically, the FUM
of most women was dominated by Lactobacillus, Gardnerella, Streptococcus, or
Corynebacterium with a small percentage not dominated by a single genus6,65,203. The main
difference between the results of this study and those of previous studies was the increased
biomass potentially caused by vulvovaginal contamination.
Even given the potential for vulvovaginal contamination, we detected an association
with UUI in this cohort of women undergoing SUI surgery. This association illustrates that
voided urine can be used to detect bladder phenotypes. But, to ensure appropriate data
interpretation of voided sample data, one must possess prior information of FUM composition
from women of a similar cohort using catheter collection methods that obtain urine directly
from the bladder.
Research Implications
Our finding of a relationship between microbial evenness to hormonal status may
provide clues for further study. Menopausal women not on exogenous hormones had increase
microbial evenness and their FUM was less likely to be predominated by a single microbe.
These results suggest that predominance (most often by Lactobacillus species) is typical of
hormone-positive women and that loss of that predominance might be associated with UUI
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symptoms. Increased microbial diversity, in particular community evenness, positively
correlates with UUI and BMI symptoms, but not with SUI symptoms. BMI is considered a
contributing factor to urgency symptoms 217, and the FUM of UUI women have been reported
to be associated with BMI 3. Obesity is also associated with an increase in circulating estrogens,
emphasizing that complex nature of vaginal and urinary health 218,219.
It is well known that estrogen receptors are found throughout the lower urinary tract,
supporting the likelihood that estrogen has a role in optimizing bladder function 220-222.
Intriguingly, the use of intravaginal estrogen has been reported to improve the lower urinary
tract symptoms of urinary urgency, frequency, SUI, UUI, and UTI 223. Direct effects of estrogen
on the bladder could include maintenance of bladder structural and functional integrity via
bladder wall thickness, expression of vascular epithelial growth factor, and effects on β3adrenoreceptor activity, as described in rats 224,225. Given that use of intravaginal estrogen
correlated with an increase in Lactobacillus species and a decrease in anaerobic bacteria 18, it
might also influence the FUM.
Although we did not assess the vaginal microbiota of Value of Urodynamic Evaluation
study subjects, we note the FUM’s similarity to published data regarding the vaginal microbiota.
We acknowledge the possibility that the vulvovaginal flora contributes to bacterial diversity.
However, it is biologically plausible that both these adjacent anatomical sites experience
microbial alterations related to estrogen status. The bladder is a low biomass niche that
contains many organisms similar to those of the vagina, including Lactobacillus, Gardnerella,
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and a diverse set of anaerobes. The relationship between these 2 biological niches deserves
further study.
Our study has a number of strengths, including rigorous participant characterization,
multisite recruitment, cutting-edge sequencing techniques and state-of-the-art analytical
approaches. The use of voided urine might be considered a limitation, but its use allowed us to
determine that voided urine could be used to phenotype women given the critical caveat that
appropriate studies with catheterized urine had already been performed. In contrast, the study
has limitations associated with the cross-sectional study design. The study also would have
benefitted from controls matched for age, BMI, and estrogen status; paired vaginal samples
and/or longitudinal sampling; further details regarding hormone status; a higher proportion of
participant samples; increased proportion of catheterized urine specimens; and concurrent
enhanced urine cultures 7. Finally, the known relationship between estrogen status and aging
may mask a biological relationship that is rightfully attributed to only 1 of these variables. A
larger study that includes women with various forms of urinary incontinence and matched
controls will be needed.
Conclusion
Women undergoing SUI surgery have detectable urinary microbiota that may be of
value for phenotyping patients. This cross-sectional analysis revealed that diversity of the
microbiota was associated with UUI symptoms, hormonal status, and BMI.
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Addendum
Only two analyses were done for this study that did not make it into the paper and both
of them were attempts to visually represent statistical data. A common method for showing
similarity between samples is principle component analysis (or PCA), where similar data points
will cluster together. Each data point is color-coded to hopefully illustrate what drives the
clustering. Our data in this study, and many other studies, cluster based on urotype rather than
any other demographic (Figure E.3). Thus, we know that the difference between samples is
most likely driven by the dominant organism.
This paper relies heavily on statistical methods and a therefore a trust in the p-values
generated through the GEE modeling. I wanted to have a visual representation of the p-values
we had calculate. A biostatistician, Stephanie Kliethermes PhD, helped me generate graphs with
lines of best fit that showed the association between UUI and Shannon diversity, but did not
show an association between SUI and diversity (Figure E.4). These types of graphs did not
provide any further information and were therefore not included in the published manuscript.
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Figure E.3. Principal Component Analysis (PCA) of sequencing data at the family and phyla levels
(from replica 1) does not show clustering by any demographic or symptom, but does show
clustering by urotype. A PCA matrix was calculated using an R-script (Appendix I.3) using an input of a
sequencing count table from replica 1 classified to the family level. The output was then uploaded into
an online graphical interface, (Plotly Technologies Inc). The three dimensional graph was generated
and color-coded by all tested demographics and symptoms (Age, race, UUI score, etc). No
demographic revealed clustering. Only one representative graph is shown (hormone replacement
therapy – Figure D.3A). The only metadata to indicate clustering was urotype or dominant organisms
(Figure D.3B). This protocol was repeated for sequencing read tables at the OTU, Genus, Order, Class,
and Phyla levels.
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Figure E.4. Graphical representations of the p-values generated by GEE. The p-values (A)
followed by the line of best fit for Stress index (B) and Urge index (C).

APPENDIX F
THE INTERACTION BETWEEN ENTEROBACTERIACEAE AND CALCIUM OXYLATE DEPOSITES

Barr-Baer, E., Saxena,V., Hilt, E.E., Thomas-White, K., Schober, M., Li, B., Becknell,
B., Hains, D.S., Wolfe, A.J., and Schwarderer, A.L. The Interaction between Enterobacteriaceae
and Calcium Oxalate Deposits, PLoS One. 2015 Oct 8;10(10):e0139575. DOI:
10.1371/journal.pone.0139575. eCollection 2015.
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Overview of Appendix F
This study was completed in collaboration with Andy Schwaderer at Nationwide
Children’s Hospital. This was a published pilot study on the microbiome of kidney stones. It is
the first documented case of bacterial DNA and live bacteria in oxalate kidney stones (a type of
stone not normally associated with bacteria). Andy’s lab was able to take the E. coli isolates
from our EQUC, add them back into mice, and induce stone formation. The mice infected with
E. coli had an increased bacterial and stone burden compared to those not infected.
Abstract
Background. The role of calcium oxalate crystals and deposits in UTI pathogenesis has
not been established. The objectives of this study were to identify bacteria present in pediatric
urolithiasis and, using in vitro and in vivo models, to determine the relevance of calcium oxalate
deposits during experimental pyelonephritis.
Methods. Pediatric kidney stones and urine were collected and both cultured and
sequenced for bacteria. Bacterial adhesion to calcium oxalate was compared. Murine kidney
calcium oxalate deposits were induced by intraperitoneal glyoxalate injection and kidneys were
transurethrally inoculated with uropathogenic Escherichia coli to induce pyelonephritis
Results. E. coli of the family Enterobacteriaceae was identified in patients by calcium
oxalate stone culture. Additionally Enterobacteriaceae DNA was sequenced from multiple
calcium oxalate kidney stones. E. coli selectively aggregated on and around calcium oxalate
monohydrate crystals. Mice inoculated with glyoxalate and uropathogenic E. coli had higher
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bacterial burdens, increased kidney calcium oxalate deposits and an increased kidney innate
immune response compared to mice with only calcium oxalate deposits or only pyelonephritis.
Conclusions. In a murine model, the presence of calcium oxalate deposits increases
pyelonephritis risk, likely due to preferential aggregation of bacteria on and around calcium
oxalate crystals. When both calcium oxalate deposits and uropathogenic bacteria were present,
calcium oxalate deposit number increased along with renal gene transcription of inner stone
core matrix proteins increased. Therefore, renal calcium oxalate deposits may be a modifiable
risk factor for infections of the kidney and urinary tract. Furthermore, bacteria may be present
in calcium oxalate deposits and potentially contribute to calcium oxalate renal disease.
Introduction
Approximately 10% of people develop a kidney stone during their lifetime226. Calcium
oxalate (CaOx) accounts for 74% of stones227. Considerable overlap in CaOx urine supersaturation exists between individuals with and without kidney stones; therefore, urine
chemistries cannot be the only factor in stone formation228. Magnesium-ammonium-phosphate
(struvite) stones form as a result of a urinary tract infection (UTI) with a urease-producing
bacterium and are a conglomeration of bacteria, struvite crystals and protein matrix 229.
Furthermore emerging evidence indicates an interaction between bacteria and CaOx kidney
stones. First, patients with kidney stones are more likely to have UTIs than the general
population230,231. Second, in previous studies, bacteria have been cultured from 19–32% of
CaOx stones, with non-urease-producing E. coli most commonly present232,233. E. coli, a major
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member of the Gram-negative bacterial family Enterobacteriaceae, is a contributor to a wide
range of kidney pathologies ranging from pyelonephritis to kidney allograft rejection 234,235.
Despite its role in other pathologies, the association between E. coli and CaOx disease has not
been extensively investigated.
Traditionally, the urinary tract has been considered sterile; however, high throughput
sequencing technology and enhanced quantitative urine culture (EQUC) protocols have
identified a urinary microbiome in culture-negative urine samples 6,7,203. Whether kidney stones
also have a microbiome has not yet been evaluated. The objectives of this study were to
determine whether bacteria are present in human CaOx kidney stones and, using in vitro and in
vivo models, evaluate potential associations between E. coli and renal CaOx deposits.
Materials and Methods
Human Studies.
Patients and Sample Collection. Human studies were approved by the Nationwide
Children’s Hospital (NCH, Columbus, OH) Institutional Review Board (IRB13-00709) and adhered
to the Declaration of Helsinki. Inclusion criteria consisted of patients with a kidney stone
removal procedure by the NCH Urology Division. Exclusion criteria consisted of a history of
known struvite, cysteine or uric acid stones. Written consent was obtained from legal guardians
if the research subject was a minor additionally assent was obtained if children were ≥ 9 years
of age. Following kidney stone removal, the urologist bisected the stone. Half of the stone was
placed in a sterile eppendorf tube and the other half was sent for routine clinical stone analysis
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(Louis C. Herring and Company, Orlando FL) Upper tract and bladder urine was collected with
the kidney stones during the stone removal procedure. Immediately following sample
acquisition, study staff was notified to process the samples. Patient history, including urine
chemistries, were recorded and urine oxalate, calcium and citrate to creatinine ratios were
compared to reported normal ranges236,237.
Sample Processing. Stone fragments were rinsed with sterile PBS, and then
homogenized in a bullet blender (Next Advance, Averill Park, NY). Stone homogenate and urine
were aliquoted between urine C&S preservative (Becton Dickenson, Franklin Lakes NJ, United
States) and 10% AssayAssure universal urine collection media (Thermo Scientific, Waltham MA)
for culture and sequencing analysis, respectively. Sterile PBS with and without bullet blender
beads was used as control to evaluate for contamination during stone processing.
Enhanced Quantitative Urine Culture (EQUC). 0.1 mL of urine or kidney stone
homogenate was inoculated onto BAP, Chocolate, Colistin, Naladixic Acid (CNA) agars or CDC
anaerobe 5% sheep blood agar plates (BD BBL™ Prepared Plated Media) and EQUC was
performed as previously described7. The detection level was 10 CFU/mL. Matrix Assisted Laser
Desorption Ionization Time of Flight Mass Spectrophotometry (MALDI-TOF MS) was used to
identify the bacterial isolates.
DNA Isolation and 16S Amplicon Sequence Analysis. DNA extraction along with 16S
rRNA gene library generation and DNA sequencing with a MiSeq desktop sequencer (Illumina,
San Diego, CA) were performed as described previously203. The DNA from the kidney stones was
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extracted as described previously with the exception that we used lysis buffer ALT in the Qiagen
DNeasy kit. All samples were processed in duplicate, replicas were comparable; therefore, only
the first replica was used for downstream analysis. Since urine is a low biomass environment,
genera were reported only if a group representing 10% of the total reads in at least one sample;
the rest of the reads are reported as “other”7,203.
In vitroSstudies. CaOx monohydrate and dihydrate crystals were generated as
previously described238. For the in vitro binding assay 100μg of CaOx or control silicon dioxide
crystals (Strem Chemicals, Newburyport, MA) were mixed with 1x105 colony forming units
(CFU)/ml GFP-labeled uropathogenic E. coli (UPEC, a gift from Matthew Mulvey, University of
Utah) and incubated in Luria Broth (LB) in a 37°C orbital shaker (Thermo Scientific, Waltham
MA). Silicon dioxide crystals were chosen as a control because they are commercially available
and similar in size (10–20 nm) to the generated CaOx crystals. Additionally, silicon has been
reported to cause kidney stones in human and is a well-established kidney stone component in
veterinary medicine239,240.
To quantify the area of crystals, Keyence BZ-II analyzer software was used. The area of
the crystals was outlined using the Freehand Line feature of the Area Measure function. Within
the area of the crystal, GFP-expressing UPEC were then counted within the area of the stone
using the Count function. The same technique was employed for the background, outlining an
area of the background using the Freehand Line and then counting the E. coli within the
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outlined area. A ratio of E. coli per μm2 area was then generated by dividing the number of E.
coli by the corresponding outlined area
Murine Studies.
Mice. In vivo murine studies were approved by the Institutional Animal Care and Use
Committee (IACUC) protocol AR12-00067 and adhered to NIH Guide for the Care and Use of
Laboratory Animals or the equivalent. C57BL/6 mice (Jackson lab, Bar Harbor, Maine, Stock no.
000664) aged 6–10 weeks of were used for induction of pyelonephritis and/or CaOx
nephropathy. Mice were euthanized by CO2 inhalation at the end of the study for assessment of
kidney bacterial burden, CaOx deposits and kidney innate immune gene transcript evaluation.
Induction of Kidney CaOx Induced Nephropathy and Pyelonephritis.
Kidney CaOx deposits were induced in mice by injecting sodium glyoxalate
(80mg/kg/day of glyoxalate (Sigma Aldrich, St Louis, MO) intraperitoneally (i.p.); this causes
CaOx deposits to appear by 3 days and to peak at day 6241. Equivalent normal saline was used as
negative control. Experimental pyelonephritis was induced by inoculating 10 8colony forming
units (CFU) of the uropathogenic E. Coli (UPEC strain; CFTO73) transurethrally with a second
inoculum of the same size performed 4 hours later242.
Experimental Groups; Innate Immune Response Induced by CaOx Deposits.
1. CaOx deposits: Sodium glyoxalate injection i.p for 6 days
2. Negative control: Normal saline (NaCl) injections i.p. for 6 days
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Male C57BL/6 mice were used for this experiment and evaluated at peak kidney CaOx
deposition. The goal was to identify candidate innate immune genes to study the interaction of
CaOx deposition and UPEC at an early time point.
Experimental Groups; Early Innate Immune Response with CaOx Deposits and UPEC, Alone or
in Combination.
1. Kidney CaOx deposits: Sodium glyoxalate injection i.p. for 3 days
2. UPEC inoculation: NaCl injections i.p. for 3 days, UPEC inoculation on day 1
3. Kidney CaOx deposits and UPEC inoculation: Sodium glyoxalate injection i.p. for 3 days
and 108 CFU UPEC inoculation on day 1. A schematic of the experimental design for this
group is presented in Figure F.1.
4. Negative control: NaCl injection i.p. for 3 days
Figure F.1. Induction of CaOx deposits and experimental pyelonephritis in mice
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The 3-day CaOx treatment/2-day experimental pyelonephritis time period was chosen
because C57BL/6 mice clear infections by 3rd day242. Female mice were used for this
experiment because UPEC inoculation is not possible with the male murine anatomy.
Outcome Studies.
Kidneys were bisected longitudinally and bacterial burden was determined by plating
serial dilutions of half-kidney homogenate on a LB plate. The other half kidney was used for
CaOx deposit and/or pyelonephritis confirmation or snap frozen for RNA extraction. Kidney
deposits were visualized and quantified with Pizzolato staining using BZII analyzer software
(Figure F.S1). Kidneys were cultured for bacterial burden as previously described243. The local
renal CaOx induced innate immune response was determined using the RT2 Profiler
Antibacterial Response Array (Qiagen, Valencia, CA, Catalog no. PAM148Z) according to the
manufacturer’s directions. Gene expression was normalized using a panel of five housekeeping
genes (Actb, B2m, Gapdh, Gusb, and Hsp90ab1). Targeted PCR was performed using KicqStart
SYBR green primers (Sigma-Aldrich, St Louis, MO) for candidate innate immune genes identified
in RT2 profiler assay. Gapdh (Real Time Primers, LLC, Elkins Park, PA) was used as a
housekeeping gene for targeted PCR. All PCR reactions were performed on a 7500 PCR system
(Applied Biosystems, Carlsbad, CA).
Statistics.
Statistical analysis was performed and graphs were generated using Prism software
(GraphPad Software Inc, La Jolla, CA). The D’Agostino-Pearson Omnibus Test was used to
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determine if data was normally distributed. Differences between groups were compared with
the Student’s T-test or One-Way Anova if data was normally distributed; otherwise, the Mann
Whitney or Kruskal Wallis methods were used. Percentages were transformed to arcsine values
for analysis. Arrays were analyzed with the RT2 Profiler Data Analysis Software. For targeted
PCR, expression was quantified using the 2-ΔΔCt method and normalized values to the reference
gene Gapdh.
Results
Patients.
Five patients were enrolled (Table E.1) between August 2013 and February 2014.
Patient 5 did not have documented CaOx stones, but had a history of hypercalciuria and a urine
pH of 6, inconsistent with struvite. Only patients 1 and 2 had a history of UTIs. No patients were
diagnosed with a UTI during or 30 days prior to the stone removal procedure. However, patient
1 was treated for a UTI following stone removal.
Bacteria and/or Bacterial DNA is Present in Pediatric Kidney Stones.
To guide murine studies and determine which, if any, bacteria are present in pediatric
kidneys stones, we screened a limited number (5) of patients by EQUC and 16S rRNA gene
sequencing. Bacterial DNA and live bacteria were detected in the kidney stones, upper tract
(UT) urine, and bladder urine (Figure E.2). From each of these 5 patients, we obtained kidney
stones, bladder urine and/or upper tract urine for a total of 13 samples. Of these 13 samples,
EQUC isolated viable bacteria from 5 samples: 2 out of 5 kidney stones, 1 out of 5 UT urine
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samples, and 2 out of 5 bladder urine samples. In contrast, 16S rRNA gene sequencing
produced data from 8 out of 13 samples, including all 5 kidney stones. From these 8 samples,
we obtained a total of 329,298 sequences. Excluding all sequences that were <0.01% of the
reads in any sample, we identified 240 genera, 123 families, 66 orders, 42 classes, and 22 phyla.
Table F.1. Patient characteristics
Subj Age
Dx
Procedure
(yrs)
/sex
1
20/M History of
Right percutaneous
tuberculosis nephrosto-lithotomy
for 22 mm stone
2
13/F
Right percutaneous
nephro-lithotomy for
16mm stone
3
15/F
Left ureteroscopy and
laser lithotripsy for
5mm stone
4

12/F

5

12/M Seizures,
treated
with
topiramate

^

Ovarian
cyst

Right ureteroscopy
and laser lithotripsy
for 4mm stone

Right ureteroscopy
and laser lithotripsy
for 11mm stone

Stone analysis

24 urine stone risk
profile (mg/mg)

-CaOx monohydrate,
98%; Protein, 2%

Cit/Cr, 0.23 Ox/Cr,
0.02 Ca/Cr, 0.16
Ca/Cr, 0.23↑
No urine stone risk
profile completed

CaOx monohydrate,
18%; CaOx dihydrate,
80%; Protein, 2%
CaOx monohydrate,
50%; CaOx dihydrate,
40%; CaPhos (hydroxyl
form), 8%; Protein, 2%
CaOx monohydrate,
55%; CaOx dihydrate,
15%; CaPhos (carbonate
form), 8%; CaPhos
(hydroxyl form), 20%;
Protein, 2%
Not completed.

Cit/Cr, 0.31 Ox/Cr,
0.03 Ca/Cr, 0.17

No urine stone risk
profile completed

Cit/Cr, 0.13↓ Ox/Cr,
0.04 Ca/Cr,
0.10 #Ca/Cr, 0.23↑

different stone from same patient than stone used for microbiome sequencing.
random urine sample. Citrate/creatinine (Cit/Cr) normal is > 0.18 mg/mg. Oxalate to
creatinine normal is < 0.1 mg/mg. Calcium/creatinine (Ca/Cr) normal is < 0.21 mg/mg.
#
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Figure F.2. Kidney stones contain bacteria and/or DNA
(A) Bacteria key. (B) All stones contained multiple bacterial taxa on sequencing (left column)
Bacteria identified included the family Enterobacteriaceae (which includes E. coli), and the
genera Pseudomonas, Gardnerella, Lactobacillus, Brucella, Phyllobacterium and
Bradyrhizobium. Bacteria were cultured (right column) from 2 stones and represented the
most abundant bacteria identified by sequencing. (C) Bacteria were only sequenced and
cultured from upper tract urine in 1 patient. (D) When detected in the bladder urine, the
taxa were similar to those observed in the stones, although the ratios were often dissimilar.
To allow low percentage organisms to be visualized, the data was graphed on a logarithmic
Y-axis.
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Figure F.3. UPEC selectively aggregate around CaOx monohydrate crystals
Following incubation with GFP labeled UPEC, bacteria (green) could be seen aggregating
around CaOx monohydrate (A, arrows) but not CaOx dihydrate (A, arrowheads) or silicon
dioxide (B, arrows) crystals.
At 12 hours, significantly more bacteria per crystal surface area were seen with CaOx
monohydrate crystals than with CaOx dihydrate crystals, silicon dioxide crystals or
background. There were no other significant differences between groups. Magnification
40X right panels, 100X left panels Scale bars = 20 microns. Incubation time = 6 hours for left
panels and 12 hours for right panels.
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From 3 urine samples, we obtained a total of 188,099 sequences. Excluding all
sequences that were <0.01% of the reads in any sample, we identified 108 genera, 70 families,
39 orders, 26 classes, and 12 phyla. From the 5 stones, we obtained a total of 158,848
sequences. Excluding all sequences that were <0.01% of the reads in any sample, we identified
201 genera, 109 families, 59 orders, 39 classes, and 19 phyla. All stones contained multiple
bacterial taxa; however, Pseudomonas (85%) and Enterobacteriaceae (85%) dominated the
stones from patients 1 and 2, respectively. These taxa were matched by EQUC, which
cultured Pseudomonas aeruginosa from patient 1 and Escherichia coli from patient 2. Due to
the lack of enough diversity in the V4 region, sequencing could not classify Enterobacteriaceae
beyond the family level; however, this assignment matches the EQUC results, which
identified E. coli. When detected in the bladder urines, the taxa were similar to those observed
in the stones, although the ratios were often dissimilar. For example, whereas
Enterobacteriaceae/E. coli dominated the stone microbiome of patient 2, Gardnerella was
predominant in bladder urine. We selected uropathogenic E. coli (UPEC) for further in
vitro and in vivo murine studies because experimental models for UPEC kidney infections are
well established and there was evidence for Enterobacteriaceae/E. coli in human stones
screened for by complementary EQUC and sequencing approaches.
In vitro UPEC and CaOx Culture.
Uropathogenic E. coli (UPEC) aggregate on and around CaOx monohydrate crystals in
significantly greater numbers compared to CaOx dihydrate and control silicon dioxide crystals
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Figure F4. Bacteria increases the murine CaOx deposit burden.
A. The mean right (A), left (B) and combined mean (C) kidney bacterial burdens were lower with UPEC
inoculation alone compared to kidneys with CaOx deposits and UPEC inoculation at 56,157±1.68x105 versus
2.14x106±3.34x106; 24,843±69,527 versus 4.5x106±7.83x106 and 40,500±1.12x105 versus 5.28x106±1.78x106
respectively. To present on a log scale graph, but not during statistical analysis, 0 values were assigned a value
of 0.01 (D). Following glyoxalate injection, CaOx deposits are seen around the corticomedullary junction
(arrows) (E) Following UPEC inoculation and glyoxalate injection, an increased distribution and number of CaOx
deposits (arrows) is noted, extending into the medulla (arrowheads). D-E, representative 4X magnification
image stitches, background cropped for clarity, scale bar = 1000μm. (F) CaOx deposit number per mean 4X
imaging stitch cross-section area was significantly higher in the CaOx deposits and UPEC inoculation group
compared to kidney stones alone. There was a higher percentage of CaOx deposit/total kidney cross section
area (H) with CaOx deposits and UPEC than CaOx deposits alone. The location on the scatterplot for the
representative images (D) and (E) are indicated by an arrowhead and arrow respectively.
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(Figure F.3). A time-lapse movie of UPEC aggregation on/around to CaOx is presented in Video
S1 (online).
Renal CaOx Deposits Increase the Murine Bacterial Burden Following UPEC Inoculation.
The bacterial burden was quantified 3 days after CaOx deposits induction (2 days postUPEC inoculation). When both CaOx deposits and UPEC inoculation were present (n = 9), the
bacterial burden was 181, 38 and 82-fold higher in the right kidney, left kidney and mean
kidney, respectively compared to UPEC inoculation alone (n = 9); (Figure F.4A-C). Kidney
cultures from saline control mice or mice inoculated with only CaOx demonstrated no bacterial
growth at 24 hours.
UPEC Inoculation Results in Increased CaOx Deposition.
Mice with CaOx deposits and UPEC inoculation (n = 10) had a significantly higher
number of CaOx deposits per mean 4X image stitch cross section than mice inoculated with
CaOx alone (n = 10); (Figure F.4D-F). (Figure F.4G-H). Renal CaOx deposits were not seen in the
saline controls or in mice with UPEC inoculation alone (data not shown).
CaOx Deposits Induce a Murine Renal Innate Immune Response.
To identify innate immune genes with increased expression in response to CaOx
deposits, we performed the RT2 Antibacterial Response Array. CaOx deposits induced a robust
innate immune response at peak (6th day) CaOx deposits formation. Twelve of 84 genes were
upregulated (>4-fold, P < 0.01) in mice with kidney CaOx deposits (n = 6) compared to saline
controls (n = 6) (Figure F.5A). The upregulated genes were involved with inflammation, toll-like
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Figure F.5. PCR results
(A) At peak murine CaOx deposit formation (6 days), the RT2 Bacterial Response Array
revealed that 12/83 genes were significantly up-regulated > 4 fold. These genes included
the inflammatory genes Chemokine (C-C motif) ligand 5 (Ccl5), Cluster of differentiation
14 (Cd14), Interleukin 1β (Il1b), Interleukin 6 (Il6), Lysozyme 2 (Lyz2), Mediterranean
fever (Mefv), and Tumor necrosis factor (Tnf); the toll-like signaling genes, Interleukin–1
receptor-associated kinase 3 (Irak3) Toll-like receptor adaptor molecule 1 (Ticam1) and
Toll-like receptor 2 (Tlr2) along with the inflammasome genes NLR family, apoptosis
inhibitory protein 1 (Naip1) and NOD-like receptor family, pyrin domain containing 3
(Nlrp3). (B) In female C57Bl/6 mice, targeted RT-PCR revealed that at day 3 the
inflammatory genes CD14 and Il6 are not increased in UPEC alone inoculated mice or
CaOx alone inoculated mice compared to saline control, but are when both CaOx
deposits and UPEC inoculation are present. (C) Toll-like signaling genes: Tlr2 followed a
similar pattern to the inflammatory genes while Irak3 was not increased at day 3. (D) The
inflammasome genes were not up-regulated at 3 days in any of the groups (E) Stone
matrix protein inner core components were markedly up-regulated, but only when both
CaOx deposits and UPEC inoculation were present.
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Figure F.5. Continued

receptor signaling and inflammasome formation. A table outlining the 84 genes, heat map and
complete results are presented in Table F.S1, Figure F.S1, and File S1 (online) respectively.
UPEC and CaOx together protentiate the murine renal innate immunce response
To determine whether UPEC alters the CaOx induced innate immune response, we
evaluated expression of innate immune genes in mice with UPEC inoculation alone (n = 5),
kidney stones alone (n = 6), combined UPEC and CaOx inoculation (n = 6), and saline controls (n
= 4). We also evaluated the expression of Osteopontin (Spp1) and Calgranulin B (S100A9), since
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they encode proteins present in the inner core of CaOx stones (15). No significant differences in
inflammatory response, toll-like receptor signaling, inflammasome genes or stone matrix
protein inner core genes were found with UPEC inoculation only, CaOx inoculation only or
saline control mice. However, when mice were inoculated with both CaOx and UPEC, 2/2
inflammatory genes, ½ toll-like receptor gene and most notably 2/2 stone matrix protein genes
were significantly elevated (Figure F.5B-D).
Discussion
We hypothesize that bacteria and renal CaOx deposits potentiate individually induced
nephropathy (Figure F.6). Urine is not always sterile and contains a microbiome8,162. Thus,
dysbiosis may create a urinary environment conducive to kidney stone formation; conversely,
CaOx crystals or deposits may form a nidus for bacteria, increasing UTI risk. In support of our
hypothesis, we have demonstrated that human kidney stones have a microbiome (Figure F.2),
UPEC aggregate around CaOx monohydrate crystals (Figure F.3), renal CaOx deposits potentiate
murine pyelonephritis (Figure F.4A-C). UPEC inoculation of the murine kidney increases calcium
oxalate deposition (Figure F.4D-H) and induces local expression of innate immune proteins
(Figure F.5) associated with the stone inner core.
Children with idiopathic hypercalciuria have increased rates of urinary tract
infections244,245. Furthermore, patients with non-struvite kidney stones often have positive
urine cultures233. We were able to detect bacteria in human kidney stones but not in upper
tract urine; this suggests that the CaOx stones represent an area of concentrated bacteria. Our
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murine studies provide the first experimental evidence that renal CaOx deposits increase
pyelonephritis susceptibility. Despite the frequency of kidney stones and UTIs, the biologic,
diagnostic, and therapeutic relevance of their association remains largely unknown.

Figure F.6. Speculated mechanisms for bacterial contribution to CaOx stones
(A) Figure key. (B) Bacteria bind to CaOx crystals that may provide a nidus for
pyelonephritis or remain persist in a subclinical state (1) and bacterial communities form a
biofilm (2). The biofilm results in crystal aggregation (3). (C) The bacterial enzymes citrate
lyase splits citrate resulting in increased CaOx supersaturation (1). CaOx crystals form
providing a key element of lithogenesis. (D) Bacteria bind to the urothelium (1) that results
in secretion of innate immune proteins from recruited inflammatory cells (2) and the
urothelium (3) The innate immune proteins are incorporated as stone matrix proteins.
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Determining whether treatment of hypercalciuria and kidney stones reduces UTI risk remains to
be determined. Additionally, a more extensive evaluation of CaOx crystal and UPEC adhesion
forces with atomic force microscopy warrants consideration.
The identification of bacteria in CaOx kidney stones raises the possibility that bacteria or
bacterial biofilms are components of CaOx stone formation (Figure F.6) as they are in struvite
stones229. Four out of 5 (80%) of the kidney stones were positive for Enterobacteriaceae family
by sequencing. EQUC identified E. coli, a major member of family Enterobacteriaceae in one of
the three kidney stones. These complementary methods for bacterial identification indicate
that Enterobacteriaceae may be associated with pediatric kidney stones. Since the positive
cultures were from large kidney stones (Table F.1, Figure F.2) it is possible that EQUC may not
be sensitive in smaller kidney stones with smaller bacterial loads. Additionally, sequencing was
positive for Pseudomonas and Gardnerella in 5/5 and 4/5 stones, respectively; both species
have been detected previously in adult CaOx stones. Sequencing identified bacteria in 100% of
stones, well above the 19–32% positive CaOx culture rate previously reported232,233. Whenever
EQUC identified a bacterium, sequencing also identified it. In contrast, sequencing identified
many more bacteria than did EQUC. The increased sensitivity of sequencing relative to culture
may be due to the inability of some bacteria to be readily cultured, the ability of sequencing to
detect and identify bacteria that are not viable or culturable, and the ability of sequencing to
detect smaller numbers of bacteria. This increased likelihood of finding bacteria with
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sequencing compared to culture correlates with what has been described previously for the
urinary microbiome4.
We are not aware of prior reports of Bradyrizobium in urine or kidney stones, but it has
been identified elsewhere in the human microbiome246. Phyllobacterium is an environmental
organism247. Brucella does not appear to be a contaminating organism because it was not
present in controls including sterile PBS and the bullet blender beads. It also was not found in
the upper tract urine. Furthermore Brucella is not an environmental organism or found
spontaneously in mice but may be found in livestock and unpasteurized milk, which the
investigating facilities do not study248. Our high throughput sequencing uses the V4
hypervariable region of the 16S rRNA gene and is therefore only able to classify to the genus
level. Therefore, what the sequence analysis identified as Brucella could represent an organism
that has a similar V4 region such as Ochrobactrum249. Ochrobactrum has been identified in
human urine and we submit that our findings may demonstrate that it may also be found in
kidney stones250.
With the exception of patient 1, the upper tract urine was culture-negative and
sequence-negative. Therefore it is unlikely that bacteria DNA from the surrounding upper tract
urine contaminated the kidney stone. This discrepancy in bacterial loads between the upper
tract urine and kidney stones could be explained by pre-operative prophylactic antibiotics that
patients received, which might have had time to sterilize the upper tract urine but not reach
the inner stone or the bladder urine. Alternatively, the upper tract with higher flow may not be
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conducive to bacterial growth compared to the relative urine stasis in the bladder. Additionally,
the CaOx surface characteristics may be more prone to bacterial growth or colonization than
urine or urine epithelial cells.
We demonstrated that E. coli aggregates around CaOx monohydrate crystals compared
to CaOx dihydrate crystals and control silicon dioxide crystals. Bacterial adhesion to crystals is
complex because biological properties very based on crystalline form251. Future studies will
include direct evaluation of adhesive forces between a wide variety of crystals and bacteria
with atomic force microscopy252. Our findings build upon the findings by Chutipongtanate and
co-workers who demonstrated that bacteria including E. coli interact with CaOx crystals253.
Specifically they demonstrated that intact viable, but not dead, bacteria enlarged CaOx
aggregates253.
Traditionally, supersaturation of CaOx has been considered the primary mechanism for
stone formation. Bacteria in kidney stones or urine may alter urine supersaturation (Figure
F.6C). Prior research demonstrated that culture positive urine samples have lower citrate levels
than culture-negative samples and lower bacterial utilization of citrate via citrate lyase 254,255.
The correlation of urine chemistries with the urine and kidney stone microbiome was beyond
the scope of this project, but remains an area for future research.
Human kidney stones are increasingly recognized to have an inflammatory
component256,257. The kidney stone matrix is predominated by inflammatory proteins. It has
been shown that CaOx crystals induce an inflammatory response through dendritic cell
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secretion of Il–1β, inflammasomes are involved in kidney stone pathogenesis and urine Il–6
levels are increased in patients with kidney stones258-261. Furthermore, the innate immune
proteins Osteopontin (Spp1) and Calgranulin B (S100A9) have consistently been identified in the
inner core of CaOx deposits262. A potential mechanism for kidney stone formation consists of
bacteria/CaOx induction of innate immune proteins that are incorporated into the kidney stone
matrix inner core, leading to progression from crystalluria to stone formation (Figure F.6D). The
finding that most inflammatory mediators were not significantly elevated in oxalate loaded
mice versus saline controls or UPEC alone indicated that the immune response is not due to
oxalate poisoning but represent synergy between CaOx and UPEC (Figure F.5). A similar
mechanism occurs in extra-renal calcifications. Specifically, bacteria are present in vascular
calcifications and innate immune recognition of bacteria accelerates atherosclerosis263,264. At an
early time point in murine CaOx induced disease, an oxalate load or UPEC inoculation
individually did not significantly increase the innate immune response, whereas the
combination of CaOx deposit and UPEC inoculation increased both the innate immune
response, most importantly the stone inner core matrix protein gene expression and the renal
CaOx deposit burden.
Conclusion
Kidney stones have a microbiome that includes Enterobacteriaceae. E. coli aggregate
around CaOx monohydrate crystals, and murine UPEC inoculation is associated with increased
renal CaOx deposition along with the innate immune response, including increased expression
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of stone matrix proteins, during experimental murine CaOx nephropathy. Further renal CaOx
depositions increase the bacterial burden during murine pyelonephritis. Perhaps kidney stones
and/or CaOx crystalluria represents a reversible risk factor that should be screened for in
patients with recurrent pyelonephritis. Limitations of this study include lack of documentation
of stone composition in the kidney stone of one patient and the previously mentioned
limitations in bacterial DNA sequencing technology. Future studies will be needed to confirm
whether low abundance organisms are passive environmental contaminants or directly
involved in lithogenesis. Additionally, murine renal CaOx models have key differences from
human kidney stone disease. We studied human urolithiasis, in vitro CaOx crystals and murine
CaOx deposits under the broad umbrella of CaOx disease. CaOx deposition in mice occurs
acutely and is located mostly in the interstitial space. In humans CaOx deposition is mostly
tubular and occurs over a long period of time. Because of these key differences, our murine
findings will need to be validated in human patients or an animal model, when one is available
that closely approximates human urolithiasis, to determine whether bacteria have any
relevance in human kidney stone disease. Whether bacteria are essential for CaOx kidney stone
formation, a disease-modifying factor or largely an uninvolved association remains to be
determined. However, this study provides proof-of-concept that bacteria can worsen the CaOx
kidney deposit disease course and vice versa. Our screen of 5 kidney stones for bacteria was
meant to guide our murine studies, clearly sequencing of a much larger cohort of patients is
needed to characterize the kidney stone microbiome and determine if the bacteria we
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identified are frequently present in other cohorts. Future studies will also be needed to
determine mechanisms responsible for the association and/or interaction between bacteria
and calcium oxalate disease.
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Supplemental Material

Figure F.S1. Quantifying kidney deposits
(A) Pizzolato stain of a 4X cross-section image stitch (upper panel) in which the CaOx deposits
are stained black. A zoom view (lower panel) demonstrates individual CaOx deposits (B) The
“dynamic cell count” feature of the BZ900 microscope software identifies and outlines the
CaOx deposits (yellow) in the 4X image stitch (upper panel) with the outlines of individual
software-identified CaOx deposits visible in zoom view (lower panel).
Subsequently the software records the number, major axis and area of the kidney CaOx
deposits.
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Figure F.S2. Heatmap of the antibacterial response array
A heatmap (upper panel) and table (lower panel) of the RT2 Profiler Antibacterial Response Array
results.
Appendix F – Video 1.
Not included in this document. Online at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598009/
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Addendum
We had never before detected Brucella in any sample, yet in this study, we sequenced
Brucella in 3/5 samples (Figure F.8). At first, we were curious about this new organism and
decided that we should try to culture it in the future. It did not take us long to realize that we
were incredibly lucky that we did not cultivate this organism. According to the CDC, Brucella
causes a severe zooinotic infection, Brucellosis, which can cause fever, swelling, and
neurological conditions. In developing nations, it is usually transmitted to humans through milk
or raw meat, but the main source of Brucellosis infection in the US is from laboratory use 265.
Furthermore, Brucella is a BSL3 organism and considered to be a bioweapon; simply opening a
plate growing Brucella is sufficient for infection by aerosolization 265,266. In hindsight, we were
thankful that we had accidentally failed to grow it.
However, we soon discovered that Brucella is very closely related to a non-pathogenic
bacterium, Ochrabactrum (Figure F.7). Ochrabactrum is commonly misidentified as Brucella
with 16S sequencing 267. We sent the V4 amplicons from this study to a Brucella expert, Jeffery
Foster from Northern Arizona University, and he could not determine if it was truly Brucella or
Ochrabactrum from the 250bp V4 segment. About a year later, we were able to isolate
Ochrabactrum from kidney stone samples. Therefore, we think that these samples actually
contain Ochrabatrum, not Brucella. Oddly, we have never cultured or sequenced Ochrabactrum
in bladder urine; so far, it seems to be confined to kidney stones.
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All other kidney stone-associated organisms are species that we commonly find in the
bladder. This led us to question if Brucella or Ochrabactrum have ever been associated with
calcium deposits before. We did find that Brucellosis infection can cause calcium deposits in the
liver and spleen, but it was a more common occurrence in the pre-antibiotic era 268. There have
also been reports of Brucella-filled calcium nodules in and on skeletons from archeological digs
269,270.

All of this may be coincidence, but it may be interesting to study Ochrabactrum and

kidney stones or even the connection between bacteria and calcium deposits elsewhere in the
body.
We did find that Brucellosis infection can cause calcium deposits in the liver and spleen,
but it was a more common occurrence in the pre-antibiotic era 268. There have also been
reports of Brucella filled calcium nodules in and on skeletons from archeological digs 269,270. All
of this is coincidence, but it may be interesting to study the connection between bacteria and
calcium deposits elsewhere in the body.
Finally, the paper only briefly compares sequencing to culture. Therefore, I have
included a relative abundance graph (Figure F.8) as well as a table comparing the two (Table
F.2). Overall, (besides the Brucella/Ochrabactrum samples) both methods provide similar
results.
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Figure F.7. Phylogenetic tree of Brucella and Ochrabactrum
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Figure F.8. Relative abundance of sequenced patient urine and stones
Depicting the same data as in Figure E.2. Microbiome profile as determined by 16S amplicon
sequencing. Stacked bar plots depict the sequence abundance of the most abundant genus- or
family- level taxa. The y axis represents the percentage of sequences for a particular bacterial
taxa; the x axis represents the kidney stone and urine samples separated by study participant.
Family Enterobacteriaceae could not be classified to the genus level. Black bars indicate
unamplifiable samples, meaning that the 16S DNA could not be distinguished above
background levels. The remainder of sequences were combined in the category Other.
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Table F.2. Comparison of EQUC results to sequencing
Kidney Stones, Upper Urinary Tract (UUT), and bladder urine isolates were cultured via EQUC
and identified using MALDI-TOF. The culture results are compared to the most abundant
species sequenced in each sample.
Colony
Most Abundant
Forming
Sequence
Site
Cultured Organism
Units/mL
Organism
KS-13
Pseudomonas
10,000
UUT
aeruginosa
CFU/mL
Pseudomonas
Kidney
Pseudomonas
10,000
Stones
aeruginosa
CFU/mL
Pseudomonas
KS-19
Escherichia coli
Bladder Urine Gardnerella vaginalis
300 CFU/mL
Gardnerella
UUT
None
Negative
Kidney
10,000
Stones
Escherichia coli
CFU/mL
Enterobacteriacea
KS-24
Bladder Urine None
None
Lactobacillus
UUT
None
None
Negative
Kidney
Stones
None
None
Brucella
KS-23
Bladder Urine None
None
Negative
UUT
None
None
Negative
Kidney
Stones
None
None
Brucella
KS-30
Bladder Urine Actinomyces turicensis 10 CFU/mL
Negative
Kidney
Stones
None
None
Brucella

APPENDIX G
GENOMES OF GARDNERELLA STRAINS UNCOVER AN ABUNDANCE OF PROPHAGES WITHIN THE
BLADDER MICROBIOME

Malki, R., Shapiro, J., Price, T.K., Hilt, E.E., Thomas-White, K., Sircar, T., Rosenfeld, A.B., Kuffel,
G., Zilliox, M.J., Wolfe, A.J., Putonti, C. Genomes of Gardnerella Strains Uncover an Abundance
of Prophages within the Bladder Microbiome. PloS one 2016;11:e0166757, PMID: 27861551
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Overview of Appendix G
This work was performed in collaboration with the Putonti Lab at the Lakeshore Campus
and the majority of the bioinformatics was done in their lab. However, their Gardnerella
analysis supports the hypothesis that 2 unique species of Gardnerella exist. Furthermore, within
each species, there is no specific clading correlating with collection site. This suggests that
Gardnerella is not specific to a given niche.
Abstract
Bacterial surveys of the vaginal and bladder human microbiota have revealed an
abundance of many similar bacterial taxa. As the bladder was once thought to be sterile, the
complex interactions between microbes within the bladder have yet to be characterized. To
initiate this process, we have begun sequencing isolates, including the clinically relevant
genus Gardnerella. Herein, we present the genomic sequences of four Gardnerella strains
isolated from the bladders of women with symptoms of urgency urinary incontinence; these
are the first Gardnerella genomes produced from this niche. Congruent to genomic
characterization of Gardnerella isolates from the reproductive tract, isolates from the bladder
reveal a large pangenome, as well as evidence of high frequency horizontal gene transfer.
Prophage gene sequences were found to be abundant amongst the strains isolated from the
bladder, as well as amongst publicly available Gardnerella genomes from the vagina and
endometrium, motivating an in depth examination of these sequences. Amongst the
39 Gardnerella strains examined here, there were more than 400 annotated prophage gene

- 275 -

sequences that we could cluster into 95 homologous groups; 49 of these groups were unique to
a single strain. While many of these prophages exhibited no sequence similarity to any lytic
phage genome, estimation of the rate of phage acquisition suggests both vertical and horizontal
acquisition. Furthermore, bioinformatic evidence indicates that prophage acquisition is ongoing
within both vaginal and bladder Gardnerella populations. The abundance of prophage
sequences within the strains examined here suggests that phages could play an important role
in the species’ evolutionary history and in its interactions within the complex communities
found in the female urinary and reproductive tracts.
Background
Gardnerella, a member of the Bifidobacteriaceae family, is a genus of facultative
anaerobes within the vaginal microbiota of both healthy women and those diagnosed with
bacterial vaginosis (BV)181,271-273. Similarly, our group found Gardnerella in urine collected from
adult female bladders by transurethral catheter4,6,7,65. This corresponds with microbiome
studies of voided urine: Gardnerella was present regardless of sex or symptom
status13,60,172,204,274. Furthermore, the bladders of healthy individuals include other bacterial
taxa also detected within the vaginal microbiota4,6,7,13,14,60,65,204,274. To date, thirty-nine G.
vaginalis isolates from the vagina or endometrium have been sequenced275-279, including four
complete genomes; the remaining genomes are represented as scaffolds or contigs. Analysis of
G. vaginalis genomes found evidence of a large pangenome that consists of a modestly sized
core genome in addition to strain-specific genes275,280.
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Prior investigations of G. vaginalis genomes from the reproductive tract have uncovered
indications of substantial horizontal gene transfer (HGT), including the acquisition of genes
from other human-associated taxa275,280,281. In addition to natural competence, G. vaginalis may
also include phage-mediated gene transfer, as coding regions of bacteriophage (phage) origin
are ubiquitous within these genomes280. Similarly, genomic sequences from other bacterial taxa
within the vaginal microbiota also contain parts of or entire temperate phage genomes282,283.
Prior studies have posited that lysogenic lactobacilli phages could contribute to a shift in the
vaginal microbiota leading to BV (for a review, see Turovskiy et al 2011273). Phages have been
found to play a crucial role in the structuring of microbial communities, including those residing
within the human body284, driving bacterial genetic diversity103 and adaptation to changes in
the environment285. Although several phages induced from vaginal lactobacilli have been
identified158,286, currently no phages have been characterized for Gardnerella. While evidence
suggests that phages are likely contributors to HGT in commensal communities282,285,287, the
extent of their effect on the human microbiome is just now being explored 288-290. Within many
other microbiota, including the bladder, the virome remains largely unexplored.
Herein, we present the genomic sequences of four Gardnerella strains isolated from the
bladders of adult women with symptoms of urgency urinary incontinence (UUI). Comparative
genomics between these strains and publicly available isolates revealed a highly conserved core
genome across the bladder and vaginal isolates. Analogous to prior observations for this
species, the Gardnerella strains isolated from the bladder also contain a large number of
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prophage gene sequences. The pervasiveness of prophage sequences in Gardnerella genomes
from both the female urinary and reproductive tracts motivated our thorough bioinformatic
investigation. A comprehensive interrogation of the over 400 annotated prophage gene
sequences identified here provides insight into the adaptive ability of Gardnerella, as well as
the larger community of phages within the female urinary community.
Materials and Methods
Strain Isolation and DNA Extraction.
The Gardnerella and Gardnerella vaginalis isolates were isolated from transurethral
catheterized urine specimens of adult women with UUI6 using the previously described
Enhanced Quantitative Urine Culture (EQUC) protocol7. Microbial identification was determined
using a Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometer (MALDITOF MS, Bruker Daltonics, Billerica, MA) as described7. Pure cultures were stored at -80°C in a 2
ml CryoSaver Brucella Broth with 10% Glycerol, no beads, Cryovial, for preservation (Hardy
Diagnostics).
The preserved pure culture isolates were grown on CDC Anaerobic 5% sheep blood
(Anaerobic BAP) agar (BD BBL™ Prepared Plated Media) under anaerobic conditions at 35°C for
48 hours. MALDI-TOF MS was performed for species/genus verification. An isolated colony was
transferred to 5mL tryptic soy broth (TSB) supplemented with 10% fetal bovine serum (FBS) and
grown under anaerobic conditions at 35°C for 48 hours. 1 mL of culture was collected, and cells
were resuspended in 1 mL of buffered saline peptone (PBS).
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Genomic DNA extraction was performed using a phenol-chloroform extraction protocol.
Briefly, cells were resuspended in 0.5 mL DNA Extraction Buffer (20 mM Tris-Cl, 2 mM EDTA,
1.2% Triton X-100, pH 8) followed by addition of 50 μL Lysozyme (20mg/mL), 30 μL
Mutanolysin, and 5 μL RNase (10 mg/mL). After a 1-hour incubation at 37°C, 80 μL 10% SDS,
and 20 μL Proteinase K were added followed by a 2-hour incubation at 55°C. 210 μL of 6 M NaCl
and 700 μL phenol-chloroform were then added. After a 30-minute incubation with rotation,
the solutions were centrifuged at 13,500 RPM for 10 minutes, and the aqueous phase was
extracted. An equivalent volume of Isopropanol was then added, and solution was centrifuged
at 13,500 RPM for 10 minutes after a 10-minute incubation. The supernatant was decanted and
the DNA pellet was precipitated using 600 μL 70% Ethanol.
Genome Sequencing, Assembly, and Annotation.
DNA samples were diluted in water to a concentration of 0.2 ng/μl as measured by a
fluorometric-based method (Life Technologies) and 5 μl was used to obtain a total of 1 ng of
input DNA. Library preparation was performed using the Nextera XT DNA Library Preparation
Kit (Illumina) according to manufacturer’s instructions. The isolates were barcoded, pooled and
each isolate was sequenced twice, on two separate runs, using the Illumina MiSeq platform and
the MiSeq Reagent Kit v2 (300-cycles) to produce 150 bp paired-end reads. Sequencing reads
were parsed into individual folders according to the respective barcodes.
The following protocol produced an assembly with the least number of scaffolds and the
highest overall coverage (Table G.1). Reads were paired using Geneious (Biomatters Ltd.,

- 279 -

Auckland, New Zealand) for each isolate for each sequencing run. De novo assembly was
performed, combining the two runs per isolate, using the Geneious plug-in for Velvet120 (k =
99). Sequence contigs were then extended and scaffolds were constructed using the tool
SSPACE121. Resulting contigs were again assembled using the Geneious de novo assembler at
the Medium-Low sensitivity setting. Annotations were performed for each of the contigs using
the RAST annotation pipeline291, as well as the BASys bacterial annotation system292. RISPR
arrays were predicted using CRISPRdb293. A local nucleotide database was created for each
strain using the protein coding regions predicted by RAST. Each predicted coding region was
then reciprocally BLASTed (blastn). Genes were determined to be homologs if the query
coverage and the sequence identity were both greater than 70%.
Raw sequencing reads as well as assembled contigs are available through NCBI: Gv18-4
(SRA: SRX1688291, WGS: LWSP00000000), Gv23-12 (SRA: SRX1688198, WGS: LWSQ00000000),
G26-12 (SRA: SRX1688301, WGS: LWSR00000000), and G30-4 (SRA: SRX1688300,
WGS: LXJL00000000). S1 Table lists the annotated protein functionalities within the four strains;
annotations are available and can be queried through NCBI.
Phylogenetic Analysis.
Single Gene Trees: 16S rRNA gene sequence analysis was performed by excising the full
length 16S sequence from the assembled genomes and querying each against the NCBI nr/nt
database via blastn. Sequences producing full-length hits were collected and aligned using
MUSCLE169. The phylogenetic tree was constructed using RAxML130 and visualized using
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PhyloWidget294. Phylogenetic analysis of the VLY gene sequences was aligned using ClustalW295.
As before, RAxML and PhyloWidget were used to derive and visualize the tree, respectively.
Core Genome Tree. While 43 strains are presently publicly available through NCBI
for G. vaginalis, this study considered only those that were (1) isolated from the vagina or
endometrium and (2) are documented within the literature182,275-279. Supplementary Table 3
lists the 35 publicly available strains meeting these criteria. The species tree was derived by first
identifying the core set of genes within the 39 Gardnerella strain sequences (genome, scaffold,
or contig collections). Incomplete genomes (scaffold or contig status) were retrieved from NCBI.
Their sequences were individually submitted to the RAST server and annotated 291. For the three
complete genomes, G. vaginalis 409–05 (NC_013721), 14019 (NC_014644), and HMP9231
(NC_017456), the ffn format files were retrieved from NCBI’s FTP site. The core gene set was
determined by first creating a local nucleotide BLAST database with the coding regions
annotated for the G. vaginalis 14019 strain. Annotated coding regions in other sequences were
BLASTed locally (using BLASTn, e-value<10−5), returning the top hit only. Genes producing hits in
all other 38 genomes were identified as members of the core genome. The core gene set
contains 183 genes (S4 Table), a significantly smaller group than previously used when
considering smaller numbers of strains275,280. Each core gene and its orthologs were aligned
using ClustalW295. Alignments were concatenated producing a concatenated gene alignment
(super-gene alignment) using an in-house script in R (available upon request). The Maximumlikelihood tree was derived using RAxML130. Trees were visualized using PhyloWidget294.
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Assessing Presence/Absence of Coding Regions of Interest.
The absence of coding regions identified with key carbohydrate metabolism
functionalities within the G26-12 and G30-4 genome analyses was experimentally verified via
PCR. Coding regions within the Gv18-4 genomic sequence with the following functional
annotations were retrieved: (1) chitin and N-acetylglucosamine utilization, (2) deoxyribose and
deoxynucleoside catabolism, (3) D-gluconate and ketogluconates metabolism, (4) formaldehyde
assimilation, (5) lactose and galactose uptake and utilization, (6) trehalose biosynthesis, uptake
and utilization, and (7) xylose utilization. In total, 22 genes were identified. Each was BLASTed
against the nr/nt database, specifying the genus Gardnerella, to retrieve orthologs from other
strains. All annotations within the GenBank files retrieved were manually inspected verifying
similar confirmed/predicted protein functions. Primers were designed for each gene, targeting
conserved regions amongst all orthologs, and obtained from Eurofins MWG Operon (Huntsville,
AL). In total, 66 PCR reactions were conducted, testing each of the primer pairs against: Gv18-4
(serving as a positive control), G30-4, and nuclease-free water (serving as a negative control).
All Gv18-4 reactions produced amplicons of the expected sizes. G30-4 and the negative controls
did not produce amplicons. Primer sequences are listed in S6 Table.
Prophage Identification.
Genes annotated as phage or viral in origin were extracted from each of the genome
sequence annotations. Local BLAST databases were used for both identifying the orthologous
clusters of prophage sequences, as well as the putative origin of prophage clusters. First, a local
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nucleotide database was created, including all of the sequences predicted as phage from all
39 Gardnerella strains. Each individual putative phage coding region sequence was then
BLASTed (blastn) against this local database (maximum 100 results), detecting identity to itself,
as well as similarity to other sequences. Each hit was further qualified; hits with a sequence
identity and query coverage greater than or equal to 80% were considered homologous. Once
clusters were identified, the sequences within the cluster were aligned using ClustalW and
manually inspected to guarantee correct clustering (File S1 [not included here due to size]).
Identification for the origin of each cluster was performed similar to above; the local database
used for conducting blastn searches was the complete collection of viral RefSeq coding regions.
The all.fna.tar.gz file was retrieved from ftp://ftp.ncbi.nlm.nih.gov/genomes/Viruses/.
Homologs were called when query coverage was ≥80%. The sequence identity threshold was
considerably lower ≥35%. A cluster was considered to show no homology to any RefSeq coding
region if it did not meet both of these conditions.
Estimating Rates of Phage Acquisition.
Rates of phage acquisition were estimated using the R package corHMM296, which
implements a Hidden Markov Model to estimate the rate of evolution of traits occurring across
a phylogeny. Each phage was encoded as a binary trait according to its presence/absence as
visualized in Figure G.3. Using this method to estimate the “rate of evolution,” therefore,
provides a meaningful proxy for the rate of phage acquisition across the tree. For any given
phage, the rate of acquisition is expected to scale with its total number of occurrences in the
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tree, and horizontally transmitted phages are expected to have faster relative rates than
vertically transmitted phages (as seen in Figure G.4).
Results and Discussion
Genome Features.
Four Gardnerella strains were previously isolated from the bladders of four different
female patients with symptoms of urgency urinary incontinence3,6. While MALDI-TOF identified
two of these strains as G. vaginalis (henceforth denoted as Gv18-4 and Gv23-12), it did not
resolve the other two strains to the species level (G26-12 and G30-4). 16S rRNA gene
sequencing for each isolate confirmed the strains belong to the genus Gardnerella (Figure
G.S1). All four isolates were sequenced, assembled, and annotated and are publicly available
via NCBI. The genomic sequences varied slightly in size from 1.48 to 1.62 Mbp (Table G.1).
Table G.1. Genomic characteristics of four Gardnerella strains isolated from female bladders
Genome
G26-12
G30-4
G18-4
G23-12
Length
1,484,647
1,590,395
1,624,172
1,595,255
GC%
42.5
41.9
40.9
41.2
# Protein coding regions 1172
1242
1240
1243
# RNAs
48
48
45
46
# CRISPR arrays
5
8
2
4
# Scaffolds
175
183
324
301
Max Scaffold Length
57,529
42,968
11,232
11,376
N50 Length
16,568
20,497
11,232
11,376
Average Coverage
526
714
197
631
INSDC ID
LWSR00000000 LXJL00000000 LWSP00000000 LWSQ00000000

Homologs, as well as strain-specific coding regions, were identified within the genomes
of these bladder Gardnerella strains (Figure G.1A). Although Gv18-4 and Gv23-12 were
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indistinguishable on the basis of their 16S rRNA sequences (Figure G.S1), instances of both
strain-specific gene acquisition and loss within their genomes were detected (Table S1 [Not
included here due to size]). Annotation also revealed the type I CRISPR/Cas system in all four
genomes, with multiple CRISPR loci per genome (Table G.1).
Comparison between the two strains identified by MALDI-TOF analysis to the species
level (Gv18-4 and Gv23-12) and those identified to the genus level (G26-12 and G30-4) revealed
disparity in the number of genes with the annotated functionalities of carbohydrate
metabolism, membrane transport, and cell wall and capsule synthesis (Figure F.1B); however,
the genetic variation observed between the Gv and G strains is statistically significant only for
loci that regulate carbohydrate metabolism. Consistent with previous studies that illustrated
the ability of different Gardnerella strains to ferment and use different carbohydrates182,
annotation of the genome for G26-12 and G30-4 suggest that they lack coding regions with the
following functionalities: chitin and N-acetylglucosamine utilization, trehalose biosynthesis,
trehalose uptake and utilization, lactose and galactose uptake and utilization, lactose
utilization, formaldehyde assimilation, xylose utilization, deoxyribose and deoxynucleoside
catabolism, D-gluconate and ketogluconates metabolism. The absence of these coding regions
within the G26-12 and G30-4 genome sequences was confirmed experimentally via PCR.
The genomes of these bladder strains were further examined with respect to the
presence/absence of coding regions associated with virulence, as previously defined by
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Yeoman et al.280 (Table F.S2). Genes associated with biofilm formation (glycosylases and
glycosyltransferases) and epithelial adhesion (fimbria/pili) were identified in all four genomes;

Figure G.1. Characterization of predicted coding regions
(A) Homology and (B) annotated frequency within the four bladder Gardnerella strains. (**p
value <0.05 between the two predicted Gardnerella strains and the two predicted G.
vaginalis strains; *p value <0.1). Strains are represented using the same colors in both
panels.
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however, type-1 fimbrial precursors were found only within the genomes of G26-12 and G30-4.
Genes associated with antibiotic/antimicrobial resistance, including those that encode the ABCtype multidrug transport system and the DedA protein (which has been shown to be required
for drug resistance in E. coli297) were present within all four genomes. However, tetracycline
resistance proteins were encoded within the Gv18-4, Gv23-12, and G26-12 strains, but not in
the G30-4 strain. Genes associated with protection or evasion from the immune response (alkyl
hydroperoxide reductase and Rib-family surface protein) were found within all four of the
bladder strains. Furthermore, the coding region for the vaginolysin (VLY) gene, which is
selective for human cells280,298, was highly conserved within all four strains, in spite of the two
amino acid substitutions that separate the Gv18-4 strain from the type strain for the genus
ATCC 14019 (Figure G.S2). Finally, the Gardnerella strains G26-12 and G30-4 contained an
annotated rRNA methyltransferase associated with Gardnerella cytotoxicity280 and with
haemolytic activity in other bacterial species299. Interestingly, only the Gv18-4 and Gv23-12
strains contained genes that encode sialidase, which has been experimentally proven to
contribute to mucin degradation in BV276, although presence of the gene is not predictive of
actual sialidase activity 300 and thus warrants further investigation.
Phylogenetic Analysis and the Gardnerella Pangenome.
In an effort to assess the similarity/difference between Gardnerella strains isolated from
the female bladder and those isolated from the female reproductive system, all publicly
available sequenced strains isolated from the vagina or endometrium were retrieved from NCBI
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(Table G.S3). This set includes 35 complete, scaffold, or contig genome sequences. Extending
beyond the 16S rRNA gene marker, the evolutionary history of this genus was considered by
investigating sequence homologies within the “core” Gardnerella genome (Methods; Table
G.S4. In total, 183 genes were identified as belonging to this core gene set, less than identified
in prior studies of far fewer genomes275,280. As shown in Figure G.2, the strains isolated from the
bladder are not monophyletic, establishing that the Gardnerella core genome does not
correlate with a single isolation location. Examination of all coding sequences for all 39
investigated genomes revealed no gene(s) exclusive to the bladder strains. While the vast
majority of the genes within the core set demonstrated an evolutionary history identical to that
of the species tree (Figure G.2), genes indicative of intragenic recombination, such as VLY (S2
Figure), were also identified. Nevertheless, the species tree (Figure G.2) we derived largely
concurs with the tree produced by Ahmed et al275. In comparison to the phylogeny of Ahmed et
al., which included 17 genomes and a core genome of 473 genes, their Group 3 and 4 are both
contained within Clade A in Figure G.2. Our Clade B corresponds to their Group 2 and our Clade
C is within their Group 1; only two of the genomes within Clade C were included in the prior
analysis of Ahmed et al. As expected, each clade had significantly more homologous genes (404,
799, 762 and 635 for Clades A through D, respectively) (Figure G.2A), a likely residual of
undersampling, biased sampling, and/or clade-specific functional conservation.
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Figure G.2. Phylogenetic analysis of Gardnerella strains
Maximum Likelihood species tree of Gardnerella strains based upon sequence homology
within the core gene set. (A) Phylogenetic tree listing branch supports and distinction of the
four clades within the tree. Numbers within black circles indicate the number of homologous
genes within each clade and the core Gardnerella genome.
(B) Maximum Likelihood tree including branch lengths and isolation information with respect
to location and diagnosed symptom. Strains isolated from the bladder and sequenced in this
study are labeled in red; strains listed in green were isolated from the vagina/endometrium of
BV+ patients; strains in light blue were isolated the vagina/endometrium of STD+ patients. All
remaining strains (indicated in black font) were isolated from the vagina or endometrium.

The bladder strains G26-12 and G30-4 were determined to belong to Clade A, which also
includes three strains isolated from BV+ patients (Figure G.2B). While the phylogeny based
upon the core gene set does not correspond with isolation location, some clades appear to
have a higher incidence of strains isolated from patients diagnosed as BV+. Because genes
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associated with virulence are not exclusively present within genomes isolated from
symptomatic patients275,280, it is not surprising that several are included within the core gene
set identified here. The lack of correspondence between phylogenetic history and symptoms is
supported by prior studies, which hypothesized that gene expression variation
within G. vaginalis strains may trigger BV development301 and single point mutations may result
in greater potential for cytotoxicity182. Thus, there appears to be no single gene that correlates
with BV symptoms. This is, however, not surprising given that G. vaginalis strains are present
within both the BV- and BV+ vagina302, and it is but one of the taxa that coincides with BV
symptoms272.
Mobile Elements.
The four bladder Gardnerella genomes varied in their number of ORFs predicted to be
viral (bacteriophage) in origin. The number of prophage gene sequences per genome had no
correspondence to evolutionary history (Figure G.2). This is true for the four Gardnerella strains
isolated from the bladder, as well as for the 35 strains isolated from the reproductive system.
For example, the G. vaginalis strain JCP8522, a vaginal BV+ strain276, has only one ORF
annotated as a phage gene. In contrast, the Gv18-4 strain sequenced as part of this study
contains the most, 33, phage-like gene sequences within a Gardnerella genome to date. Table
G.S5 (not included due to size) lists the 442 annotated prophage genes within the 39 genomes
examined. Due to the incomplete (scaffold/contig) status of the majority of the genomes

- 290 -

included in the analysis here, we evaluated predicted prophage genes (median length 939 bp)
individually.
To identify homologs, the nucleotide sequences for all annotated prophage genes across
all Gardnerella genomes were examined. Based upon the combination of sequence identity and
query coverage, 104 clusters of orthologous prophage genes were identified (File S1 – not
included due to size). Within larger clusters, prophage homolog sequences were highly
conserved between genomes. Forty-nine clusters, however, included only a single prophage
gene sequence, indicative of frequent independent acquisition of viral sequences. This is
further supported by the variation in prophage genes identified within strains isolated from the
same patient. While the genomes of JCP8481A and JCP8481B (both isolated from a single
patient as denoted by A and B276) contain the same set of prophage gene sequences, the
genomes of JCP8151A/B and JCP8017A/B do not (Figure G.3, Table G.S5); this captures the
likely prevalence of lysogenic phage excision, as well as gene loss, events. Likewise, the
genomes of 00703Bmash, 00703C2mash, and 00703Dmash, which are from sequential isolates
from the same patient275, vary in their prophage gene content (Figure G.3, Table G.S5). This
diversity, even within a single patient, suggests intra-host prophage gene gain/loss.
Examination of the 37 largest prophage gene clusters suggested that prophage
introduction within the Gardnerella genus has occurred by both vertical and lateral inheritance.
These larger clusters include orthologous prophage gene sequences present within five or
more Gardnerella genomes; the most pervasive prophage gene sequences were present within
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Figure G.3. Presence/absence of prophage gene sequences from larger clusters
Clusters of orthologous prophage genes found within five or more of the
39 Gardnerella genomes are shown using a distinct color. Open circles indicate that the
prophage sequences belonging to the particular cluster show no/poor sequence homology
to characterized lytic phages. Closed circles indicate moderate (query coverage ≥80%,
nucleotide sequence identity ≥35%) to high homology to a phage genome sequence record
in NCBI. Nucleotide sequence identity for the prophage genes in each cluster is indicated by
the bar chart at the top of the figure.
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21 of the 39 Gardnerella genomes examined here. As shown in Figure G.3, several of the larger
prophage gene clusters have representatives across the entire phylogenetic tree and some sets
of clusters appeared to have been lost within particular lineages. Half of the 104 prophage gene
clusters identified exhibit little to no resemblance to any sequence within the current GenBank
nr/nt nucleotide database of characterized phage sequences; this includes several of the
prophage genes within the larger clusters (represented as open circles in Figure G.3). For those
prophage gene sequences that exhibit homology to characterized phage genes, hits were
frequently identified to the genomes of Bacillus-, Mycobacterium-, and Staphylococcusinfecting phages. Previous targeted gene surveys of the bladder have routinely found
Staphylococcus within the community7,65,203.
Although Gardnerella-infecting phages have yet to be isolated, the abundance of
prophage gene sequences in the genomes (Table G.S5) and the presence of the CRISPR/Cassystem (Table G.1) suggests that phages capable of infecting Gardnerella spp. exist. This
assumption is corroborated by prior analyses of spacer sequences within
21 G. vaginalis genomes, in which 70.7% of the spacers showed no homology to sequences
within the GenBank database281. While many of the clusters exhibiting homology to sequences
in GenBank identified lytic phages annotated as infecting an array of different bacterial genera,
analysis of eleven of the 104 clusters resulted in the description of phages thought to infect a
single taxon. These included several of the larger clusters shown in Figure G.3: clusters 12, 15,
and 30 were found to have homology to Bacillus-infecting phages; clusters 22 and 35 were
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determined to be similar to phages infecting Mycobacterium species; while cluster 29 exhibited
a likeness to Staphylococcus-infecting phages (Table G.S5). Yet, all of these phages are of the
family Siphoviridae. Homologies identified for these prophage sequences provide a foundation
for future work in the isolation of Gardnerella-specific phages. More broadly, these prophage
gene sequences provide insight into the phage community within the human microbiota.
Lateral gene acquisition is ubiquitous; however, there is a strong discordance between
the evolutionary tree (Figure G.2; Figure G.S1) and trees derived from strain:prophage gene
presence/absence profiles (results not shown). To distinguish clusters acquired via HGT from
those linearly inherited from a common ancestor, the genomes of 39 Gardnerella strains were
examined. Clusters were compared given the number of occurrences and the rate of evolution
of viral infection (Figure G.4). From this analysis, two groups can be observed. The phage gene
clusters in the top right quadrant appear to have evolved quickly relative to their prevalence
across strains and have likely been integrated into the Gardnerella genomes via HGT. In
contrast, the four clusters in the bottom right quadrant appear to have been acquired by
vertical transmission. Thus, we hypothesize that prophage integration has been occurring over
a long time scale.
Given this evidence of phage-host interactions and the results of recent studies
illuminating the vital contributions of viruses within other human microbioata 104,289,290, one can
surmise that phages are playing a significant role within both the bladder and reproductive
system communities.
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Figure G.4. Determining mechanisms of prophage gene acquisition
Colors correspond with the cluster colors in Figure 3. Dashed lines are the mean value for
each axis
As the bladder microbiota have only recently been discovered and subsequently
surveyed4,6,7,14,60,65,174,203, their microbiome remains largely uncharacterized. The presence of
the CRISPR/Cas system within the four Gardnerella strains sequenced here suggest phages are
present and prolific within the bladder. Given the existence of both Gardnerella and
Lactobacillus within both the female bladder4,6,7,65,203 and the vaginal17,303,304 microbiota, some
insight can be gleaned from the latter. It is likely that phages play an important role in bacterial
genome evolution and potentially disease in both niches. Evidence of phages has previously
been found within the vaginal microbiota158,305. The incidence of Lactobacilli phages may have
medical significance, as vaginal lactobacilli may be culled or repressed by phages within the
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microbiota leading to BV158,273. Increased prophage numbers within L. crispatus genomes from
the human vagina relative to avian isolates suggests high frequency of phage within the human
microbiota283. Phage-like sequences within both the bladder and vaginal bacterial
microbiomes–prophage sequences as well as CRISPR spacer sequences–often show little to no
homology to characterized sequenced phage species, insinuating that numerous genetically
diverse phages have yet to be discovered.
Conclusion
Comparison of four new bladder-associated Gardnerella genomes to genomes from the
reproductive system identifies strain-specific and lineage-specific genes, suggesting a
large Gardnerella pangenome may exist. There is, however, no distinct difference between
strains isolated from a particular niche. Of particular interest is the high incidence of prophages
within the Gardnerella genomes and the variability in the number per strain, as well as their
putative origin. While prior studies into the prophages of vaginal lactobacilli propose that phage
may play a significant role in community dynamics within the vagina, this proposal has yet to be
empirically tested. The Gardnerella genome analyses conducted here find evidence of ancient,
as well as contemporary, phage infection; the fact that isolates from the same individual vary in
their prophage gene sequences supports the latter. Bioinformatic inspections of prophage and
CRISPR spacer sequences find little to no correspondence with characterized phage sequences,
suggesting that Gardnerella-infecting phages exist, although they have yet to be isolated in the
laboratory. Nonetheless, evidence presented here suggests that phages play a role within the
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complex microbial communities of both the reproductive tract and the bladder, warranting
future exploration of their viromes. The continued isolation and empirical characterization
of Gardnerella species from the human microbiota is necessary to learn whether microbiomevirome interactions help to establish and maintain ones’ bladder health and, if so, how
perturbations of this equilibrium result in bladder pathologies.
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Supplemental Data

Figure G.S1. Phylogenetic tree based on the 16S rRNA gene
Notice that the 16S gene is not sufficient to discriminate between the different clades seen in
Figure G.2., suggesting horizontal transfer of the 16S gene.
Table G.S1. Presence/absence of gene functionality within the four bladder isolates. This table
was excluded from this document due to its large size.
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Figure G.S2. Phylogenetic analysis of VLY gene
(A) Amino acid sequence alignment of four bladder Gardnerella isolates and representatives
from other clades; clades are indicated to the left of each strain/isolate name. Mismatches
within the alignment are highlighted (red/blue text). (B) Maximum likelihood phylogenetic tree
for the VLY gene. Bran supports are indicated.

- 299 -

Table G.S2. Presence/absence of virulence genes within the four bladder isolates
Glycosyltransferases (biofilm formation
Gv
Gv
G
G
Function
18-4
23-12
26-12
30-4
X
X
A/G-specific adenine glycosylase (EC 3.2.2.-)
X
X
X
X
glycosyl transferase, group 1 family protein
X
Glycosyl transferase, group 2 family protein
X
X
X
X
Glycosyltransferase
X
X
Glycosyltransferase (EC 2.4.1.-)
X
X
X
X
Multimodular transpeptidase-transglycosylase (EC 2.4.1.129) (EC
3.4.-.-)
X
X
X
X
probable glycosyltransferase
X
X
X
X
putative glycosyl transferase domain protein
Fimbria/Pili
Gv
Gv
G
G 30- Function
18-4
23-12
26-12
4
X
X
Fimbrial subunit type 1 precursor
Type-1 fimbrial major subunit precursor (FIG00672113: hypothetical
X
X
protein)
X
X
X
X
TadE pilus assembly (FIG00672510: hypothetical protein)
Type IV prepillin peptidase (Permeases of the major facilitator
X
X
X
X
superfamily)
Type-II fimbrial major subunit precursor (COG4932: Predicted outer
X
X
X
membrane protein)
Antibiotic/Antimicrobial resistance
Gv
Gv
G
G 30- Function
18-4
23-12
26-12
4
Multidrug resistance ABC transporter ATP-binding and permease
X
protein
X
X
X
Similar to tetracycline resistance protein
X
X
X
X
ABC-type multidrug transport system, ATPase component
X
X
X
X
DedA protein
Protection function or evasion of immune response
Gv
Gv
G
G 30- Function
18-4
23-12
26-12
4
X
X
X
Alkyl hydroperoxide reductase protein C (EC 1.6.4.-)
X
X
X
X
Alkyl hydroperoxide reductase protein F (EC 1.6.4.-)
X
X
X
X
Rib-family surface protein (FIG00672534: hypothetical protein)
Cytotoxicity
Gv
Gv
G
G 30- Function
18-4
23-12
26-12
4
X
X
X
X
Vaginolysin (vly) (Thiol-activated cytolysin)
X
X
RNA binding methyltransferase FtsJ like
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Table G.S3. List of 35 genomes retrieved from NCBI for genome comparisons
Strain (All G.
vag)
00703Bmash
00703C2mash
00703Dmash
0288E
1400E
14019

14019 MetR
1500E

284V
315-A
3549624
409-05
41V
1-May
55152
6119V5
75712
AMD
HMP9231
JCM 11026
(ATCC 14018)
JCP7275
JCP7276
JCP7659
JCP7672
JCP7719
JCP8017A
JCP8017B
JCP8066
JCP8070
JCP8108

Isolation Site
Vagina
Vagina
Vagina
Endometrium
Endometrium
Vagina
Laboratory
culture of
ATCC strain
14019
Endometrium

Endometrium
Vagina
Vagina
Vagina
Vagina
Vagina
Endometrium
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina
Vagina

Disease State
BV+; STD (Herpes
simplex virus 2)
BV+; STD (Herpes
simplex virus 2)
BV-; STD (Herpes
simplex virus 2)
BV+
BV+
BV-

Size (Mb)

GC%

Accession

Genome
Status

Ref
275

1.56605

42.3

ADET01

Contig
275

1.54668

42.3

ADEU01

Contig
275

1.4908
1.70877
1.71633
1.66735

43.4
41.2
41.2
41.4

ADEV01
ADEN01
ADER01
NC_01464
4

Contig
Contig
Contig
Complete
Genome

275
275
280

279

BVBV+
BV+;
STD(Chlamydia
trachomatis)
Unknown
Unknown
BV+
BVBVBV+
BVBVBV+
BVBVBV+
BV Intermediate
BV+
BVBV+
BV+
BV+
BVBV+
BV+

1.6611
1.54824

41.3
43

LIYA01
ADES01

Contig
Contig

275
275

1.65084
1.65328
1.73225
1.61755
1.65937
1.67284
1.64319
1.4996
1.67297
1.60676
1.72652
1.66741
1.56223
1.65959
1.53594
1.60353
1.56315
1.60792
1.60225
1.52073
1.47925
1.66559

41.2
41.4
41.4
42
41.3
42
41.3
43.3
41.3
42.1
41.2
41.4
41
41
41.9
41.2
42
42.1
42
42.2
42.2
41.1

ADEL01
AFDI01
LFWD01
NC_01372
1
AEJE01
ADAN01
ADEQ01
ADEW01
ADEM01
ADAM01
NC_01745
6
NZ_AP012
332
ATJS01
ATJR01
ATJQ01
ATJP01
ATJO01
ATJN01
ATJM01
ATJL01
ATJK01
ATJJ01

Contig
Contig
Contig
Complete
Genome
Contig
Contig
Contig
Contig
Contig
Contig
Complete
Genome
Complete
Genome
Scaffold
Scaffold
Scaffold
Scaffold
Scaffold
Scaffold
Scaffold
Scaffold
Scaffold
Scaffold

278
280

182
275
275
275
182
280

277

276
276
276
276
276
276
276
276
276
276
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Strain (All G.
vag)
JCP8151A
JCP8151B
JCP8481A
JCP8481B

Isolation Site
Vagina
Vagina
Vagina
Vagina

Disease State
BV+
BV+
BV+
BV+

Size (Mb)
1.56045
1.55414
1.57288
1.57388

GC%
42
42.2
42.9
42.9

Accession
ATJI01
ATJH01
ATJG01
ATJF01

Genome
Status
Scaffold
Scaffold
Scaffold
Scaffold

Ref
276
276
276
276

Tables G.S4-G.S6 and File S1. were not included due to size. These can be found online at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115800/
Table G.S4. Core genes Identified for the 39 Gardnerella genomes examined.
Table G.S5. Prophage sequences, clusters and putative orgins within the 39 Gardnerella
genomes.
Table G.S6. PCR primers for amplification of Gv-specific carbohydrate metabolism coding
regions.
File G.S1. Fasta sequence for the individual prophage gene clusters.

APPENDIX H
THE CLINICAL URINE CULTURE: ENHANCED TECHNIQUES IMPROVE DETECTION OF CLINICALLY
RELEVENT MICROORGANISMS

Price TK, Dune T, Hilt EE, Thomas-White KJ, Kliethermes S, Brincat C, Brubaker L,
Wolfe AJ, Mueller ER, Schreckenberger P. The Clinical Urine Culture: Enhanced Techniques
Improve Detection of Clinically Relevant Microorganisms. J Clin Microbiol. 2016
May;54(5):1216-22. doi: 10.1128/JCM.00044-16. PMID: 26962083
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Overview of Appendix H
This paper was our team’s first attempt to match EQUC to standard urine culture (SUC)
results and patient symptoms of UTIs. We discovered that the operational definition of a UTI
was vague and insufficient. EQUC detected uropathogens in 84% of women who thought they
had a UTI, while SUC only detected uropathogens in 33% of those women This study provided
the groundwork for an upcoming EQUC versus SUC clinical trial that I have been highly involved
in planning. This trial will randomize each patient into either an EQUC or SUC culture protocol
to determine if EQUC provides improved patient outcomes, including increased resolution of
symptoms and decreased recurrence.
Abstract
Enhanced quantitative urine culture (EQUC) detects live microorganisms in the vast
majority of urine specimens reported as “no growth” by the standard urine culture protocol.
Here, we evaluated an expanded set of EQUC conditions (expanded-spectrum EQUC) to identify
an optimal version that provides a more complete description of uropathogens in women
experiencing urinary tract infection (UTI)-like symptoms. One hundred fifty adult urogynecology
patient-participants were characterized using a self-completed validated UTI symptom
assessment (UTISA) questionnaire and asked “Do you feel you have a UTI?” Women responding
negatively were recruited into the no-UTI cohort, while women responding affirmatively were
recruited into the UTI cohort; the latter cohort was reassessed with the UTISA questionnaire 3
to 7 days later. Baseline catheterized urine samples were plated using both standard urine
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culture and expanded-spectrum EQUC protocols: standard urine culture inoculated at 1μl onto
2 agars incubated aerobically; expanded-spectrum EQUC inoculated at three different volumes
of urine onto 7 combinations of agars and environments. Compared to expanded-spectrum
EQUC, standard urine culture missed 67% of uropathogens overall and 50% in participants with
severe urinary symptoms. Thirty-six percent of participants with missed uropathogens reported
no symptom resolution after treatment by standard urine culture results. Optimal detection of
uropathogens could be achieved using the following: 100 μl of urine plated onto blood (blood
agar plate [BAP]), colistin-nalidixic acid (CNA), and MacConkey agars in 5% CO2 for 48 h. This
streamlined EQUC protocol achieved 84% uropathogen detection relative to 33% detection by
standard urine culture. The streamlined EQUC protocol improves detection of uropathogens
that are likely relevant for symptomatic women, giving clinicians the opportunity to receive
additional information not currently reported using standard urine culture techniques.
Introduction
The diagnostic gold standard for clinically relevant urinary tract infection (UTI) continues
to be questioned for both clinical and research purposes. Since the 1950s, clinical practice has
relied on detecting ≥105CFU/ml of a known uropathogen using the standard clinical urine
culture protocol306. The standard urine culture was initially described for detection of patients
at risk for pyelonephritis36; interpretation has been generalized to diagnose lower urinary tract
infection despite studies reporting limitations of the ≥105-CFU/ml threshold37,39,207,209. While
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the clinical focus has centered on various cutoff thresholds, the basic uropathogen detection
method remains unchanged.
Given emerging evidence that documents the presence of urinary microbiota in many
adult women 4,6,7,14,60,65,93,174,203, it is clear that the mere presence of an organism should not
prompt antibiotic treatment. However, clinicians are likely to benefit from a more complete
report of organisms present within a symptomatic patient's urine. Recent evidence reports
bacteria in ∼90% of “no-growth” standard urine cultures7,203. We hypothesized that, in women
experiencing UTI-like symptoms, an improved culture protocol would provide a more complete
description of potentially treatable, clinically relevant uropathogens. This study evaluated
various combinations of urine volumes, media, atmospheric environments, and incubation
durations to determine conditions that optimally balance uropathogen detection with
feasibility.
Materials and Methods
Study Design and Patient Population.
Following institutional review board (IRB) approval, we enrolled 75 women who
reported UTI symptoms and 75 who did not based on their yes/no response to the question
“Do you feel you have a UTI?” Participants were seeking clinical care at Loyola University
Medical Center's Female Pelvic Medicine and Reconstructive Surgery center between June 2014
and August 2015.
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Participants gave verbal and written research consent and provided permission for
abstraction of their demographic and clinical information from the electronic medical record. At
baseline, urinary symptoms were characterized using a self-completed, validated UTI symptom
assessment (UTISA) questionnaire, completed by both cohorts307. Participants were
dichotomized based on their yes/no response to the question “Do you feel you have a UTI?”
Those who responded affirmatively (UTI cohort) completed the UTISA questionnaire again by
phone 3 to 7 days post enrollment and were queried about the magnitude of symptom
resolution, if any. All clinical treatment was individually based on physician assessment of
patient symptoms and standard urine culture results. Exclusion criteria included age of <18
years, pregnancy, catheterization (indwelling or intermittent), or insufficient English skills to
complete study measures.
Sample Collection and Analysis
Consistent with patient care clinical protocol, urine was collected via transurethral
catheter and then placed into two BD Vacutainer Plus C&S preservative tubes: one sent to the
clinical microbiology laboratory for diagnostic purposes and one sent to the researchers for
testing.
Table H.1 displays all culture protocols used by the clinical microbiology laboratory staff
and the researchers. The standard urine culture protocol used 1 μl of urine, spread
quantitatively (i.e., pinwheel streak) onto 5% sheep blood (blood agar plate [BAP]) and
MacConkey agars (BD BBL Prepared Plated Media; Cockeysville, MD) and incubated aerobically
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at 35°C for 24 h. The modified standard urine culture used the same agars and temperature but
changed the incubation condition to 5% CO2; if pinpoint growth was seen at 24 h, the agars
were held for another 24 h under the same conditions. Unrelated to this study, the clinical
microbiology laboratory adopted the modified standard urine culture for diagnosis during
patient recruitment for this study. Thus, diagnostic testing for patients 1 to 107 was the
standard urine culture, while the modified standard urine culture was used for patients 108 to
150. However, this change did not impact data presented in this study, as standard urine
culture data for patients 108 to 150 were obtained by analyzing the corresponding subset of
expanded enhanced quantitative urine culture (EQUC) conditions (i.e., 1 μl BAP and MacConkey
agars; aerobic, 35°C; 24 h).
The conditions of the original enhanced quantitative urine culture (EQUC) protocol were
described previously7. In this study, we expanded those conditions (i.e., expanded-spectrum
EQUC protocol), using three urine volumes (1 μl, 10 μl, and 100 μl) and additional plating
conditions (Table H.1). Each urine sample was spread quantitatively onto BAP, chocolate, and
colistin-nalidixic acid (CNA) agars (BD BBL Prepared Plated Media) and incubated in 5% CO2 at at
35°C for 48 h; BAP and MacConkey agars were incubated aerobically at 35°C for 48 h; two CDC
anaerobic 5% sheep blood (anaerobic BAP) agars (BD BBL Prepared Plated Media) were
incubated either in microaerophilic Campy gas mixture (5% O2, 10% CO2, 85% N) or
anaerobically at 35°C for 48 h.
Three sets of these conditions were used for each urine sample, each using one of the
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Table H.1. Summary of urine cultivation protocols for catheterized urine specimens
Protocol
Vol (µl) Medium or
Conditions
Incubation(s) Patient
of
media
(h) for
sample
urine
microbial
identifier a
identification
Standard
1
BAP,
Aerobic, 35°C
24
1-107
urine
MacConkey
culture
agar
Modified
1
BAP,
5% CO2, 35°C
24, 48
108-150
urine
MacConkey
culture
agar
Expanded1,10,
BAP,
Aerobic, 35°C
24, 48
1-150
spectrum
and
MacConkey
EQUC
100
agar
BAP,
5% CO2, 35°C
24, 48
chocolate
agar, CNA
agar
CDC
Anaerobic, 35°C
48
anaerobic
BAP
CDC
Miroaerophilic gas
48
anaerobic
mixture (5% O2, 10%
BAPb
CO2, 85% N), 35°C
Streamlined 100
BAP,
5% CO2, 35°C
48
1-150d
EQUC
MacConkey
agarc, CNA
agar
a

Refers to the patient samples on which the corresponding protocol assessed the urinary microbiota. For
diagnosis, the standard urine culture protocol was used on patient samples 1 to 107; the modified standard urine
culture was used on patient samples 108 to 150. For research, all patient samples were assessed by expandedspectrum EQUC.
b
The CDC anaerobic BAP microaerophilic gas mixture condition was used only for samples 10 to 150.
c
The MacConkey 5% CO2 condition was not part of the expanded-spectrum EQUC protocol.
d
The streamlined EQUC protocol was performed using a subgroup of agars/conditions from the expandedspectrum EQUC protocol; therefore, it was used on all patient samples.

urine volumes, for a total of 21 agars per sample. All agars were documented for growth (i.e.,
for morphologies and CFU per milliliter) at 24 and 48 h, except the two anaerobic BAP
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conditions. Each distinct colony morphology was subcultured at 48 h to obtain pure culture for
microbial identification.
Microbial identification was determined using a matrix-assisted laser desorption
ionization–time of flight mass spectrometer (MALDI-TOF MS; Bruker Daltonics, Billerica, MA) as
described previously7. Only clinically relevant microbes (i.e., known and emerging
uropathogens) were used to calculate uropathogen detection. These uropathogens were
selected based on previously published case reports of UTI.
UTISA Questionnaire.
This questionnaire asks the participant to rate the degree of severity and bother for
seven common UTI symptoms: frequency of urination, urgency of urination, incomplete bladder
emptying (urinary retention), pain or burning during urination (dysuria), lower abdominal
discomfort or pelvic pain/pressure, lower back pain, and blood in the urine (hematuria). Scores
for each symptom range from 0 to 3; a 0 corresponds to no symptom present, whereas a 3
indicates highest severity or bother. The seven symptoms can be clustered into four symptom
domains: urination regularity (frequency and urgency), problems with urination (incomplete
bladder emptying and pain or burning), pain associated with the UTI (abdominal or pelvic pain
and lower back pain), and blood in the urine307.
Statistical Analyses
Continuous variables were reported as means and standard deviations (SDs) or medians
and interquartile ranges (IQRs); categorical variables were reported as frequencies and
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percentages. Pearson chi-square tests (or Fisher's exact tests, when necessary) and 2sample t tests (or Wilcoxon rank sum tests, when appropriate) were used to compare
demographics and culture results (e.g., abundance and diversity) between cohorts. Measures of
alpha diversity (diversity within a population) were represented as Shannon diversity indices
and/or graphically by species accumulation curves (which plot accumulation of unique species
per group for each additional sample included). All statistical analyses were conducted using
SAS software v9.4 (SAS Institute, Cary, NC) or Systat software version 13.1 (Systat Software Inc.,
Chicago, IL).
Results
Participant Demographic and Symptoms.
Table H.2 describes demographics of the two cohorts (75 no-UTI and 75 UTI patients).
Most participants were white (81%) and overweight (mean body mass index [BMI] = 29.3
kg/m2). Most participants (92%, 138/150) reported at least one urinary symptom; as expected,
women in the UTI cohort had higher UTISA questionnaire scores.
Expanded-spectrum EQUC: urinary microbiota characteristics
Nearly all (93% [139/150]) catheterized urine samples grew bacterial colonies with at
least one combination of the expanded-spectrum EQUC protocol's conditions (Table H.1). The
no-UTI and UTI cohorts had similar proportions of cultivatable urine samples (89% [67/75]
versus 96% [72/75]; P = 0.12), similar numbers of total unique species detected per cohort (75
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versus 66), and similar median numbers of species detected per urine sample (3 [IQR = 1 to 5]
versus 2 [IQR = 1 to 4]; P = 0.12) (see Table S1 in the supplemental material).
However, the cohorts differed in organism diversity, genus-level composition, and species-level
composition. The no-UTI cohort had more diversity with greater species richness as depicted by
species accumulation curves (see Figure H.S1 in the supplemental material) and greater alpha
diversity as measured by the Shannon diversity index (no-UTI = 3.89 versus UTI = 3.49). The
genera Streptococcus (P = 0.003) and Gardnerella (P = 0.04) were more prevalent in the no-UTI
cohort, while the genus Escherichia (P < 0.001) was detected more often in the UTI cohort (see
Figure H.S2). Five species, namely, Gardnerella vaginalis (P = 0.4), Streptococcus
mitis/oralis/pneumoniae (P = 0.01), Streptococcus parasanguinis (P = 0.02), Streptococcus
salivarius (P = 0.05), and Streptococcus sanguinis (P = 0.01), were detected more often in the
no-UTI cohort; in contrast, the species Escherichia coli (P < 0.001) was more prevalent in the UTI
cohort (see Figure H.S3).
The genera Streptococcus (P = 0.003) and Gardnerella (P = 0.04) were more prevalent in
the no-UTI cohort, while the genus Escherichia (P < 0.001) was detected more often in the UTI
cohort (see Figure H.S2). Five species, namely, Gardnerella vaginalis (P = 0.4), Streptococcus
mitis/oralis/pneumoniae (P = 0.01), Streptococcus parasanguinis (P = 0.02), Streptococcus
salivarius (P = 0.05), and Streptococcus sanguinis (P = 0.01), were detected more often in the
no-UTI cohort; in contrast, the species Escherichia coli (P < 0.001) was more prevalent in the UTI
cohort (see Figure H.S3).
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Table H.2. Demographic characteristics and symptoms
Clinical variable

Entire cohort
(n=150)
62.3 (14.9)
29.3 (6.3)

No-UTI cohort
(n=75)
60.6 (12.3)
28.8 (5.9)

UTI cohort
(n=75)
64.0 (17.1)
29.9 (6.6)

p-valued

Age (yr), mean (SD)
0.16a
2
BMI (kg/m ), mean (SD)
0.27 a
Race/ethnicity, no. (%)
White
121 (81)
59 (79)
62 (83)
Hispanic
15 (10)
9 (12)
6 (8)
Black
9 (6)
5 (7)
4 (5)
0.90c
Asian
4 (3)
2 (3)
2 (3)
Other
1 (1)
0 (0)
0 (0)
No. of vaginal deliveries,
2 (0-11)
2 (0-6)
2 (0-11)
0.80b
median (IQR)
Sexually active, no. (%)
58 (39)
37 (49)
21 (28)
0.01
Previous antibiotic treatment, no. (%)
45 (30)
20 (27)
25 (33)
0.37
Current anticholinergic treatment, no. (%)
26 (17)
9 (12)
17 (23)
0.08
Type of anticholinergic used, no. (%)
Oxybutynin
9 (6)
3 (4)
6 (8)
Solifenacin
8 (5)
3 (4)
5 (7)
Fesoterodine
4 (3)
2 (3)
2 (3)
0.75c
Tolterodine
2 (1)
1 (1)
1 (1)
Oxybutynin patch
1 (1)
0 (0)
1 (1)
Trospium chloride
1 (1)
0 (0)
1 (1)
Mirabegron (Myrbetriq)
1 (1)
0 (0)
1 (1)
Previous vaginal estrogen use, no. (%)
32 (21)
11 (15)
21 (28)
0.05
Current vaginal estrogen use, no. (%)
29 (19)
10 (13)
19 (25)
0.06
Prior urogynecologic surgery, no. (%)
40 (27)
13 (17)
27 (36)
0.01
Symptoms of incontinence,
no. (%)
Stress urinary incontinence
17 (11)
10 (13)
7 (9)
0.44
Urgency urinary incontinence
26 (17)
11 (15)
15 (20)
0.39
Mixed urinary incontinence
42 (28)
27 (36)
15 (20)
0.03
Urgency-frequency syndrome,
18 (12)
9 (12)
9 (12)
0.99
no. (%)
Myofascial pain, no. (%)
55 (37)
20 (27)
35 (47)
0.01
Painful bladder syndrome, pelvic pain, and
4 (3)
0 (0)
4 (5)
0.06c
dyspareunia, no. (%)
UTISA score, mean (SD)e
Urination regularity
6.6 (4.3)
5.4 (4.3)
7.9 (3.9)
<0.001a
Problems with urination
3.4 (3.6)
2.0 (2.5)
5.4 (3.7)
<0.001a
Pain associated with UTI
3.2 (3.6)
2.1 (3.1)
4.3 (3.8)
<0.001a
Blood in the urine
0.2 (0.8)
0.1 (0.4)
0.4 (1.1)
0.08a
a
b
c
Independent t test. Wilcoxon rank sum test. Fisher's exact test.
d
Chi-square test used unless otherwise indicated. Boldface indicates P values that are significant at ≤0.05.
e
UTISA scores for urinary regularity, problems with urination, and pain associated with UTI range from 0 to 12.
UTISA scores for blood in the urine range from 0 to 6.
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Uropathogen Detection.
We next modeled our evaluation to uropathogen detection by the expanded-spectrum
EQUC protocol with regard to the following parameters: detection compared to standard urine
culture, detection with different urine volumes, and detection using different plating
conditions. With these findings, we then identified an optimal subset of expanded-spectrum
EQUC conditions for improved detection of uropathogens, which we call the streamlined EQUC
protocol.
Expanded-Spectrum EQUC Versus Standard Urine Culture.
The expanded-spectrum EQUC protocol detected a total of 182 uropathogens in all the
catheterized urine samples, 110 uropathogens in the UTI cohort urine samples, and 72
uropathogens in in the non-UTI cohort urine samples. Whereas the expanded-spectrum EQUC
did not miss any uropathogen detected by standard urine culture, the standard urine culture
protocol detected 33% (60/182) of all detected uropathogens, 50% (55/110) of those detected
in the UTI cohort, and only 7% (5/72) of those detected in the non-UTI cohort.
The expanded-spectrum EQUC protocol detected all uropathogens at a higher average
CFU per milliliter in the UTI cohort than in the no-UTI cohort (Figure H.1). This protocol
detected E. coli in a total of 50 samples obtained from both cohorts; of these, standard urine
culture detected E. coli in 88% (44/50). From the UTI cohort alone, expanded-spectrum EQUC
detected E. coli in 43 samples; of these, standard urine culture detected E. coli in 91% (39/43).
In contrast, standard urine culture detected a strikingly low fraction (12% [16/132]) of the non-
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Figure H.1. Average CFU per milliliter of uropathogens between the UTI and no-UTI cohorts
Depicted are the average CFU per milliliter with which the various uropathogens were
cultured for both cohorts: UTI (blue bars) and no-UTI (red bars). Average CFU of Klebsiella
pneumoniae (P = 0.04) and Streptococcus agalactiae (P = 0.02) are significantly higher in the
UTI cohort (*). Several uropathogens had substantially lower average CFU-per-milliliter
values in the no-UTI cohort than in the UTI cohort: Aerococcus urinae (P = 0.12), Enterococcus
faecalis (P = 0.09), Escherichia coli (P = 0.08), Staphylococcus aureus (P = 0.06), and
Streptococcus anginosus (P = 0.08). Independent t test (*, P < 0.05). Black bars depict
common UTI thresholds (≥105 CFU/ml and ≥103 CFU/ml).

- 315 -

E. coli uropathogens detected in the two cohorts by the expanded-spectrum EQUC protocol.
This percentage was only slightly better in the UTI cohort alone, where standard urine culture
detected 24% (16/67) of the non-E. coli uropathogens detected by the expanded-spectrum
EQUC protocol. Therefore, standard urine culture's capacity to detect E. coli dramatically
skewed its overall uropathogen detection value.
Table H.3. Optimal detection of specific uropathogens by the expanded-spectrum EQUC
protocol a.

a

Listed are the uropathogens and the number of times that each was cultured under each expanded-spectrum
EQUC plating condition. The condition(s) that best detected each uropathogen is shaded.
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Expanded-Spectrum EQUC: Urine Volumes.
Uropathogen detection differed greatly based on expanded-spectrum EQUC urine
volumes: for 100 μl, 96% detection (174/182); for 10 μl, 65% detection (118/182); and for 1 μl,
52% detection (95/182) versus standard urine culture (33% [60/182]). Some uropathogens
were detected equally by all volumes (e.g., E. coli and Pseudomonas aeruginosa); others most
often required 100 μl for detection (e.g., Aerococcus urinae, Alloscardovia
omnicolens, Enterococcus faecalis, and Streptococcus anginosus) (see Figure H.S4).
Expanded-Spectrum EQUC: Plating Conditions.
Table H.3 displays uropathogens and the number of times that each was cultured under
the various expanded-spectrum EQUC plating conditions. After 48 h incubation, CDC anaerobic
BAP incubated anaerobically detected the most uropathogens (63% [115/182]), followed by
BAP in 5% CO2 (62% [112/182]), CDC anaerobic BAP incubated microaerophilically (54%
[98/182]), chocolate agar in 5% CO2 (53% [96/182]), BAP incubated aerobically (52% [94/182]),
CNA agar in 5% CO2 (43% [79/182]), and MacConkey agar incubated aerobically (34% [62/182]).
Although the CNA agar condition detected fewer uropathogens, it ideally detected Grampositive uropathogens when Gram-negative bacteria overwhelmed other agars. For example, of
the 47 samples where a Gram-negative uropathogen was present at ≥50,000 CFU/ml, the CNA
agar condition detected 27 underlying Gram-positive uropathogens, all of which were missed
by standard urine culture (see Table S2A in the supplemental material). Conversely, of the
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seven samples where a Gram-positive uropathogen was present at ≥50,000 CFU/ml, the
MacConkey condition detected two underlying Gram-negative uropathogens (see Table H.S2B).
Table H.4. Detection of uropathogens in UTI cohort without symptom improvement
Postenrollment
questionnaire
response
(sample ID)
Same (145)
Same (048)
Same (134)
Same (033)
Same (060)
Same (109)
Same (122)
Same (135)
Same (136)
Worse (082)
Same (140)
Same (116)
Worse (128)
Same (126)
Same (121)
Same (029)
Same (139)
Same (052)
Same (067)
Worse (025)
Worse (112)
Worse (142)
Same (084)
Same (108)
a

Antibiotic
prescribed
SMZ-TMPb
Nitrofurantoin
SMZ-TMPb
Ciprofloxacin
Nitrofurantoin
Nitrofurantoin
Ciprofloxacin
Nitrofurantoin
Nitrofurantoin
Nitrofurantoin

Uropathogen(s) detected by protocol(s):
Standard urine
culture and
Expanded-spectrum EQUC only d
expanded
spectrum EQUC
E. coli
Strep. anginosus
E. coli
Strep. anginosus
E. coli
A. urinae, C. riegelii
Kleb. pneumoniae
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
Staph. lugdunensis
E. coli
E. coli
Lactobacillus
Staph. lugdunensis, Strep. anginosus
speciesc
P. mirabilis
A. urinae, Kleb. Pneumoniae
Allo. omnicolens, O. urethralis, M. morganii
Strep. anginosus
Strep. anginosus
Candida albicans
Strep. agalactiae, Strep. anginosus
E. coli

Uropathogens detected and missed by the standard urine culture in urine samples obtained by catheter from the
UTI cohort patients who reported feeling the same or worse for the postenrollment questionnaire. Antibiotics
were prescribed based on the reporting of the standard urine culture results.
b
SMZ-TMP, sulfamethoxazole-trimethoprim.
c
Lactobacillus species is not considered a uropathogen, but it was detected at >100,000 CFU/ml by standard urine
culture.
d
All of the uropathogens detected by the expanded-spectrum EQUC protocol would have been detected using the
streamlined EQUC protocol.
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Streamlined EQUC Protocol.
One hundred microliters of urine plated on a combination of BAP and CNA agars in 5%
CO2 and MacConkey agar under aerobic conditions would have detected 84% (152/182) of all
uropathogens detected by the expanded-spectrum EQUC protocol. This is vastly superior to the
33% (60/182) uropathogen detection by standard urine culture. In the UTI cohort alone, the
streamlined EQUC protocol (Table H.1) would have detected 91% (100/110) of uropathogens,
compared to only 52% (57/110) by standard urine culture.
Symptom Resolution.
Seventy-nine percent (59/75) of the participants in the UTI cohort completed the followup UTISA questionnaire. Following clinically selected treatment based on standard urine culture
(or modified standard urine culture), 59% (35/59) of participants reported symptom
improvement, while 41% (24/59) reported no improvement (same or worse) (Table H.4). Half
(12/24) of the 24 participants who did not improve had at least one uropathogen detected only
by the expanded-spectrum EQUC protocol, and 13 (54%) had microorganisms of unknown
pathogenicity, which were detected only by the expanded-spectrum EQUC protocol (see Table
S3 in the supplemental material). Importantly, all of these missed uropathogens would have
also been detected using the streamlined EQUC protocol. Ten of the 24 patients who did not
improve had been clinically treated with antibiotics based on the finding of a standard urine
culture-detected uropathogen. However, in 3 (30%) of these 10 patients, the expanded-
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spectrum EQUC (as well as streamlined EQUC) detected an additional Gram-positive
uropathogen (Aerococcus urinae, Corynebacterium riegelii, or Streptococcus anginosus).
Discussion
Accurate diagnosis for women with UTI symptoms is critical, both to target appropriate
therapy and to limit inappropriate antibiotic use. Our study demonstrates deficiencies in the
standard urine culture protocol that limit potentially important information that should be
provided to clinicians. Our findings suggest that improved detection of clinically relevant urinary
microbes can be achieved in all diagnostic clinical laboratories using the following conditions: a
100-μl urine sample obtained by transurethral catheter plated onto BAP, CNA, and MacConkey
agars, with incubation of all agars in 5% CO2 for 48 h. While incubation of MacConkey agar in
5% CO2 may not improve Gram-negative bacillus recovery, we recommend that all agars be
incubated in 5% CO2 for the convenience of using a single incubator. All detected uropathogens
will grow under the conditions described in the streamlined EQUC protocol.
Our findings support the use of the streamlined EQUC protocol to more fully describe
uropathogens. We also recommend that 1μl of the catheterized urine be plated onto BAP and
MacConkey agars and incubated in 5% CO2 for 24 h with an option to incubate for 48 h
(modified standard urine culture). The streamlined EQUC protocol provides the most thorough
detection of uropathogens, while the modified standard urine culture ensures accurate colony
count assessment and is beneficial for species detection of underlying uropathogens when
bacterial colony counts of a predominant uropathogen exceed 10 5 CFU/ml. The need for
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modified standard urine culture inclusion is apparent from the observation that the expandedspectrum EQUC (and the streamlined EQUC) protocols were not 100% sensitive. In the
expanded-spectrum EQUC protocol, the use of 100 μl urine detected the most microbes and
the most uropathogens. However, a small number of uropathogens were detected only with
the use of a smaller urine volume (10 μl). This apparent paradox likely results from microbial
overcrowding in samples containing high numbers of CFU; in these circumstances, 100 μl was
not ideal for distinguishing morphologies. While addition of selective media (i.e., CNA and
MacConkey agars) helped detect underlying uropathogens, some samples contained both
Gram-positive and Gram-negative bacteria at high CFU numbers, likely making the 100-μl
expanded-spectrum EQUC volume less efficient.
Streamlined EQUC would provide more information to clinicians who are considering
the clinical need for uropathogen(s) treatment; many of these are currently missed by the
standard urine culture protocol. Until better information is available concerning the
relationship between clinically important UTI and CFU per milliliter, we recommend that these
testing conditions (i.e., streamlined EQUC) be used for patients with recurrent UTIs or patients
with clear UTI-like symptoms despite a negative standard urine culture result. Nonetheless, it is
clear that treatment based on standard urine culture results limits diagnostic information that
may be useful for symptom resolution. This study did not assess symptom relief in patients
whose uropathogens were detected only with the streamlined EQUC protocol. Such studies are
clearly needed.
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Compared to the expanded-spectrum EQUC, the standard urine culture missed 67%
(122/182) of all detected uropathogens and 88% (116/132) of non-E. coli uropathogens.
Detection of uropathogens by the standard urine culture was slightly better for the UTI cohort
alone (50% total missed [55/110]; 76% non-E. coli missed [51/67]). This improvement may
result from the higher average uropathogen CFU per milliliter in the UTI cohort (Figure H.1),
making detection by standard urine culture more likely. The data in Table H.1 also reveal that
the use of one threshold for UTI diagnosis is likely incorrect. Use of the ≥105-CFU/ml threshold
would result in untreated uropathogens in the UTI cohort (Figure H.1). Lowering the threshold
to ≥103 CFU/ml, however, creates other concerns. While use of the ≥103-CFU/ml threshold
would leave fewer uropathogens in the UTI cohort untreated, it would detect some
uropathogens in the no-UTI cohort. Since individuals in the no-UTI cohort presumably do not
have an infection (i.e., no/low severity of urinary symptoms), it is unlikely that they would
benefit from antibiotic use. This creates a problem in diagnosis and treatment of UTIs and is
likely the reason for the current ambiguity surrounding urine cultures. From these data, we
suggest the possibility that, for UTI diagnosis, each uropathogen may have its own unique
threshold (e.g., ≥102 CFU/ml for Aerococcus urinae, ≥103 CFU/ml for Streptococcus agalactiae,
and ≥104 CFU/ml for Klebsiella pneumoniae).
Our findings in a selected, health care-seeking population of women should be
generalized with caution to community-dwelling women who may or may not have similar
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microbial profiles in health or during UTI. Microbial characterization of women longitudinally
may provide additional context for interpretation of standard and streamlined culture results.
It appears that simple changes to the commonly performed standard urine culture
protocol have the capacity to provide potentially useful clinical information. Importantly, the
urine must be collected by catheter, as we have previously shown that vulvovaginal
contamination renders clean-catch voided specimens obsolete4. At this time, we suggest that
the recommended culture conditions (i.e., streamlined EQUC) be considered both as a
supplemental test when individuals with UTI-like symptoms have “no growth” via standard
urine culture and for use with individuals with persistent UTI-like symptoms (i.e., recurrent UTI).

- 323 -

Supplementary Data

Figure H.S1. Species accumulation curves of UTI and No-UTI Cohorts
Species accumulation data depicts the number of unique species cultured (using the Expanded
Spectrum EQUC) with each new patient sampled. When the curve plateaus, it indicates that the
community is fully sampled and few, if any, new species will be identified. Therefore, it also
measures the overall diversity of the population in terms of species richness. The UTI cohort
(blue line) is comprised of 66 species. The No-UTI cohort (red line) is comprised of 75 species.
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Figure H.S2. Frequency of detection of genera in the UTI and No-UTI cohorts
Depicts the frequency (i.e., percentage) of detection (using the Expanded Spectrum EQUC) of
the urine samples containing each genus between the UTI (blue bars) and No-UTI (red bars)
cohorts. Streptococcus (p=0.003), Gardnerella (p=0.04), and Escherichia (p<0.001).
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Figure H.S3. Species significantly different between the UTI and No-UTI cohorts
Depicts the frequency (i.e., percentage) of detection (using the Expanded Spectrum EQUC) of
the species that are statistically associated with either the UTI (blue bars) and No-UTI (red bars)
cohorts. Gardnerella vaginalis (p=0.04), Streptococcus mitis/oralis/pneumoniae (p=0.01),
Streptococcus parasanguinis (p=0.02), Streptococcus salivarius (p=0.05) and Streptococcus
sanguinis (p=0.01) are associated with the No-UTI cohort. Escherichia coli (p<0.001) is
associated with the UTI cohort. Pearson chi-square and Fisher’s exact test (* p<0,05; **p<0.01,
*** p<0.001). The species S. mitis, S. oralis, and S. pneumoniae were grouped together because
they cannot accurately be distinguished using MALDI-TOF MS.
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Figure H.S4. Detection of Uropathogens by each expanded spectrum EQUC urine volume
Depicts the total number of times each uropathogen was identified by each of the urine
volumes (1 µL, 10 µL, 100 µL) in the Expanded Spectrum EQUC protocol as well as the Standard
Urine Culture protocol: Standard Urine Culture (blue bars), 1µL Expanded Spectrum EQUC
(purple bars), 10 µL Expanded Spectrum EQUC (green bars), and 100 µL Expanded Spectrum
EQUC (red bars).
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Table H.S1. Urinary microbiota characteristics

Cultivatable Urine Samples
Total number of unique species
Median number of unique specie per isolate, mdn (IQR)
Shannon Diversity index
IQR = Interquartile Range. Mdn = median
* Chi-Square Test
**Wilcoxon Rank Sum Test

UTI
(n=75)
72 (96%)
66
2 (1-4)
3.49

No-UTI
(n=75)
6 (89%)
75
3 (1-5)
3.89

p-value
0.12*
0.12 **

APPENDIX I
MICROORGANISMS IDENTIFIED IN THE MATERNAL BLADDER:
DISCOVERY OF THE MATERNAL URINARY MICROBIOME
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Overview of Appendix I
This paper was the first characterization of the bladder microbiome during pregnancy,
or the maternal urinary microbiome (MUM). The patient population in all our work thus far has
been in older women (peri- or post-menopausal). Characterizing women during pregnancy was
our first opportunity to look at the bladder in younger and primarily healthy women. Because of
the small sample size, we were not able to find any significant associations between the
microbiome and pre-term birth (for those data see the Addendum). However, we did show that
standard culture was insufficient to detect uropathogens in these women.
This study was also the impetus for our methods paper. These samples were collected in
the Labor and Delivery Department at Loyola, not the Urogynecology Department. The
differences in the facilities and staff led to some unforeseen issues; in particular, we realized
that samples were sometimes collected in the middle of the night and thus sat at room
temperature until the morning, resulting in bacterial growth. Due to this growth, the
sequencing data and culture data do not match as well as in other studies. We decided to
follow up on this discrepancy by testing all our standard procedures. The data from these tests
will be put together into a methods paper.
Abstract
Objective. To characterize the bladder microbiota in pregnancy
Methods. A prospective observational study of 51 pregnant women, admitted to a
tertiary care hospital, who underwent straight catheterization urine collection or transurethral
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foley catheter placement. 16S rRNA gene sequencing and enhanced quantitative urine culture
(EQUC) assessed the maternal bladder microbiota with comparisons made to standard urine
culture results.
Results. EQUC and 16S rRNA gene sequencing detected bacteria in the majority of
participants. Lactobacillus and Gardnerella were the most commonly detected microbes. In
contrast, standard urine culture had a 100% false negative rate and failed to detect several
known or emerging urinary pathogens.
Conclusions. There are live bacteria in the bladders of most pregnant women. This
challenges the definition of asymptomatic bacteriuria.
Introduction
Asymptomatic bacteriuria (ASB) is defined as the presence of a uropathogen in the
absence of physical symptoms 308. ASB strains have long been thought to be non-pathogenic
variants of pathogenic species, especially Escherichia coli or Streptococcus agalactiae (also
known as Group B Strep). However, in certain populations, such as the general obstetric
population, untreated ASB is associated with subsequent urinary tract infection (UTI). This
includes pyelonephritis 309, which is associated with adverse pregnancy outcomes, maternal
sepsis and preterm labor 309,310. Thus, routine screening and treatment of ASB is recommended
during pregnancy 311,312.
However the current approach to ASB screening is limited by the assumption that the
female bladder naturally exists in a sterile state 313,314; thus, the presence of bacteria in urine is

- 331 -

currently considered abnormal. However, several recent studies have revealed the existence of
bacterial communities in the bladders of non-pregnant peri-menopausal women8,9,162,202,315.
One of the earliest studies compared multiple urine collection methods4, including suprapubic
aspiration (SPA), which bypasses vulvo-vaginal contamination. This study noted that the
bacterial DNA (microbiome) detected in urine obtained by transurethral catheter closely
resembled those obtained by SPA, and diverged substantially from the microbiomes in vaginal
swabs and mid-stream voided urine. Thus, transurethral catheterized urine specimens
accurately sample the bladder and is thus the appropriate urine collection method for
investigation of the bacteria present in the urinary bladders of women (the female bladder
microbiota) 4.
To determine whether bacterial DNA detected by 16S rRNA gene sequencing originated
from live bacteria within the bladder, our group developed an enhanced quantitative urine
culture (EQUC) protocol that detects bacteria in the vast majority of catheterized urine samples
deemed “no growth” by standard clinical microbiology urine culture methods 3,7. Thus,
standard urine culture does not detect the presence of a large number of bacterial species,
including most uropathogens 43.
Given compelling enhanced culture and DNA sequence evidence that the female urinary
bladder of peri-menopausal women is not sterile, we questioned the sterility of urine obtained
from the bladders of younger pregnant women. Specifically, we used the complementary
approaches of EQUC and 16S rRNA gene sequencing to determine if urine obtained by
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transurethral catheterization contains microbiota and then compared those results to a
standard clinical microbiology urine culture protocol. We found that the standard culture
protocol typically used to diagnose ASB misses many diverse microbes, including known and
emerging uropathogens. We conclude that bladder urine of most pregnant women is not
sterile.
Materials and Methods
Participant Recruitment.
Following Loyola Institutional Review Board approval, we prospectively invited pregnant
patients presenting to labor and delivery to participate in the study if they were ≥18 years of
age, proficient in English and undergoing straight catheterization urine collection or placement
of a transurethral foley catheter as part of their clinical care. We excluded patients who had
used antibiotics within the last 4 weeks for any reason. Participants gave written informed
research consent. At enrollment, participants provided demographic information, UTI history,
medication (including antibiotic) use, obstetric history, tobacco use and other comorbidities. As
part of standard obstetric care, this cohort had undergone screening for ASB. For all patients,
we recorded gestational age at time of sample collection
Sample Collection and Urine Culture.
Urine was collected aseptically via the transurethral catheter into a sterile collection
cup. As per clinical protocol, a portion of the urine sample was placed into a BD Vacutainer Plus
C&S preservative tube and sent to the research lab for standard urine culture and EQUC
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assessment. Due to the lack of appropriate refrigeration facilities in the clinic, the remainder of
the urine was stored at room temperature for 1-8 hours before being processed and stored
down at -80°C with 10% AssayAssure (Sierra Molecular; Incline Village, NV) for subsequent
sequencing.
Within 24 hours of urine collection, both standard and enhanced (EQUC) urine cultures
were set up. Both protocols are provided in Table H.S1 and have been described previously 7.
The detection limit for the standard protocol was 1000 colony forming units per milliliter
(CFU/ml); for EQUC, it was 10 CFU/ml. If EQUC was unable to detect bacteria, the sample was
considered to be below the detection threshold. For samples with bacteria detected, alpha
diversities were measured, the Bray-Curtis distance calculated 196, and the complete method
was used for hierarchical clustering using RStudio 115. The resulting dendrogram was divided
into fourteen clusters (termed urotypes) that were named on the basis of the predominant
organism. When a cluster had no predominant organism, it was called a “diverse” urotype.
16S rRNA Gene Sequencing.
DNA isolation protocols and 16S rRNA gene sequence analysis have been described
previously 3. Briefly, total DNA was extracted from 1ml of catheterized urine under a laminar
flow hood, using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). The 4 th
variable region was amplified using Illumina adapted universal primers (515F and 806R).
Extraction negative controls (no urine) and PCR negative controls (no template) were included
to assess contribution of extraneous DNA from reagents. Final PCR products were purified from
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unincorporated nucleotides and primers using Agencourt AMPure XP-PCR magnetic beads
(Beckman Coulter). Purified samples were normalized to equal DNA concentration, as
determined by the Bioanalyzer (Aligent, Santa Clara, CA). The sample library and PhiX
sequencing control library (Illumina) were denatured and added to the MiSeq 2x250 bp
sequencing reagent cartridge, according to manufacturer’s instructions (Illumina).
Sequence Processing.
Each specimen was sequenced in duplicate. MiSeq sequence reads were processed
following mothur’s MiSeq SOP at http://www.mothur.org/wiki/MiSeq_SOP 194, with minor
modifications. Mothur software (version 1.34.4) 167 was used to process raw reads and, using
default mothur parameters, to remove low quality and chimeric sequences. Taxonomic
classification from phylum to genus level of sequence reads was performed by the RDP
Classifier (version 2.5) 195], using the default 0.8 confidence threshold. To determine if each
sample is accurate and reliable, all samples must have greater than 2000 reads, be distinct from
the corresponding extraction control, and be comparable to its replicate.
Using genus-level classification, from a single replica, alpha diversities were measured,
the Bray-Curtis distance calculated 196, and the complete method was used for hierarchical
clustering using RStudio 115. The resulting dendrogram was divided into six clusters, termed
urotypes, named on the basis of the predominant organism. When a cluster had no
predominant organism, it was termed the “diverse” urotype.
Statistical Analysis.
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For cultured organisms, abundance was measured using total colony forming units per
millileter (CFU/ml). Continuous variables are reported as means and standard deviations (SD) or
medians and interquartile ranges (IQR). Post-hoc pairwise comparisons were made using
Wilcoxon Rank sum tests for continuous variables with significant overall p-values using
statistical software, SAS software v9.4 (SAS Institute, Cary, NC).
Results
All 51 recruited participants were included in the study analysis. Table I.1 displays the
cohort’s demographic characteristics. The average age was 30 years, and most (68%)
participants were obese. The average gestational age at sample collection was 36 weeks, the
majority (74%) were enrolled within 2 days of delivery, and seventeen (33%) subjects delivered
prior to 37 weeks.
Sequencing Results.
A bladder microbiome was detected in 68.6% (35/51) of participants by 16S rRNA
sequencing, which resulted in a total of 3,605,762 reads from 7 phyla, 14 classes, 18 orders, 28
families, and 31 genera. Figure I.1 displays the maternal bladder microbiome profile for each
participant grouped by predominant organism. The majority of sequenced individuals were of
the Lactobacillus-predominant urotype (60%, 21/35), followed by Gardnerella (25.7%, 9/35)
(Table I.2). A small number of individuals were dominated by the genus Staphylococcus (N=1),
the order Bacilliales (which includes the genus Enterococcus, N=2), or the family
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Enterobacteriaceae (which contains the species Escherichia coli, N=1). Only one patient had no
predominant organism, thereby that individual’s urotype was considered to be “diverse.”
Table I.1. Patient Demographics for the Maternal Urinary Microbiome Project
N=51
Mean Maternal age (years)
Nulliparity (%)
Race/Ethnicity
Caucasian
African-American
Hispanic
Asian
BMI (kg/m2)
Normal (18.5 – 24.9)
Overweight (25 – 29.9)
Obese (30 – 34.5)
Morbidly Obese (>35)
Mean BMI (range)
Education
High School
Some College
College
Graduate
Gestational age at delivery (weeks)
Gestational age at collection (weeks)
GU Infection/Colonization
GBS positive
UTI during this pregnancy
History of any UTI
Medical Comorbidities
Gestational Diabetes Mellitus
Diabetes Mellitus
Gestational Hypertension
Chronic Hypertension
Renal Disease

30 (19-41)
49.0%
N (%)
16 (31.3%)
17 (33.3%)
14 (27.5%)
4 (7.8%)
5 (9.8%)
11 (21.6%)
19 (37.3%)
16 (31.3%)
34.3 (22.0-58.4)
11 (21.6%)
19 (37.3%)
11 (21.6%)
10 (19.6%)
37 (19w2d - 41w2d)
36 (19w0d – 41w1d)
6 (11.8%)
4 (7.8%)
12 (23.5%)
3 (5.9%)
2 (3.9%)
2 (3.9%)
6 (11.8%)
2 (3.9%)
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Table I.2. Frequency of profiles using either sequence or EQUC data
Frequency of Sequencing Profiles
BDT a
16/51 (31.4%)
Sequenced
35/51 (68.6%)
Lactobacillus
21/35 (60%)
Gardnerella
9/35 (25.7%)
Bacilli/Enterococcus
2/35 (5.7%)
Enterobacteriaceae
1/35 (2.9%)
Staphylococcus
1/35 (2.9%)
Diverse b

a

1/35 (2.9%)

Frequency of Culture Profiles
BDT a
17/51 (33.3%)
Cultured
34/51 (66.7%)
G. vaginalis
7/34 (22.6%)
L. iners
5/34 (14.3%)
L. crispatus
5/34 (14.3%)
E. faecalis
3/34 (8.8%)
L. gasseri
3/34 (8.8%)
L. jensenii
3/34 (2.9%)
S. epidermidis 2/34 (5.9%)
A. schaalii
1/34 (2.9%)
C. coyleae
1/34 (2.9%)
C. glabrata
1/34 (2.9%)
Diverse
1/34 (2.9%)
L. johnsonii
1/34 (2.9%)
S. anginosus
1/34 (2.9%)

BDT, below detection threshold
A diverse profile indicates a diverse community lacking a single predominant organism

b

The microbiome of participants with a Lactobacillus urotype was significantly less
diverse than Gardnerella urotype subjects as determined by the Shannon Diversity Index and
Inverse Simpson Index, which measure both richness and evenness (Table I.3). The
microbiomes of participants with a Gardnerella urotype were more even, as measured by the
Peilou Index. This is visible in the Gardnerella urotype profiles, which show a greater presence
of other genera, including Lactobacillus, Ureaplasma, Aerococcus, Atopobium and/or
Lachnospiraceae (Figure I.1A).
Enhanced Culture Results.
EQUC detected live microbes in the majority of participants (66.7%, 34/51), similar to
that proportion of samples that were positive by sequencing (Table H.2, Figure H.1B). At the
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Figure I.1. Sequencing and Culture profiles of the Maternal Urinary Microbiome.
The sequencing profiles (A) and culture profiles (B) are shown. Each bar represents a urine
sample from one patient. On the y-axis is the relative abundance, or percent of classified
sequencing reads (A) or colony forming units per ml (B) per individual. Each bar or taxon is
color coded by family or genus (A) or species (B). All samples were phylogenetically
compared to each other using Bray-Curtis similarity, resulting in a phylogenetic tree or
dendrograms. The length of each branch of the dendrograms represents the similarity
between samples. We divided the samples into clades by identifying a profile threshold. The
clades group together by dominant organism; these groups are termed “sequence profiles”
(A) or “culture profiles” (B), which are listed underneath. The sequencing dataset (A) divided
into 6 profiles, Lactobacillus, Enterobacteriaceae, Bacilli, Gardnerella, Staphylococcus, and a
mixed profile termed ‘Diverse’. The culture profile (B) divided into 13 profiles, S.
epidermidis, L. gasseri, S. anginosus, L. jensenii, C. glabrata, E. faecalis, L. iners, L. johnsonii,
C. coyleae, A. schaalii, G. vaginalis, and a mixed profile termed ‘Diverse’.
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Figure I.1. Continued

genus level, the most common culture profile was predominated by Lactobacillus (50%, 17/34),
similar to that observed by sequencing. This genus level Lactobacillus profile was composed of
the following species: L. gasseri, L. jensenii, L. iners, L. johnsonii and L. crispatus. Thus, with
respect to the major dominant profiles, sequencing and EQUC obtained similar results.
The combination of 16S sequencing and EQUC detected bacteria in 80% (41/51) of
participants and reached the same conclusion regarding urotype in 64% (33/51) of all the
participants. Considering only participants with positive results for both methods, these two
methods reached the same conclusion in 82% (23/28) of participants (Figure I.1).
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Table I.3. Differences in alpha diversity measurements between the Lactobacillus and
Gardnerella sequencing Four different alpha diversity measurements were calculated from the
sequencing data: Shannon diversity (a measurement of richness and evenness), Inverse
Simpson (richness and evenness), total number of species (richness only) and Pielou (evenness
only). P-values were generated using a Wilcoxon rank sum test.
Gardnerella
Lactobacillus
P-value
urotype (N=9) urotype (N=21)
Shannon Diversity Index,
1.28
0.54
0.0003
Mdn (IQR)
(1.13-1.53)
(0.35-0.91)
Inverse Simpson Index,
2.5
1.8
0.0005
Mdn (IQR)
(2.02-3.10)
(1.10-1.53)
Total number of Species,
83
77
0.8562
Mdn (IQR)
(63-94)
(74-87)
Pielou Index,
0.3
0.13
0.0003
Mdn (IQR)
(0.28-0.34)
(0.08-0.20)

Standard Urine Culture Results Versus EQUC.
Standard urine culture results were available for all participants. The standard urine
culture was negative for all samples. In contrast, EQUC detected bacteria in 34/51 subjects.
Thus, the standard urine culture had a 100% false negative rate. In 15 participants, the standard
protocol also did not detect several known or emerging urinary pathogens, including
Actinobaculum schaalii (N=1), Alloscardovia omnicolens (N=1), Candida albicans (N=1), Candida
parapsiosis (N=1), Corynebacterium urealyticum (N=1), Enterococcus faecalis (N=7), Escherichia
coli (N=1), Staphylococcus aureus (N=1), Streptococcus agalactiae (also known as GBS, N=1),
and Streptococcus anginosus (N=5) (Table I.4). Five patients grew two or more of these
uropathogens. Some of these organisms (A. schaalii, A. onmicolens, and C. urealyticum) would
not normally grow under standard urine culture conditions. Many of these patients contained
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organisms at thresholds below the detectable level of standard urine culture (10-100 CFU/ml).
However, four individuals contained one of these organisms at greater than 1000 CFU/ml; thus,
in theory, these bacteria could have been detected by standard culture, but they were not.
Table I.4: Colony Forming Units/ml of EQUC Detected Uropathogens. Fifteen patients
contained detectable uropathogens using EQUC. Here we show the colony forming units per ml
of urine of all detectable uropathogens in those individuals.

MUM_07
MUM_03
MUM_22
MUM_55
MUM_56

MUM_11
MUM_15
MUM_19
MUM_25
MUM_35
MUM_41
MUM_42
MUM_47
MUM_58

Actinobaculum Alloscardovia. Candida Corynebcaterium Staphylococcus
schaalii
omnicolens albicans
urealyticum
aureus
0
0
0
0
10
10
0
0
0
0
0
0
310
0
0
0
0
0
100
0
0
100
0
0
0
Candida
parapsiosis
10
0
0
0
0
0
0
0
0

Enterococcus Escherichia
facalis
coli
0
0
70
0
10
0
700
0
10000
1000
0
0
10
0
10
0
5000
0

Streptococcus
agalactiae
0
0
0
0
0
0
30
0
0

Streptococcus
anginosus
10
20
10
0
0
1100
60
0
0

History of UTIs During the Current Pregnancy.
Uropathogens have been known to recur and it is possible that some of these patients
had a prior infection. To determine if the patients with detectable uropathogens had previously
been treated for UTIs we looked at the medical records for prior UTI treatment during the
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current pregnancy. Four patients reported UTI-like symptoms during their current pregnancy.
One PTL/pPROM patient had an Enterococcus UTI in the 1st trimester and was treated with
cephalexin. An indicated pre-term patient was treated in the second trimester with cephalexin
for a UTI caused by an unknown organism. Two full term patients documented a single UTI
during this pregnancy: one was treated early in their pregnancy but their records are
unavailable; the second patient was treated with ceftriaxone for Gonorrhea in the first
trimester and nitrofurantoin in the second trimester for symptoms with a negative urine
culture. At time of sample collection, none of these four patients had detectable uropathogens
by either EQUC or standard culture.
Discussion
In this prospective observational pilot study of pregnant women admitted to labor and
delivery and undergoing a clinically indicated bladder catheterization, a large majority of
pregnant women had evidence of bladder microbes by 16S RNA sequencing or EQUC or both.
Most importantly, EQUC demonstrates the existence of live microbes in catheterized urine
samples obtained from women late in gestation. This high rate of microbe detection stands in
stark contrast to the low rate of detection by the standard urine culture method, which had a
100% false negative rate for identification of bladder microbes compared to EQUC. Critically,
standard urine culture did not identify several known or emerging uropathogens.
The evidence of live microbes in the bladders of most pregnant women questions the
notion that the urine of pregnant women is sterile. Additionally, these findings challenge the
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utility of the term ASB; if the bladders of most pregnant women contain bacteria, then what
does the term asymptomatic bacteriuria mean? We believe these data support the findings of
studies from non-pregnant women, namely that the majority of women have an identifiable
urinary microbiome. As with microbiota of other human microbial niches, the maternal bladder
microbiota likely vary in response to nearby microbial niches and/or system influences, such as
antibiotic use, systemic disease or perturbations in the immune system. As current standard of
care suggests screening and treating ASB during pregnancy, an expanded understanding of the
maternal urinary microbiome is needed using new approaches that refine our working
definition of what are problematic urinary microbes during pregnancy. Further research is
needed to understand how the microbiota might also play preventative or protective roles and
to determine the dysbiotic effects of antibiotics.
The strengths of this investigation are the prospective design, the use of catheterized
urine specimens and the use of the robust combination of EQUC and 16S rRNA sequencing
techniques 3,6,7. Together, these techniques illustrate the limited view provided by the standard
urine culture, which was specifically designed to detect fast growing bacteria with limited
nutrient requirements and no aversion to oxygen (especially Escherichia coli, the most common
cause of UTI). In contrast, EQUC utilizes larger urine volumes, varied media and incubation
states, and longer incubation times to also detect anaerobes, slow growing bacteria and those
that require special nutrients 7 (Table I.S1). Because EQUC can classify bacteria to the species
level, the total number of culture profiles was much greater than the number of profiles
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detected by sequencing, which typically classifies only to the genus level. However, 16S rRNA
gene sequencing complements EQUC by detecting bacteria independent of culture 51,316.
We acknowledge that our study has limitations. First, the small sample size reduces our
ability to statistically compare important subgroups, such as preterm versus term deliveries. In
addition, we were unable to account for potential confounding factors, such as demographics
or medical comorbidities. Further studies also are needed to characterize the bladder
microbiome throughout each trimester of pregnancy.
A theoretical concern exists that the detected bacteria may represent urethral or vaginal
contamination. However, as described previously, a prior investigation comparing the bacterial
profiles of vaginal swabs and urine obtained by transurethral catheter, suprapubic aspirate, and
the mid-stream voided method concluded that bacteria detected in urine obtained by
suprapubic aspirate or transurethral catheter represent true residents of the bladder. As the
samples in the current study were obtained by transurethral catheterization, we conclude that
our findings are not the result of contamination and instead document the presence of live
bladder microbiota in pregnant women.
We also recognize that EQUC and 16S sequencing did not universally agree regarding
specimen profile, potentially due to differences in sample storage prior to processing. The
culture tubes contain a preservative that prevents bacterial growth at room temperature, but
the sequencing tubes did not. Therefore, bacterial growth in the sequencing tubes could
account for the majority of the discrepancies between the data (Figure I.1). This is an issue that
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should be considered in the design of future studies. Even given these discrepancies with
sequencing data, however, the culture data clearly shows the presence of greater than 10 3
CFUs of many different organisms, including known and emerging uropathogens.
Because this study also documents the poor performance of the standard urine culture,
these findings offer us the opportunity to improve our understanding of the maternal bladder
microbiota, especially as it relates to clinically relevant definitions of ASB. Of particular concern
was the finding of bacteria by our EQUC technique that had gone undetected by the standard
urine culture method. Of the bacteria identified by EQUC, several are known or emerging
urinary pathogens, including Enterococcus faecalis, Streptococcus anginosus, and
Actinobaculum schaalii (recently renamed Actinotignum schaalii 317). These results require
confirmation in a larger study.
Currently, we do not recommend a change in clinical practice because we do not yet
know the impact of the previously undetected microbes. Some of the newly detected microbes
are likely beneficial and antibiotic treatment could preclude their ability to protect. Future
study into the roles of the detected microbes is indicated.
While the majority of the pregnant women in this study possessed detectable and
identifiable bladder microbiota, the microbiota of several women was below the detection
threshold, similar to previous reports of peri-menopausal women 308-310,318,319. We use the term
below the detection threshold instead of “negative” or “sterile” to emphasize that these urines
likely have a low biomass that cannot be detected using the current methods. Since we are
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unable to prove sterility, we believe this is a more accurate scientific approach. Indeed, a recent
study showed that the use of larger volumes of urine could result in detection of bacteria by
DNA sequencing in all samples 320.
In conclusion, we believe this study documents the presence of live microbiota in the
bladders of pregnant women, an observation that warrants further study. Future investigations
should clarify the normal bladder microbiota in pregnancy and identify changes over the course
of pregnancy. This would allow for a deeper understanding of the normal maternal bladder
microbiota and how they can become altered in ways that lead to pathologic conditions. For
example, this new knowledge would clarify the definition and risk factors associated with ASB
during pregnancy. Other factors should be investigated, especially the relationship between the
maternal bladder microbiota and those of other pelvic floor niches, especially the vagina.
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Supplementary Material
Table I.S1. Culture protocols
Protocol

Volume

Media

Atmospheric
Conditions

Time

Standard Urine
Culturea,c

1 uL

Blood Agar
MacConkey Agar

Aerobic

24 hrs
35°

Enhanced
Quantitative Urine
Culture (EQUC)b,c

100 uL

Blood Agar
Chocolate Agar
CNA Agar
Anaerobic Blood Agar

Aerobic
CO2
Anaerobic

48 hrs
35°

aFor

standard urine culture, we struck 0.001 ml of urine onto 5% sheep blood (BAP) and
MacConkey agars (BD BBL prepared plated media), which were incubated aerobically at 35°C
for 24 hours. Each separate morphological colony type was counted and identified in any
amount. The detection level was 1,000 colony-forming units per milliliter (CFU/ml), represented
by 1 colony of growth on either plate. If no growth was observed, the culture was reported as
“no growth,” indicating no growth of bacteria at the lowest dilution, i.e., 1:1,000.
bFor EQUC, we struck 0.1 ml of urine onto BAP, chocolate and colistin, naladixic acid (CNA)
agars (BD BBL prepared plated media), which were incubated in 5% CO2 at 35°C for 48 hours. A
second BAP plate and CDC anaerobe 5% sheep blood agar plate (BD BBL prepared plated
media) were also inoculated with 0.1 ml of urine and incubated under anaerobic conditions at
35°C for 48 hours. The detection level was 10 CFU/ml, represented by 1 colony of growth on
any of the plates. Each morphologically distinct colony type was isolated on a different plate of
the same medium to prepare a pure culture for identification.
cTo identify bacterial isolates, matrix-assisted laser desorption ionization–time of flight mass
spectrophotometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 software program (Bruker
Daltonics, Billerica, MA) was used.
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Figure I.S1. Comparison of culture and sequencing for all 51 individuals.
To compare each individual’s sequencing results and culture results we lined up the relative
abundance graphs for each. The relative abundance (or total classified CFU/ml per individual)
culture profiles (A) are compared to the relative abundance (or total classified reads per
individual) of the sequencing profiles (B). The culture classification is given at the genus level
to better compare to sequencing results. Each genus is represented as a color-coded bar for
each individual, where each color represents a family or genus.
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Addendum
One of the initial analyses we attempted was the comparison between pre-term births
and full term births. We tried grouping our women in two ways: (1) by gestational age at time
of urine collection (Table I.5 and Figure I.2) and (2) by the type of pre-term birth (Figure I.3).
We ran into a few problems.
First, our sample size was too small, so even if we saw a trend, it would not be
statistically significant. Second, we have not measured the microbiome over the course of
pregnancy; therefore, we do nott know if it normally changes. This was problematic for
interpretation. Were any changes we were seeing due to the normal fluctuation of the
microbiome or an indication of a pre-term birth?
Finally, we found out later that our groupings in Figure I.3 were arbitrary designations.
The idea was that indicated pre-term birth would not be associated with a change in the
microbiome because there was nothing medically wrong with these women. Women with Preterm Labor with Pre-Mature Rupture of Membranes (PTL-PPROM) had a sudden severe
reaction that caused their pre-term birth and that could have a microbiological component
(such as an infection with GBS). However, when we went back to confirm these designations,
we were informed that they were arbitrary. Therefore, these data were removed from the final
version of the manuscript.
Finally, because we wanted to compare these women to a fairly healthy cohort, we
compared these data to our control women from Appendix B-C. However, those control
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samples had been previously published and that published patient population was significantly
older, so the analysis was only presented in a poster (Table I.6).

- 351 -

Table I.5. Comparison of the MUM dataset by gestational age at time of sample collection.
The percentage of urotype profiles by EQUC and sequencing are compared between full term
(<37 weeks) and pre-term (<20-36 weeks).
EQUC
Sequencing
Gestational Age
Gestational Age
Urotype
>37
<20-36
Urotype
>37
<20-36
weeks
weeks
weeks weeks
N
33
17
N
33
17
27.3%
47%
21.2%
47.1%
Undetermined*
Undetermined*
(9/33)
(8/17)
(7/33)
(8/17)
72.3%
52.9%
78.8%
52.9%
Total Processed
Total Processed
(24/33)
(9/17)
(26/33) (9/17)
Lactobacillus
Gardnerella
Staphylococcus

45.8%
(11/24)
29.2%
(7/24)
8.3%
(2/24)

Enterobacteriaceae
Candida
Streptococcus

4.2%
(1/24)
4.2%
(1/24)
4.2%
(1/24)
4.2%
(1/24)

Lactobacillus
Gardnerella
Staphylococcus

33.3%
(3/9)

Diverse
Enterococcus

22.2%
(2/9)
22.2%
(2/9)

Diverse
Enterococcus
Enterobacteriaceae
Ureaplasma
Bacillales

50%
(13/26)
23.1%
(6/26)
3.8%
(1/26)
15.4%
(4/26)
3.8%
(1/26)
3.8%
(1/26)

55.5%
(5/9)
22.2%
(2/9)

11.1%
(1/9)
11.1%
(1/9)

11.1%
(1/9)
11.1%
Actinobaculum
(1/9)
*Samples that were either culture or sequences negative were deemed “Undetermined”
because we think they are below our level of detection, but are not “sterile”.
Corynebacterium
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Figure I.2. Relative abundance of 16S rRNA profiles by Gestational Age. A graphical
representation of the sequence part of Table H.5.
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Figure I.3. Relative Abundance Profiles separated by Pre-Term versus Full Term Pregnancies.
The patients were divided into three groups: Pre-term labor with premature rupture of
membranes (PTL-PPROM), Indicated pre-term, and full term. The relative abundance for each
individual at the genus level, for (A) sequence data and (B) culture data. To allow for
comparison between sequencing and culture, the patient samples are in the same order for
both A and B. To compare the biomass within each population, the distribution of colony
forming units per milliliter (CFU/ml) is graphed as a boxplot (C). Underneath is the mean and
interquartile range (IQR) for each group. Because the microbiota might change during the
course of pregnancy, for the full term population, we considered only those samples that were
collected within two days of delivery (N=45).
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Table I.6. Comparison of the Urotype Frequencies found in the MUM data set to older
controls. The older controls dataset was collected and published during the Astellas project
(Appendix C-D).
MUM dataset
EQUC
51
33.3%
Undetermined*
(17/51)
66.7%
Total Processed
(34/51)
Urotype
N

Lactobacillus
Gardnerella

38.2%
(13/34)
32.4%
(11/34)

Diverse
Staphylococcus
Streptococcus
Enterobacteriaceae
Candida
Corynebacterium
Actinobaculum
Aerococcus
Bacilliales
Ureaplasma
Mean Age
Median Alapha Diversity
Median # of Isolates

5.9%
(2/34)
5.9%
(2/34)
2.9%
(1/34)
5.9%
(2/34)
2.9%
(1/34)
2.9%
(1/34)
2.9%
(1/34)

Seq
51
31.4%
(16/51)
68.6%
(35/51)
51.4%
(18/35)
22.9%
(8/35)
8.6%
(3/35)
2.9%
(1/35)

Control Samples
EQUC
33
21.2%
Undetermined*
(7/33)
78.8%
Total Processed
(26/33)
Urotype
N

Lactobacillus
Gardnerella
Diverse
Staphylococcus
Streptococcus

2.9%
(1/35)
2.9%
(1/35)

Enterobacteriaceae
Enterococcus
Candida
Alloscardovia
Micrococcus

2.9%
(1/35)
2.9%
(1/35)
30 yrs
1.2
1 [IQR:0-3]**

Strep/Bifido
Unknown
Mean Age
Median Alapha Diversity
Median # of Isolates

45.5%
(15/33)
6.1%
(2/33)
6.1%
(2/33)
6.1%
(2/33)
6.1%
(2/33)
6.1%
(2/33)
6.1%
(2/33)
3.0%
(1/33)
3.0%
(1/33)
3.0%
(1/33)
6.1%
(2/33)
3.0%
(1/33)

Seq
17
47.1%
(8/17)
52.9%
(9/17)
61.5%
(16/26)
15.4%
(4/26)
15.4%
(4/26)

3.9%
(1/26)

52yrs
2.1
1 [IQR:0-2]**

*We use the term undetermined instead of “negative” to make the distinction that these urines are not sterile
** p-value= 0.3827

APPENDIX J
PRESENT BUT UNACCOUNTED FOR:
THE UROPATHOGENS IN PRE-SURGICAL URINARY MICROBIOMES

Thomas-White, K., Fok, C, Ghanayem, K., Mueller, E.R., Wolfe, A.J., and Brubaker, L. PreOperative Urinary Microbiome Reveals Post-Operative Urinary Tract Infection Risk. Presented at
ICS and AUGS annual meeting 2015. Received a Young Investigator Award from ICS and Best
Clinical Paper Award from AUGS 2015
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Overview of Appendix J
For the American Society for Urognycology (AUGS) and International Continence Society
(ICS) meetings, if an abstract is accepted for an oral presentation the authors are required to
submit the data in manuscript form. Therefore, I wrote this “placeholder paper” to accompany
my abstract entitled, “Pre-Operative Urinary Microbiome Reveals Post-Operative Urinary Tract
infection Risk”. The presentation for this abstract was awarded a Young Investigator Award at
ICS and the placeholder paper was awarded Best Clinical Paper Award at AGUS.
Patients for this study were recruited by Cynthia Fok prior to my joining LUEREC. Initial
analysis of these patient samples were previously published in Fok et al. 2013 63. The initial
study design recruited patients prior to surgery and collected catheterized urine, vaginal swabs,
and perineal swabs on the day of surgery (DOS). The patients were then followed through
surgery and assessed for adverse effects including, post-operative UTI. In this manuscript, I
compared the results of 16S rDNA sequencing to standard culture results. All samples have
currently been sequenced with help from Kathryn Ghanayem. Currently the data is going
through an in-depth analysis by Qunfeng’s bioinformatics group. A complete manuscript is
planned for late 2017.
Abstract
Objective. Women have a 1 in 5 risk of developing a post-operative urinary tract
infection (UTI) following urogynecologic surgery, even with pre-operative screening and
treatment. Patients with positive day of surgery (DOS) standard urine cultures (>1000 CFU/ml)
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were about six times more likely to develop a post-operative UTI than patients with negative
standard urine cultures. This study assessed whether a distinct pre-operative urinary
microbiome is associated with post-operative UTI.
Methods. This analysis used catheterized urine samples that were collected and
cultured using the standard urine culture protocol in a prior study 63. For this analysis, we
paired these urine samples with the vaginal and perineal swabs obtained from the same
participant. Samples were sequenced using the V4 region of the 16S rRNA gene and classified
using the mothur software package 167. The cohort was grouped first by standard DOS culture
result, then by post-operative UTI development. Finally, for each patient, the urinary
microbiome was compared to her vaginal and perineal microbiomes.
Results. Of 303 patients, 25 had detectable bacteria in their DOS urine sample by
standard culture. The standard culture results primarily detected uropathogenic taxa, e.g.
Pseudomonas, Staphylococcus, and Enterobacteriaceae (which includes E. coli, Proteus, and
Klebsiella); the sequencing data matched these DOS culture results. The urinary microbiomes of
the 278 patients who were DOS culture-negative tended to be dominated by Lactobacillus,
Gardnerella, or Corynebacterium or they were diverse. The UTI organism cultured postoperatively was often detected in baseline DOS samples: in women with DOS culture-positive
urines, it was generally detected in the urine; in women with DOS culture-negative urines, it
was typically detected in the vaginal and perineal swabs.
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Conclusion. Detectable differences in pathogenic taxa are present prior to surgery in
most women who developed a post-operative UTI, suggesting that the causative organism may
be present before the onset of surgery. Detection and treatment of this uropathogenic
reservoir offers an opportunity to reduce the risk of post-operative UTI.
Brief Summary. 16S rRNA sequence data of urinary, perineal and vaginal microbiomes
suggest that a uropathogenic reservoir is associated with post-operative urinary tract
infections.
Introduction
Hospital-acquired urinary tract infections (UTI) are an important clinical quality metric.
Approximately 7-24% of urogynecology surgery patients develop a post-operative UTI 203
despite prophylactic antibiotics and other preventive measures. The conceptual model for postoperative UTIs is based on introduction of uropathogens into the bladder during surgical
events, such as catheterization, cystoscopy and/or systemic antibiotics 321-324. This notion,
however, is challenged by the recent discovery of bacteria in the female bladder 3-5,7,13,60 in the
absence of vulvo-vaginal contamination 4. In addition, emerging evidence suggests that the
bacterial cause of the UTI (i.e., the uropathogen) can be present in the bladder prior to surgery
63.

It is also possible that the uropathogen that that causes the post-operative infection is

present prior to surgery in a separate niche (i.e., a niche-reservoir).
Disruption of the urinary microbiome could occur in response to any number of events
that happen during urogynecologic surgical intervention (e.g., physical disruption, antibiotic
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use, or inflammation). Similar to microbial communities in other body sites, when a niche is
disturbed, it could easily be re-colonized post-operatively with an infectious agent. A prime
example is Clostridium difficile, which often flourishes in the gastrointestinal tract following
antibiotic treatment 325.
We previously reported that patients with positive day of surgery (DOS) urine cultures
(>1,000 CFU/ml) were almost six times as likely to develop a post-operative UTI as patients with
negative DOS standard urine cultures 63. Therefore, we hypothesized that patients who develop
a post-operative UTI carry one or more uropathogens prior to surgery that increase that
individual’s risk of a post-operative secondary infection. To test this hypothesis, we analyzed
DOS samples by 16S rRNA gene sequencing, seeking to detect the subsequent UTI uropathogen
in one or more of three potential reservoirs: the bladder, the vagina, and/or the perineum.
Methods
Study Design.
Patient-participant recruitment and initial characterization was completed in a previous
study 63, during which transurethral catheter urine, and standardized vaginal swabs and
perineal swabs were collected from surgical patients immediately prior to initiation of POP/UI
surgery. In this previous study 63, the urine samples taken on the DOS and those taken for
diagnosis of post-operative UTI were analyzed by the standard culture protocol. In the current
study, we sequenced all urine samples with at least 2 ml of urine remaining. Twenty-three of
the original urine samples had insufficient volume and thus were not included in the current
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analysis. In contrast, we were able to include 24 participants who had been excluded from the
previous study due to incomplete symptom data, which are not required for this analysis.
Based on standard urine culture results, we grouped the patients into two cohorts: DOS
culture-positive or DOS culture-negative. Standard urine cultures were considered positive if
they contained >1,000 CFU/ml of a known or emerging uropathogen. We subdivided the
cohorts based on DOS culture results by post-operative UTI development, resulting in 4 groups:
DOS culture-negative and UTI-negative (neg/neg), DOS culture-negative UTI-positive (neg/pos),
DOS culture-positive UTI-positive (pos/pos), and DOS culture-positive UTI-negative (pos/neg).
Following 16S rRNA gene sequencing of the urines and of both vaginal and perineal
swabs, we compared the microbiomes of the three pelvic floor niches (i.e., bladder, vagina, and
perineum) to the standard culture results obtained in the previous study.
DNA Isolation from Urine.
DNA isolation, PCR amplification, and 16S rRNA sequencing of urine cultures has been
described previously 203. To avoid contamination, isolation of DNA was performed in a laminar
flow hood. Genomic DNA was extracted from 1 ml of urine, or from 100ul of swab solution,
using previously validated protocols developed for the Human Microbiome Project 7,166,203. To
isolate genomic DNA from urine samples, this protocol includes the addition of the
peptidoglycan degrading enzymes, mutanolysin and lysozyme, that ensure robust lysis of Grampositive and Gram-negative species 166. For consistency, all swabs were processed using the
same protocol. Briefly, 1 ml of urine was centrifuged at 13,500 rpm for 10 min, and the
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resulting pellet was resuspended in 200 µl of filter-sterilized buffer consisting of 20 mM Tris-Cl
(pH 8), 2 mM EDTA, 1.2% Triton X-100, and 20 µg/ml lysozyme and supplemented with 30 µl of
filter-sterilized mutanolysin (5,000 U/ml; Sigma-Aldrich, St. Louis, MO). The mixture was
incubated for 1 h at 37°C, and the lysates were processed through the DNeasy blood and tissue
kit (Qiagen, Valencia, CA), according to the manufacturer’s protocol. The DNA was eluted into
50 µl of buffer AE, pH 8.0, and stored at -20° C.
Variable region 4 (V4) of the bacterial 16S rRNA gene was amplified via a two-step
polymerase chain reaction (PCR) protocol, as described previously 7,203. Briefly, in the first
amplification, the V4 region was amplified using Illumina MiSeq modified universal primers
515F and 806R. Extraction negative controls (no urine) and PCR negative controls (no template)
were included to assess the contribution of extraneous DNA from reagents. Ten-microliter
aliquots of each reaction mixture were run on a 1% agarose gel. Samples containing a band of
approximately 360 bp were considered PCR-positive and subjected to further library
preparation. Samples with no visible amplified product were considered PCR-negative and not
processed further. The PCR positive reaction mixtures were diluted 1:50 and amplified for an
additional 10 cycles, using primers encoding the required adapter sequences for Illumina MiSeq
sequencing and an 8-nucleotide sample index. The PCR reaction was purified and size selected
using Agencourt AMPure XP-PCR magnetic beads (Beckman Coulter, Pasadena, CA). Each
sample was quantified using the Qubit flourometeric system (Thermo-Fisher). The samples
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were pooled, quantified to a standard volume, and placed in the 2 X 250 bp sequencing reagent
cartridge, according to the manufacturer’s instructions (Illumina, San Diego, CA).
DNA Sequence Analysis
The Illumina MiSeq post-sequencing software preprocessed sequences by removing
primers and sample indices. The open-source program mothur (v1.31.2) combined the paired
end reads and removed contigs (overlapping sequence data) of incorrect length (<285 bp, >300
bp) and/or contigs containing ambiguous bases 167. We aligned the remaining modified
sequences to the SILVA reference database, and discarded sequences if 50% or more of their
nucleotides failed to align. Chimeric sequences were removed using UCHIME 169. The remaining
sequences were taxonomically classified using a naïve Bayesian classifier and the RDP training
set v9, and clustered into operational taxonomic units (OTUs) 195. METAGENassist was used to
link OTU nomenclature to taxonomic assignments 170.
Urine samples typically contain small amounts of bacteria (i.e., low biomass). Given our
desire to confirm results with technical replicates, all urine samples were processed in duplicate
and were classified as either sequence-positive or sequence-negative. A sequence-positive
sample was one in which DNA was amplified from both replicas and, if present, the dominant
taxon (representing >50% of sequences from the sample) was the same in both replicas. For
each sequence-positive sample, a representative sequence profile was used for further analysis.
A sequence-negative sample was one in which DNA was not amplified in either technical
replica. To avoid accidentally sequencing rare contaminants, we conservatively considered
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samples to be negative if DNA amplification was not visible on an agarose gel. Swab samples
tend to be high biomass; therefore, very few were PCR-negative. As such, we only performed a
replicate if the swab sample was PCR-negative to confirm the result.
We considered samples with cultivatable bacteria at ≥1,000 CFU/ml as a high biomass
population. Sequencing is sensitive but not quantitative; therefore, we considered urines to
have a high abundance of an organism if the reads represented greater than 10% of the total
sequences for a given sample. Sequences representing less than 10% were considered low
abundance sequences within a sample. To display the sequence abundance for each sample, a
histogram was produced and color-coded by bacterial taxa. Next, Bray-Curtis distance was
calculated between samples and the complete method was used for hierarchical clustering
using RStudio 196. The resulting dendrogram was divided into clusters, which were termed
sequence urotypes, and named by the dominant taxa present or as ‘diverse’ if no single taxon
was dominant. Sequence-negative samples were given the designation ‘undetermined’ urotype.
Results
Most (91.7%, 278/303) of the 303 patients with complete, qualifying sample sets had
negative DOS urine cultures; only 3.7% (10/278) developed post-operative UTI. However, of the
25 individuals with DOS culture positive urines, 32% (8/25) developed post-operative UTI.
Therefore, the risk of post-operative UTI is significantly greater in the DOS culture-positive
population (32% vs 3.7% p≤0.001).
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Table J.1. Comparison between DOS culture-positive and -negative, UTI-positive and negative for sequence urotypes. The population was divided into those that had a positive
standard culture at DOS and those that did not. Within each group, the risk of developing a
post-operative UTI was calculated. Each sample was classified by the dominant organism (i.e.,
Urotype) or classified as diverse if no one organism dominated.
Day of Surgery
Day of Surgery
Culture Negative
Culture Positive
UTI
UTI
UTI
UTI
P-value
Negative
Positive Negative Positive
3.7%
32%
Frequency of UTIs
<0.001
(10/278)
(8/25)
60.8%
80%
5.8%
0%
Undetermineda
<0.001
(163/268)
(8/10)
(1/17)
(0/8)
39.2%
20%
94.1%
100%
Sequenced
(105/268)
(2/10)
(16/17)
(8/8)
2.9%
37.5%
12.5%
Enterobacteriaceae b
<0.001
(3/105)
(6/16)
(1/8)
31.3%
37.5%
Pseudomonas
<0.001
(5/16)
(3/8)
1%
12.5%
25%
Staphylococcus
<0.001
(1/105)
(2/16)
(2/8)
19%
12.5%
12.5%
Diverse
0.24
(20/105)
(3/16)
(1/8)
56.2%
100%
6.3%
12.5%
Lactobacillus
0.11
(59/105)
(2/2)
(1/16)
(1/8)
12.4%
Gardnerella
1.0
(13/105)
6.7%
Corynebacterium
1.0
(7/105)
1%
Actinobaculum
1.0
(1/105)
1%
Aerococcus
1.0
(1/105)
1%
Streptococcus
1.0
(1/105)
a

We use the term “undetermined” instead of “negative” to make it clear that these urines might not be sterile.
“Undetermined” samples are below the level of detection by the current methods.
b
This family contains Escherichia, Klebsiella and Proteus. The V4 region of the 16S rRNA gene does not have
enough information to classify the family Entrobacteriaceae into its respective genera. Averages are means and Pvalues were calculated using Fischer’s exact test.
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Table J.1 displays the results within the 4 subgroups: DOS culture-negative and UTInegative (Figure J.1A), DOS culture-negative UTI-positive (Figure J.1B), DOS culture-positive
UTI-positive (Figure J.1C), and DOS culture-positive UTI-negative (Figure J.1D). The proportion
of urines with an undetermined urotype (i.e., sequence-negative) differed significantly by group
(p≤0.001). There were few undetermined urotypes in the DOS culture-positive groups; we
reproducibly sequenced 94.1% (16/17) and 100% (8/8) of the baseline DOS culture-positive
urine samples from the UTI-negative and UTI–positive groups, respectively. In contrast, many of
the DOS culture-negative group had undetermined urotypes; we reproducibly sequenced only
39.2% (105/268) and 20% (2/10) of the DOS culture-negative urines for the UTI-negative and
UTI-positive groups, respectively. We infer that the culture-positive urine samples possess more
bacterial biomass than do the culture-negative samples.
Characterization of the Urinary Reservoir.
The frequency, or distribution, of organisms differed between the 4 groups. The DOS
culture-negative women who did not develop a post-operative UTI (Table J.1, Figure J.1A) were
more likely to have urinary microbiomes dominated by the following urotypes: Lactobacillus
(56.2%, 59/105, blue), Gardnerella (12.4%, 13/105, red), Corynebacterium (6.7%, 7/105,
orange), or Diverse (no dominant organism) (19%, 20/105, multi-colored). DOS culture-negative
women who developed a post-operative UTI (3.7%) tended to have bacterial DNA below the
threshold for sequencing, i.e., undetermined urotype (80%, 8/10, Table J.1). The remainder of
the culture-negative women (20%, 2/10) each had a Lactobacillus urotype. In contrast, DOS
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Figure J.1. Urine sequencing profiles by day-of-surgery (DOS) culture and post-operative
UTI results. The relative abundance (or total classified sequences per individual) is
represented as a color-coded bar for each individual, where each color represents a family or
genus classified by sequencing. The cohort is divided into 4 groups: DOS culture negative UTI
negative (A), DOS culture negative UTI positive (B), DOS culture positive UTI negative (C),
DOS culture positive UTI positive (D).

culture-positive urines were significantly more dominated by uropathogenic species, e.g.
Pseudomonas (green, p≤0.001), Staphylococcus (light blue, p≤0.001) and Enterobacteriaceae (in
yellow, including E. coli, Proteus, and Klebsiella, p≤0.001) (Table J.1 and Figure J.1 C-D).
Although the DOS culture-positive group that developed a UTI had a urotype profile similar to
those that did not develop a UTI (Table J.1, Figure J.1D), the microbiome of the former group
tended to be more diverse. Most urine samples in this group contained both a uropathogen
and another organism (e.g Staphylococcus with Actinobaculum, Pseudomonas with
Lactobacillus, Enterobacteriaceae with Bifidobacterium).
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Figure J.2. Day of Surgery urines, vaginal swabs and perineal swabs. The relative abundance
(or total classified sequences per individual) is represented as a color-coded bar for each
individual, where each color represents a family or genus classified by sequencing. Each
group of sample represents one patient with their urine, vaginal and perineal microbiomes
for each. Black bars indicated a low biomass sample that did not amplify beyond background
levels (i.e., PCR negative or undetermined urotype).
Characterization of the Vaginal and Perineal Microbiomes.
For each participant, we compared the urinary microbiome to the vaginal and perineal
microbiomes, using the percent of total sequences, where greater than 10% of sequences was
considered high abundance, and between 10% and 0.01% was considered low abundance
(Figure J.2A-C). Most DOS culture-positive samples (76.9% (20/26), Table J.3) contained a high
abundance of sequences belonging to the family or genus identified by standard culture,
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indicating that sequencing tended to match the culture results. For the DOS culture-positive
group that developed a post-operative UTI, the family or genus of the bacterium identified by
standard culture was often detected by sequencing in the urine at high abundance (50.0%, 4/8).
When the bacterium was not detected or present at low abundance in the urine, it was present
in the vagina and perineum at high abundance (12.5%, 1/8) or at low abundance (37.5%, 3/8).
Thus, the organism of interest was found in one of the three niches in all patients (Table J.2 and
Table J.3).
Table J.2. Percent of sequence detection of cultured organism in each of three pelvic floor
microbiomes. The genus of the culture organism was compared to the percent of sequences detected
for that genus or family in each of the three locations (urine, vagina, and perineum). Samples with large
numbers of reads are in red, and samples with lower numbers of read are in green. The three groups
with culture information are shown: (A) DOS culture-positive, UTI-positive, (B) DOS culture-positive, UTInegative, (C) DOS culture-negative, UTI-positive.

Group

A.
Pos/
Pos

a

DOS Culture
Results
GUM_223:
Clost
GUM_225:
Strept
GUM_263:
Enterobact
GUM_267:
Staphy
GUM_271:
Staphy
GUM_273:
Pseudo
GUM_309:
Enterobact
GUM_314:
Pseudo

DOS Urine

DOS Vag

0

0

0

0

0.4

88.70
%

13.90
%

13.60
%

35%

0.60%

2.50%

91%

0.10%

0.10%

97%

0

0.01%

0.17%

0.11%

0.06%

0.04%

99.10
%
89.90
%

DOS Per

UTI Culture
results
GUM_223:
Enterobact
GUM_225:
Pseudo
GUM_263:
Enterobact
GUM_267:
Enterobact
GUM_271:
Enterobact
GUM_273:
Lacto
GUM_309:
Enterobact
GUM_314:
Pseudo

DOS Urine

DOS Vag

0

0.07%

39.30%

0.03%

0

88.70%

13.90%

13.60%

0.08%

0.30%

0.30%

0

0.01%

0.15%

1.60%

83.50%

75.90%

99.10%

0.17%

0.11%

89.90%

0.06%

0.04%

sequences were in high abundance if present at >10% of total sequences.
sequences were considered low abundance if present between 10% and 0.01%
c
N/A indicates samples that were undetermined, or had a biomass below our level of detection
b

DOS Per
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Table J.2. Continued
DOS Culture Results
GUM_062:
Enterobacteriaceae
GUM_097:
Staphylcoccus
GUM_104:
Enterobacteriaceae
GUM_147:
Enterobacteriaceae
GUM_164:
Staphylococcus
GUM_179:
Pseudomonas
GUM_212:
Pseudomonas
GUM_213:
Enterobacteriaceae
B. Pos/
GUM_237:
Neg
Enterobacteriaceae
GUM_255:
Enterobacteriaceae
GUM_261:
Enterobacteriaceae
GUM_265:
Pseudomonas
GUM_268: Bacilli
GUM_284:
Pseudomonas
GUM_285:
Pseudomonas
GUM_327:
Enterococcus
GUM_330:
Streptococcus

DOS - Urine

DOS - Vag

DOS - Per

N/A

0

N/A

99.60%
99.80%

0.16%
0.30%

99.90%

0.70%
84.40%

98.70%

0.02%

0.02%

49.30%

0

N/A

82.60%

0

0

98.20%

0.04%

0.39%

99.70%

0.82%

1.80%

90.90%

0.60%

0.16%

0.07%

0.04%

96.40%

0.05%

0

0

0

0

95.30%

0.02%

0.02%

94.60%

0.01%

0

0

0

0

16.30%

0.01%

0.30%
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Table J.2. Continued
UTI Culture results
DOS - Urine
DOS - Vag
DOS - Per
GUM_027:
N/A
0
0
Enterococcus
GUM_038:
N/A
0
0.04%
Enterococcus
GUM_125:
N/A
0
0.11%
Enterococcus
GUM_153:
N/A
0
0.73%
Enterobacteriaceae
GUM_226:
12.40%
17.30%
40.90%
C.Neg/ Corynebacterium
Pos
GUM_235:
4.90%
32.40%
2.30%
Streptococcus
GUM_274:
N/A
90%
3.70%
Lactobacillus
GUM_298:
N/A
0.11%
0.34%
Peptoniphilus
GUM_315:
N/A
0.44%
Enterobacteriaceae
GUM_320:
N/A
0.01%
0.94%
Enterobactiaceae
a sequences were in high abundance if present at >10% of total sequences.
b sequences were considered low abundance if present between 10% and 0.01%
cN/A indicates samples that were undetermined, or had a biomass below our level of detection
While a similar pattern was observed for the DOS culture-negative population, the
organism of interest was detected in the perineum in 80% (8/10) of patients, albeit often in
very low abundance (with one exception <4%, Table J.2C). Thus, the contribution from the
perineum and vaginal microbiomes was much more striking due to the low bacterial biomass,
and therefore lack of sequencing result, in the bladder (Table J.2C, green vs red and yellow).
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Table J.3. Cumulative sequence detection results by pelvic floor niche. The percent of high
and low abundance sequence detection of the culture organisms is listed cumulatively for all
three UTI groups show in Table J.2.
Percent of Sees that DOS DOS DOS UTI Culture
match culture
Urine
Vag
Per
results
a
At high abundance
76.9%
3.8%
7.7%
(20/26) (1/26)
(2/26)
b
At low abundance
0%
53.8%
57.7%
(0/26) (14/26) (15/26)

DOS Urine
33.3%
(6/18)
16.7%
(3/18)

DOS Vag
22.2%
(5/18)
38.9%
(7/18)

DOS Per
22.2%
(4/18)
66.7%
(12/18)

Discussion
Our data suggest that most post-operative UTIs are related to uropathogens that are
either present in the bladder or in the adjacent pelvic niches of the vagina or perineum prior to
surgery. Our prior analysis 63 demonstrated that a pre-surgical DOS standard urine culture
effectively identifies a group of urogynecologic patients at increased short-term risk for UTI.
The current analysis extends those findings to document the detectable pre-surgical presence
of the likely post-operative UTI-associated uropathogen.
Currently, urine cultures at the onset of urogynecologic surgery are not widely included
as a standard of care practice. Moreover, the adjacent pelvic microbial niches in the vaginal or
perineal swabs are not routinely assessed prior to surgery. While clinicians could increase preoperative (or DOS) urine culture assessment to screen for women at increased UTI risk,
standard urine culture results typically do not become available to the clinician until 24-48 hour
following initial plating. Development of rapid culture-independent diagnostics, involving
sequencing or PCR of known or suspected uropathogens, could expedite identification of
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individuals at increased risk for post-operative UTI, allowing targeted studies of risk-reducing
interventions.
Clinicians will incorporate the emerging evidence that demonstrates that bacterial DNA
exists in the bladders of healthy women 4,7,13,60,93,203,204 and women with lower urinary tract
symptoms (LUTS) 7,60,203,326,327, including patients undergoing urogynecologic surgery 4,93.
Results from the current study require clinicians to consider modified clinical algorithms that
complement urinary results with information about pelvic niches whose microbiomes may
interact with those of the bladder.
Similar to other human microbial niches, it is inappropriate to attempt suppression of all
microorganisms with antibiotic use. Clinicians will need additional information in order to
judiciously prescribe antibiotics to effectively prevent clinical infection and/or associated
morbidity, especially in women with an increased risk of post-operative UTI.
This analysis demonstrates that valuable information can be made available through the
use of culture-independent methods to describe pelvic floor specimens obtained on the DOS.
Not surprisingly, in women with positive DOS urine cultures, sequencing almost always
detected the genus or family of the previously cultured bacterial species in their DOS urine. In
this urine sample, sequencing often detected the genus or family of the suspected postoperative UTI-associated uropathogen, verifying that uropathogens could be present in the
bladder on the DOS. When sequencing did not detect the suspected post-operative UTIassociated uropathogen in DOS urine, it detected it in one or more of the two adjacent pelvic
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floor niches albeit at lower abundance. In contrast, women whose DOS urine culture was
negative and developed a post-operative UTI typically had an undetermined (low bacterial
biomass) urinary microbiome. However, in these women, sequencing typically detected the
suspected UTI-associated uropathogen in at least one adjacent microbiome, most often the
perineum. The observation that potential uropathogenic organisms can be present in the
bladder, vagina and/or perineum of urogynecological surgery patients prior to surgery suggests
the involvement of a uropathogenic reservoir, a microbial niche that allows for a secondary
post-operative infection.
We were intrigued to detect potential uropathogens in a subgroup of women with DOS
urine samples who did not develop a UTI. This may be related to a variety of biologic scenarios:
(1) her immune system could resist infection, (2) the standard surgical prophylaxis effectively
eradicated the organism and/or (3) the bacterium detected by standard culture was a nonpathogenic strain of a known uropathogenic species.
The larger group of DOS culture-negative women who did not develop a UTI tended to
have detectable urinary microbiomes that resemble those of other cohorts of women without
UTI 3,7. These microbiomes could contain ‘good’ bacteria that protect against post-operative
UTIs. A similar concept has been proposed for protection against post-instrumentation UTIs 5.
The concept of cross-inoculation and microbial sharing is not surprising in the pelvis,
where activities include urinary tract instrumentation, routine hygienic events such as wiping,
and/or sexual activities. This concept must be revisited to include the resident bacterial
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community of the bladder in order to understand the interaction between the different pelvic
floor microbiomes and their contribution to health and disease.
A limitation of this study is the use of the standard urine culture protocol, which has a
high false negative rate; enhanced culture protocols that more effectively identify urinary
bacteria are now available 7,14. In addition, 16S rRNA sequencing has limitations (e.g.,
classification depth and detection threshold for low biomass samples); however, sequencing
did generally detect the bacterium identified by standard culture, as well as numerous other
bacteria that standard culture cannot detect.
Future studies that test UTI risk-reduction strategies will require intervention beyond
reliance on a standard peri-operative antibiotic administration. Patients and clinicians will
mutually benefit from a reduction in potentially preventable post-operative UTIs in
urogynecologic patients.

APPENDIX K
A NEW SPECIES OF GARDNERELLA: G. URINALIS

Thomas-White, K., Putonti, C., Nitin, K., Forster, S., Lawley, T., and Wolfe, A.J.,
(In preparation)
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Overview of Appendix K
Bacterial vaginosis (BV) is defined as a dysbiosis of the vaginal flora that leads to
irritation of the vaginal tract and can lead to an increase risk of preterm birth, and sexually
transmitted infections 271,328. The cause of BV is unknown, but many suspect Gardnerella
vaginalis to either be the cause or at least a biomarker of this dysbiosis, however on G.
vaginalis pathogenicity are inconclusive 302. Many women, particularly of African American or
Hispanic descent, will have low levels vaginal Lactobacillus and a more mixed community
dominated by Gardnrella 15.
Until recently the 16S gene was considered the gold standard for speciation, but it is not
perfect. Although uncommon, the 16S gene can be horizontally transferred (HRT) 329. If HRT is
suspected, there are other means to speciate (e.g. comparing the 40 marker genes and Average
Nucleotide Identity(ANI)), particularly if the full genome is sequenced 330.
G. vaginalis is the only known species of this genus and it has been shown to have a high
rate of horizontal gene transfer (HGT) 105. Additionally, the genomes that have been sequenced
to date show a large variation in the number and type of genes (pan genome) between isolates
with similar 16S regions (Appendix G)105,275,280. Culture urine isolates have identified two
separate morphologies of Gardnerella, identified as G. vaginalis and “Gardnerella species” by
MALDI-TOF mass spec. In studies of women with over active bladder (OAB), G. vaginalis is
associated with symptoms of UUI and Gardnrella species is associated with controls
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(unpublished data). We propose that two separate species of Gardnerella exist, G. vaginalis and
the newly identified G. urinalis.
Results
Figure K.1 shows the preliminary comparison of 13 Gardnerella strains isolated from
catheterized urine from women with OAB, continence controls (“C”), and two isolates from
pregnant women (MUM). All strains were identified by MALDI-TOF mass spec as either G.
vaginalis or G. species. From this point forward, I will refer to G. species as G. urinalis.
As expected, the 16S gene shows high amount of similarity between all strains. There do
seem to be two clades of Gardnerella but the difference is not sufficient to identify different
species (Figure K.1A). The differences between clades becomes much more apparent when we
analyze the 40 marker genes which clearly shows two distinct clades, one for each species
(Figure K.1B). There is one exception, MUM02, which contained two strains of Gardnrella and
both cladded in the G. urinalis side of the tree. ANI comparison shows that the G. vaginalis
clade is 88% different from the G. urinalis clade (Figure K.1C). A difference of 90-95% is usually
sufficient to differentiate between species, 88% might even indicate a new genera. Within the
G. urinalis clade, there seems to be two subclades that are 93% similar to each other. This
suggests the possibility of two separate species within the G. urinalis clade.
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A. 16S gene

B. 40 marker genes

Figure K.1. Genomic analysis of 13 Gardnerella strains. (A) A maximum likelihood tree of
16S genes from Gardnerella strains and reference strains.(B) A maximum likelihood tree
of 40 marker genes
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Figure K.1. Continued
C.

Discussion
The data presented here is preliminary. An additional 12 isolates have been sequenced
and will be added to this dataset. It is possible that I will have those genomes analyzed and
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figures ready by the time I submit my thesis. If not, I do think that these data are compelling
enough to claim that there are at least two distinct species of Gardnerella.
If these results are verified, it would provide an explanation as to why Gardnerella has
never been proven to be a causative factor for BV. We hypothesize that G. urinalis is a
commensal, as it is normally associated with continent controls. While G. vaginalis may be
pathogenic or an opportunistic pathogen. Delineation of these two species may help future
research into etiology and treatment of BV. Additionally, the genomes sequenced here will be
publicly available and will provide important references for future research.

APPENDIX L
MOTILITY OF URINARY ISOLATES
Montelongo-Hernandez, C., Zemaitaitis, B, Christiensen, D, and Thomas-White, K.
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Overview of Appendix L
At least one strain from each species isolated from the bladder was tested for motility.
Each isolate was grown on Tryptic Soy Agar, Brain Heart Infusion (BHI) Agar, or MRS agar, tested
on a range of agar concentrations (1%, 0.85%, 0.55%, and 0.4%). The majority of isolates were
non-motile (Table K.1). The only organisms that were motile were known uropathogens
(Bacillus, Enterobacter, Escherichia, Klebsiella, and Proteus, Table K.1). This deomonstrates that
the commensal bacteria do not seem to have motility when tested in vitro.
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Table L.1. Results of Motility Tests
Motility Genus
#
Species
tested
Actinobaculum
1
Actinomyces
7
Aerococcus
2
Alloscardovia
1
Arthrobacter
1
Bifidobacterium
2
Brevibacterium
1
Campylobacter
1
Corynebacterium
14
Enterococcus
1
Facklamia
1
Gamella
5
Gardnerella
1
Globicatella
1
All NonKocuria
1
Motile
Lactobacillus
7
Micrococcus
1
Neisseria
3
Oligella
1
Pasteurella
1
Peptinophilus
1
Propionobacterium
2
Pseudomonas
1
Rothia
1
Streptococcus
15
Staphylococcus
8
Trueperella
1
Veilonella
1
Weeksella
1

Motility

Genus

All
Motile

Bacillus
Enterobacter
Escherichia
Klebsiella
Proteus

#
Species
tested
4
4
1
1
1

No
Growth

Anaerococcus
Fingoldia
Fusobacterium
Prevotella
Propionibacterium
Slackia

2
1
1
2
1
1

APPENDIX M
SCRIPTS
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Versions of these scripts can be found in the Wolfe lab share drive at: N:\Krystal\scripts
1. Calculating percent of total for relative abundance graphs, and create Dendrograms
#R script to run PCA from a count table
#This example uses an input from the UITN dataset. Input is located in the Wolfe Share
drive at: N:\LUREC\UITN\2015_Analysis\PCoA_Plots\Rep1_Phylum\ Rep12000UITN_all_Phylum_Metadata.csv
#load the packages required
library(vegan)
library(gplots)
#Read in your count table
Rep1_Family <- read.csv("Rep1-2000UITN_all.summary.family.csv")
#Give the dimensions of the table for your reference
dim(Rep1_Family)
#Remove and save row names
row.names(Rep1_Family) <- Rep1_Family$Sam_ID
Rep1_Family <- Rep1_Family[, -1]
#Convert to percentages
Rep1Family.prop <- Rep1_Family/2000 #The sequences were sub-sampled to 2000
#Print the percentages to a csv
write.csv(Rep1Family.prop, file = "Rep1_Family_Percent", quote = FALSE)
#Create Dendrogram
Rep1Family.dist <- vegdist(Rep1Family.prop, method = "bray")
# Chose average/complete/or single linkage hierarchical clustering.
Rep1Family_row.clus <- hclust(Rep1Family.dist, "complete")
#To change the size of the writing
par(ps = 2) #Size 2 font is small enough to see the sample names of each sample in a 300
sample set.
#Plot the dendrogram with the ends of the branches in alignment
plot(Rep1Family_row.clus, hang = -1)
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2. Calculate Diversity measurements from a count table216
#R script to run PCA from a count table
#This example uses an input from the UITN dataset. Input is located in the Wolfe Share
drive at: N:\LUREC\EST_Effect of Estrogen_KTW_ST\Data\Previous Analysis\EQUC Diversity
in R
#load packages
library(vegan)
#set the file you want to work in:
setwd("N:/LUREC/EST_Effect of Estrogen_KTW_ST/Data/Previous Analysis/EQUC Diversity
in R")
#Read your Count table in
EST1_20_gen <- read.csv("EST_Genus_samples1-20_1-9.csv")
#give the dimensions of the table for your reference
dim(EST1_20_gen)
# Remove and save row names
row.names(EST1_20_gen) <- EST1_20_gen$Sam_ID
EST1_20_gen <- EST1_20_gen[, -1]
dim(EST1_20_gen)
#Calculate diversity measurements:
H <- diversity(EST1_20_gen) #Shannon Index (richness and evenness)
simp <- diversity(EST1_20_gen, "simpson") #Simpson index
invsimp <- diversity(EST1_20_gen, "inv") #Inverse simpson index (richness and evenness)
alpha <- fisher.alpha(EST1_20_gen)
pairs(cbind(H, simp, invsimp, alpha), pch="+", col="blue")
## Species richness (S) and Pielou's evenness (J):
S <- specnumber(EST1_20_gen) ## Sum of all the species in that sample (richness only)
J <- H/log(S) ## Peilou (evenness only)
#Print out all calculations as new columns on your dataframe
EST_div <- cbind(H, simp, invsimp, S, J, alpha)
write.csv(EST_div, file="EST_genus_1-20_DivOnly.csv", row.names=TRUE)
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3. PCA – this script was modified from an online tutorial: Computing and visualizing PCA in
R331.
#R script to run PCA from a count table
#This example uses an input from the UITN dataset. Input is located in the Wolfe Share
drive at: N:\LUREC\UITN\2015_Analysis\PCoA_Plots\Rep1_Phylum\ Rep12000UITN_all_Phylum_Metadata.csv
#load packages
library(stats)
library(ggbiplot)
library(rgl)
# Read in your count table
R1P <- read.csv("Rep1-2000UITN_all_Phylum_with_metadata.csv", header = T)
head(R1P, 3)
#Remove and save row names
row.names(R1P) <- R1P$Sam_ID
R1P <- R1P[, -1]
dim(R1P)
#Which columns contain PCA data (versus any with metadata)
R1P <- R1P[, 1:23]
R1P_pca <- prcomp(R1P,
center = TRUE,
scale = TRUE)
summary(R1P_pca)
#Save the PCA lines plot as pdf
pdf("R1P_lines.pdf")
plot(R1P_pca, type = "lines")
dev.off()
#Save the PCA output as a csv file
R1P_pca <- R1P_pca$x[,1:23]
write.csv(R1P_pca, file="R1P_pca.csv", quote=FALSE)
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Table N.1. A List of the Vaginal Isolates Used in Chapter III. These vaginal genomes are all
publicly available, the majority of which were collected by the HMP 11. Vaginal genomes were
only included if the metadata specifically stated that the isolate had been collected from the
vagina (“urogenital” isolates were excluded)
Species
Actinomyces_neuii
Actinomyces_sp
Actinomyces_sp
Actinomyces_urogenitalis
Aerococcus_christensenii
Aerococcus_viridans
Alloscardovia_omnicolens
Anaerococcus_hydrogenalis
Anaerococcus_lactolyticus
Anaerococcus_tetradius
Arcanobacterium_sp
Atopobium_deltae
Atopobium_parvulum
Atopobium_vaginae
Bacillus_coagulans
Bacteroidales_bacterium
Bacteroidales_bacterium
Bifidobacterium_bifidum
Bifidobacterium_breve
Bifidobacterium_breve
Bifidobacterium_breve
Bifidobacterium_dentium
Citrobacter_freundii
Citrobacter_koseri
Clostridiales_bacterium
Clostridiales_bacterium
Clostridium_perfringens
Coriobacteriales_bacterium
Corynebacterium_freneyi
Corynebacterium_kroppenstedtii
Corynebacterium_sp
Corynebacterium_tuscaniense
Dialister_micraerophilus
Enterococcus_faecium
Finegoldia_magna
Fusobacterium_equinum
Fusobacterium_nucleatum
Fusobacterium_nucleatum
Gardnerella_vaginalis
Gardnerella_vaginalis
Gardnerella_vaginalis

Strain
MJR8396A
S4-C9
S6-Spd3
S6-C4
KA00635
ATCC11563
CMW7705A
MJR7738A
S7-1-13
MJR8151
S3PF19
DNF00019
DNF00906
DSM15829
GED7749B
KA00251
KA00344
MJR8628B
ACS-071-V-Sch8b
GED8481
JCP7499
ATCC27679
GED7749C
GED7778C
KA00274
S5-A14a
MJR7757A
DNF00809
DNF00450
DNF00591
DNF00584
DNF00037
DSM19965
MJR8396B
ATCC53516
CMW8396
MJR7757B
Subsp-nucleatum_ATCC23726
409-05
ATCC14019
GED7275B

Assembly Accession
GCA_001546135.1
GCA_000758775.1
GCA_000758755.1
GCA_000758745.1
GCA_001552755.1
GCA_000178435.1
GCA_001546145.1
GCA_001546155.1
GCA_000758765.1
GCA_001546165.1
GCA_000758825.1
GCA_001552785.1
GCA_000758945.1
GCA_000159235.2
GCA_001546215.1
GCA_001552775.1
GCA_001552765.1
GCA_001546225.1
GCA_000213865.1
GCA_001546235.1
GCA_000466545.1
GCA_000146775.1
GCA_001546285.1
GCA_001546305.1
GCA_001552885.1
GCA_000758905.1
GCA_001546355.1
GCA_001552935.1
GCA_000758965.1
GCA_001552955.1
GCA_001552965.1
GCA_000759055.1
GCA_000194985.1
GCF_001546375.1
GCA_000159695.1
GCA_001546395.1
GCA_001546435.1
GCA_000178895.1
GCA_000025205.1
GCA_000159155.2
GCA_001546445.1

- 390 Gardnerella_vaginalis
Gemella_asaccharolytica
Gemella_haemolysans
Lachnoanaerobaculum_saburreum
Lactobacillus_gasseri
Lactobacillus_iners
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_crispatus
Lactobacillus_gasseri
Lactobacillus_gasseri
Lactobacillus_gasseri
Lactobacillus_gasseri
Lactobacillus_gasseri
Lactobacillus_gasseri
Lactobacillus_iners
Lactobacillus_iners
Lactobacillus_iners
Lactobacillus_iners
Lactobacillus_jensenii
Lactobacillus_jensenii
Lactobacillus_jensenii
Lactobacillus_oris
Lactobacillus_rhamnosus
Lactobacillus_salivarius
Lactobacillus_vaginalis
Leptotrichia_wadei
Mageeibacillus_indolicus
Megasphaera_sp
Mobiluncus_curtisii
Mobiluncus_curtisii
Mobiluncus_curtisii
Mobiluncus_curtisii
Mobiluncus_mulieris
Mycobacterium_parascrofulaceum

GED7760B
KA00071
DNF01167
DNF00896
SV-16A-US
DSM_13335
125-2-CHN
214-1
CTV-05
FB049-03
FB077-07
JV-V01
MV-1A-US
SJ-3C-US
vmc3
vmc4
vmc5
vmc6
vmc7
vmc8
2016
202-4
224-1
JV-V03
MV-22
SJ-9E-US
ATCC55195
LEAF_2052A-d
LEAF_2032A-d
SPIN_2503V10-d
115-3-CHN
JV-V16
SJ-7A-US
PB013-T2-3
51B
ACS-116-V-Col5a
ATCC49540
KA00185
0009-5_S7-24-11
MJR8396C
ATCC43063
ATCC51333
Subsp_curtisii_ATCC35241
Subsp_holmesii_ATCC35242
ATCC35239
BAA614

GCA_001546455.1
GCA_001553005.1
GCA_001553035.1
GCA_001552975.1
GCA_000177035.2
GCA_000160875.1
GCA_000162255.1
GCA_000177575.1
GCA_000165885.1
GCA_000301115.1
GCA_000301135.1
GCA_000160515.1
GCA_000161915.2
GCA_000176975.2
GCA_001541385.1
GCA_001541405.1
GCA_001541515.1
GCA_001541505.1
GCA_001541535.1
GCA_001541585.1
GCA_000439915.1
GCA_000175055.1
GCA_000177415.1
GCA_000143645.1
GCA_000155935.2
GCA_000176995.2
GCA_000185405.1
GCA_000179955.1
GCA_000179935.1
GCA_000149145.2
GCA_000162435.1
GCA_000159335.1
GCA_000162335.1
GCA_000180015.1
GCA_000699985.1
GCA_000179475.1
GCA_000159435.1
GCA_001553045.1
GCA_000733145.1
GCA_001546855.1
GCA_000196535.1
GCA_000185425.1
GCA_000146285.1
GCA_000185445.1
GCA_000146895.1
GCA_000164135.1

- 391 Oligella_urethralis
Olsenella_sp
Parvimonas_sp
Peptoniphilus_coxii
Peptoniphilus_duerdenii
Peptoniphilus_harei
Peptoniphilus_lacrimalis
Peptoniphilus_sp
Peptostreptococcus_anaerobius
Peptostreptococcus_sp
Porphyromonadaceae_bacterium
Prevotella_amnii
Prevotella_amnii
Prevotella_bivia
Prevotella_bivia
Prevotella_bivia
Prevotella_bivia
Prevotella_buccalis
Prevotella_buccalis
Prevotella_corporis
Prevotella_denticola
Prevotella_disiens
Prevotella_histicola
Prevotella_melaninogenica
Prevotella_sp
Prevotella_sp
Prevotella_timonensis
Propionibacterium_avidum
Proteus_mirabilis
Pseudoglutamicibacter_albus
Roseomonas_cervicalis
Staphylococcus_haemolyticus
Staphylococcus_lugdunensis
Staphylococcus_simulans
Streptococcus_equinus
Streptococcus_mitis
Streptococcus_salivarius
Tissierella_bacterium
Tissierella_bacterium
Tissierella_bacterium
Varibaculum_cambriense
Veillonella_atypica
Veillonella_dispar
Veillonella_montpellierensis
Veillonella_parvula
Veillonella_sp

DNF00040
DNF00959
KA00067
DNF00729
BAA-1640
CMW7756A
DNF00528
DNF00840
KA00810
MV1
KA00676
DNF00058
DNF00307
DNF00188
DNF00320
DNF00650
GED7760C
DNF00853
DNF00985
MJR7716
DNF00960
DNF00882
JCM15637_DNF00424
DNF00666
DNF00663
S7-1-8
S9-PR14
MJR7694
GED7834
DNF00011
ATCC49957
DNF00585
MJR7738
MJR7712
ATCC700338
CMW7705B
GED7778A
KA00581
S5-A11
S7-1-4
DNF00696
CMW7756B
DNF00926
DNF00314
ACS-068-V-Sch12
DNF00869

GCA_000759065.1
GCA_001553055.1
GCA_001553085.1
GCA_001553115.1
GCA_000146345.1
GCA_001546555.1
GCA_000759145.1
GCA_001553125.1
GCA_001553145.1
GCA_000758885.1
GCA_001553165.1
GCA_000759315.1
GCA_001553225.1
GCA_000759045.1
GCA_000759245.1
GCA_000759165.1
GCA_001546565.2
GCA_000759185.1
GCA_000759265.1
GCA_001546595.1
GCA_000759205.1
GCA_000759225.1
GCA_000759075.1
GCA_000144405.1
GCA_001553265.1
GCA_000758925.1
GCA_000762405.1
GCA_001546875.1
GCA_000758985.1
GCA_000164635.1
GCA_000759125.1
GCA_001546615.1
GCA_001546635.1
GCA_000146405.1
GCA_001546795.1
GCA_001546835.2
GCA_001552895.1
GCA_000758865.1
GCA_000758845.1
GCA_001553285.1
GCA_001546845.1
GCA_001553315.1
GCA_000759285.1
GCA_000215025.2
GCA_001553345.1

- 392 Veillonellaceae_bacterium
Veillonellaceae_bacterium
Veillonellaceae_bacterium

DNF00626
DNF00751
KA00182

GCA_001553355.1
GCA_001553395.1
GCA_001553405.1
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Table N.2. A List of the Gut Isolates Used in Chapter III. These isolates were collected by the
Lawley lab and are publicly available 146.
Species
Alistipes_finegoldii
Alistipes_finegoldii
Anaerostipes_hadrus
Anaerostipes_hadrus
Anaerotruncus_colihominis
Anaerotruncus_colihominis
Anaerotruncus_colihominis
Anaerotruncus_colihominis
Anaerovorax_odorimutans
B_glucerasea
Bacteroides_caccae
Bacteroides_coprocola
Bacteroides_coprocola
Bacteroides_finegoldi
Bacteroides_finegoldii
Bacteroides_intestinalis
Bacteroides_ovatus
Bacteroides_plebius
Bacteroides_plebius
Bacteroides_salyersiae
Bacteroides_thetaiotaomicron
Bacteroides_thetaiotaomicron
Bacteroides_thetaiotaomicron
Bacteroides_uniformis
Bacteroides_vulgatus
Bacteroides_xylanisolvens
Bifidobacterium_adolescentis
Bifidobacterium_adolescentis
Bifidobacterium_bifidum
Bifidobacterium_pseudocatenulatum
Blautia_hydrogenotrophica
Blautia_hydrogenotrophica
Blautia_luti
Blautia_luti
Blautia_luti
Blautia_luti
Blautia_luti
Blautia_luti
Blautia_luti
Blautia_producta
Blautia_producta
Blautia_producta
Blautia_producta

Strain
R_Hilary_H2_8
Hilary_H6_8
Hilary_H4_24
H5_19
DSMZ_H4_64_HMI_6
Hilary_H4_64
Hilary_H5_63
Nature_Treg_PRJDB532_st13
R_DSMZ_FMT23_9get5_HMI_23
R_DSMZ_FMT23_BA916F__HMI_29
Hilary_H1_3
DSMZ_HMI_42
Hilary_H4_3
Hilary_H1_5
Hilary_H3_6
Hilary_H5_4
Hilary_H6_4
DSMZ_HMI_43
Hilary_H4_5
Hilary_H3_17
R_Hilary_H4_6
Hilary_H5_3
Hilary_H6_6
Hilary_H4_4
Hilary_H4_2
Hilary_H1_4
Hilary_H3_7
Hilary_H4_11
Hilary_H3_38
Hilary_H3_40
R_Hilary_H2_20
Hilary_H2_36
DSMZ_FMT23_12get12_HMI_26
DSMZ_HMI_35
DSMZ_HMI_41
Hilary_H1_41
Hilary_H3_45
Hilary_H4_26
Hilary_H5_23
DSMZ_FMT23_jet16HMI_28
DSMZ_HMI_46
Hilary_H5_31
Nature_Treg_st6

- 394 Blautia_wexlerae
Butyricicoccus_pullicaecorum
Butyricicoccus_pullicaecorum
Butyricicoccus_pullicaecorum
Butyricoccus_pullicaecorum
C_maritium
Catenibacterium_mitsuokai
Clostridaceae_sp
Clostridium_asparagiforme
Clostridium_baratti
Clostridium_bartlettii
Clostridium_boltae
Clostridium_bolteae
Clostridium_bolteae
Clostridium_celerecrescens
Clostridium_celerecrescens
Clostridium_celerescens
Clostridium_celerescens
Clostridium_clostridioforme
Clostridium_clostridioforme
Clostridium_clostridioforme
Clostridium_clostridioforme
Clostridium_clostridioforme
Clostridium_cocleatum
Clostridium_disporicum
Clostridium_disporicum
Clostridium_disporicum
Clostridium_ghonii
Clostridium_hathewayi
Clostridium_hathewayi
Clostridium_hathewayi
Clostridium_hathewayi
Clostridium_hatyewayi
Clostridium_indolis
Clostridium_innocuum
Clostridium_innocuum
Clostridium_lituseburense
Clostridium_methylpentosum
Clostridium_methylpentosum
Clostridium_nexile
Clostridium_nexile
Clostridium_orbiscindens
Clostridium_orbiscindens
Clostridium_oroticum
Clostridium_oroticum
Clostridium_oroticum

R_Hilary_H4_27
DSMZ_HMI_48
Hilary_H5_45
Hilary_H5_46
DSMZ_FMT23_12get7 _HMI_31
R_DSMZ_FMT23_16get2_HMI_32
R_Hilary_H1_10
Nature_Treg_PRJDB527_st8
Nature_Treg_PrJDB534_st15
Hilary_H5_17
Hilary_H1_15
Hilary_H5_27
Bature_Treg_PRJDB526_st7
Nature_Treg_PRJDB529_st10
DSMZ_H5_39_ HMI_18
Hilary_H5_39
DSMZ_H4_37_HMI_19
Hilary_H4_37
R_DSMZ_FMT23_B060_HMI_27
DSMZ_H5_37_ HMI_16
R_Hilary_H2_21
Hilary_H4_30
Hilary_H5_37
Hilary_H3_28
Hilary_H4_18
Hilary_H4_19
R_Hilary_H6_18
R_Hilary_H6_15
DSMZ_H3_49_HMI_14
Hilary_H2_25
Hilary_H3_49
Hilary_H5_29
Nature_Treg_st4
Nature_Treg_PRJDB528_st9
Hilary_H4_16
Hilary_H5_11
Hilary_H4_22
R_DSMZ_HMI_36
R_Hilary_H2_30
DSMZ_HMI_47
Hilary_H5_34
DSMZ_H4_63_HMI_4
DSMZ_HMI_50
DSMZ_H2_18_HMI_10
DSMZ_H5_35_HMI_8
Hilary_H2_18

- 395 Clostridium_oroticum
Clostridium_oroticum
Clostridium_paraputrificum
Clostridium_perfringens
Clostridium_ramosum
Clostridium_saccharogumia
Clostridium_saccharogumia
Clostridium_saccharogumia
Clostridium_saccharogumia
Clostridium_saccharolyticum
Clostridium_saccharolyticum
Clostridium_scindens
Clostridium_scindens
Clostridium_sp
Clostridium_straminisolvens
Clostridium_thermocellum
Clostridium_thermocellum
Clostridium_thermocellum
Clostridium_thermocellum
Clostridium_xylanolyticum
Clostridium_xylanolyticum
Clostridium_xylanolyticum
Clostridium_xylanolyticum
Collinsella_aerofaciens
Collinsella_aerofaciens
Collinsella_aerofaciens
Coprococcus_comes
Coprococcus_eutactus
Coprococcus_eutactus
Dorea_formicigenerans
Dorea_longicatena
Eubacterium_contortum
Eubacterium_contortum
Eubacterium_contortum
Eubacterium_eligens
Eubacterium_fissicatena
Eubacterium_fissicatens
Eubacterium_fissicatens
Eubacterium_halii
Eubacterium_hallii
Eubacterium_infirmum
Eubacterium_infirmum
Eubacterium_infirmum
Eubacterium_infirmum
Eubacterium_ramulus
Eubacterium_rectale

Hilary_H4_38
Hilary_H5_35
Hilary_H4_20
Hilary_H3_1
Nature_Treg_PRJDB536_st18
R_DSMZ_FMT23_B054_HMI_24
DSMZ_FMT23_H4_15_HMI_25
Hilary_H4_15
Nature_Treg_st1
DSMZ_HMI_34
Hilary_H1_39
Nature_Treg_PRJDB540_st26
Nature_Treg_st5
Nature_Treg_PRJDB535_st16
DSMZ_FMT23_15e_HMI_30
DSMZ_H5_59_HMI_1
DSMZ_H5_66_HMI_22
Hilary_H5_59
Hilary_H5_66
DSMZ_H4_41_HMI_7
R_DSMZ_HMI_37
R_Hilary_H2_19
Hilary_H4_41
R_Hilary_H2_9
Hilary_H4_10
Hilary_H5_8
Hilary_H1_34
Hilary_H1_22
R_Hilary_H2_11
Hilary_H4_33
Hilary_H6_29
DSMZ_H4_39_HMI_9
Hilary_H4_39
Hilary_H4_43
Hilary_H4_42
Nature_Treg_PRJDB537_st21
DSMZ_HMI_33
Hilary_H1_29
R_Hilary_H1_25
Hilary_H6_32
DSMZ_H3_30_HMI_20
DSMZ_H5_15_HMI_21
Hilary_H3_30
Hilary_H5_15
Hilary_H3_53
Hilary_H4_46

- 396 Eubacterium_siraeum
Faecalibacterium_prausnitzii
Faecalibacterium_prausnitzii
Faecalibacterium_prausnitzii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Flavonifractor_plautii
Fusicatenibacter_saccharivorans
Fusicatenibacter_saccharivorans
Fusicatenibacter_saccharivorans
Lachnosipraceae_sp
Lachnospira_pectinoschiza
Lachnospira_pectinoschiza
Lachnospira_pectinoschiza
Lachnospira_pectinoschiza
Lachnospiraceae_sp
Lachnospiraceae_sp
Lachnospiraceae_sp
Megasphaera_elsdenii
Megasphaera_elsdenii
Mitsuokella_jalaludinii
Oscillibacter_valericigenes
Oscillibacter_valericigenes
Oscillospiraceae_sp
Parabacteroides_distasonis
Parabacteroides_distasonis
Parabacteroides_distasonis
Parabacteroides_merdae
prausnitzii_
Prevotella_copri
Roseburia_faecis
Roseburia_faecis
Roseburia_faecis
Roseburia_hominis
Roseburia_intestinalis
Roseburia_inulinivorans

Hilary_H5_47
Hilary_H1_17
Hilary_H5_50
Hilary_H6_39
DSMZ_H4_62_HMI_2
DSMZ_H5_64_HMI_3
R_Hilary_H2_32
Hilary_H4_58
Hilary_H4_62
Hilary_H4_63
Hilary_H5_16
Hilary_H5_54
Hilary_H5_55
R_Hilary_H5_56
Hilary_H5_60
Hilary_H5_64
Nature_Treg_st3
DSMZ_H5_42_HMI_15
Hilary_H5_38
Hilary_H5_42
Nature_Treg_PRJDB538_st23
DSMZ_H1_27_ HMI_11
Hilary_H1_27
Hilary_H2_16
Hilary_H4_49
Nature_Treg_PRJDB531_st12
Nature_Treg_PRJDB541_st27
Nature_Treg_PRJDB543_st29
DSMZ_HMI_40
Hilary_H4_17
Hilary_H1_16
DSMZ_HMI_38
Hilary_H2_39
Nature_Treg_PRJDB539_st24
Hilary_H3_21
Hilary_H5_6
Hilary_H6_9
Hilary_H4_9
H5_51
Hilary_H1_1
DSMZ_H3_52_HMI_12
Hilary_H3_52
Hilary_H3_8
Hilary_H1_36
Hilary_H6_28
DSMZ_HMI_44

- 397 Roseburia_inulinivorans
Roseburia_inulinivorans
Ruminococcus_albus
Ruminococcus_albus
Ruminococcus_albus
Ruminococcus_albus
Ruminococcus_bromii
Ruminococcus_bromii
Ruminococcus_bromii
Ruminococcus_bromii
Ruminococcus_flavefaciens
Ruminococcus_flavefaciens
Ruminococcus_flavefaciens
Ruminococcus_flavefaciens
Ruminococcus_gnavus
Ruminococcus_gnavus
Ruminococcus_obeum
Ruminococcus_obeum
Ruminococcus_obeum
Ruminococcus_obeum
Ruminococcus_obeum
Ruminococcus_sp
Ruminococcus_torques
Ruminococcus_torques
Ruminococcus_torques
Ruminococcus_torques
Sarcina_ventriculi
Turibacter_sanguinis

Hilary_H3_54
Hilary_H4_51
DSMZ_HMI_45
DSMZ_HMI_52
Hilary_H4_61
Hilary_H6_42
DSMZ_HMI_51
Hilary_H3_4
Hilary_H5_48
Hilary_H6_38
DSMZ_H5_62_HMI_62
DSMZ_HMI_49
Hilary_H5_58
Hilary_H5_62
R_Hilary_H2_28
Hilary_H4_53
R_DSMZ_HMI_39
Hilary_H1_44
Hilary_H3_47
Hilary_H5_20
Hilary_H5_36
Nature_Treg_PRJDB533_st14
DSMZ_H4_55_ HMI_17
R_Hilary_H2_10
Hilary_H3_59
R_Hilary_H5_33
Hilary_H4_21
Hilary_H1_12
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Table N.3. A List of Urinary Isolates used in Chapter III. These isolates were sequenced by the
Wellcome Trust for a niche comparison study. Most of the strains sequenced were collected as
part of the Astellas study (Appendix C-D), the maternal urinary microbiome (Appendix I), with 2
E. coli genomes from a UTI study (Appendix H).
Sequence ID

Species

16933_8#1
16933_8#10
16933_8#11
16933_8#12
16933_8#13
16933_8#16
16933_8#17
16933_8#18
16933_8#19
16933_8#2
16933_8#20
16933_8#21
16933_8#24
16933_8#25
16933_8#26
16933_8#27
16933_8#29
16933_8#30
16933_8#31
16933_8#32
16933_8#33
16933_8#34
16933_8#36
16933_8#37
16933_8#38
16933_8#39
16933_8#4
16933_8#40
16933_8#41
16933_8#44
16933_8#46
16933_8#47
16933_8#48
16933_8#49
16933_8#5
16933_8#50
16933_8#52
16933_8#53
16933_8#54

Corynebacteriaceae
Micrococcaceae
Streptococcaceae
Corynebacteriaceae
Lactobacillaceae
Micrococcaceae
Brevibacteriaceae
Lactobacillaceae
Enterobacteriaceae
Bifidobacteriaceae
Enterobacteriaceae
Streptococcaceae
Enterobacteriaceae
Micrococcaceae
Moraxellaceae
Streptococcaceae
Actinomycetaceae
Enterobacteriaceae
Neisseriaceae
Enterococcaceae
Bifidobacteriaceae
Streptococcaceae
Neisseriaceae
Bifidobacteriaceae
Actinomycetaceae
Aerococcaceae
Actinomycetaceae
Bifidobacteriaceae
Lactobacillaceae
Actinomycetaceae
Lactobacillaceae
Propionibacteriaceae
Actinomycetaceae
Lactobacillaceae
Bifidobacteriaceae
Bifidobacteriaceae
Bifidobacteriaceae
Lactobacillaceae
Pseudomonadaceae

Isolate
Collection ID
UMB0147
UMB0867
UMB0252
UMB0338
UMB0099
UMB0031
UMB0426
UMB0045
UMB0789
UMB0061
UMB0140
UMB0832
UMB0900
UMB0131
UMB0416
UMB0008
UMB0319
UMB0901
UMB0321
UMB0891
UMB0912
UMB0839
UMB0023
UMB0913
UMB0086
UMB0111
UMB0063
UMB0682
UMB0803
UMB0402
UMB0044
UMB0211
UMB0116
UMB0007
UMB0233
UMB0032A
UMB0386
UMB0085
UMB0740

Patient ID
OAB033
MUM_05
OAB040
OAB048
OAB027
C022
OAB051
C037
C033
OAB018
OAB031
MUM_12
EQUC078
OAB030
OAB041
C012
OAB040
EQUC075
OAB040
OAB061
MUM_02
MUM_15
C019
MUM_02
OAB025
OAB029
OAB019
OAB030
C031
OAB041
C037
OAB018
OAB029
C012
OAB023
C023
OAB045
OAB024
OAB055
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16933_8#57
16933_8#58
16933_8#59
16933_8#6
16933_8#60
16933_8#61
16933_8#62
16933_8#7
16933_8#8
16933_8#9
17957_1#1
17957_1#11
17957_1#12
17957_1#13
17957_1#17
17957_1#20
17957_1#26
17957_1#35
17957_1#39
17957_1#41
17957_1#42
17957_1#43
17957_1#45
17957_1#46
17957_1#47
17957_1#49
17957_1#50
17957_1#52
17957_1#54
17957_1#57
17957_1#58
17957_1#59
17957_1#61
17957_1#65
17957_1#66
17957_1#68
17957_1#69
17957_1#73
17957_1#74
17957_1#75
17957_1#77
17957_1#79
17957_1#81
17957_1#82
17957_1#88

Enterobacteriaceae
Bifidobacteriaceae
Streptococcaceae
Bifidobacteriaceae
Staphylococcaceae
Bifidobacteriaceae
Micrococcaceae
Micrococcaceae
Actinomycetaceae
Aerococcaceae
Lactobacillaceae
Lactobacillaceae
Lactobacillaceae
Streptococcaceae
Bacillaceae
Actinomycetaceae
Veillonellaceae
Neisseriaceae
Enterobacteriaceae
Lactobacillaceae
Clostridiales Family XI
Streptococcaceae
Corynebacteriaceae
Bacillaceae
Dermacoccaceae
Deleted
Corynebacteriaceae
Aerococcaceae
Dermabacteraceae
Aerococcaceae
Streptococcaceae
Actinomycetaceae
Aerococcaceae
Streptococcaceae
Bifidobacteriaceae
Aerococcaceae
Aerococcaceae
Nocardiaceae
Aerococcaceae
Streptococcaceae
Actinomycetaceae
Actinomycetaceae
Enterobacteriaceae
Lactobacillaceae
Actinomycetaceae
Actinomycetaceae

UMB0315
UMB0032B
UMB0820
UMB0915
UMB0894
UMB0298
UMB0083
UMB0024
UMB0125
UMB0844
UMB0824
UMB0003
UMB0187
UMB0329
UMB0728
UMB0018
UMB0371
UMB0112
UMB0210
UMB1297
UMB0040
UMB0119
UMB0220
UMB0763
UMB0893
UMB1298
UMB0042
UMB0126
UMB0490
UMB0898
UMB0050
UMB0138
UMB0232
UMB0776
UMB0064
UMB0139
UMB0514
UMB0777
UMB0072
UMB0142
UMB0250
UMB0796
UMB0660
UMB0077
UMB0181
UMB0183

OAB039
C023
OAB072
MUM_05
C042
OAB045
OAB023
C019
OAB023
MUM_19
OAB047
C008
OAB035
OAB031
C01
C019
OAB043
OAB029
OAB018
EQUC146
C030
OAB021
OAB031
OAB047
C030
EQUC146
C037
OAB023
OAB045
OAB059
C038
OAB031
OAB023
C027
OAB019
OAB031
OAB059
C025
OAB015
OAB031
OAB040
OAB041
OAB062
OAB021
OAB035
OAB035

- 400 17957_1#9
21837_8#14
21837_8#15
21837_8#16
21837_8#17
21837_8#19
21837_8#20
21837_8#21
21837_8#22
21837_8#23
21837_8#24
21837_8#26
21837_8#27
21837_8#28
21837_8#29
21837_8#31
21837_8#32
21837_8#34
21837_8#35
21837_8#36
21837_8#37
21837_8#38
21837_8#39
21837_8#42
21837_8#43
21837_8#44
21837_8#45
21837_8#46
21837_8#49
21837_8#50
21837_8#51
21837_8#52
21837_8#53
21837_8#55
21837_8#56
21837_8#59
21837_8#61
21837_8#62
21837_8#63
21837_8#64
21837_8#65
21837_8#66
21837_8#67
21837_8#68
21837_8#69
21837_8#70

Lactobacillaceae
Staphylococcaceae
Lactobacillaceae
Streptococcaceae
Bifidobacteriaceae
Bifidobacteriaceae
Corynebacteriaceae
Corynebacteriaceae
Lactobacillaceae
Streptococcaceae
Streptococcaceae
Bifidobacteriaceae
Bifidobacteriaceae
Streptococcaceae
Lactobacillaceae
Aerococcaceae
Actinomycetaceae
Bifidobacteriaceae
Corynebacteriaceae
Propionibacteriaceae
Staphylococcaceae
Staphylococcaceae
Enterococcaceae
Bifidobacteriaceae
Streptococcaceae
Staphylococcaceae
Enterobacteriaceae
Micrococcaceae
Bifidobacteriaceae
Lactobacillaceae
Streptococcaceae
Streptococcaceae
Lactobacillaceae
Enterobacteriaceae
Lactobacillaceae
Lactobacillaceae
Enterobacteriaceae
Corynebacteriaceae
Actinomycetaceae
Streptococcaceae
Bifidobacteriaceae
Bifidobacteriaceae
Streptococcaceae
Corynebacteriaceae
Staphylococcaceae
Enterococcaceae

UMB0004
UMB0202
UMB0505
UMB0540
UMB0558
UMB0670
UMB0736
UMB0770
UMB0775
UMB0830
UMB0833
UMB0277
UMB0358
UMB0001
UMB0012
UMB0028
UMB0045
UMB0072
UMB0079
UMB0092
UMB0100
UMB0113
UMB0184
UMB0214
UMB0216
UMB0226
UMB0243
UMB0272
UMB0406
UMB0444
UMB0489
UMB0507
UMB0646
UMB0683
UMB0819
UMB0006
UMB0011
UMB0017
UMB0021
UMB0025
UMB0026
UMB0038
UMB0039
UMB0043
UMB0048
UMB0051

C008
OAB017
OAB049
OAB060
SUI08
OAB052
K-19
OAB049
SUI12
MUM_12
MUM_19
OAB042
OAB049
C008
C015
C019

OAB022
OAB017
OAB027
OAB029
OAB035
OAB018
OAB018
OAB035
OAB039
OAB041
OAB041
OAB053
OAB045
OAB049
OAB032
OAB017
OAB062
C009
C014
C018
C019
C019
C019
C029
C029
C037
C041
C038

- 401 21837_8#71
21837_8#73
21837_8#74
21837_8#75
21837_8#76
21837_8#78
21837_8#79
21837_8#80
21837_8#82
21837_8#83
21837_8#85
21837_8#86
21837_8#87
21837_8#90
21837_8#92
21837_8#94
21837_8#95
21837_8#96

Streptococcaceae
Bifidobacteriaceae
Bifidobacteriaceae
Aerococcaceae
Staphylococcaceae
Streptococcaceae
Streptococcaceae
Lactobacillaceae
Bifidobacteriaceae
Streptococcaceae
Bifidobacteriaceae
Lactobacillaceae
Bifidobacteriaceae
Bifidobacteriaceae
Alcaligenaceae
Lactobacillaceae
Corynebacteriaceae
Bifidobacteriaceae

UMB0054
UMB0057
UMB0058
UMB0611
UMB0722
UMB0727
UMB0731
UMB0733
UMB0767
UMB0788
UMB0797
UMB0799
UMB0829
UMB0989
UMB1341
UMB1398
UMB1400
UMB1428

C046
C053
C054
C03
C02
C02
C056
C056
C032
C027
C032
C033
C033
C016
C28
C33
C33
C040
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Table N.4. A List of Genomes used in Chapter V.
A. A list of Urinary and Vaginal Isolates collected from participants in the Estrogen Study. Clinical
isolates sequenced for this study. Patients that contained the same species in both the bladder and
vagina at baseline and 12 weeks were chosen for this arm of the study. Each set of 4 is delineated by
highlighting. The only exception is patient EST11’s G. vaginalis group which did not have a baseline
bladder isolate. Only one isolate from patient EST15’s S. anginosus set is currently sequenced. The other
4 are still being processed.
Sequence ID
AW-002
AW-003
AW-015
AW-017
AW-006
AW-010
AW-012
AW-024
AW-005
AW-007
AW-011
AW-013
AW-020
AW-021
AW-028
AW-029
AW-001
AW-004
AW-014
AW-016
AW-025
AW-030
AW-031
AW-022
AW-023
AW-032
AW-033
AW-008
AW-009
AW-018
AW-019
AW-026
AW-027
AW-034
AW-035
AW-036

Patient ID
EST08
EST08
EST08
EST08
EST11
EST11
EST11
EST11
EST11
EST11
EST11
EST11
EST05
EST05
EST05
EST05
EST08
EST08
EST08
EST08
EST11
EST11
EST11
EST10
EST10
EST10
EST10
EST16
EST16
EST16
EST16
EST14
EST14
EST14
EST14
EST15

Location
vag
cath
cath
vag
vag
vag
cath
cath
cath
vag
cath
vag
cath
vag
cath
vag
vag
cath
cath
vag
vag
cath
vag
cath
vag
cath
vag
cath
vag
cath
vag
cath
vag
cath
vag
cath

Time
Point
Base
Base
12w
12w
Base
12w
12w
Base
Base
Base
12w
12w
base
base
12w
12w
Base
Base
12w
12w
base
12w
12w
base
base
12w
12w
Base
Base
12w
12w
base
base
12w
12w
base

Species
Aerococcus urinae
Aerococcus urinae
Aerococcus urinae
Aerococcus urinae
Corynebacterium amycolatum
Corynebacterium amycolatum
Corynebacterium amycolatum
Corynebacterium amycolatum
Corynebacterium coyleae
Corynebacterium coyleae
Corynebacterium coyleae
Corynebacterium coyleae
Corynebacterium coyleae
Corynebacterium coyleae
Corynebacterium coyleae
Corynebacterium coyleae
Eschericia coli
Eschericia coli
Eschericia coli
Eschericia coli
Gardnerella vaginalis
Gardnerella vaginalis
Gardnerella vaginalis
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus iners
Lactobacillus iners
Lactobacillus iners
Lactobacillus iners
Streptococcus anginosus
Streptococcus anginosus
Streptococcus anginosus
Streptococcus anginosus
Streptococcus anginosus

Isolate
Collection ID
UMB2324
UMB2325
UMB3669
UMB3673
UMB2514
UMB3570
UMB3560
UMB2505
UMB2503
UMB2517
UMB3558
UMB3562
UMB1939
UMB1951
UMB2890
UMB2897
UMB2277
UMB2328
UMB3668
UMB3670
UMB2512
UMB3559
UMB3565
UMB2389
UMB2407
UMB4313
UMB4315
UMB3008
UMB3029
UMB5013
UMB5018
UMB2816
UMB2825
UMB4619
UMB4628
UMB2908
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B. A list of the publicly available reference genomes used for comparison, downloaded from
NCBI
Species
Abiotrophia defectiva
Aerococcus urinae
Aerococcus urinae
Aerococcus urinae
Aerococcus urinae
Corynebacterium amycolatum
Corynebacterium amycolatum
Corynebacterium bovis
Corynebacterium coyleae
Escherichia coli
Escherichia coli
Escherichia coli
Escherichia coli
Gardnerella vaginalis
Gardnerella vaginalis
Gardnerella vaginalis
Klebsiella pneumoniae
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus crispatus
Lactobacillus iners
Lactobacillus iners
Lactobacillus iners
Lactobacillus iners
Lactococcus lactis
Pediococcus acidilactici
Streptococcus agalactiae
Streptococcus anginosus
Streptococcus anginosus
Streptococcus anginosus
Streptococcus anginosus
Streptococcus anginosus

Strain
ATCC49176
ACS120_VCol10a
CCUG36881
NBRC15544
AU3
SK46
ICIS53
DSM20582
DSM4418
BL21
K12_MG1655
O83:H1_NRG857C
UPEC_CFT073
409-05
ATCC14019
HMP9231
HS11286
FB077
CTV-05
FB049-03
JV V01
125-2-CHN
214-1 HMP
ST1
DSM1335
ATCC55195
LactinV11V1-d
AB1
II1403
DSM20284
2603VR
C1051
C238
MAS624
SA1_831165
SK1138

Assembly Accession
GCA_000160075.2
GCA_000193205.1
GCA_001543175.1
GCA_001544335.1
GCA_001649715.1
GCA_000173655.1
GCA_001722255.1
GCA_000183325.2
GCA_900105505.1
GCA_000009565.2
GCA_000005845.2
GCA_000183345.1
GCA_000007445.1
GCA_000025205.1
GCA_000159155.2
GCA_000213955.1
GCA_000240185.2
GCA_000301135.1
GCA_000165885.1
GCA_000301115.1
GCA_000160515.1
GCA_000162255.1
GCA_000177575.1
GCA_000091765.1
GCA_000160875.1
GCA_000185405.1
GCA_000149065.2
GCA_000177755.1
GCA_000006865.1
GCA_000146325.1
GCA_000007265.1
GCA_000463465.1
GCA_000463505.1
GCA_000478925.1
GCA_000831165.1
GCA_000287595.1
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